<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.3" xml:lang="EN" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Chem Res Toxicol</journal-id><journal-id journal-id-type="iso-abbrev">Chem Res Toxicol</journal-id><journal-id journal-id-type="publisher-id">tx</journal-id><journal-id journal-id-type="coden">crtoec</journal-id><journal-title-group><journal-title>Chemical Research in Toxicology</journal-title></journal-title-group><issn pub-type="ppub">0893-228X</issn><issn pub-type="epub">1520-5010</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40314361</article-id><article-id pub-id-type="pmc">PMC12093382</article-id>
<article-id pub-id-type="doi">10.1021/acs.chemrestox.5c00033</article-id><article-categories><subj-group><subject>Review</subject></subj-group></article-categories><title-group><article-title>Machine Learning
for Toxicity Prediction Using Chemical
Structures: Pillars for Success in the Real World</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="ath1"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2790-8679</contrib-id><name><surname>Seal</surname><given-names>Srijit</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath2"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-3867-996X</contrib-id><name><surname>Mahale</surname><given-names>Manas</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath3"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4372-4706</contrib-id><name><surname>Garc&#x000ed;a-Orteg&#x000f3;n</surname><given-names>Miguel</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Joshi</surname><given-names>Chaitanya K.</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Hosseini-Gerami</surname><given-names>Layla</given-names></name><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Beatson</surname><given-names>Alex</given-names></name><xref rid="aff6" ref-type="aff">#</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Greenig</surname><given-names>Matthew</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath8"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8089-8858</contrib-id><name><surname>Shekhar</surname><given-names>Mrinal</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath9"><name><surname>Patra</surname><given-names>Arijit</given-names></name><xref rid="aff7" ref-type="aff">&#x02297;</xref></contrib><contrib contrib-type="author" id="ath10"><name><surname>Weis</surname><given-names>Caroline</given-names></name><xref rid="aff8" ref-type="aff">&#x025cf;</xref></contrib><contrib contrib-type="author" id="ath11"><name><surname>Mehrjou</surname><given-names>Arash</given-names></name><xref rid="aff8" ref-type="aff">&#x025cf;</xref></contrib><contrib contrib-type="author" id="ath12"><name><surname>Badr&#x000e9;</surname><given-names>Adrien</given-names></name><xref rid="aff9" ref-type="aff">&#x025cb;</xref></contrib><contrib contrib-type="author" id="ath13"><name><surname>Paisley</surname><given-names>Brianna</given-names></name><xref rid="aff10" ref-type="aff">&#x025c6;</xref></contrib><contrib contrib-type="author" id="ath14"><name><surname>Lowe</surname><given-names>Rhiannon</given-names></name><xref rid="aff11" ref-type="aff">&#x025c7;</xref></contrib><contrib contrib-type="author" id="ath15"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3150-3025</contrib-id><name><surname>Singh</surname><given-names>Shantanu</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath16"><name><surname>Shah</surname><given-names>Falgun</given-names></name><xref rid="aff12" ref-type="aff">&#x025a0;</xref></contrib><contrib contrib-type="author" id="ath17"><name><surname>Johannesson</surname><given-names>Bjarki</given-names></name><xref rid="aff13" ref-type="aff">&#x025a1;</xref></contrib><contrib contrib-type="author" id="ath18"><name><surname>Williams</surname><given-names>Dominic</given-names></name><xref rid="aff13" ref-type="aff">&#x025a1;</xref></contrib><contrib contrib-type="author" id="ath19"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7796-7418</contrib-id><name><surname>Rouquie</surname><given-names>David</given-names></name><xref rid="aff14" ref-type="aff">&#x025b2;</xref></contrib><contrib contrib-type="author" id="ath20"><name><surname>Clevert</surname><given-names>Djork-Arn&#x000e9;</given-names></name><xref rid="aff15" ref-type="aff">&#x025b3;</xref></contrib><contrib contrib-type="author" id="ath21"><name><surname>Schwab</surname><given-names>Patrick</given-names></name><xref rid="aff8" ref-type="aff">&#x025cf;</xref></contrib><contrib contrib-type="author" id="ath22"><name><surname>Richmond</surname><given-names>Nicola</given-names></name><xref rid="aff16" ref-type="aff">&#x025bc;</xref></contrib><contrib contrib-type="author" id="ath23"><name><surname>Nicolaou</surname><given-names>Christos A.</given-names></name><xref rid="aff17" ref-type="aff">&#x025bd;</xref></contrib><contrib contrib-type="author" id="ath24"><name><surname>Gonzalez</surname><given-names>Raymond J.</given-names></name><xref rid="aff12" ref-type="aff">&#x025a0;</xref></contrib><contrib contrib-type="author" id="ath25"><name><surname>Naven</surname><given-names>Russell</given-names></name><xref rid="aff9" ref-type="aff">&#x025cb;</xref></contrib><contrib contrib-type="author" id="ath26"><name><surname>Schramm</surname><given-names>Carolin</given-names></name><xref rid="aff18" ref-type="aff">&#x000b6;</xref></contrib><contrib contrib-type="author" id="ath27"><name><surname>Vidler</surname><given-names>Lewis R</given-names></name><xref rid="aff19" ref-type="aff">&#x003b1;</xref></contrib><contrib contrib-type="author" id="ath28"><name><surname>Mansouri</surname><given-names>Kamel</given-names></name><xref rid="aff20" ref-type="aff">&#x003b2;</xref></contrib><contrib contrib-type="author" id="ath29"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2860-7958</contrib-id><name><surname>Walters</surname><given-names>W. Patrick</given-names></name><xref rid="aff21" ref-type="aff">&#x003b3;</xref></contrib><contrib contrib-type="author" id="ath30"><name><surname>Wilk</surname><given-names>Deidre Dalmas</given-names></name><xref rid="aff22" ref-type="aff">&#x003b4;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath31"><name><surname>Spjuth</surname><given-names>Ola</given-names></name><xref rid="cor2" ref-type="other">*</xref><xref rid="aff23" ref-type="aff">&#x003f5;</xref><xref rid="aff24" ref-type="aff">&#x003b6;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath32"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1555-8261</contrib-id><name><surname>Carpenter</surname><given-names>Anne E.</given-names></name><xref rid="cor3" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath33"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6683-7546</contrib-id><name><surname>Bender</surname><given-names>Andreas</given-names></name><xref rid="cor4" ref-type="other">*</xref><xref rid="aff26" ref-type="aff">&#x003b8;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><aff id="aff1"><label>&#x02020;</label><institution>Broad
Institute of MIT and Harvard</institution>, Cambridge, Massachusetts 02142, <country>United States</country></aff><aff id="aff2"><label>&#x02021;</label>Department
of Chemistry, <institution>University of Cambridge</institution>, Cambridge CB2 1EW, <country>U.K.</country></aff><aff id="aff3"><label>&#x000a7;</label>Department
of Pharmaceutical Chemistry, <institution>Bombay College
of Pharmacy</institution>, Mumbai 400098, <country>India</country></aff><aff id="aff4"><label>&#x02225;</label>Department
of Computer Science and Technology, <institution>University
of Cambridge</institution>, Cambridge CB3 0FD, <country>U.K.</country></aff><aff id="aff5"><label>&#x022a5;</label><institution>IgnotaLabs</institution>, Cambridge CB4 0GA, <country>U.K.</country></aff><aff id="aff6"><label>#</label><institution>Axiom Bio</institution>, San Francisco, California 94107, <country>United States</country></aff><aff id="aff7"><label>&#x02297;</label><institution>UCB
Pharma U.K.</institution>, Slough SL1 3WE, <country>U.K.</country></aff><aff id="aff8"><label>&#x025cf;</label><institution>GSK</institution>, London WC1A 1DG, <country>U.K.</country></aff><aff id="aff9"><label>&#x025cb;</label><institution>Novartis
Biomedical Research</institution>, Cambridge, Massachusetts 02139, <country>United States</country></aff><aff id="aff10"><label>&#x025c6;</label><institution>Eli Lilly &#x00026;
Company</institution>, Indianapolis, Indiana 46285, <country>United States</country></aff><aff id="aff11"><label>&#x025c7;</label><institution>Relation Therapeutics</institution>, London NW1 3BG, <country>U.K.</country></aff><aff id="aff12"><label>&#x025a0;</label><institution>Non Clinical Drug Safety,
Merck Inc.</institution>, West Point, Pennsylvania 19486, <country>United States</country></aff><aff id="aff13"><label>&#x025a1;</label><institution>AstraZeneca</institution>, Pepparedsleden 1 43183 Molndal, <country>Sweden</country></aff><aff id="aff14"><label>&#x025b2;</label>Toxicology
Data Science, <institution>Bayer SAS Crop Science Division</institution>, Valbonne Sophia-Antipolis 06560, <country>France</country></aff><aff id="aff15"><label>&#x025b3;</label><institution>Pfizer,
Worldwide Research, Development and Medical, Machine Learning
&#x00026; Computational Sciences</institution>, Berlin 10922, <country>Germany</country></aff><aff id="aff16"><label>&#x025bc;</label><institution>Recursion</institution>, London N1C 4AG, <country>U.K.</country></aff><aff id="aff17"><label>&#x025bd;</label><institution>Computational Drug Design, Digital Science
&#x00026; Innovation, Novo
Nordisk US R&#x00026;D</institution>, Lexington, Massachusetts 02421, <country>United States</country></aff><aff id="aff18"><label>&#x000b6;</label><institution>Sanofi,
Babraham Research Campus</institution>, Cambridge CB22 3AT, <country>U.K.</country></aff><aff id="aff19"><label>&#x003b1;</label><institution>Eli
Lilly and Company</institution>, Bracknell RG12 1PU, <country>U.K.</country></aff><aff id="aff20"><label>&#x003b2;</label><institution>NIH/NIEHS/DTT/NICEATM</institution>, Research
Triangle Park, North Carolina 27709, <country>United States</country></aff><aff id="aff21"><label>&#x003b3;</label><institution>Relay
Therapeutics</institution>, Cambridge, Massachusetts 02141, <country>United States</country></aff><aff id="aff22"><label>&#x003b4;</label><institution>Nonclinical
Safety</institution>, Collegeville Pennsylvania 19426, <country>United States</country></aff><aff id="aff23"><label>&#x003f5;</label>Department
of Pharmaceutical Biosciences and Science for Life Laboratory, <institution>Uppsala University</institution>, Uppsala 751 24, <country>Sweden</country></aff><aff id="aff24"><label>&#x003b6;</label><institution>Phenaros
Pharmaceuticals AB</institution>, Uppsala 75239, <country>Sweden</country></aff><aff id="aff26"><label>&#x003b8;</label>College
of Medicine and Health Sciences, <institution>Khalifa
University of Science and Technology</institution>, Abu Dhabi 127788, <country>United Arab Emirates</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label><email>seal@broadinstitute.org</email>.</corresp><corresp id="cor2"><label>*</label><email>ola.spjuth@uu.se</email>.</corresp><corresp id="cor3"><label>*</label><email>anne@broadinstitute.org</email>.</corresp><corresp id="cor4"><label>*</label><email>andreas.bender@ku.ac.ae</email>.</corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>05</month><year>2025</year></pub-date><pub-date pub-type="collection"><day>19</day><month>05</month><year>2025</year></pub-date><volume>38</volume><issue>5</issue><fpage>759</fpage><lpage>807</lpage><history><date date-type="received"><day>26</day><month>01</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>03</month><year>2025</year></date><date date-type="rev-recd"><day>24</day><month>03</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_0012" id="ab-tgr1"/></p><p>Machine learning (ML) is increasingly valuable for predicting
molecular
properties and toxicity in drug discovery. However, toxicity-related
end points have always been challenging to evaluate experimentally
with respect to <italic>in vivo</italic> translation due to the required
resources for human and animal studies; this has impacted data availability
in the field. ML can augment or even potentially replace traditional
experimental processes depending on the project phase and specific
goals of the prediction. For instance, models can be used to select
promising compounds for on-target effects or to deselect those with
undesirable characteristics (e.g., off-target or ineffective due to
unfavorable pharmacokinetics). However, reliance on ML is not without
risks, due to biases stemming from nonrepresentative training data,
incompatible choice of algorithm to represent the underlying data,
or poor model building and validation approaches. This might lead
to inaccurate predictions, misinterpretation of the confidence in
ML predictions, and ultimately suboptimal decision-making. Hence,
understanding the predictive validity of ML models is of utmost importance
to enable faster drug development timelines while improving the quality
of decisions. This perspective emphasizes the need to enhance the
understanding and application of machine learning models in drug discovery,
focusing on well-defined data sets for toxicity prediction based on
small molecule structures. We focus on five crucial pillars for success
with ML-driven molecular property and toxicity prediction: (1) data
set selection, (2) structural representations, (3) model algorithm,
(4) model validation, and (5) translation of predictions to decision-making.
Understanding these key pillars will foster collaboration and coordination
between ML researchers and toxicologists, which will help to advance
drug discovery and development.</p></abstract><funding-group><award-group><funding-source><institution-wrap><institution>National Institute of General Medical Sciences</institution><institution-id institution-id-type="doi">10.13039/100000057</institution-id></institution-wrap></funding-source><award-id>R35 GM122547</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Swedish Research Council</institution><institution-id institution-id-type="doi">NA</institution-id></institution-wrap></funding-source><award-id>2020-03731</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Swedish Research Council</institution><institution-id institution-id-type="doi">NA</institution-id></institution-wrap></funding-source><award-id>2020-01865</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Svenska Forskningsr&#x000c3;&#x000a5;det Formas</institution><institution-id institution-id-type="doi">10.13039/501100001862</institution-id></institution-wrap></funding-source><award-id>2022-00940</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Swedish Cancer Foundation</institution><institution-id institution-id-type="doi">10.13039/100012538</institution-id></institution-wrap></funding-source><award-id>22 2412 Pj 03 H</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Massachusetts Life Sciences Center</institution><institution-id institution-id-type="doi">10.13039/100011495</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>tx5c00033</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>tx5c00033</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>In recent years, machine learning (ML)
approaches for toxicity
prediction using chemical structures and sometimes additional data
sources have attracted widespread interest, particularly in drug discovery.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> There are constant innovations in ML for investigating
biological systems and understanding their interactions with drugs,
resulting in therapeutic activity and/or adverse outcomes. Still,
these improvements must be reflected in practice. Currently, the costs
of bringing a drug to market are increasing,<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> while the overall success rates in clinical drug development remain
poor.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> ML models can be trained on data
from empirical assays to predict the properties of compounds from
molecular structure (see <xref rid="box1-fo" ref-type="chart">Box 1</xref> for standard
definitions for ML related to predictive models for molecular toxicity).
These models are often termed Quantitative Structure Activity/Property
Relationship (QSAR/QSPR) models. By enabling the assessment and triage
of compound toxicity prior to synthesis and physical testing, these
approaches can streamline the drug discovery and development process.
Rapid <italic>in silico</italic> screening procedures allow a larger
number of potential candidates to be assessed in a shorter time and
at decreased cost.</p><p>ML models can be used to predict compound
properties including
efficacy, toxicity (both on-target and off-target biology), and Absorption,
Distribution, Metabolism, and Excretion (ADME) or Pharmacokinetic
(PK) properties. On-target toxicity occurs when a drug affects its
intended target and this itself causes adverse effects, while off-target
toxicity arises from interactions of the drug with unintended biological
targets.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> Certain PK properties and dosing
schedules can help mitigate on-target toxicity by optimizing how the
drug is absorbed, distributed, metabolized, and excreted, effectively
controlling its exposure levels. Moreover, more potent compounds with
favorable pharmacokinetic properties often requires smaller doses
to achieve the desired efficacy. This reduction in the level of necessary
exposure can decrease the likelihood of off-target toxicity, thereby
improving the overall benefit-risk profile of the drug. Therefore,
efficacy and PK/ADME properties drive target engagement and, thus,
potential toxicity, all three need to be combined to arrive at a human-relevant
toxicity estimation.</p><p>For ML-based QSAR/QSPR models, chemical
structures of compounds
are usually the basis for predictions of continuous (numerical) or
categorical labels (properties) biologically relevant to toxicity.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> In addition to predictive models, recent advancements
in generative models have emerged as powerful tools for designing
novel chemical structures while optimizing for properties like low
toxicity.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> This Perspective consolidates
insights from both academia and industry on the application of ML
models across various stages of drug discovery&#x02014;ranging from
early screening and alert systems in hit identification to compound
optimization. We focus on discussing the role of ML models in predicting <italic>in vitro</italic> toxicity assays, <italic>in vivo</italic> animal
study outcomes, and human-relevant toxicity throughout the drug discovery
process.</p></sec><sec id="sec2"><title>Challenges in Translating Preclinical Toxicity Data to Human-Relevant
Predictions</title><p>In the early stages of drug discovery, High-Throughput
Screens<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> (HTSs) are commonly applied to
screen extensive
chemical libraries and find compounds with potential efficacy against
a target or phenotype of interest (on-target effects), albeit with
some arguments for<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> and against<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> its efficiency. Screens can be cellular or cell-free
(isolated protein), with the former testing some aspects of permeability
that the latter does not consider. After identifying hits, molecules
are optimized to enhance their potency, selectivity, and ADME properties.
Usually, <italic>in vitro</italic> assessment of toxicity, including
off-target screens, are not conducted in a high-throughput manner;
at early screening phases, unless there is an obvious off target activity,
selective secondary-pharmacology screens are often run in multiple
&#x02018;waves&#x02019;.<sup><xref ref-type="bibr" rid="ref10">10</xref>,<xref ref-type="bibr" rid="ref11">11</xref></sup></p><p>In later stages of the
drug discovery pipeline, <italic>in vitro</italic> human and <italic>in vivo</italic> animal data are used to predict
human-relevant toxicity, which is the ultimate goal. However, though
widely used, these have shown variable accuracy. For instance, <italic>in vitro</italic> assays have been reported to detect only 50&#x02013;60%
of rare and idiosyncratic drug-induced liver injury (DILI) cases in
humans,<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> while animal models often fail
to fully capture human-specific toxicity due to species differences
in drug metabolism and response.<sup><xref ref-type="bibr" rid="ref13">13</xref>&#x02212;<xref ref-type="bibr" rid="ref16">16</xref></sup> While studies in preclinical
species can give insights into the drug&#x02019;s effects on a whole
organism, they have significant drawbacks. These <italic>in vivo</italic> models are also expensive and not scalable and raise ethical concerns.
Therefore, there is a growing desire for alternative models that can
more closely mimic human physiology. Complex models using human cells,
such as <italic>ex vivo</italic> tissue slices and <italic>in vitro</italic> primary cells or spheroids/organoids, are increasingly used in an
attempt to better predict human responses to drugs and decrease animal
use in line with the FDA modernization act 2.0<sup><xref ref-type="bibr" rid="ref17">17</xref>&#x02212;<xref ref-type="bibr" rid="ref19">19</xref></sup> and related
regulations worldwide. There is ongoing work on New-Approach Methodologies
(NAMs) that avoid animals for early screening and gaining regulatory
acceptance;<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> over 250 regulatory-relevant
NAMs have been proposed (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nams.network/explore">https://nams.network/explore</uri>). These advancements align with
the FDA Harmonization Act and the 3Rs (Replacement, Reduction, and
Refinement) principles, which advocate for reducing the need for animal
testing and instead opting for more ethical and scalable alternatives.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> Tissue slices, spheroid or organoid models are
usually more physiologically relevant than traditional 2D cultured
cancer-derived cell lines. For example, HepaRG, a human hepatic <italic>in vitro</italic> cell line, is widely used because it closely mimics
primary human hepatocytes.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> These cells
retain essential functions, such as major cytochrome P450 (CYP) enzymes,
key phase 2 enzymes, nuclear receptors, and transporters, making them
a valuable tool for studying hepatic drug metabolism and toxicity.
However, they do not recapitulate the three-dimensional (3D) structure
of the organ and some other aspects; hence a push toward the more
expensive tissue slices or spheroids/organoids.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> Overall, progress in replacing animal testing with human-based
NAMs has advanced significantly.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup></p><p>Many toxicity hurdles that slow down the development process are
detected in animal experiments rather than in the less-expensive initial
screening stages.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> This underscores the
urgent need for more reliable ML models for preclinical safety assessments.
Since animal data remains a critical factor in determining a compound&#x02019;s
viability, predicting human findings using animal data will remain
critical in the near term. Still, advancing toward methods that offer
better understanding, more predictive power, and cost-effectiveness
represents clear scientific progress. By integrating <italic>in vitro</italic> systems with advanced omics technologies and ML, there is potential
to reduce the reliance on animal testing. The key challenge lies in
recapitulating biological complexity to improve predictivity, which
is needed for better decision making.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> Therefore, models that integrate PK/ADME with toxicity and predict <italic>in vitro</italic> to <italic>in vivo</italic> translation, or animal-to-human
translation could accelerate drug discovery<sup><xref ref-type="bibr" rid="ref26">26</xref>,<xref ref-type="bibr" rid="ref27">27</xref></sup> by incorporating interspecies and intersex toxicodynamic and toxicokinetic
properties.<sup><xref ref-type="bibr" rid="ref28">28</xref>,<xref ref-type="bibr" rid="ref29">29</xref></sup> Prioritizing such translational
models may bridge the gap between <italic>in vitro</italic> or animal
data and human data, enabling faster, cost-effective development of
safer and more effective medicines.</p></sec><sec id="sec3"><title>Guidelines for ML-Based Toxicity Models</title><p>For the use
of ML-based models in drug discovery, model reliability
is key. Deprioritization of compounds with undesired properties and
progression of those without any early risk flags requires decision-making
based on ML models. To ensure the credibility of QSAR/QSPR models,
the Organisation for Economic Co-operation and Development (OECD)
has defined five principles for model validation.<sup><xref ref-type="bibr" rid="ref30">30</xref>,<xref ref-type="bibr" rid="ref31">31</xref></sup> These include: (i) a defined end point, (ii) an unambiguous algorithm,
(iii) a defined domain of applicability (in terms of chemical structures),
(iv) appropriate measures of goodness-of-fit, robustness, and predictivity,
and (v) a mechanistic interpretation, if possible. These five principles
serve as a foundational framework for evaluating the quality and reliability
of QSAR/QSPR models in regulatory contexts, ensuring that predictions
are applicable to real-world scenarios. A complementary set of four
guidelines was recently proposed for using ML models for ADME/PK for
small molecule lead optimization.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> They
include frequently retraining models using data sets from multiple
sources (global data) as well as new experimental data (local data),
and ensuring models are interactive, interpretable, and integrated
into chemists&#x02019; tools. Bender et al. propose a general set of
guidelines for the development and evaluation of ML tools, particularly
focusing on supervised learning.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> Their
guidelines emphasize the importance of comprehensive data reporting,
conducting retrospective evaluations, comparing models against baselines,
performing prospective testing, and ensuring a thorough model interpretation.
Additionally, they provide specific recommendations for reporting
standards and evaluation metrics, aiming to enhance the reliability
and applicability of ML models in addressing real-world chemical challenges.</p><p>The risks of reliance on ML include the potential for inaccurate
or mis-calibrated models to select drug candidates with undesirable
properties, including safety risks. Mis-calibration, here, refers
to when the model predicted probabilities do not accurately reflect
the true likelihood of observed outcomes. Mis-calibrated models can
be a result of (a) low information content (<xref rid="box1-fo" ref-type="chart">Box 1</xref>) in the feature space being used
to train models, (b) exposure to narrow chemical space in training
data, which then leads to a narrow applicability domain (because of
overfitting of models to a small chemical space), or (c) improper
(and often nonexistent) prospective validation of models (for future
projects), which can lead to overoptimizing and deployment of models
that do not generalize.</p><fig id="box1-fo" position="float"><label>Chart Box 1</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_0015" id="fx15" position="float"/></fig><p>Building on these principles in the context of
ML-driven drug discovery,
in this work, we propose five critical pillars for success using ML
tools for toxicity prediction (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>):<list list-type="simple"><list-item><label>1.</label><p>Selecting appropriate data sets that
accurately represent the toxicity of interest ensures that model predictions
are relevant.</p></list-item><list-item><label>2.</label><p>Chemical
structures must be encoded
into relevant representations that capture essential molecular &#x02018;information&#x02019;
to generate ML-ready features.</p></list-item><list-item><label>3.</label><p>Model algorithms must be suitable to
learn the signal in the data and representation characteristics mentioned
above.</p></list-item><list-item><label>4.</label><p>Models must be
validated to assess
their predictive performance, both retrospectively and prospectively,
within their applicability domain.</p></list-item><list-item><label>5.</label><p>In practical model applications, it
is crucial to consider project scenarios and desired outcomes to facilitate
real-world drug discovery and development.</p></list-item></list></p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Five critical pillars deserving attention from researchers using
ML tools for toxicity prediction are discussed in this review. Pillar
1: Choice of data end points, data sets, and data preparation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_0001" id="gr1" position="float"/></fig><p>Adopting these five pillars would enhance the translatability
and
reliability of predictive models in toxicity prediction, potentially
accelerating the design of safe and effective therapeutic candidates.
In the subsequent sections, we provide a detailed examination of these
five pillars.</p><p>When predicting toxicity, there is typically limited
data available
for the specific end point of interest. Although human toxicity prediction
is the ultimate goal, animal studies are more common than in humans
and can provide granular information, including dose response, time
response, and target organ characterization. Recently, one of the
largest data set with <italic>in vivo</italic> toxicity data for 80,000
compounds against a total of 59 acute systemic toxicity end points
was analyzed by Sosnin et al. and later made publicly available by
Jain et al.<sup><xref ref-type="bibr" rid="ref43">43</xref>,<xref ref-type="bibr" rid="ref44">44</xref></sup> However, <italic>in vivo</italic> data is only available at advanced stages of compound characterization
and <italic>in vitro</italic> data is used for early screening. Thus, <italic>in vitro</italic> assays correlate with one or multiple aspects of
the end point of interest, but <italic>they are not the</italic> in
vivo <italic>relevant end point itself</italic>. Due to data availability,
training data sets for ML models very often include data from such
experimental <italic>in vitro</italic> assays that typically proxy
for a human clinical end point (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>a). Where mechanisms are better understood, well-studied
proxy assays can be used, hence leading to both better predictivity
and better interpretability (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>b).<sup><xref ref-type="bibr" rid="ref45">45</xref>,<xref ref-type="bibr" rid="ref46">46</xref></sup> For example, these could involve
functional or binding assays for proteins involved in known mechanisms
of toxicity (for example, human ether-a-go-go-related, hERG channel
inhibitors in cardiotoxicity<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> or imaging
screens for organelle toxicity such as mitochondrial membrane depolarization<sup><xref ref-type="bibr" rid="ref48">48</xref>,<xref ref-type="bibr" rid="ref49">49</xref></sup>). Hence, the situation differs from case to case quite significantly,
where better mechanistic understanding is present different (e.g.,
target-based) assays might be employed; but in either case the prediction
of <italic>in vivo relevant toxicity</italic> is the goal (as opposed
to just assay labels), in order to arrive at a prediction in the end
that can be used for real-world decision making.</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>(a) The general criteria
when choosing the <italic>in vitro</italic> or <italic>in vivo</italic> assay as a proxy end point that could
represent human toxicity learned by an ML model. (b) The choice of
proxy end point will influence what the model learns and whether mechanistic
insights are possible.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_0002" id="gr2" position="float"/></fig></sec><sec id="sec4"><title>Choosing Relevant (Predictive) Assay End Points for <italic>In Vivo</italic> Toxicity</title><p>An ideal proxy end point strongly
predicts the phenotype observed
in humans. The design or selection of proxy end points requires careful
consideration to ensure reliability, translatability, and relevance
to the application area the model&#x02019;s predictions aim to serve.<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> For example, an assay commonly used to gauge
a common cardiotoxicity mechanism detects Human Ether-a-Go-Go-Related
Gene (hERG) channel inhibitors. However, the hERG assay is merely
a proxy end point for some cardiotoxicity signals such as prolonging
the QT interval of ECG in a beating heart.<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> It does not convey the potential severity of the induced cardiotoxicity
by itself; rather, the extent of QT prolongation (extended interval
between the heart contracting and relaxing) and the risk of progressing
to TdP (Torsades de Pointes, a type of atypical heart rhythm) vary
significantly among compounds known to inhibit hERG (even at very
similar activity against hERG itself), illustrating the importance
of taking into account the ADME properties of drugs in toxicity prediction.<sup><xref ref-type="bibr" rid="ref52">52</xref></sup> Some proxy end points have been very well established,
such as skin sensitization for cosmetics, where the European Union
(EU) has already phased out animal-based experiments.<sup><xref ref-type="bibr" rid="ref53">53</xref></sup> Key Events (KEs) are well-defined for skin sensitization,
which often involves chemical reactivity, offering detailed mechanistic
insight into how chemicals trigger skin sensitization. The OECD has
specified a series of <italic>in vitro</italic> assays to accurately
measure many of the early key events in skin sensitization. For instance,
KE1, which involves the covalent binding of haptens to skin proteins,
is effectively assessed by the Direct Peptide Reactivity Assay (DPRA),
Amino Acid Derivative Reactivity Assay (ADRA), and the kinetic DPRA
assay, and these are well-established methods from the OECD.<sup><xref ref-type="bibr" rid="ref54">54</xref></sup> Proxy end points such as activity against protein
targets are mechanistically understood and help gather information
on the bioactivity profile of the compounds (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">1</xref></xref>). Secondary pharmacology (off-target effect)
is usually screened for using a panel of targets with a relatively
well-established relationship to human toxicity (for details, see
Bowes et al.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> and Brennan et al.<sup><xref ref-type="bibr" rid="ref55">55</xref></sup>).</p><table-wrap id="tbl2" position="float"><label>Table 1</label><caption><title>Commonly Used <italic>In Vitro</italic> Assays That Can Be Used as Proxies for Human-Relevant Toxicity End
Points<xref rid="tbl2-fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">Toxicity</th><th style="border:none;" align="center">Assays
for Proxy End points</th><th style="border:none;" align="center">Comment</th><th style="border:none;" align="center">Commonly Used Data sets in Published Predictive
Models</th></tr></thead><tbody><tr><td style="border:none;" align="left">Hepatotoxicity</td><td style="border:none;" align="left">HepG2 cell viability assays, CYP inhibition assays,<sup><xref ref-type="bibr" rid="ref62">62</xref></sup> mitochondrial membrane depolarization, transporter
and reactive metabolite assays</td><td style="border:none;" align="left">Assess liver function
and potential for liver damage through
cell viability and enzyme inhibition</td><td style="border:none;" align="left">Gates Library screen
for HepG2 cell viability,<sup><xref ref-type="bibr" rid="ref63">63</xref></sup> CYP P450 Inhibition<sup><xref ref-type="bibr" rid="ref64">64</xref></sup></td></tr><tr><td style="border:none;" align="left">Cardiotoxicity</td><td style="border:none;" align="left">Human induced pluripotent stem cell-derived cardiomyocytes
(hiPSC-CMs) assays,<sup><xref ref-type="bibr" rid="ref65">65</xref></sup> hERG, Nav1.5, and
Cav1.2 assays</td><td style="border:none;" align="left">Evaluate effects on cardiac cells and
potential for arrhythmia
through cardiac cell function and ion channel activity</td><td style="border:none;" align="left">qHTS for Inhibitors of hERG,<sup><xref ref-type="bibr" rid="ref66">66</xref></sup> hERGCentral<sup><xref ref-type="bibr" rid="ref67">67</xref></sup></td></tr><tr><td style="border:none;" align="left">Nephrotoxicity</td><td style="border:none;" align="left">Kidney proximal tubule cell assays,<sup><xref ref-type="bibr" rid="ref68">68</xref>,<xref ref-type="bibr" rid="ref69">69</xref></sup> HK-2 cell cytotoxicity assays<sup><xref ref-type="bibr" rid="ref68">68</xref>,<xref ref-type="bibr" rid="ref69">69</xref></sup></td><td style="border:none;" align="left">Assess
kidney cell damage and function, focusing on tubule
cells and cytotoxicity</td><td style="border:none;" align="left"><italic>in vitro</italic> models
based on HK-2 cells<sup><xref ref-type="bibr" rid="ref70">70</xref></sup></td></tr><tr><td style="border:none;" align="left">Neurotoxicity</td><td style="border:none;" align="left">Neuronal cell viability assays,<sup><xref ref-type="bibr" rid="ref71">71</xref>,<xref ref-type="bibr" rid="ref72">72</xref></sup> Neurite outgrowth
assays,<sup><xref ref-type="bibr" rid="ref71">71</xref>,<xref ref-type="bibr" rid="ref72">72</xref></sup> and RNAi screen for <italic>Drosophila</italic> neurons</td><td style="border:none;" align="left">Evaluate potential damage to neurons and effects
on neurite
growth, indicating neurotoxicity</td><td style="border:none;" align="left"><italic>in silico</italic>, <italic>in vitro</italic>, and <italic>in vivo</italic> end points
of neurotox including sedation, ataxia,
and seizure detection<sup><xref ref-type="bibr" rid="ref73">73</xref></sup></td></tr><tr><td style="border:none;" align="left">Genotoxicity and Carcinogenicity</td><td style="border:none;" align="left">Ames test, Micronucleus
assay,<sup><xref ref-type="bibr" rid="ref74">74</xref></sup> Comet assay, Cell transformation
assays<sup><xref ref-type="bibr" rid="ref75">75</xref>&#x02212;<xref ref-type="bibr" rid="ref79">79</xref></sup></td><td style="border:none;" align="left">Assess DNA damage and mutagenic potential, indicating
genetic
toxic risks. Evaluate the potential for causing cancer through cell
transformation and chromosomal damage</td><td style="border:none;" align="left">Ames data set
collated by Xu et al. (<xref ref-type="bibr" rid="ref80">80</xref>) CCRIS (Chemical
Carcinogenesis Research Information System) Data<sup><xref ref-type="bibr" rid="ref81">81</xref></sup></td></tr><tr><td style="border:none;" align="left">Endocrine Disruption</td><td style="border:none;" align="left">Reporter gene assays (e.g., for estrogen receptor activity),
H295R steroidogenesis assay<sup><xref ref-type="bibr" rid="ref82">82</xref>,<xref ref-type="bibr" rid="ref83">83</xref></sup></td><td style="border:none;" align="left">Assess
interference with hormone activity, focusing on receptor
binding and hormone production</td><td style="border:none;" align="left">Endocrine-related <italic>in vitro</italic> assays from ToxCast<sup><xref ref-type="bibr" rid="ref84">84</xref></sup></td></tr><tr><td style="border:none;" align="left">Skin Sensitization</td><td style="border:none;" align="left">Local
lymph node assay (LLNA),<sup><xref ref-type="bibr" rid="ref85">85</xref></sup> guinea pig maximization
test (GPMT)</td><td style="border:none;" align="left">Evaluate the potential for causing skin
irritation or damage
using human skin models</td><td style="border:none;" align="left">AOP-related assays in SkinSensDB<sup><xref ref-type="bibr" rid="ref86">86</xref></sup>&#x02013; KeratinoSens/LuSens, human Cell Line
Activation Test (h-CLAT),
Local lymph node assay (LLNA)</td></tr><tr><td style="border:none;" align="left">Ocular Toxicity</td><td style="border:none;" align="left">Bovine corneal opacity and permeability (BCOP) assay, HET-CAM
assay<sup><xref ref-type="bibr" rid="ref87">87</xref></sup></td><td style="border:none;" align="left">Assess the potential
for causing eye irritation or damage through
corneal and membrane assays</td><td style="border:none;" align="left">GHS classifications based
on Draize rabbit eye test<sup><xref ref-type="bibr" rid="ref88">88</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="tbl2-fn1"><label>a</label><p>Data from these assays are commonly
used in the ML models. For more details on the secondary pharmacology
panel of targets, see Bowes et al.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> and
Brennan et al.<sup><xref ref-type="bibr" rid="ref55">55</xref></sup></p></fn></table-wrap-foot></table-wrap><p>Selecting an end point to be predicted goes hand in
hand with selecting
data sets containing values for that end point. Companies have their
own in-house toxicity data and there are also publicly available data
sets, such as reviewed in Vo et al.,<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> Cavasotto
et al.,<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> Huang et al.,<sup><xref ref-type="bibr" rid="ref58">58</xref></sup> and Schapin et al.<sup><xref ref-type="bibr" rid="ref59">59</xref></sup> Regardless
of the source, data sets often suffer from technical issues that require
careful preprocessing and data curation. For instance, there might
be invalid chemical structures, inconsistent chemical representations,
or undefined stereochemistry. Moreover, data sets might include irrelevant
toxicity end points or high assay artifact rates, which do not allow
for proper ML benchmarking.<sup><xref ref-type="bibr" rid="ref60">60</xref></sup> Here, we
hence present a list of data sets structured by the type of organ-based
toxicity they aim to predict (<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">2</xref></xref>) that were carefully examined and represent clearly
defined end points, with outcomes that are likely to be reproducible.
Data sets such as the Novartis Secondary Pharmacology Database (SPD)<sup><xref ref-type="bibr" rid="ref61">61</xref></sup> and Biogen ADME<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> provide a large number of data points from consistently measured
state-of-the-art <italic>in vitro</italic> assays and commercially
available compounds, which might be particularly useful for newcomers
seeking to understand the available data landscape when building and
benchmarking ML models. Nevertheless, the precise use of a data set
for a particular purpose requires case-by-case consideration and can
hence not be generically answered here.</p><table-wrap id="tbl3" position="float"><label>Table 2</label><caption><title>Data Sets Examined by Authors of This
Study That Are Recommended for Machine Learning Models as They Represent
Large Data Sets with Well-Defined End Points</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">Data Set</th><th style="border:none;" align="center">Type of Data
(<italic>in vivo</italic>/<italic>in vitro</italic>)</th><th style="border:none;" align="center">Data Type in Original Publication</th><th style="border:none;" align="center">Data Points and End Point</th><th style="border:none;" align="center">Comments</th><th style="border:none;" align="center">Link to Data Set</th><th style="border:none;" align="center">Source</th></tr></thead><tbody><tr><td style="border:none;" align="left">Novartis
SPD</td><td style="border:none;" align="left"><italic>in vitro</italic> - targets</td><td style="border:none;" align="left">Quantitative/Numerical</td><td style="border:none;" align="left">1958 drugs assayed for 200 secondary
pharmacology targets linked
to ADEs; 150k AC<sub>50</sub> values with 121k unique entries; Cmax(free)
for 940 drugs; Dose&#x02013;response measurements</td><td style="border:none;" align="left">Internal
data (<italic>in vitro</italic> safety pharmacology
assays)</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://zenodo.org/records/7378746">https://zenodo.org/records/7378746</uri></td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref61">61</xref>)</td></tr><tr><td style="border:none;" align="left">Biogen ADME</td><td style="border:none;" align="left"><italic>in vitro</italic> - ADME</td><td style="border:none;" align="left">Quantitative/Numerical</td><td style="border:none;" align="left">3521 pharmaceuticals; 6 <italic>in vitro</italic> ADME end
points&#x02013;Human and rat liver microsomal stability, MDR1-MDCK
efflux ratio, solubility, and human and rat plasma protein binding
assays</td><td style="border:none;" align="left">Internal prospective data sets (six ADME <italic>in vitro</italic> end points over 20 time points)</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/molecularinformatics/Computational-ADME">https://github.com/molecularinformatics/Computational-ADME</uri></td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref41">41</xref>)</td></tr><tr><td style="border:none;" align="left">Activity
Cliff Eindhoven</td><td style="border:none;" align="left"><italic>in vitro</italic> - Activity
Cliff/Bioactivity</td><td style="border:none;" align="left">Qualitative/Categorical</td><td style="border:none;" align="left">48,707 molecules for 30 targets, including kinases, nuclear
receptors, G-protein-coupled receptors, transferases, and proteases</td><td style="border:none;" align="left">Curated data on 30 macromolecular targets from ChEMBL; Nonproprietary;
Small molecules</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/molML/MoleculeACE">https://github.com/molML/MoleculeACE</uri></td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref89">89</xref>)</td></tr><tr><td style="border:none;" align="left">Activity Cliffs Zhang</td><td style="border:none;" align="left"><italic>in vitro</italic> - Activity
Cliff/Bioactivity</td><td style="border:none;" align="left">Qualitative/Categorical</td><td style="border:none;" align="left">400 K Matched Molecular Pairs (MMPs) against 190 targets (142,307
activities), including over 20K MMP-cliffs and 380 K non-AC MMPs</td><td style="border:none;" align="left">Collected from publicly available database ChEMBL; Nonproprietary;
Available to Buy; Small molecules</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://drugai.github.io/ACNet/">https://drugai.github.io/ACNet/</uri></td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref90">90</xref>)</td></tr><tr><td style="border:none;" align="left">Activity Cliffs Morris</td><td style="border:none;" align="left"><italic>in vitro</italic> -
Activity Cliff/Bioactivity</td><td style="border:none;" align="left">Quantitative/Numerical</td><td style="border:none;" align="left">Three binding affinity data sets testing for small molecule
inhibitors: 8883 compounds for dopamine receptor D2; 3605 compounds
for factor Xa; 1924 compounds for SARS-CoV-2 main protease</td><td style="border:none;" align="left">Collected from sources: ChEMBL compounds with <italic>K</italic><sub>i</sub> values for DRD2 and FXA, Covid Moonshot IC50 compounds
from COVID moonshot</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/MarkusFerdinandDablander/QSAR-activity-cliff-experiments">https://github.com/MarkusFerdinandDablander/QSAR-activity-cliff-experiments</uri></td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref91">91</xref>)</td></tr><tr><td style="border:none;" align="left">AZ ADMET - Clearance (Hepatocytes)</td><td style="border:none;" align="left"><italic>in vitro
- Pharmacokinetic</italic></td><td style="border:none;" align="left">Quantitative/Numerical</td><td style="border:none;" align="left">408 compounds with intrinsic clearance measured in human hepatocytes;
837 compounds with intrinsic clearance measured in rat hepatocytes</td><td style="border:none;" align="left">Internal Experimental data determined at AstraZeneca</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3301372/">https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3301372/</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3301371/">https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3301371/</uri></td><td rowspan="3" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref92">92</xref>)</td></tr><tr><td style="border:none;" align="left">AZ ADMET - Clearance (Microsomal)</td><td style="border:none;" align="left"><italic>in vitro - Pharmacokinetic</italic></td><td style="border:none;" align="left">Quantitative/Numerical</td><td style="border:none;" align="left">1102 compounds with intrinsic clearance measured in human liver
microsomes</td><td style="border:none;" align="left">Internal Experimental data determined at
AstraZeneca</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3301370/">https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3301370/</uri></td></tr><tr><td style="border:none;" align="left">AZ ADMET - PPB</td><td style="border:none;" align="left"><italic>in
vitro - Pharmacokinetic</italic></td><td style="border:none;" align="left">Quantitative/Numerical</td><td style="border:none;" align="left">1614 compounds with percentage bound to plasma by equilibrium
dialysis</td><td style="border:none;" align="left">Internal Experimental data determined at AstraZeneca</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3301365/">https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3301365/</uri></td></tr><tr><td style="border:none;" align="left">Genetox (Ames/IVMN) - US EPA</td><td style="border:none;" align="left"><italic>in vitro</italic> - Genetox</td><td style="border:none;" align="left">Qualitative/Categorical</td><td style="border:none;" align="left">8442 compounds; measures presence of <italic>in vitro</italic> micronucleus (IVMN)</td><td style="border:none;" align="left">Compiled from several public sources
(e.g., TOXNET, COSMOS,
eChemPortal)</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/g-patlewicz/genetox">https://github.com/g-patlewicz/genetox</uri></td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref93">93</xref>)</td></tr><tr><td style="border:none;" align="left">Genetox (Ames/IVMN) - US EPA</td><td style="border:none;" align="left"><italic>in vitro</italic> - Genetox</td><td style="border:none;" align="left">Qualitative/Categorical</td><td style="border:none;" align="left">211
Ames negative, 682 Ames positive and other equivocal and <italic>in
vitro</italic> micronucleus (IVMN) measurements</td><td style="border:none;" align="left">Compiled
from several public sources (e.g., TOXNET, Carcinogenicity
and Genotoxicity eXperience (CGX) database)</td><td style="border:none;" align="left">EURL-ECVAMNegative
Ames - <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.sciencedirect.com/science/article/pii/S1383571820300693?via%3DihubPositive">https://www.sciencedirect.com/science/article/pii/S1383571820300693?via%3DihubPositive</uri> Ames - <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://data.europa.eu/data/datasets/jrc-eurl-ecvam-genotoxicity-carcinogenicity-ames?locale=en">https://data.europa.eu/data/datasets/jrc-eurl-ecvam-genotoxicity-carcinogenicity-ames?locale=en</uri></td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref94">94</xref>,<xref ref-type="bibr" rid="ref95">95</xref>)</td></tr><tr><td style="border:none;" align="left">Ames
- ISSTOX</td><td style="border:none;" align="left"><italic>in vitro</italic> - Genetox</td><td style="border:none;" align="left">Qualitative/Categorical</td><td style="border:none;" align="left">5536 compounds evaluated
for Ames test</td><td style="border:none;" align="left">Compiled from public data sets</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://data.mendeley.com/datasets/ktc6gbfsbh/2">https://data.mendeley.com/datasets/ktc6gbfsbh/2</uri></td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref96">96</xref>)</td></tr><tr><td style="border:none;" align="left">Ames - Benchmark
Data Set for <italic>in silico</italic> Prediction
of Ames Mutagenicity</td><td style="border:none;" align="left"><italic>in vitro</italic> - Mutagenicity</td><td style="border:none;" align="left">Qualitative/Categorical</td><td style="border:none;" align="left">6512 compounds evaluated
for Ames test</td><td style="border:none;" align="left">Compiled from several public sources (e.g.,
CCRIS, VITIK, GeneTox)</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/10.1021/ci900161g">https://pubs.acs.org/doi/10.1021/ci900161g</uri></td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref97">97</xref>)</td></tr><tr><td style="border:none;" align="left">Ames -<italic>in silico</italic> Prediction of Chemical Ames
Mutagenicity</td><td style="border:none;" align="left"><italic>in vitro</italic> - Mutagenicity</td><td style="border:none;" align="left">Qualitative/Categorical</td><td style="border:none;" align="left">8348 compounds evaluated
for Ames test</td><td style="border:none;" align="left">Compiled from several public literature
sources</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/10.1021/ci300400a">https://pubs.acs.org/doi/10.1021/ci300400a</uri></td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref80">80</xref>)</td></tr><tr><td style="border:none;" align="left">Prenatal developmental toxicity</td><td style="border:none;" align="left"><italic>in vivo</italic> - prenatal developmental toxicity</td><td style="border:none;" align="left">Qualitative/Categorical</td><td style="border:none;" align="left">Chemicals with developmental toxicity classifications.</td><td style="border:none;" align="left">Compiled from public repositories and literature sources</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/10.1021/acs.est.2c01040?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.est.2c01040?goto=supporting-info</uri></td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref98">98</xref>)</td></tr></tbody></table></table-wrap></sec><sec id="sec5"><title>Chemical Diversity and Applicability Domain</title><p>The diversity
of the represented chemical space is a key aspect
to consider when choosing a data set for modeling. The extrapolation
of ML models to novel chemistry (not observed during model training)
is difficult to achieve in many cases, due to the size of chemical
space available and the &#x0201c;local&#x0201d; behavior of properties
for highly similar compound. Therefore, the data set for the selected
proxy end point should ideally cover a wide range of chemical structures
on which the model might be used. For this reason, models are often
regularly updated by using assay results from the latest round of
project compounds.</p><p>A local model built with a small data set
lacking structural diversity
will have a narrow applicability domain, i.e., strong performance
only within a particular area of chemical space. Nevertheless, this
might be very useful for a particular project. Local models typically
have poor performance on novel chemical scaffolds; that is, scaffolds
that represent different features from the chemicals used for training
a model.<sup><xref ref-type="bibr" rid="ref99">99</xref>,<xref ref-type="bibr" rid="ref100">100</xref></sup> Generally, most ML models predicting toxicity
(but also bioactivity and other domains) are in practice local models
with limited applicability in the larger chemical space, and extrapolation
can only be expected to a limited extent due to the high dimensionality
of input space and limited data.<sup><xref ref-type="bibr" rid="ref101">101</xref>,<xref ref-type="bibr" rid="ref102">102</xref></sup> In theory,
with large and diverse data sets, ML models ought to have stronger
performance and generalizability. Such models are referred to as global
models, and are typically trained with data from different series
or scaffolds.<sup><xref ref-type="bibr" rid="ref100">100</xref></sup> However, despite their
conceptually greater generalization potential, global models for toxicity
prediction are often infeasible. One reason is data availability or
large experimental variability as data sets are often published with
inadequate metadata to be able to effectively combine measurements
from different laboratories and/or with different equipment. One example
is hERG inhibition, where we often see a massive variability in measured
IC50 values due to how compounds were measured.<sup><xref ref-type="bibr" rid="ref103">103</xref></sup> Despite this variability, many charged hERG blockers share
a basic nitrogen pharmacophore, which classification models&#x02014;commonly
used for this end point&#x02014;can recognize when predicting across
a broad chemical space.<sup><xref ref-type="bibr" rid="ref104">104</xref>,<xref ref-type="bibr" rid="ref105">105</xref></sup> Global models work
only in cases where the data available is sufficiently large and where
the relationship of the end point with chemical structure is sufficiently
simple for a global model to capture predictive trends (in the given
descriptor space employed, see next section). For example global models
may work better in the prediction of logD where large data sets are
available<sup><xref ref-type="bibr" rid="ref106">106</xref>,<xref ref-type="bibr" rid="ref107">107</xref></sup> (compared to models predicting
toxicity outcomes). LogD is in principle largely additive in nature;
that is, the same group on different scaffolds makes similar contributions
(which then enables the model to extrapolate to new cases). Mannhold
et al. observed RMSE = 1 for prediction of logP/logD7.4 for over 95,000
Pfizer compounds and mentioned this result as failure.<sup><xref ref-type="bibr" rid="ref108">108</xref></sup> The time split validation model for logD in
the article reported an RMSE of 0.92 and is still worse than the 0.3
expected experimental error of this property. End points that are
correlated with logD also show some additivity, but for examples where
lipophilicity is not the driver of behavior (e.g., high logD, low
unbound intrinsic clearance), usually ML models tends to predict incorrectly.
A drug&#x02019;s biological activity (potency), in contrast, tends
to be more specific to the overall chemical structure (due to the
dependency of bioactivity on a particular spatial arrangement of features
in a protein binding pocket), and while it has a lipophilicity component,
it is more often influenced by nonadditive effects from group combinations
and shows less additivity across targets. Validating models within
their applicability domain (and establishing this applicability domain
in the first place) is an important topic that is discussed later
in this work.</p></sec><sec id="sec6"><title>Standardizing Chemical Structures</title><p>Preprocessing chemical
data should include a clearly outlined and
reproducible method to standardize molecules and generate ML-ready
representations,<sup><xref ref-type="bibr" rid="ref109">109</xref></sup> considering validity,
stereochemistry, solvents and counterions, tautomerism, and protonation
states. Each of these factors plays a critical role in the molecule&#x02019;s
interaction with biological targets and also for the descriptors that
are generated from the chemical structures as input for ML models.</p><p>Enantiomers can have vastly different pharmacokinetic and pharmacodynamic
properties, impacting efficacy and safety. For example, (R)- and (S)-fluoxetine
show differences in metabolism, receptor binding, and side effects.<sup><xref ref-type="bibr" rid="ref110">110</xref>,<xref ref-type="bibr" rid="ref111">111</xref></sup> At the biological receptor level, enantiomers can also show stereoselectivity; <sc>d</sc>-asparagine tastes sweet whereas <sc>l</sc>-asparagine does
not.<sup><xref ref-type="bibr" rid="ref112">112</xref></sup> At an experimental level, the presence
of multiple enantiomers within a single screening compound sample
reduces the potential concentration of active species and complicates
the identification of hits from the assays. Separating the activity
of various isomers from a racemic mixture is difficult because individual
enantiomers must be tested to find which causes the true biological
activity. At the modeling level, some molecular fingerprint representations
do not encode stereochemistry, which needs to be taken into account
(see next section). Moreover, in public databases, stereochemistry
annotation is usually poor and absolute configuration is often unknown,<sup><xref ref-type="bibr" rid="ref113">113</xref></sup> particularly for natural products. Unfortunately,
in our experience, where stereochemistry information is present, some
of it is often arbitrarily chosen, as enantiomers may get separated
early in preprocessing. One common approach in modeling is to remove
stereochemistry information altogether before generating representations,
and as most drug molecules are usually not chiral, this approach generally
retains information content of the majority of the training data set
(losing information only where stereochemistry has an impact on the
respective end point). Unfortunately, some processing workflows involve
selecting a single, arbitrary enantiomer, which is clearly not optimal.
Another approach in modeling is determining all stereocenters, correcting
invalid stereochemistry, and generating canonical isomeric SMILES
that retain stereochemistry.<sup><xref ref-type="bibr" rid="ref114">114</xref>,<xref ref-type="bibr" rid="ref115">115</xref></sup> In cases where stereochemistry
has an impact on the respective end point, and where sufficient data
is available for the model to learn this relationship, this approach
may sometimes be advantageous.</p><p>Tautomers are structural isomers
that are readily interconvertible
due to the transfer of one or more protons.<sup><xref ref-type="bibr" rid="ref116">116</xref></sup> Tautomerism can explain certain bioactivity, for example, the presence
of a double bond at the &#x003b1;,&#x003b2;-position adjacent to the keto
carbonyl in &#x003b1;-ketoamide derivatives allows the formation of
inactive tautomers that exist in equilibrium, and this leads to reduced
efficacy against Dengue virus proteases.<sup><xref ref-type="bibr" rid="ref117">117</xref></sup> Thus, considering tautomers is important from a modeling perspective,
as they vary in physicochemical properties such as logP, hydrophobicity,
and solubility. Many attempts to predict low-energy tautomers have
been unsatisfactory.<sup><xref ref-type="bibr" rid="ref118">118</xref></sup> The standardized
molecule from tautomer enumeration will typically not represent the
&#x0201c;correct&#x0201d; form in the solution, and exhaustive searches
can yield nonphysical forms that cannot exist in the solution. The
best approach in a standardization pipeline, in practice, can often
be to be consistent throughout because often being <italic>consistent</italic> is more important than being <italic>correct</italic> for subsequent
model generation steps. Significant efforts have been made in cheminformatics
to study tautomerism in large data sets, in particular, on selecting
the most consistent tautomer and capturing their molecular descriptors.<sup><xref ref-type="bibr" rid="ref119">119</xref>&#x02212;<xref ref-type="bibr" rid="ref121">121</xref></sup> Tools like RDKit and others provide methods to enumerate tautomers;
however, they often handle tautomerism differently, and not all types
of tautomerism are implemented in every software package, leading
generally to different results. For example, PubChem standardizer
generates a canonical tautomer during compound standardization, but
ChEMBL does not.<sup><xref ref-type="bibr" rid="ref114">114</xref>,<xref ref-type="bibr" rid="ref115">115</xref></sup> Overall, tautomers are often
not trivial to handle when preprocessing structures for predictive
modeling.</p><p>The protonation state of a molecule affects, among
other biological
properties, binding to transporters and enzymes, permeability across
biological membranes, and pharmacokinetic and pharmacodynamic properties.<sup><xref ref-type="bibr" rid="ref122">122</xref></sup> Due to effects on distribution of a molecule,
protonation state may be even more important for toxicity prediction
than other end points. For example, drugs such as proton pump inhibitors,
with a p<italic>K</italic><sub>a</sub> between 3.8 and 4.9, selectively
accumulate in the acidic secretory canaliculi of parietal cells and
are converted into active forms only under specific protonation conditions.<sup><xref ref-type="bibr" rid="ref123">123</xref></sup> When predicting pharmacokinetic parameters,
a relevant pH must be considered for protonating compounds during
compound standardization (such as the pH of blood, or the pH in the
GI tract in case of absorption, etc.).<sup><xref ref-type="bibr" rid="ref124">124</xref>,<xref ref-type="bibr" rid="ref125">125</xref></sup> The impact
of protonation on featurization varies according to the descriptor
used. For example, MACCS keys (Molecular ACCess System) have a key
(key no. 49) that indicates the presence or absence of charge, while
Morgan fingerprints are invariant to protonation states. Descriptors
such as the Hammett electronic parameter (&#x003c3;), logD, and the
Taft constant are also impacted by the protonation state of the molecule.
Hence, protonation states of molecules are important, but challenging
aspects of preparing small molecules for modeling.<sup><xref ref-type="bibr" rid="ref126">126</xref></sup></p></sec><sec id="sec7"><title>Checking End Point Data for Inconsistencies or Ambiguities</title><p>The next stage of preparing data for modeling involves assessing
the biological data (end point space). Often more so than traditional
ML data sets (for example, from the image or speech domain), biological
data sets are conditional on experimental factors such as compound
concentration, cell type, time points, and <italic>in vivo</italic> pharmacokinetics.<sup><xref ref-type="bibr" rid="ref127">127</xref></sup> Therefore, data
from such end points require careful curation to remove inconsistencies
or ambiguities in the measured end points and minimize the risk of
introducing biases into ML models. For example, the Kendall Tau test
can measure the ordinal association between two measured quantities,
helping to identify inconsistencies in ranked data.<sup><xref ref-type="bibr" rid="ref128">128</xref></sup> For example, Landrum et al. demonstrated that in nearly
65% of instances, multiple IC50 assays for the same compound-target
pair showed discrepancies of over 3-fold, with 27% of cases differing
by more than 10-fold, and a Kendall&#x02019;s Tau correlation of 0.51
between multiple assays measuring the same compound against the same
target.<sup><xref ref-type="bibr" rid="ref129">129</xref></sup> Outlier detection methods, such
as <italic>Z</italic>-scores or the Tukey IQR method, can highlight
anomalies that may indicate errors.<sup><xref ref-type="bibr" rid="ref130">130</xref></sup> For
example, Kalliokoski et. al recommends if discrepancies are observed
in &#x00394;pIC50 are greater than 2.5, there is a high probability
they may contain errors and those inconsistent experimental records
can be removed before modeling.<sup><xref ref-type="bibr" rid="ref131">131</xref></sup> For
example, models designed to predict specific toxicities, such as mitochondrial
membrane depolarization or DNA damage from <italic>in vitro</italic> assays, often inadvertently capture and predict broader indicators
of overall cell viability instead.<sup><xref ref-type="bibr" rid="ref132">132</xref></sup> Such
models may have been trained without confirmatory assay data&#x02014;which
combines results from a screening assay with a cytotoxicity counter
screen to exclude highly cytotoxic compounds.<sup><xref ref-type="bibr" rid="ref133">133</xref>,<xref ref-type="bibr" rid="ref134">134</xref></sup> Some modeling methods, such as Huber regression,<sup><xref ref-type="bibr" rid="ref135">135</xref>,<xref ref-type="bibr" rid="ref136">136</xref></sup> are less sensitive to outliers, and given the noise in biological
data, these can be preferable (an analogy being that median-averaging
is less sensitive to outliers than mean-averaging). Other models,
such as Probabilistic Neural Networks,<sup><xref ref-type="bibr" rid="ref137">137</xref></sup> can take large variations into account while training, and can generate
predictions along with confidence intervals or prediction ranges that
reflect the uncertainty or variability in the data. Overall, curating
the biological end points to avoid biases or inaccuracies that could
compromise model performance is essential for ensuring that models
produce meaningful and actionable predictions.</p></sec><sec id="sec8"><title>The Conditional Nature of Data and Categorization</title><p>A
given compound is not simply &#x0201c;toxic&#x0201d; or &#x0201c;non-toxic&#x0201d;,
as famously quoted by Paracelsus in 1538, &#x0201c;What is there that
is not poison? All things are poison, and nothing is without poison.
Solely the dose determines that a thing is not a poison&#x0201d;.<sup><xref ref-type="bibr" rid="ref138">138</xref></sup> The effective dose, Cmax (maximum concentration
in the blood), and concentrations in relevant organs can vary by orders
of magnitude depending on a molecule&#x02019;s efficacy and its ADME
properties.<sup><xref ref-type="bibr" rid="ref139">139</xref></sup> Therefore, any measurement
of toxicity&#x02014;whether through a simplified binary classification
or a detailed dose&#x02013;response curve&#x02014;is useful only when
it reflects clinically relevant doses. Given that toxicity (as other
effects) can vary significantly depending on the experimental conditions,
such as the dosage, duration of exposure, and the biological model
used (organism, sex, target tissue, etc.), this &#x02018;conditionality&#x02019;
of biological data often represents a problem when training predictive
models; it is rarely practical to capture experimental conditions
in the model itself, given the sparsity of data across experiment
variables.</p><p>Converting toxicity data sets into simplistic binary
prediction
problems can hence simplify ML strategies but serve as poor representations
of biological realities. For example, selective estrogen receptor
modulators stimulate estrogen receptors at very low (picomolar) concentrations,
but at much higher (micromolar) concentrations, they impact microtubules,
leading to a distinct activity profile.<sup><xref ref-type="bibr" rid="ref140">140</xref></sup> Binarization of continuous values leads to loss of information,
especially for compounds that lie close to the threshold for binarization.<sup><xref ref-type="bibr" rid="ref127">127</xref></sup> Mervin et al. presented a compelling case for
employing particular modeling methods to better use binary labels
based on readouts that were originally continuous in nature, given
reasonable constraints upon modeling objective and data sets.<sup><xref ref-type="bibr" rid="ref141">141</xref></sup> The presence of activity cliffs (where small
changes in chemical structure lead to major changes in bioactivity)
in data sets makes the distribution of labels highly heteroscedastic
(uneven over the range of values measured). Given the unequal distribution
of measurement error across the range of activity values, the authors
argue that regression is also not favorable for <italic>in silico</italic> target prediction and suggest using Probabilistic Random Forest
models. These models were shown to improve bioactivity predictions
close to the classification threshold by taking into account the experimental
uncertainty. To avoid choosing a single particular threshold for binary
classes, one could incorporate multiclass categories such as &#x0201c;highly
toxic&#x0201d;, &#x0201c;toxic&#x0201d;, &#x0201c;nontoxic&#x0201d;, and
&#x0201c;ambiguous&#x0201d;. Multiclass categorization can use dose,
exposure, or margins to set thresholds for classification calls. For
example, models using <italic>in vivo</italic> toxicity data might
set a threshold of total <italic>C</italic><sub>max</sub> value less
than 10 &#x003bc;M but greater than 1 &#x003bc;M, which helps to set the
context around the category. Representing intermediate activity or
ambiguity can be particularly valuable in capturing the complexities
of biological data and preventing the misclassification of borderline
cases.</p><p>To summarize Pillar 1, the chosen data set must be relevant
to
the toxicity one wants to predict, represent chemical space sufficiently
diverse and relevant for the intended use case, be high in information
content, provide mechanistic insights (ideally), and be appropriately
preprocessed to remove inconsistencies. Well-curated data (with a
standardized framework for organizing and categorizing information
where possible) reliably train models only when the encoded features
capture the most relevant chemical and biological properties. Together,
these elements enable the development of accurate, reliable, and generalizable
predictive models that are more likely to be applicable in a real-world
drug discovery context.</p></sec><sec id="sec9"><title>Pillar 2: Encoding Chemical Structures into Information-Rich
and/or Meaningful Features</title><p>ML models for molecular toxicity
prediction that use chemical structures
as their input are based on the fact that a molecule&#x02019;s properties
depend on its chemical structure<sup><xref ref-type="bibr" rid="ref142">142</xref>,<xref ref-type="bibr" rid="ref143">143</xref></sup> and that,
generally, molecules with &#x02018;similar&#x02019; chemical structures
(which can be defined in a wide variety of ways) tend to exhibit similar
properties. In classical ML applied to these tasks, quantitative structure&#x02013;activity&#x02013;property
relationship (QSAR/QSPR) models are trained on predefined feature
spaces representing chemical structures (<xref rid="tbl4" ref-type="other">Table <xref rid="tbl4" ref-type="other">3</xref></xref>) and used to predict toxicity labels. As
such, these models can only learn relationships captured by the feature
representation chosen by the ML practitioner; the choice of representation
strongly influences the ability to predict particular molecular toxicities
(<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref> and described
in more detail in subsequent sections).<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref144">144</xref></sup> Descriptors
derived from a molecule&#x02019;s structure are used to represent its
chemical and physical properties in this particular feature space,
and hence model performance (and interpretability) is intrinsically
linked to feature choice. For example, physicochemical properties
of a structure are related to ADME end points such as permeability
or solubility; omitting features such as charge or molecular weight
will generally decrease model performance for those end points. Alternatively,
features can be learned directly from chemical structures, such as
structural keys, chemical fingerprints, etc., but each featurization
method is based on inherent assumptions that might not apply in the
universal chemical space, encompassing approximately 10<sup>60</sup> compounds.<sup><xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref145">145</xref></sup> Further, structure&#x02013;property
dependencies are often not smoothly related: exceptions to the general
structure&#x02013;property rule are called activity cliffs&#x02014;structurally
similar compounds that exhibit significantly different properties.<sup><xref ref-type="bibr" rid="ref89">89</xref></sup> Activity cliffs test the limits of structure-only
prediction and require experiment-based inputs for successful prediction,
whether biological or physicochemical assays differentiate structurally
similar compounds. Overall, the choice of features to represent a
molecule is nontrivial.</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>An example selection process for chemical representations.
Chemical
representations vary in their ability to capture the complexity of
the molecular structures. When building models for specific categories,
like small molecules or natural products, it is important to choose
a suitable representation, based on factors such as predictive performance.
For instance, circular fingerprints often work well for small molecules,
while pharmacophore-based fingerprints may be better suited for natural
products. However, studies show that no single representation consistently
outperforms others across all QSAR data sets.<sup><xref ref-type="bibr" rid="ref151">151</xref>,<xref ref-type="bibr" rid="ref152">152</xref></sup></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_0003" id="gr3" position="float"/></fig><table-wrap id="tbl4" position="float"><label>Table 3</label><caption><title>Most Commonly Used Representations
in ML Models, Such as Those Used to Predict Compound Toxicity</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">Representation</th><th style="border:none;" align="center">Description</th><th style="border:none;" align="center">Examples</th><th style="border:none;" align="center">Advantages</th><th style="border:none;" align="center">Limitations</th><th style="border:none;" align="center">Implications for ML Model Performance</th></tr></thead><tbody><tr><td style="border:none;" align="left">Structural keys</td><td style="border:none;" align="left">Bit
format indicating the presence/absence of specific substructures;
was intended for cataloging compounds and substructure filtering</td><td style="border:none;" align="left">MACCS keys<sup><xref ref-type="bibr" rid="ref155">155</xref></sup></td><td style="border:none;" align="left">High
interpretability; often direct correspondence to molecular
substructures</td><td style="border:none;" align="left">Limited chemical space coverage; no 3D
information present;
missing information on some substructures</td><td style="border:none;" align="left">Limited coverage
of chemical space, because it was not originally
intended to fully represent structure (but empirically often performing
rather well)</td></tr><tr><td style="border:none;" align="left">Chemical 2D Fingerprints</td><td style="border:none;" align="left">Encodes chemical structures into a fixed-size bit string, capturing
molecular connectivity</td><td style="border:none;" align="left">Extended Connectivity Fingerprints
(ECFPs)<sup><xref ref-type="bibr" rid="ref161">161</xref></sup></td><td style="border:none;" align="left">Compresses feature
space; captures broader and more specific
chemical space than fixed substructure keys</td><td style="border:none;" align="left">No 3D information
present; algorithms are predefined to generate
fingerprints from connectivity</td><td style="border:none;" align="left">Balances coverage and
compactness. It is often possible to
obtain structural contributions to model predictions. Often favored
in benchmarks, partially due to data set biases (especially analogue
bias)</td></tr><tr><td style="border:none;" align="left">2D Descriptors</td><td style="border:none;" align="left">Properties
calculated from simple two-dimensional (2D) chemical
structures</td><td style="border:none;" align="left">Hydrophobicity, E-state indices, polar surface
area, molecular
weight and other physicochemical properties<sup><xref ref-type="bibr" rid="ref143">143</xref></sup></td><td style="border:none;" align="left">Provides insight into molecular properties; interpretable
because
related to measurables</td><td style="border:none;" align="left">Does not capture spatially dependent
information of molecular
structure</td><td style="border:none;" align="left">Enhances model interpretability and predictive
power (for example,
logD is often predictive of complex toxicity)</td></tr><tr><td style="border:none;" align="left">3D Descriptors</td><td style="border:none;" align="left">Properties calculated from the three-dimensional
structure
of molecules, considering spatial arrangements and capturing stereochemistry</td><td style="border:none;" align="left">Solvent accessible surface area with positive partial charge
in the structure,<sup><xref ref-type="bibr" rid="ref166">166</xref></sup> Weighted Holistic
Invariant Molecular Descriptors (WHIMs) and Grid-Independent Descriptors
(GRINDs)</td><td style="border:none;" align="left">Captures detailed structural information; potential
to encode
other 3D properties such as surface area</td><td style="border:none;" align="left">Computationally
intensive due to conformational sampling and
complex encodings; usually, bioactive conformations are unknown</td><td style="border:none;" align="left">Improves model precision by leveraging detailed 3D structural
information, essential for tasks requiring stereochemical details
(but has conformational sampling trade-off)</td></tr><tr><td style="border:none;" align="left">2D graph-based representations<sup><xref ref-type="bibr" rid="ref153">153</xref></sup></td><td style="border:none;" align="left">Encode the two-dimensional connectivity of molecules</td><td style="border:none;" align="left">Message-Passing Neural Networks (MPNNs), graph transformers</td><td style="border:none;" align="left">Alternative to 2-dimensional fingerprints and leverages deep
learning architectures</td><td style="border:none;" align="left">Computationally efficient compared
to 3D models, but lack spatial
information</td><td style="border:none;" align="left">Useful for predicting molecular properties
related to connectivity</td></tr><tr><td style="border:none;" align="left">3D graph-based representations<sup><xref ref-type="bibr" rid="ref153">153</xref></sup></td><td style="border:none;" align="left">Encode the three-dimensional
structure of molecules, considering
spatial arrangements</td><td style="border:none;" align="left">Message-Passing Neural Networks
(MPNNs), graph transformers</td><td style="border:none;" align="left">Captures stereochemistry
and has potential to encode other
properties such as surface area</td><td style="border:none;" align="left">Computationally intensive
and increased memory requirements</td><td style="border:none;" align="left">Potential to improve
model precision by leveraging connectivity
from structural information</td></tr><tr><td style="border:none;" align="left">Descriptors from
experiments</td><td style="border:none;" align="left">Experimental data that capture changes in
a biological system
upon perturbation with chemicals</td><td style="border:none;" align="left">Cell Painting, Transcriptomics,
Proteomics, etc.</td><td style="border:none;" align="left">Captures biological <italic>response</italic> space that may
not be captured by structure-derived representations</td><td style="border:none;" align="left">Requires experiments with actual synthesized compounds, processing,
quality control, etc. to prepare feature space</td><td style="border:none;" align="left">Potential
to improve the applicability domain of models and
identify activity cliffs, as well as interpretability in cases where
features are found to be predictive for end point of interest</td></tr><tr><td style="border:none;" align="left">Learned/pretrained representations</td><td style="border:none;" align="left">Automatically extract features from input data (whether chemical
structures or experimental data) using pretrained encoders (supervised/semisupervised)
and convert them to a latent space</td><td style="border:none;" align="left">ChemProp, CLOOME</td><td style="border:none;" align="left">Captures complex patterns and relationships; adaptable to various
data types; improves with more data</td><td style="border:none;" align="left">May require large
data sets for training and generation of
features that are suitable for future use cases; can be less interpretable
than traditional descriptors</td><td style="border:none;" align="left">Enhances model accuracy
and generalizability; potential to
integrate diverse data sources for a comprehensive understanding of
molecular behavior</td></tr></tbody></table></table-wrap><p>Besides chemical structure-based descriptors, phenotypic
data are
sometimes available to aid predictions. These omics descriptors can
be collected from cells treated with each chemical, including readouts
like the Cell Painting assay, transcriptomics, proteomics and metabolomics.<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref146">146</xref>&#x02212;<xref ref-type="bibr" rid="ref148">148</xref></sup> These are relatively unbiased or hypothesis-free
descriptors, and unlike computed structural features, they report
on the actual interaction of the chemical with a biological system.
The experimental costs for phenotypic assays can be high, but descriptors
from them have been shown to improve the chemical applicability domain
of models to predict toxicity.<sup><xref ref-type="bibr" rid="ref146">146</xref>,<xref ref-type="bibr" rid="ref149">149</xref>,<xref ref-type="bibr" rid="ref150">150</xref></sup> Nevertheless, representations from phenotypic data sets might not
always be relevant to predict a specific biological end point; that
is, they have limitations in their biological applicability domain
(i.e., mode of action coverage). The signal present in phenotypic
data needs to be established and validated for each end point of interest,
in many cases empirically. Whereas Pillar 1 covered compound standardization,
the focus of this Pillar is on representations directly derived from
chemical structures, given that this representation does not require
experimentally determining compound effects, and it is hence universally
applicable.</p></sec><sec id="sec10"><title>Molecular Keys and Fingerprints</title><p>One common representation
of molecules using only their chemical
structure as input is molecular keys (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>a, top).<sup><xref ref-type="bibr" rid="ref153">153</xref></sup> Structural
keys such as Molecular ACCess System (MACCS) keys are a straightforward
representation, originally developed for cataloging compounds, but
also performing surprisingly well in predictive models.<sup><xref ref-type="bibr" rid="ref154">154</xref></sup> These keys encode molecular structures into
a 166-bit format (publicly available) or a 960-bit format (in the
commercial implementation) by recording the presence or absence of
specific predefined substructures or chemical patterns within a molecule,
such as the presence of ring systems, particular functional groups,
etc.<sup><xref ref-type="bibr" rid="ref155">155</xref></sup> Because each bit in structural
keys corresponds to a predefined feature, often a molecular substructure,
it is easy to interpret what features are vital for the model&#x02019;s
predictions. Thus, encoding molecules using structural keys facilitates
interpretation due to the direct correspondence between specific values
in the fingerprint and particular predefined features.<sup><xref ref-type="bibr" rid="ref156">156</xref>,<xref ref-type="bibr" rid="ref157">157</xref></sup> However, these predefined features limit the chemical space represented,
because structural keys were not intended to capture all relevant
aspects of the chemical structure.</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>(a) Encoding chemical structures using
Molecular ACCess System
(MACCS) keys, top, and Extended Connectivity Fingerprints (ECFP),
bottom. MACCS keys, originally used for cataloging, directly map specific
predefined features with bits representing distinct rules, such as
the presence of atoms, bonds, etc. ECFP encodes a broader range of
substructures. (b) Learned representations encapsulate the learned
embeddings of atoms within a molecule aggregated to form a comprehensive
molecular embedding. Typically, they focus on molecular topology and
connectivity with nodes as atoms and edges as bonds with an iterative
message-passing process.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_0004" id="gr4" position="float"/></fig><p>An alternative to structural keys are chemical
fingerprints, such
as extended connectivity fingerprints (ECFPs),<sup><xref ref-type="bibr" rid="ref158">158</xref></sup> which represent the chemical structure of a molecule as
a count-based vector or fixed-length binary vector (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>a, bottom). Count-based fingerprints
in principle benefit by counting the presence of multiple substructures,
which can be especially useful in the case of, for example, repeat
units (peptide backbones, terpenes, sugar attachments, etc.). Although
count-based fingerprints capture more information, not all ML methods
can leverage them as they are always very large (&#x0223c;2<sup>32</sup>-1).<sup><xref ref-type="bibr" rid="ref159">159</xref></sup> Thus, counts are usually converted
into binary bits, and therefore some details about the molecule&#x02019;s
specific structural or chemical features are lost. This loss of information
does not necessarily mean lower predictive power as the signal and
predictive ability will be retained if the relevant information is
retained. As for interpretability, it is possible to store a correspondence
table between bits and chemical substructures to allow the unambiguous
interpretation of the bits in a chemical fingerprint.<sup><xref ref-type="bibr" rid="ref160">160</xref></sup> Due to the vast number of possible substructures,
most commonly employed chemical fingerprints use a folding and hashing
algorithm to encode the chemical structure into a fixed-size bit string.<sup><xref ref-type="bibr" rid="ref161">161</xref></sup> Here, the same bit could correspond to multiple
substructures, known as a hash collision (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>a). The transformation is usually one way
that introduces ambiguity, as the relationship between the original
substructures and the resulting bits is not easily discernible. Overall,
molecular fingerprints have been successful in toxicity prediction
tasks and capture certain aspects of the chemical structures being
analyzed; they are able to encode wider aspects of the chemical structure
than predefined keys.</p></sec><sec id="sec11"><title>2D Descriptors</title><p>2D continuous descriptors are numerical
properties calculated from
a molecule&#x02019;s 2D graph representation, typically derived from
the connection table, molecular topology or chemical graphs, such
as hydrophobicity, topological polar surface area<sup><xref ref-type="bibr" rid="ref162">162</xref></sup> and E-state indices.<sup><xref ref-type="bibr" rid="ref163">163</xref></sup> This
level of information includes details about how atoms are connected
within the molecule but does not account for the actual spatial arrangement
of atoms in three-dimensional space. Physicochemical descriptors are
often highly relevant to the effects of drugs within biological systems
and they are readily interpretable, since they correspond to measurable
properties of a molecule.<sup><xref ref-type="bibr" rid="ref164">164</xref></sup> Further, 2D
descriptors are more computationally efficient to calculate, given
that they are derived solely from molecular connectivity matrices.
In summary, using 2D descriptors for molecular representation can
add information to chemical structural information, such as chemical
fingerprints, and enhance predictive accuracy.<sup><xref ref-type="bibr" rid="ref165">165</xref></sup> The quality of data, but then also problem-relevant and
consistent preprocessing, is a key factor controlling model quality
in cheminformatics models.</p></sec><sec id="sec12"><title>3D Descriptors</title><p>3D descriptors are calculated using
the three-dimensional structure
of a molecule, taking into account the spatial and geometric properties,
including bond angles, distances, and overall geometry (<xref rid="tbl5" ref-type="other">Table <xref rid="tbl5" ref-type="other">4</xref></xref>). 3D descriptors can distinguish
different three-dimensional conformations, but require accurate 3D
structures, which are not always available or reliable, and the generation
thereof leads to &#x02018;combinatorial explosion&#x02019; (a large
number of possible conformations). 3D information is needed in some
cases such as for docking, where a spatial fit of the ligand into
the target is performed.<sup><xref ref-type="bibr" rid="ref167">167</xref></sup> Studies have
reported 3D descriptors to be more effective than 2D descriptors for
predicting biological targets of ligands with low structural similarity,
given the ability of 3D descriptors to capture pharmacophoric alignments.<sup><xref ref-type="bibr" rid="ref168">168</xref></sup> Overall, 3D descriptors can capture critical
stereochemical and conformational information that can enhance predictions
involving complex interactions and stereochemistry; however, they
intrinsically need more computing resources to calculate, in particular,
due to conformational sampling. When it comes to the information content
that they contain, the signal-to-noise ratio needs to be considered
(which does not always increase with descriptor complexity). Moreover,
benchmark data sets often contain analogues that can already be well
predicted by 2D descriptors, thereby intrinsically favoring 2D descriptors
(and disfavoring 3D ones that are computationally expensive).</p><table-wrap id="tbl5" position="float"><label>Table 4</label><caption><title>Commonly Used 3D Descriptors</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">3D Descriptor</th><th style="border:none;" align="center">Description</th><th style="border:none;" align="center">Source</th></tr></thead><tbody><tr><td style="border:none;" align="left">MoRSE Descriptors</td><td style="border:none;" align="left">3D
molecular representations of structure based on electron
diffraction descriptors</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref173">173</xref>)</td></tr><tr><td style="border:none;" align="left">Gravitational Index Descriptors</td><td style="border:none;" align="left">Based on analogies to gravitational physics, it measures the
distribution of atomic mass within a molecule</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref174">174</xref>)</td></tr><tr><td style="border:none;" align="left">3D Autocorrelation
Descriptors (3DAc)</td><td style="border:none;" align="left">The relative position of atoms (or
atom properties) based on
the separation between atom pairs in Euclidean distance</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref175">175</xref>)</td></tr><tr><td style="border:none;" align="left">RDF (Radial
Distribution Function)</td><td style="border:none;" align="left">Provides information about the
probability distribution of
interatomic distances within a molecule</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref176">176</xref>)</td></tr><tr><td style="border:none;" align="left">WHIM Descriptors</td><td style="border:none;" align="left">Weighted Holistic Invariant Molecular descriptors are derived
from the atomic coordinates of a molecule and capture features like
size, shape, symmetry, and atom distribution</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref177">177</xref>)</td></tr><tr><td style="border:none;" align="left">Flexophore/Pharmacophores</td><td style="border:none;" align="left">Uses a reduced graph with atom types and encodes molecular
flexibility through node distance histograms across diverse conformers</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref178">178</xref>)</td></tr></tbody></table></table-wrap><p>Among the challenges when incorporating 3D descriptors
into ML
models, the most common is the conformation-dependent nature of most
3D descriptors; this dependence results in substantial variations
of the descriptors based on the conformer selected for descriptor
calculation. In principle, an ML model could leverage a set of descriptors
derived from an ensemble of conformations to capture the inherent
flexibility of molecules. However, typical data sets do not map activity
to different conformations and 3D representations are mostly incompatible
with most contemporary ML algorithms, which are designed to map a
single instance to a single label. Multi-Instance Learning (MIL) offers
a solution by representing each ligand as a bag containing multiple
instances (conformers), and the task is to predict a property or activity
associated with the entire bag rather than individual instances. MIL
models are still in early stages of development and their application
in toxicity prediction is yet to be validated.<sup><xref ref-type="bibr" rid="ref169">169</xref>,<xref ref-type="bibr" rid="ref170">170</xref></sup></p><p>Studies combining 2D and 3D descriptors sometimes yield better
performance due to their complementary information.<sup><xref ref-type="bibr" rid="ref171">171</xref></sup> In theory, 3D information such as stereochemistry is responsible
for the selectivity in binding affinity of molecules to many protein
targets.<sup><xref ref-type="bibr" rid="ref111">111</xref></sup> In practice, for certain bioactivity
prediction tasks, 2D descriptors might outperform 3D due to a more
favorable signal-to-noise ratio in descriptor space (e.g., fewer irrelevant
conformations), and/or possibly the analogue bias in benchmark data
sets.<sup><xref ref-type="bibr" rid="ref152">152</xref>,<xref ref-type="bibr" rid="ref171">171</xref>,<xref ref-type="bibr" rid="ref172">172</xref></sup> Thus, the
choice between 2D and 3D descriptors is specific to the problem statement
and data set&#x02019;s chemical space and hence needs situation-specific
exploration.</p></sec><sec id="sec13"><title>Graph-Based Representations</title><p>Graph Neural Network (GNN)
architectures for molecular toxicity
and activity prediction have emerged as an often more expressive alternative
than using binary fingerprints with classical ML models (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>b). GNNs can directly
learn molecular representations from chemical structures on the fly
as the model is trained, which eliminates the need for manual feature
engineering and enables customizing representations to specific data
sets or tasks. These representations are learned through iterative
rounds of so-called &#x02018;message passing&#x02019; (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>b). Briefly, molecules are
initially featurized as graphs, with atoms as nodes and bonds as edges,
and atoms and edges are initially described by simple physicochemical
properties. While 2D GNNs use only simple atom and bond properties
to provide node and edge features, 3D GNNs (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>) additionally incorporate 3D coordinates,
providing spatial information for atom and edge features, and may
leverage relative coordinates in their message passing rules to capture
the molecule&#x02019;s geometric configuration. Then, atom and bond
representations are made progressively more abstract by transforming
and combining the descriptors of those atoms and bonds that are neighbors
in the graph. In this way, a message passing on the graph makes atoms
and bonds incorporate information about their chemical environment.
Finally, the representations of atoms and bonds can be combined to
obtain representations for the whole molecule.<sup><xref ref-type="bibr" rid="ref179">179</xref>,<xref ref-type="bibr" rid="ref180">180</xref></sup> Additional chemical- and surface-related information can also be
provided as initial input features to GNNs. Alternatively, transformer
architectures have also emerged as a powerful approach for graph-based
modeling, with a flexible mechanism to capture long-range dependencies
in molecular structures.<sup><xref ref-type="bibr" rid="ref181">181</xref>,<xref ref-type="bibr" rid="ref182">182</xref></sup></p><fig id="fig5" position="float"><label>Figure 5</label><caption><p>3D Graph Neural Network
(GNN) architectures applied to molecular
representations. 3D geometric GNN representations incorporate spatial
relationships and geometric transformations to capture three-dimensional
information, such as bond angles.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_0005" id="gr5" position="float"/></fig><p>The use of message passing in GNNs ensures that
all operations
performed by the model are independent of any particular ordering
of the constituent nodes, leading to model reasoning that is purely
based on the aggregated information from a node&#x02019;s local neighborhood.
GNNs can serve as an encoder that processes a molecular graph, with
nodes representing atoms and edges representing bonds (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>), to generate a compact vector
capturing the chemical structural information in the context of the
pretraining task.<sup><xref ref-type="bibr" rid="ref183">183</xref></sup> The GNN, pretrained
on large chemical spaces, refines these representations to better
capture features influencing target outcomes like compound toxicity.
Pretraining can be supervised, using labeled data sets to predict
molecular properties, or semisupervised, leveraging labeled and unlabeled
data to refine latent space representations. Message-passing neural
networks (e.g., Chemprop) have been proposed as encoders to generate
latent space representations of molecules<sup><xref ref-type="bibr" rid="ref180">180</xref></sup> and used to predict various properties including toxicity (discussed
later as representation learning).<sup><xref ref-type="bibr" rid="ref184">184</xref>,<xref ref-type="bibr" rid="ref185">185</xref></sup> An emerging
class of geometric GNN architectures for molecular toxicity prediction
represents molecular graphs in three-dimensional space and additionally
incorporates inductive biases that make them invariant to global rigid
transformations of molecules&#x02014;rotations and translations of
the 3D coordinates.<sup><xref ref-type="bibr" rid="ref186">186</xref>&#x02212;<xref ref-type="bibr" rid="ref188">188</xref></sup></p><p>Gao et al. showed that models with
access to three-dimensional
structural information on the protein&#x02013;ligand complex outperform
approaches that use 2D fingerprint representations for the prediction
of protein&#x02013;ligand binding affinity.<sup><xref ref-type="bibr" rid="ref152">152</xref></sup> Broadly, for those situations where the binding pose is relevant
for an effect, using three-dimensional binding pose-dependent properties
may provide a more comprehensive representation of the compound (albeit
with the need to handle conformational information). However, protein
flexibility is a significant factor in scenarios where binding pockets
are less defined or allosteric binding occurs; the conformational
changes in the protein induced by ligand binding can significantly
affect the binding mode and affinity. For example, enzymes like cytochrome
P450s (CYPs) as well as transporters exhibit a high degree of flexibility,
further complicating the accurate prediction of ligand&#x02013;protein
interactions.<sup><xref ref-type="bibr" rid="ref189">189</xref></sup> 3D ligand information
is also being used in protein&#x02013;ligand cofolding, which then
predicts binding, and this is rapidly evolving with recent advances
in AlphaFold<sup><xref ref-type="bibr" rid="ref190">190</xref></sup> and RosettaFold.<sup><xref ref-type="bibr" rid="ref191">191</xref></sup></p><p>In reality, three-dimensional molecules
have several possible conformers,
with proteins and ligands existing in multiple conformations and ensembles,
and their interactions can shift these conformational equilibria.
As such, a single three-dimensional graph embedding may fail to consider
molecules&#x02019; dynamic behavior and flexibility, which can adopt
various conformations in different environments, such as rotational
freedom around single bonds. For example, the conformers of acetylcholine,
such as the anti and gauche forms, demonstrate variable affinity to
nicotinic and muscarinic receptor subtypes.<sup><xref ref-type="bibr" rid="ref192">192</xref></sup> In contrast, only the anti form is preferred for catalysis by acetylcholinesterase,
an enzyme critical in the breakdown of acetylcholine and, thus, in
regulating neurotransmission.<sup><xref ref-type="bibr" rid="ref193">193</xref>,<xref ref-type="bibr" rid="ref194">194</xref></sup> However, flexibility
is not always critical to prediction for ML models&#x02014;in majority
of data, if an inhibitor fits the pharmacophore and effectively binds
to inhibit the target, it may be sufficient to train an ML model without
considering the molecule&#x02019;s flexibility. Where importance of
molecules&#x02019; dynamic behavior and flexibility is needed based
on the specific context and the nature of the interaction being studied,
one could use higher dimensional descriptors (multidimensional QSAR<sup><xref ref-type="bibr" rid="ref195">195</xref>,<xref ref-type="bibr" rid="ref196">196</xref></sup>) or use multiple instance learning (MIL), learning meaningful molecular
representations relevant to prediction tasks from multiple ligand
conformers of three-dimensional chemical structures.<sup><xref ref-type="bibr" rid="ref197">197</xref>,<xref ref-type="bibr" rid="ref198">198</xref></sup> By leveraging the diverse conformations that a molecule can adopt,
MIL enhances the accuracy of toxicity predictions.<sup><xref ref-type="bibr" rid="ref199">199</xref></sup></p><p>Whether to use 2D or 3D geometric GNNs for molecular
toxicity prediction
is a question of data availability and the expressivity of representations.
For tasks where the conformational state of a molecule is known to
be important, such as protein&#x02013;ligand interactions, 3D GNNs
that incorporate protein&#x02013;ligand poses from docking (providing
information about the ligand&#x02019;s approximate binding mode) have
been shown to outperform models based on 2D fingerprints that also
encode protein&#x02013;ligand extended connectivity, underscoring the
critical role of 3D information in accurately predicting protein&#x02013;ligand
binding affinity.<sup><xref ref-type="bibr" rid="ref200">200</xref>&#x02212;<xref ref-type="bibr" rid="ref202">202</xref></sup></p><p>The advantage of 3D information compared
to compressed representations
has not been completely established in practice for the prediction
of toxicity end points; Cremer et al. showed that 2D graph-based models
produce comparable results to a 3D equivariant graph transformer model
(which leverages geometry of conformers) and 3D geometry-based graph
neural networks on ToxCast and Tox21 assays.<sup><xref ref-type="bibr" rid="ref203">203</xref></sup> Still, the authors largely attribute the comparable results to the
limited data set size in toxicity data sets; also toxicity can be
driven by individual chemical substructures (e.g., reactive chemical
groups, electrophilicity, etc.), where 2D descriptors capture relevant
information rather well. The relative paucity of 3D protein structure
data means that overfitting is common in more expressive geometric
GNNs, leading to most published work in molecular toxicity prediction
relying on standard 2D GNNs.<sup><xref ref-type="bibr" rid="ref204">204</xref></sup></p></sec><sec id="sec14"><title>Representation Learning</title><p>Representations can be learned
on a given data set and then used
as a feature on another prediction task, for example, in a strategy
called transfer learning. Representations that have been pretrained
for this purpose are relatively novel to cheminformatics compared
to chemical fingerprints. Unlike hand-engineered or experimental descriptors,
representation learning automatically extracts relevant features from
raw data, capturing complex patterns and relationships, and is particularly
powerful when handling large data sets.<sup><xref ref-type="bibr" rid="ref106">106</xref></sup> By contrast, they are often not beneficial on smaller data sets.<sup><xref ref-type="bibr" rid="ref205">205</xref></sup> Encoders are typically pretrained on related
tasks to extract relevant features from raw data into a lower-dimensional
and abstract representation known as the latent space. The compressed
vector space retains essential features, making it easier for the
models to handle complex data. Learned representations can be used
downstream as feature vector inputs to another model or can be fine-tuned
for a specific task.</p><p>There are various strategies to learn representations,
such as
message passing neural networks, discussed in the prior section. Another
approach to automatically extract relevant features from raw data
involves comparing and contrasting samples (including the possibility
of using 3D information).<sup><xref ref-type="bibr" rid="ref170">170</xref>,<xref ref-type="bibr" rid="ref206">206</xref></sup> This method, known
as contrastive learning, trains a model to distinguish between similar
and dissimilar pairs of data points, typically by minimizing the distance
between representations of similar pairs (positive pairs) and maximizing
the distance between representations of dissimilar pairs (negative
pairs). Thus, contrastive learning involves creating an embedding
space where similar data points are located close to each other and
dissimilar points are distant. For example, in the context of compound
bioactivity data, the model might be trained to recognize that two
different chemical scaffolds with similar bioactivity should have
similar representations, while scaffolds with different bioactivity
should have distinct representations. In addition to the strategies
above, another potent method for learning representations involves
using neural machine translation between two semantically equivalent
but syntactically distinct molecular structure notations, such as
InChI and SMILES. This technique, based on continuous and data-driven
descriptors,<sup><xref ref-type="bibr" rid="ref207">207</xref></sup> compresses the shared substantive
information from both notations into a condensed, information-rich
vector representation.</p><p>One of the advantages of representation
learning is its ability
to integrate multiple data types, such as chemical structures, biological
activities, gene expression, and phenotypic profiles.<sup><xref ref-type="bibr" rid="ref208">208</xref>,<xref ref-type="bibr" rid="ref209">209</xref></sup> Liu et al. introduced the Information Alignment (InfoAlign) approach,
which uses the information bottleneck method to learn enhanced molecular
representations by integrating chemical structure data with cell morphology
and gene expression data.<sup><xref ref-type="bibr" rid="ref209">209</xref></sup> On the Biogen
ADME data set, InfoAlign was tested across five end points: MDR1-MDCK
efflux ratio (ER), solubility at pH 6.8, rat liver microsomal intrinsic
clearance, human plasma protein binding (hPPB) percent unbound, and
rat plasma protein binding (rPPB) percent unbound. InfoAlign outperformed
traditional chemical fingerprints and other contrastive learning methods
like CLOOME<sup><xref ref-type="bibr" rid="ref210">210</xref></sup> and InfoCORE<sup><xref ref-type="bibr" rid="ref211">211</xref></sup> reducing mean average errors by 6.33%, and
thus learning better representations of molecules by integrating biological
data.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> Overall, representation learning
allows the integration of various task-relevant biological data in
encoding chemical space.</p></sec><sec id="sec15"><title>Feature Selection or Reduction</title><p>Feature selection or
reduction is a key step in data analysis and
modeling, serving as a way to reduce model variance (via the elimination
of noisy features<sup><xref ref-type="bibr" rid="ref212">212</xref></sup>) or bias (via the
inclusion of relevant features).<sup><xref ref-type="bibr" rid="ref213">213</xref></sup> Thus,
feature selection methods can enhance the signal-to-noise ratio and
enable the model to concentrate on the most significant predictors.
An effective and efficient feature selection method considers both
feature relevance (high information content) and redundancy (correlations
between features).<sup><xref ref-type="bibr" rid="ref214">214</xref></sup> Including irrelevant
or redundant features can add noise (albeit models like partial least-squares
regression, as one of few exceptions, can still work with highly redundant
features), causing the model to overfit by learning the noise rather
than the true underlying patterns resulting in poor generalization
of new data and decreased model performance.<sup><xref ref-type="bibr" rid="ref214">214</xref></sup> However, eliminating useful features during the selection process
degrades performance by reducing the model&#x02019;s ability to capture
important patterns or relationships in the data. The difficulty in
practice is that data sets are limited in size, and hence feature
relevance can only be assessed on the given data; relevance of features
might change when new data becomes available.</p><p>Feature selection
or reduction (as well as any optimization of
model hyperparameters) should be done on the training data only, while
the test set, on which future performance of the model is estimated,
should not be used for feature selection; this would represent information
leakage.<sup><xref ref-type="bibr" rid="ref215">215</xref>,<xref ref-type="bibr" rid="ref216">216</xref></sup> Feature selection methods can
evaluate features based on statistical criteria without involving
a predictive model (&#x02018;filters&#x02019;), use a machine learning
model to iteratively select the best subset of features by testing
performance (&#x02018;wrappers&#x02019;), or be embedded within the
learning process of a predictive model (&#x02018;embedded methods&#x02019;).<sup><xref ref-type="bibr" rid="ref217">217</xref></sup></p><p>Several methods address the feature selection
step (<xref rid="tbl6" ref-type="other">Table <xref rid="tbl6" ref-type="other">5</xref></xref>).<sup><xref ref-type="bibr" rid="ref160">160</xref></sup> For instance, Minimum Redundancy Maximum Relevance
(MRMR) aims to
select features that are highly correlated with the target variable
while being minimally redundant with each other.<sup><xref ref-type="bibr" rid="ref218">218</xref></sup> Recursive Feature Elimination (RFE) iteratively removes
less significant features based on model performance, providing an
optimal subset of features and integrating well with different model
types.<sup><xref ref-type="bibr" rid="ref219">219</xref></sup> Other techniques like Mutual
Information measure the &#x02018;information gain&#x02019; provided
by each feature (that is, information provided about the target variable),
capturing nonlinear relationships and aiding in feature ranking.<sup><xref ref-type="bibr" rid="ref220">220</xref></sup> Boruta is an all-relevant feature selection
method: that is, selecting all features with a meaningful relationship
to the target, whether redundant or unique. Boruta iteratively compares
the importance of actual features with that of randomly shuffled features
to determine significance, making it robust to overfitting and easy
to interpret.<sup><xref ref-type="bibr" rid="ref221">221</xref></sup> Context-dependent sparse
feature selection methods, such as LASSO and other L1 methods, help
remove low-relevance features, which minimizes overfitting and improves
model interpretability and predictive power.<sup><xref ref-type="bibr" rid="ref222">222</xref></sup> Principal Component Analysis (PCA) is often employed for feature
(dimensionality) reduction by selecting a finite number of components
that explain the majority of the <italic>variance</italic>, but it
does <italic>not</italic> explicitly select features based on their
relevance to a specific task, such as predicting a target variable
such as toxicity. While some have proposed using PCA for feature selection,<sup><xref ref-type="bibr" rid="ref223">223</xref></sup> it is usually not ideal for feature selection
where task-specific relevance is key.<sup><xref ref-type="bibr" rid="ref224">224</xref></sup> Overall, in ML models, feature selection or reduction can improve
the signal in the data by removing irrelevant or redundant features,
thereby enhancing model performance as well as simplifying model interpretation
due to the reduced number of features (provided that suitable features
exist in the first place).</p><table-wrap id="tbl6" position="float"><label>Table 5</label><caption><title>Table of Commonly Used Methods for
Feature Selection (from the set of original features) and Reduction
(new features)</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">Method</th><th style="border:none;" align="center">Description</th><th style="border:none;" align="center">Strategy for Selection/Reduction</th><th style="border:none;" align="center">Advantages</th><th style="border:none;" align="center">Disadvantages</th><th style="border:none;" align="center">Category</th><th style="border:none;" align="center">Reference</th></tr></thead><tbody><tr><td style="border:none;" align="left">Minimum Redundancy Maximum Relevance
(MRMR)</td><td style="border:none;" align="left">Selects features highly correlated with the target
but minimally
redundant with each other</td><td style="border:none;" align="left">Relation to output space</td><td style="border:none;" align="left">Balances relevance and redundancy, suitable for high-dimensional
data</td><td style="border:none;" align="left">May struggle with nonlinear relationships, computationally
expensive for large data sets</td><td style="border:none;" align="left">Supervised, Filter</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref218">218</xref>)</td></tr><tr><td style="border:none;" align="left">Recursive
Feature Elimination (RFE)</td><td style="border:none;" align="left">Iteratively removes features
by training models and evaluating
their performance</td><td style="border:none;" align="left">Relation to output space</td><td style="border:none;" align="left">Provides an optimal subset of features, integrates well with
different model types</td><td style="border:none;" align="left">Computationally expensive for
large data sets</td><td style="border:none;" align="left">Supervised, Wrapper</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref219">219</xref>)</td></tr><tr><td style="border:none;" align="left">Mutual Information</td><td style="border:none;" align="left">Measures the information gained about one variable through
the other, useful for feature ranking</td><td style="border:none;" align="left">Relation to output
space</td><td style="border:none;" align="left">Nonparametric, can capture nonlinear relationships</td><td style="border:none;" align="left">Computationally expensive, sensitive to noise in the data,
can be inaccurate as well, because the true MI often involves a very
high-dimensional integral<sup><xref ref-type="bibr" rid="ref225">225</xref></sup></td><td style="border:none;" align="left">Supervised, Filter</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref220">220</xref>)</td></tr><tr><td style="border:none;" align="left">Boruta</td><td style="border:none;" align="left">Iteratively compares feature
importance with that of randomly
shuffled features to determine significance</td><td style="border:none;" align="left">Variance
in input space and relation to output space</td><td style="border:none;" align="left">Robust to
overfitting, easy to interpret</td><td style="border:none;" align="left">Computationally expensive,
may select more features than necessary</td><td style="border:none;" align="left">Supervised,
Wrapper</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref221">221</xref>)</td></tr><tr><td style="border:none;" align="left">Least Absolute Shrinkage and Selection Operator (LASSO)</td><td style="border:none;" align="left">Applies L1 regularization to linear regression to penalize
coefficients, forcing some to zero</td><td style="border:none;" align="left">Relation to output
space</td><td style="border:none;" align="left">Simple to implement, handles high-dimensional
data well, and
reduces overfitting</td><td style="border:none;" align="left">May select too few features if high
correlation exists among
predictors; difficult to interpret because it is an emergent property
of the model fitting and not based on a metric calculated per-feature</td><td style="border:none;" align="left">Supervised, Embedded</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref222">222</xref>)</td></tr><tr><td style="border:none;" align="left">Elastic Net</td><td style="border:none;" align="left">Combines L1 (LASSO)
and L2 (ridge) regularization to select
relevant features and handle correlated predictors</td><td style="border:none;" align="left">Relation
to output space</td><td style="border:none;" align="left">Handles correlated features well, useful
for data sets with
more predictors than observations</td><td style="border:none;" align="left">Can be difficult to
tune the mixing parameter between L1 and
L2 regularization</td><td style="border:none;" align="left">Supervised, Embedded</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref226">226</xref>)</td></tr><tr><td style="border:none;" align="left">ReliefF</td><td style="border:none;" align="left">Estimates feature importance by repeatedly sampling instances
and comparing nearest neighbors</td><td style="border:none;" align="left">Variance in input space
and relation to output space</td><td style="border:none;" align="left">Captures interactions between
features, works well with noisy
data sets</td><td style="border:none;" align="left">Sensitive to the choice of nearest neighbors,
may not perform
well with imbalanced data</td><td style="border:none;" align="left">Supervised, Filter</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref227">227</xref>)</td></tr><tr><td style="border:none;" align="left">Genetic
Algorithms</td><td style="border:none;" align="left">Evolves a population of potential solutions
(feature subsets)
using genetic operators like mutation and crossover</td><td style="border:none;" align="left">Natural selection and relation to output space</td><td style="border:none;" align="left">Flexible
and adaptable, can escape local optima in feature
selection</td><td style="border:none;" align="left">Computationally expensive, requires careful
tuning of parameters
like mutation rate</td><td style="border:none;" align="left">Unsupervised, Embedded</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref228">228</xref>)</td></tr><tr><td style="border:none;" align="left">Principal
Component Analysis (feature reduction method)</td><td style="border:none;" align="left">Dimensionality
reduction technique that projects data onto
orthogonal axes to maximize variance. Lower-ranking features can be
discarded.</td><td style="border:none;" align="left">Variance in input space</td><td style="border:none;" align="left">Reduces
dimensionality, improves computational efficiency,
and removes multicollinearity</td><td style="border:none;" align="left">Information loss occurs,
and the principal components often
lack direct interpretability</td><td style="border:none;" align="left">Unsupervised, Filter</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref223">223</xref>)</td></tr></tbody></table></table-wrap></sec><sec id="sec16"><title>Pillar 3: The Choice of Model Algorithm</title><p>After choosing
a suitable representation of chemicals, the choice
of modeling algorithm is the next critical factor determining the
performance and usefulness of an ML system for molecular toxicity
prediction. In the context of ML, a model is a mathematical system
designed to make predictions based on input data. Models use a set
of features (as outlined in the previous section) to capture the essential
characteristics of the molecules under study.<sup><xref ref-type="bibr" rid="ref143">143</xref></sup> Most models make predictions for a data point (chemical)
by using that data point&#x02019;s features and a set of model parameters
that need to be fitted (trained) to the data. In a simple linear model,
these parameters determine the weight of each descriptor in making
a prediction; however, in more complex models, those relationships
can be more difficult to interpret. Fitting a model involves adjusting
these parameters to minimize the error between the model&#x02019;s
predictions and observed outcomes from the training data. For a review
on classical ML methods, the reader is referred to Mitchell<sup><xref ref-type="bibr" rid="ref229">229</xref></sup> and Lavecchia et al.<sup><xref ref-type="bibr" rid="ref230">230</xref></sup></p></sec><sec id="sec17"><title>Bias-Variance Trade-Offs</title><p>As with selecting a feature
representation, the choice of ML models
also presents a trade-off between having lower prediction power (or
poor ability to generalize to novel chemical space) and overfitting
(the ability to fit the training set well, but at the cost of being
less able to generalize to unseen structures). Usually, ML models
with constrained functional forms can only approximate a limited set
of target functions, limiting their expressivity but preventing overfitting,
which hence represents a trade-off (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>). For example, linear regression models
assume a linear relationship between the input features and labels,
which limits the expressivity of the model to linear functions. Thus,
linear regression models can be insufficient for capturing the complexity
and variability present in domains where nonlinear patterns are common
but can be a useful choice when data is scarce and have the advantage
of being readily interpretable. On the other hand, deep learning models,
such as multilayer feed-forward neural networks are more flexible
(universal) approximators and can capture complex nonlinear functions
but require sufficient size, data, training, and hyperparameter tuning
(network architecture, etc.), and come at a cost of interpretability.<sup><xref ref-type="bibr" rid="ref231">231</xref></sup></p><fig id="fig6" position="float"><label>Figure 6</label><caption><p>(a) Theoretical depiction of how increased model complexity
reduces
bias but increases variance, highlighting the tipping point where
overfitting begins. Yet, recent research reveals a &#x0201c;double
descent&#x0201d; regime (toward the right), as described in the main
text. (b) Data points (in brown) alongside fitted models (blue dashed
lines) to visualize the difference in the fit quality across various
model complexities, from simple models with constrained functional
forms to neural networks that are universal approximators with high
expressivity but prone to overfitting.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_0006" id="gr6" position="float"/></fig><p>The trade-off between poor predictive power and
overfitting is
a fundamental principle of ML known as the bias-variance trade-off
(<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>).<sup><xref ref-type="bibr" rid="ref232">232</xref></sup> Both bias and variance relate to the model&#x02019;s
ability to learn feature-target relationships from the training data
set. Bias refers to the model&#x02019;s tendency to not capture (and
hence overgeneralize) real feature-target relationships that are present
in the training set. Bias can be high when a simple model is used,
such as a linear model or a small neural network, or when the model
or training algorithm includes assumptions about the shape and nature
of the data that may not be true for the data seen during deployment.
Variance, on the other hand, refers to the model&#x02019;s tendency
to capture spurious relationships in the training data set (such as
noise). For example, the presence of a rare functional group in a
single toxic compound (where this functional group, however, is not
related to toxicity) might lead the model to incorrectly predict that
other compounds with this functional group are toxic. Overly simplistic
models exhibit high bias and fail to learn from the data adequately
but are less likely to overfit to noise or spurious correlations in
the training data and can have the ability to extrapolate better to
new data. Due to their simplicity, interpretability, and robustness
to noise, classical models, such as linear models (<xref rid="tbl7" ref-type="other">Table <xref rid="tbl7" ref-type="other">6</xref></xref>), have been widely used with
binary fingerprints to predict toxicity.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref233">233</xref></sup> In contrast,
complex models can model intricate relationships but are more likely
to learn spurious correlations and overfit.<sup><xref ref-type="bibr" rid="ref234">234</xref></sup></p><table-wrap id="tbl7" position="float"><label>Table 6</label><caption><title>Evaluation of Commonly Implemented
ML Algorithms Concerning Their Simplicity, Interpretability, Robustness
to Noise, Functional Form, Expressivity, and Bias-Variance Trade-Off
When Used in Toxicity Prediction</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">ML Model Type</th><th style="border:none;" align="center">Complexity and Interpretability</th><th style="border:none;" align="center">Robustness to Noise</th><th style="border:none;" align="center">Functional
Forms Approximated</th><th style="border:none;" align="center">Expressivity (ability
capture complexity, variability
of data)</th><th style="border:none;" align="center">Bias-Variance Trade-Off</th></tr></thead><tbody><tr><td style="border:none;" align="left">Linear Models</td><td style="border:none;" align="left">Low complexity;
high interpretability</td><td style="border:none;" align="left">Low</td><td style="border:none;" align="left">Linear relationships</td><td style="border:none;" align="left">Low</td><td style="border:none;" align="left">High bias, low variance&#x02014;good for simple
relationships
but may underfit complex data</td></tr><tr><td style="border:none;" align="left"><italic>k</italic>-Nearest Neighbors (kNNs)</td><td style="border:none;" align="left">Low complexity; high interpretability<sup><xref ref-type="bibr" rid="ref238">238</xref></sup></td><td style="border:none;" align="left">Low</td><td style="border:none;" align="left">Local properties;
distance-based</td><td style="border:none;" align="left">Depends on the input data; usually high</td><td style="border:none;" align="left">Low bias, high variance (with the small <italic>k</italic>-values
that are typically necessary in moderate data regimes)</td></tr><tr><td style="border:none;" align="left">Decision Trees (DTs)</td><td style="border:none;" align="left">Moderate complexity;
high interpretability</td><td style="border:none;" align="left">Moderate</td><td style="border:none;" align="left">Hierarchical
decision rules</td><td style="border:none;" align="left">Moderate</td><td style="border:none;" align="left">Can vary; e.g.,
deep trees have low bias but high variance</td></tr><tr><td style="border:none;" align="left">Random Forests (ensembles of DTs)</td><td style="border:none;" align="left">High complexity;
moderate interpretability</td><td style="border:none;" align="left">High</td><td style="border:none;" align="left">Ensemble
of decision rules</td><td style="border:none;" align="left">High</td><td style="border:none;" align="left">Reduced variance
through averaging, better generalization,
and flexible control of bias and variance, but can overfit if not
properly tuned</td></tr><tr><td style="border:none;" align="left">Gradient Boosting Machines
(GBMs, typically ensembles of DTs)</td><td style="border:none;" align="left">High complexity;
moderate interpretability</td><td style="border:none;" align="left">High</td><td style="border:none;" align="left">Ensemble
of decision rules</td><td style="border:none;" align="left">Very high</td><td style="border:none;" align="left">Flexible control
of bias and variance but can overfit if not
properly tuned</td></tr><tr><td style="border:none;" align="left">Support Vector Machines (SVMs)</td><td style="border:none;" align="left">Moderate complexity; low interpretability</td><td style="border:none;" align="left">High</td><td style="border:none;" align="left">Linear and nonlinear (with kernels)</td><td style="border:none;" align="left">High</td><td style="border:none;" align="left">Good balance, but the choice of kernel affects the complexity</td></tr><tr><td style="border:none;" align="left">Neural Networks (NNs, multilayer perceptron/feedforward)</td><td style="border:none;" align="left">Complexity and interpretability depend on architecture (Shallow
NNs have single hidden layers); while Deep NNs have multiple hidden
layers, and hence higher complexity and lower interpretability than
classical models</td><td style="border:none;" align="left">Depends on architecture (dropout, regularizers)</td><td style="border:none;" align="left">Virtually any functional form</td><td style="border:none;" align="left">Very high</td><td style="border:none;" align="left">Flexible control of bias, high variance&#x02014;powerful but
prone to overfitting (requires regularization), requires large data
sets</td></tr><tr><td style="border:none;" align="left">Graph Neural Networks (GNNs)</td><td style="border:none;" align="left">High complexity; low-to-moderate interpretability</td><td style="border:none;" align="left">High</td><td style="border:none;" align="left">Complex graph structures</td><td style="border:none;" align="left">Very high</td><td style="border:none;" align="left">Balances bias and variance through structure-aware processing;
can be prone to overfitting with highly expressive models, requires
large data sets</td></tr></tbody></table></table-wrap><p>Recent deep learning research has challenged and modified
the traditional
understanding of the bias-variance trade-off by introducing the concept
of double descent (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>a).<sup><xref ref-type="bibr" rid="ref232">232</xref>,<xref ref-type="bibr" rid="ref235">235</xref></sup> When a model becomes too complex,
it initially leads to overfitting and high variance (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>b). As the number of parameters
approaches the number of observations, small changes in the data cause
large changes in the model. However, as complexity is increased further,
the error surprisingly decreases again, an effect known as &#x02018;double
descent&#x02019;.<sup><xref ref-type="bibr" rid="ref235">235</xref></sup> At some point, highly
overparametrized models can hence often generalize well, despite having
at the same time a large number of parameters. Double descent challenges
the traditional U-shaped curve of bias-variance trade-off, revealing
a more nuanced relationship between model complexity, training time
and data set size with the generalization error.<sup><xref ref-type="bibr" rid="ref236">236</xref></sup> Nevertheless, its relevance to toxicology data, especially
in low-data scenarios, may at the current point in time be limited.
There are only a few instances where this effect has been observed
in the drug discovery domain. For example, when training NeuralDock
to predict the binding energy and affinity of a protein-small molecule
pair based on protein pocket 3D structure and small molecule topology,
the authors observed the second descent because the 46 million parameters
was much higher than the roughly 2000 data points used in training;
the authors noted that the second descent contributed to its high
accuracy.<sup><xref ref-type="bibr" rid="ref237">237</xref></sup> However, in smaller data sets
typically used in ML models for compound toxicity, encountering double
descent is unlikely.</p><p>Algorithms described in the prior section
(<xref rid="tbl7" ref-type="other">Table <xref rid="tbl7" ref-type="other">6</xref></xref>) are widely
employed in molecular and toxicity
prediction (<xref rid="tbl8" ref-type="other">Table <xref rid="tbl8" ref-type="other">7</xref></xref>), and are based on features like molecular structure, chemical properties,
and biological data. For further reading, we recommend the compendium
of articles in &#x0201c;Introduction to the Special Issue: AI Meets
Toxicology&#x0201d; and &#x0201c;Analysis of Tox24 challenge results&#x0201d;,
which offers a comprehensive exploration of AI/ML applications in
toxicology, presenting advanced methodologies and diverse case studies
that showcase the full potential of these technologies.<sup><xref ref-type="bibr" rid="ref239">239</xref>,<xref ref-type="bibr" rid="ref240">240</xref></sup></p><table-wrap id="tbl8" position="float"><label>Table 7</label><caption><title>Reviews of the Predictive Model Algorithms
Used in Predicting Toxicity</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">Review</th><th style="border:none;" align="center">Year</th><th style="border:none;" align="center">Algorithms Described/Discussed</th><th style="border:none;" align="center">Reference</th></tr></thead><tbody><tr><td style="border:none;" align="left">Mitchell
et al.</td><td style="border:none;" align="left">2014</td><td style="border:none;" align="left">Discusses common supervised
learning algorithms: Artificial
Neural Networks (ANNs), Random Forest (RF), Support Vector Machines
(SVMs), <italic>k</italic>-Nearest Neighbors (kNNs), and Na&#x000ef;ve
Bayes (NB) classifiers.</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref229">229</xref>)</td></tr><tr><td style="border:none;" align="left">Ekins</td><td style="border:none;" align="left">2014</td><td style="border:none;" align="left">Discusses Bayesian models, SVM, kNN, and RF for predicting
various toxicities, such as hepatotoxicity and cardiotoxicity.</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref241">241</xref>)</td></tr><tr><td style="border:none;" align="left">Lavecchia
et al.</td><td style="border:none;" align="left">2015</td><td style="border:none;" align="left">Covers algorithms like SVM,
Decision Trees (DT), RF, NB classifiers,
kNN, and ANN.</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref230">230</xref>)</td></tr><tr><td style="border:none;" align="left">Raies and Bajic</td><td style="border:none;" align="left">2016</td><td style="border:none;" align="left">Discusses
rule-based systems, structural alerts, read-across
methods, dose&#x02013;response models, pharmacokinetic/pharmacodynamic
models, and QSAR models.</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref242">242</xref>)</td></tr><tr><td style="border:none;" align="left">Baskin</td><td style="border:none;" align="left">2018</td><td style="border:none;" align="left">Explains methods like multiple linear regression, kNN, SVM,
DT, RF, and deep learning, along with unsupervised methods like Kohonen&#x02019;s
self-organizing maps.</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref243">243</xref>)</td></tr><tr><td style="border:none;" align="left">Yang et al.</td><td style="border:none;" align="left">2018</td><td style="border:none;" align="left">Describes ML approaches for predicting chemical toxicity, including
SVM, RF, deep learning, and structural alerts for toxic substructure
identification.</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref244">244</xref>)</td></tr><tr><td style="border:none;" align="left">Vamathevan et al.</td><td style="border:none;" align="left">2019</td><td style="border:none;" align="left">Discusses ML applications in drug discovery, highlighting target
identification, clinical trials, and challenges like data quality
and model interpretability to reduce clinical failure rates.</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref245">245</xref>)</td></tr><tr><td style="border:none;" align="left">Ciallella
et al.</td><td style="border:none;" align="left">2019</td><td style="border:none;" align="left">Reviews AI applications in
computational toxicology, covering
data-driven and mechanism-driven models such as Adverse Outcome Pathways
using public data sets and high-throughput screening.</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref246">246</xref>)</td></tr><tr><td style="border:none;" align="left">Jim&#x000e9;nez-Luna
et al.</td><td style="border:none;" align="left">2020</td><td style="border:none;" align="left">Focuses on deep learning,
explainable AI (XAI) techniques like
feature attribution, gradient-based methods, surrogate models, and
instance-based approaches for drug discovery model interpretability.</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref247">247</xref>)</td></tr><tr><td style="border:none;" align="left">Wang
et al.</td><td style="border:none;" align="left">2021</td><td style="border:none;" align="left">Covers regression models,
kNN, DT, NB, SVM, RF, ensemble learning,
ANN, Deep Neural Networks (DNNs), and CNN for modeling.</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref248">248</xref>)</td></tr><tr><td style="border:none;" align="left">Dara et al.</td><td style="border:none;" align="left">2022</td><td style="border:none;" align="left">Describes methods such as SVM, RF, Multi-Layer
Perceptron (MLP),
deep learning, Autoencoders, and Reinforcement Learning in drug discovery.</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref249">249</xref>)</td></tr><tr><td style="border:none;" align="left">Cavasotto
et al.</td><td style="border:none;" align="left">2022</td><td style="border:none;" align="left">Reviews recent ML advances
in toxicity prediction, noting challenges,
methods, and relevant databases.</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref57">57</xref>)</td></tr><tr><td style="border:none;" align="left">Tran et al.</td><td style="border:none;" align="left">2023</td><td style="border:none;" align="left">Focuses on key toxicity properties (e.g., hERG inhibition,
drug-induced liver injury) and ML models like RF, SVM, and DNN in
toxicity prediction.</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref250">250</xref>)</td></tr><tr><td style="border:none;" align="left">Guo et al.</td><td style="border:none;" align="left">2023</td><td style="border:none;" align="left">Covers
ML and deep learning models like SVM, RF, kNN, ensemble
learning, MLP, Convolutional Neural Networks (CNNs), and Graph Convolutional
Networks (GCNs) for toxicity prediction.</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref251">251</xref>)</td></tr><tr><td style="border:none;" align="left">Tonoyan et al.</td><td style="border:none;" align="left">2024</td><td style="border:none;" align="left">Highlights opportunities in supervised,
unsupervised, and reinforcement
learning for toxicology applications.</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref252">252</xref>)</td></tr></tbody></table></table-wrap></sec><sec id="sec18"><title>Read-Across Models</title><p>While in some cases the quantitative
or qualitative prediction
of a compound property across all chemical space and all output property
space is desired, especially in the safety area, sometimes other approaches
are employed. One such approach is known as &#x02018;read-across&#x02019;,
which relies on structural similarity <italic>and contextual information</italic> to predict the toxicity of a chemical substance.<sup><xref ref-type="bibr" rid="ref253">253</xref>,<xref ref-type="bibr" rid="ref254">254</xref></sup> Read-across is particularly popular due to its application context
and the legal environment, which impose distinct requirements, such
as interpretability and confidence in assigning compound properties.
The process involves first identifying molecules that belong to the
same chemical series or category as a query compound, based on the
assumption that structurally similar compounds will exhibit similar
biological activities due to shared mechanisms of action. Once appropriate
analogs are identified, toxicological data from these substances are &#x0201c;read
across&#x0201d; (data gap filling) to the target chemical to fill data
gaps and inform safety assessments. A <italic>k</italic>-nearest neighbor
chemical structure-based strategy (often with <italic>k</italic> =
1) is one example of a read-across strategy. Given the regulatory
environment and cultural practice in toxicology, &#x02018;machine learning
is not everything&#x02019;: approaches can and should be tailored to
the particular use case.</p></sec><sec id="sec19"><title>Generative Models</title><p>Related to <italic>predictive</italic> models are <italic>generative</italic> models, which in addition
to learning patterns from a training set
are able to generate novel chemical structures and which can include
toxicity as one factor for optimization. Unlike predictive models,
where one predicts the label for a given molecule, generative models
hence &#x02018;design&#x02019; the molecule itself given the desired
label.<sup><xref ref-type="bibr" rid="ref255">255</xref></sup> These models are typically optimized
over iterations using scoring functions that predict desired properties
including novelty, activity, and synthesizability in addition to toxicity.<sup><xref ref-type="bibr" rid="ref256">256</xref>,<xref ref-type="bibr" rid="ref257">257</xref></sup> Recently, generative models have been used for this, including Variational
Autoencoders (VAEs), Generative Adversarial Networks (GANs), and Large
Language Models (LLMs).<sup><xref ref-type="bibr" rid="ref256">256</xref>,<xref ref-type="bibr" rid="ref258">258</xref></sup></p></sec><sec id="sec20"><title>Variational Autoencoders</title><p>Variational autoencoders (VAEs)
are a class of generative models
that learn representations through compression and reconstruction
(<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>a).<sup><xref ref-type="bibr" rid="ref259">259</xref></sup> In a classical autoencoder, an encoder network
maps data points from a high-dimensional input space (e.g., 2D or
3D molecular structure space) to a lower-dimensional latent space.
Then, a decoder network is reconstructed back to the original input
space, attempting to recover the data points that were fed into the
encoder network. In contrast, in a VAE, the encoder maps a point from
the input space not to a specific point in the latent space but to
the parameters of the Gaussian distribution in the latent space, and
the decoder tries to restore the point in the input space based on
the result of sampling the Gaussian distribution. The presence of
the sampling stage makes the VAE a generative model. Since reconstruction
is required, but at the same time the latent space is smaller than
the input space, the VAE encoder network must learn a compressed representation
of the data that captures its most important features and ignores
irrelevant ones. Because the ideal distribution in the trained latent
space is known, novel molecules can be generated with the trained
model by sampling points in the latent space and passing them through
the decoder.</p><fig id="fig7" position="float"><label>Figure 7</label><caption><p>(a) Variational Autoencoders (VAEs) encode molecules into
a latent
space representation and then decode to generate new molecules, aiding
in the exploration of chemical space. (b) A conceptual framework behind
Generative Adversarial Networks (GANs), illustrating how a generator
creates new molecule designs and a discriminator evaluates their realism,
facilitating the generation of novel compounds. (c) Diffusion Models,
a class of generative models that learn to generate data by transforming
noise. (d) Large Language Models (LLMs) are also used to design molecules,
emphasizing their ability to predict molecular properties and generate
new compounds based on learned patterns.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_0007" id="gr7" position="float"/></fig><p>VAEs are popular general models for molecular representation
learning
and generation.<sup><xref ref-type="bibr" rid="ref260">260</xref>,<xref ref-type="bibr" rid="ref261">261</xref></sup> Molecular generation with VAEs
can be biased to optimize various objective functions such as docking
scores<sup><xref ref-type="bibr" rid="ref262">262</xref>,<xref ref-type="bibr" rid="ref263">263</xref></sup> and drug-likeness.<sup><xref ref-type="bibr" rid="ref264">264</xref>,<xref ref-type="bibr" rid="ref265">265</xref></sup> In the context of toxicity prediction, conditional VAEs<sup><xref ref-type="bibr" rid="ref265">265</xref></sup> have been applied to explore low-toxicity regions
of chemical space, using a scalarized objective that combines labels
related to different forms of toxicity (cardiotoxicity, mutagenicity,
pulmonary toxicity and skin sensitivity).<sup><xref ref-type="bibr" rid="ref255">255</xref></sup> Other studies have used arithmetic in the latent space to predict
polypharmacology, adding or subtracting latent representations corresponding
to treatment with different substances in order to simulate cellular
states (as described by cell morphology and gene expression) when
subjected to multiple compounds.<sup><xref ref-type="bibr" rid="ref266">266</xref></sup></p></sec><sec id="sec21"><title>Generative Adversarial Networks</title><p>Generative Adversarial
Networks (GANs) are a class of generative
models consisting of a generator and a discriminator, two neural networks,
that are trained simultaneously through adversarial training.<sup><xref ref-type="bibr" rid="ref267">267</xref></sup> A conceptual framework behind a GAN is depicted
in <xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>b. The generator
network in <xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>b is trained to create novel molecular structures, while the discriminator
network evaluates whether these structures are realistic. At each
training iteration, the discriminator is shown a batch of molecules
that either were sampled randomly from a set of real molecules (&#x0201c;real&#x0201d;)
or were artificially generated by the generator (&#x0201c;fake&#x0201d;).
Using these examples, the discriminator must learn to determine whether
a molecule is real or fake. In turn, the generator must learn to fool
the discriminator by proposing molecules that mimic those in the real
set. We can bias the generator to suggest compounds with certain properties,
for example low toxicity, by designing the set of real molecules so
that it features those properties.</p><p>Recent examples of works
that explore the application of GANs to
toxicity in medicinal chemistry are MedGAN, ToxGan and TransOrGAN.
MedGAN was developed to generate new quinoline scaffold molecules
from complex molecular graphs.<sup><xref ref-type="bibr" rid="ref268">268</xref></sup> The best
model included in this study generated 25% valid compounds, of which
92% were quinolines of up to 50 atoms. Around 22&#x02013;31% of the
generated molecules were predicted to be nontoxic across the 12 Tox21
end points.<sup><xref ref-type="bibr" rid="ref269">269</xref></sup> That being said, the generation
of quinolines is a task also easily achievable by a medicinal chemist,
and the impact of such models in practice remains to be seen. In another
study, ToxGan was used to predict new animal study results from historical
data.<sup><xref ref-type="bibr" rid="ref270">270</xref></sup> Instead of training on molecular
structures, the authors used repeated dose transcriptomic profiles
from <italic>in vivo</italic> rat studies (Open TG-GATES) to train
a GAN that generated transcriptomic profiles for compounds of interest.
They could generate highly similar transcriptomic profiles that showed
over 87% agreement in Gene Ontology with the actual gene expression
data. Finally, TransOrGAN allowed molecular mapping of gene expression
profiles based on rat RNA-seq data from 288 samples in nine different
organs of both sexes and four developmental stages.<sup><xref ref-type="bibr" rid="ref271">271</xref></sup> By inferring transcriptomic profiles between any two of
the nine organs studied, TransOrGAN achieved an average cosine similarity
of 0.984 between synthetic transcriptomic profiles and the corresponding
real profiles.</p><p>The success of frameworks like MedGAN, ToxGan,
and TransOrGAN demonstrates
the principle of GANs in molecular design, offering a promising avenue
for generating novel, drug-like compounds taking all available data
into account in an unbiased fashion. As with other ML models, however,
there are some ethical concerns with generative AI, as designing molecules
with the reverse loss function has been shown to rediscover potent
chemical toxicants.<sup><xref ref-type="bibr" rid="ref272">272</xref></sup></p></sec><sec id="sec22"><title>Diffusion Models</title><p>Diffusion models have gained significant
interest in drug discovery
recently.<sup><xref ref-type="bibr" rid="ref273">273</xref></sup> They are a class of generative
models that learn to generate data by transforming noise.<sup><xref ref-type="bibr" rid="ref274">274</xref>,<xref ref-type="bibr" rid="ref275">275</xref></sup> Rather than training a generator to fool a discriminator, diffusion
models learn to transform noise to data by learning to reverse a diffusion
process that corrupts the data. The diffusion process, which is chosen
by the ML practitioner and is not trained, starts with a point from
the data set and progressively corrupts it to create a sequence of
increasingly noisy iterates (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>c). The process is chosen such that the final iterate
is completely noise, i.e., has no information from the original data
remaining such that it does not depend on the initial data point and
has a distribution that can be easily sampled from. A neural network
is then trained to reverse the diffusion process by predicting the
previous (less noisy) iteration from any of the noisy iterates. This
neural network is used to generate data by starting with a sample
from the noise distribution and progressively predicting each previous,
less-noisy iteration until it is left with an approximate sample from
the original data distribution.</p><p>Diffusion models are used for
molecular machine learning in two
main ways. First, a 2D molecular structure consisting of atom and
bond types can be generated.<sup><xref ref-type="bibr" rid="ref276">276</xref></sup> Second,
given a pre-existing 2D molecular graph, the diffusion model generates
3D atom coordinates. For example, 3D structures can be generated for
either low-energy conformers of the molecule,<sup><xref ref-type="bibr" rid="ref277">277</xref></sup> or for other molecular arrangements such as a ligand&#x02019;s
binding pose in a protein binding pocket.<sup><xref ref-type="bibr" rid="ref278">278</xref></sup> These two approaches can also be combined to generate both 2D molecular
graph and 3D structure at once.<sup><xref ref-type="bibr" rid="ref279">279</xref></sup> In each
case, the diffusion process (to corrupt the data) and the neural network
(to reconstruct the data) must be designed to suit the structure of
the data, whether they are discrete atoms and bonds or continuously
varying atom coordinates.</p><p>Another important use of diffusion
models is to avoid off-target
toxicity by designing ligands that selectively bind to targets over
specific off-targets,<sup><xref ref-type="bibr" rid="ref280">280</xref></sup> although it remains
to be seen that such model improvement also translates to future applications
(e.g., novel chemical space). Overall, diffusion models hold promise
for predicting and understanding molecule binding and biological pathways <italic>in silico</italic>; however, care needs to be taken to properly evaluate
models in a prospective setting.</p></sec><sec id="sec23"><title>Large Language Models</title><p>A key trend in machine learning,
especially with the rise of deep
learning architectures, has been the scaling of expressive power and
representation learning by harnessing available large-scale data sets.
While traditional supervised learning relies on labeled data, which
can be limited and costly to obtain, self-supervised learning enables
models to learn from unlabeled data through carefully designed pretext
tasks. These pretext tasks allow models to extract meaningful representations
from vast amounts of real-world data regardless of annotation availability,
which allows labeled data to be preserved for a later training stage
where desired. This approach has been particularly transformative
in language modeling, where popular models such as ChatGPT generate
natural language sequences by effectively using unannotated text.
Autoregressive models, such as Recurrent Neural Networks (RNNs), have
also been applied to generate molecular representations like SMILES
strings or molecular fingerprints (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>c). These models work by predicting the next
token in a sequence based on the previous tokens, making them well-suited
for tasks where the structure of the molecule is represented as a
sequence. When trained on large data sets of molecular sequences,
these models can learn the underlying patterns and relationships that
define valid chemical structures, allowing the generation of novel
molecules with similar properties.</p><p>Building on the foundation
of autoregressive models, the rise of
Large Language Models (LLMs) for Natural Language Processing (NLP)<sup><xref ref-type="bibr" rid="ref281">281</xref>&#x02212;<xref ref-type="bibr" rid="ref283">283</xref></sup> has prompted applying similar architectures to molecular tasks given
established conventions of treating molecular structures as sequences,
especially for the purposes of generation and representation learning.
LLMs are first pretrained on a large corpus of molecular data to learn
general representations, which can then be fine-tuned for specific
downstream tasks, such as molecular property prediction or reaction
prediction. This two-step process&#x02014;pretraining and fine-tuning&#x02014;enables
LLMs to generalize across different molecular tasks, making them a
powerful tool for drug discovery and cheminformatics. LLMs for chemistry
are sometimes called Chemical Language Models (CLMs). Many chemical
databases describe and store molecules in sequence representations
such as SMILES. This has facilitated the development of generative
models that treat molecules as sequences,<sup><xref ref-type="bibr" rid="ref260">260</xref>,<xref ref-type="bibr" rid="ref261">261</xref>,<xref ref-type="bibr" rid="ref284">284</xref></sup> some of which have achieved
considerable success in academia and industry.<sup><xref ref-type="bibr" rid="ref285">285</xref></sup></p><p>The idea of pretraining and fine-tuning in earlier
QSAR models
(before LLMs were used in chemistry) was inspired by neurophysiology
and is the basis of the ASNN method..<sup><xref ref-type="bibr" rid="ref286">286</xref></sup> Fine-tuning approaches in QSAR (the so-called &#x02018;Library Model&#x02019;)
increased accuracy of the logP model to predict logD7.4 values.<sup><xref ref-type="bibr" rid="ref287">287</xref>,<xref ref-type="bibr" rid="ref288">288</xref></sup> One LLM architecture that has been particularly successful in NLP
is the GPT (Generative Pretrained Transformer) architecture. The GPT
model consists of a stack of neural blocks, each of which is inspired
by the decoder of the transformer.<sup><xref ref-type="bibr" rid="ref289">289</xref></sup> This
decoder block consists of a self-attention layer and a feed-forward
layer, both wrapped in residual connections<sup><xref ref-type="bibr" rid="ref290">290</xref></sup> to avoid gradient degradation during backpropagation due to the
very deep architecture. The training of GPT is performed in two stages:
pretraining and fine-tuning (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>c).<sup><xref ref-type="bibr" rid="ref281">281</xref></sup> During pretraining,
the model learns to generate sequences from a training corpus of sequences
one element at a time (since sequences are typically tokenized, elements
are usually tokens in a token vocabulary; in NLP, tokens are common
word fragments or subwords, whereas in molecular tasks, tokens may
be common strings of characters in SMILES, e.g., strings of characters
that correspond to common functional groups in SMILES representation).
At each pretraining iteration, the model&#x02019;s parameters are modified
to maximize the conditional likelihood of a certain token in a sequence
given all previous tokens in that sequence. In this way, pretraining
is carried out in an unsupervised manner and it does not require manual
annotations, which are often costly to obtain. In the second stage,
fine-tuning, the models&#x02019; parameters are adapted to improve
performance in downstream supervised tasks with labels. Fine-tuning
to specific tasks can be done through several strategies, including
full-parameter tuning, adapter layers,<sup><xref ref-type="bibr" rid="ref291">291</xref></sup> or Low-Rank Adaptation (LoRA).<sup><xref ref-type="bibr" rid="ref292">292</xref></sup> An
example downstream task in NLP is sentiment analysis, where sentences
are labeled with positive or negative sentiment labels. An example
downstream molecular task is scaffold decoration (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>d). In order to teach a chemical
language model how to decorate scaffolds to obtain drug-like candidates
with predicted low toxicity, the scaffolds of approved drugs may be
paired with drug-like candidates. PromptSmiles is a recent CLM that
specializes in scaffold decoration and fragment linking.<sup><xref ref-type="bibr" rid="ref293">293</xref></sup></p><p>LLMs and CLMs hold great potential for
molecular generative AI
and property prediction, including exploration of predicted low-toxicity
chemical spaces, taking information on all available data into account.
Generative pretraining strategy enables this class of models to learn
from large unlabeled databases (e.g., Enamine REAL SPACE<sup><xref ref-type="bibr" rid="ref294">294</xref></sup>), which is suitable for the domain of medicinal
chemistry where collecting experimental labels from toxicity studies
involving animal or human clinical trials is costly. LLMs and CLMs
have shown high flexibility and performance in chemical tasks. Natural-language
models are able to capture information about chemistry and an ability
to assist with chemical tasks in natural language, including synthesis,
both with<sup><xref ref-type="bibr" rid="ref295">295</xref></sup> and without<sup><xref ref-type="bibr" rid="ref296">296</xref></sup> fine-tuning for chemistry. Surprisingly, they have also
been shown to produce molecular representations competitive with featurizations
such as fingerprints, even when trained on natural language rather
than chemical sequences such as SMILES.<sup><xref ref-type="bibr" rid="ref297">297</xref></sup> Specifically, representations from the NLP model LLaMA2<sup><xref ref-type="bibr" rid="ref283">283</xref></sup> achieved a mean AUC-ROC of 0.77 on the toxicity
classification benchmark Tox21 that was comparable to Morgan fingerprints
that achieved a mean AUC-ROC of 0.76 and representations from the
CLM MoLFormer-XL, trained on 1.1 billion SMILES and comparatively
small (just 12 layers),<sup><xref ref-type="bibr" rid="ref284">284</xref></sup> achieved a mean
AUC-ROC of 0.78.<sup><xref ref-type="bibr" rid="ref297">297</xref></sup> This suggests that
models for natural language hold potential in toxicity prediction
(at least in the way benchmarking has been performed in those studies).
It should be kept in mind that validation on limited data sets such
as the above does not necessarily translate to future use cases (e.g.,
in new chemical space) due to analogue bias in data sets, etc. In
addition, it is worth noting that data limitations currently (and
likely in the foreseeable future) prevent the development of extremely
large models for medicinal chemistry trained on molecular sequences
such as SMILES, in contrast to LLMs such as GPT and LLaMA that can
be trained on natural language (and hence a much larger information
corpus). This is because even unlabeled databases represent a comparatively
small sample of the chemical space (which is in the order of 10<sup>60</sup> as opposed to around 10<sup>10</sup> to 10<sup>15</sup> in
current databases).<sup><xref ref-type="bibr" rid="ref298">298</xref>,<xref ref-type="bibr" rid="ref299">299</xref></sup></p></sec><sec id="sec24"><title>Pillar 4: Validation of Predictive Models</title><p>While evaluation
on validation sets is used to guide training in
many ML models, once a model is trained on a data set, it must also
be evaluated on an appropriate, clearly defined test set with the
proper evaluation metrics.</p><p>The choice of the &#x02018;test set&#x02019;
is crucial here, since
one aims to extrapolate to the performance in <italic>future</italic> use cases from the performance obtained on the test. On the other
hand, given the size of chemical space, and that in most cases properties
behave differently in different areas of chemical space, this is no
trivial feat, as illustrated in <xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig">8</xref></xref> below. While evaluation of the model is performed
on an &#x02018;external test set&#x02019; (which may not be entirely
external, since it is derived from an existing, split data set), future
use cases are by definition in <italic>different</italic> areas of
chemical space, and hence performance extrapolation is in practice
often <italic>not</italic> trivial to perform. The closer to the future
use case, the better the choice of the test data set in general.</p><fig id="fig8" position="float"><label>Figure 8</label><caption><p>Chemical
space visualized as a universe of molecules: stars represent
compounds with clusters showing similar properties. The training set
forms a constellation guiding predictions, while scattered stars of
the test set highlight challenges in extrapolating to unseen regions,
emphasizing the vastness and diversity of chemical space.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_0008" id="gr8" position="float"/></fig><p>We discuss two major ways to assess the models
in the following:
(1) retrospective validation, which holds out test compounds from
the same data source, for example, by splitting the set into training
and test data, and (2) prospective validation, running separate experiments
on a new set of compounds.<sup><xref ref-type="bibr" rid="ref300">300</xref></sup> Beyond validation
type, realistically assessing the performance of ML models in predictive
modeling depends on selecting appropriate numerical evaluation <italic>metrics</italic> to understand the model&#x02019;s accuracy and generalizability.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> The chemical space in which the model can make
reliable predictions (known as the <italic>applicability domain</italic>(<xref ref-type="bibr" rid="ref301">301</xref>)) should also be clearly defined following
OECD principles (as discussed earlier in this work). We discuss various
ways to define the applicability domain of models and common approaches
to understanding models via feature importance and mechanistic analysis.</p></sec><sec id="sec25"><title>Choosing Evaluation Metrics for Classification</title><p>ML models
must use relevant performance metrics that are calculated
on definitive predictions, along with confidence measures, applicability
domain measures, etc.<sup><xref ref-type="bibr" rid="ref302">302</xref>,<xref ref-type="bibr" rid="ref303">303</xref></sup> in order to be helpful for decision
making. There are many evaluation metrics for predictive models; each
emphasizes a different aspect (or a combination of aspects) of model
behavior. Bender et al.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> provide a list
of recommended metrics in the evaluation of ML models in the chemical
sciences. Here, we focus on some common metrics that should be considered
when predicting assay outcomes from high-thoughoutput screens, toxicity-based
assays, and regression outputs.</p><p>For binary classification models,
predictions are classified into
two classes (e.g., positive and negative negative). A confusion matrix
helps to visualize the performance of a classification model by organizing
predictions into four categories:<list list-type="bullet"><list-item><p>True Positives (TP): Correct predictions of the positive
class</p></list-item><list-item><p>True Negatives (TN): Correct predictions
of the negative
class</p></list-item><list-item><p>False Positives (FP): Incorrect
positive predictions
of negative class instances</p></list-item><list-item><p>False Negatives
(FN): Incorrect negative predictions
of positive class instances</p></list-item></list></p><p>Some classification models produce a probability score
for each
instance. A threshold is applied to convert these probabilities into
definitive class predictions (e.g., predicting a compound as toxic
or nontoxic). By adjustment of a threshold, different trade-offs can
be made between capturing more true positives or avoiding false positives.</p><p>From the confusion matrix, a range of metrics can be derived to
evaluate different aspects of the model&#x02019;s performance, some
of which we will describe in the following. Accuracy is a fundamental
metric that measures the proportion of correct predictions (both true
positives and true negatives) among the total predictions.<disp-formula id="ueq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_m001" position="anchor"/></disp-formula></p><p>However, in contexts like drug discovery
and toxicity prediction,
data sets are often highly imbalanced, with significantly more inactive
compounds than active ones. This imbalance poses challenges because
a model could achieve high accuracy by predicting the majority class
all of the time, offering little practical value. For example, if
the inactive class comprises 99% of the total data set, a model solely
predicting this class would be 99% correct overall, but the model
would still be of no practical use (since it never predicts a compound
as active for a given end point).</p><p>To address the limitations
of accuracy in imbalanced data sets,
metrics such as balanced accuracy becomes relevant, which consider
the accuracy on the <italic>class</italic> level equally, i.e. this
metric pays the same attention to both classes, independent of the
number of data points they contain, thereby removing the above bias
(while introducing of course another).<disp-formula id="ueq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_m002" position="anchor"/></disp-formula></p><p>Precision measures the proportion of
true positives among all positive
predictions, emphasizing the model&#x02019;s ability to avoid false
positives, and describing the &#x02018;trust&#x02019; (likelihood of
a positive data label) for any positive prediction the model makes.<disp-formula id="ueq3"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_m003" position="anchor"/></disp-formula></p><p>Recall (or sensitivity) assesses the
proportion of true positives
identified out of all actual positives, focusing on the model&#x02019;s
capacity to capture, to retrieve, all relevant instances.<disp-formula id="ueq4"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_m004" position="anchor"/></disp-formula></p><p>The F1 Score is the harmonic mean of
precision and recall. Given
its ability to account for both false positives and false negatives,
the F1 score is widely used and particularly useful in imbalanced
data sets. On the other hand, it does not consider the true negatives
in this measure, and the same F1 score can be obtained by very different
precision and recall values, and hence model behaviors. It can be
seen that every metric has particular trade-offs of which aspects
of model performance it pays attention to.<disp-formula id="ueq5"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_m005" position="anchor"/></disp-formula></p><p>Because annotated toxicity data sets
are typically smaller than
in other domains, chance plays a significant role in producing hits.
Cohen&#x02019;s Kappa<sup><xref ref-type="bibr" rid="ref304">304</xref></sup> measures the agreement
between actual and predicted values, adjusted for chance agreement,
making it valuable for imbalanced data sets. However, it weighs predictions
of the positive and negative classes equally, whereas in toxicity
prediction, false positives (overpredictions) are often tolerated
more than false negatives (not detecting potential toxic compounds).</p><p>It is also common practice to visualize model performance using
Receiver Operating Characteristic (ROC) and Precision Recall (PR)
curves (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>).
The ROC curve displays the relationship between the True Positive
Rate (TPR, also known as recall or sensitivity) and the false positive
rate (FPR, 1 &#x02013; specificity) across various thresholds. The
Area Under the ROC curve (AUC-ROC) provides a summary of the model&#x02019;s
overall performance. However, in imbalanced data sets, AUC-ROC can
be misleading, as the model might achieve a high score simply by prioritizing
the majority class. PR curves plot precision against recall at different
thresholds. The Area Under the PR curve (AUC-PR) is especially useful
for imbalanced data sets, as it focuses on positive class performance.</p><fig id="fig9" position="float"><label>Figure 9</label><caption><p>Evaluating
ML model predictions in various settings: the primary
goal is to prioritize specific predictions for that setting rather
than rely on predicted probabilities across a range of possible thresholds.
Strategies include (a) selection, (b) deselection, (c) rank-ordering,
and (d) flagging toxic compounds. The choice of evaluation metrics
in regression</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_0009" id="gr9" position="float"/></fig><p>To translate predictions from models to decision
making in drug
discovery, it is often relevant to visually inspect the PRC and ROC
curves obtained (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>). Although often reported in benchmarking studies where large numbers
of predictions and tasks are summarized, AUC-ROC and AUC-PR consider
the <italic>overall quality</italic> of models based on a full range
of thresholds for classification, so they are less helpful for a particular
real-world use case where a particular decision needs to be made.
In the real world, we may need, e.g., ML models in virtual screening
(<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>a; early selection),
removing the bottom 20% of least suitable predictions (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>b; say compounds certain to
be unsuitable due to high clearance), prioritizing specific predictions,
such as identifying the top 1% of predictions (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>c), or rank-ordering which compounds to test
first (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>c).
For these decisions, it is often important that models should be evaluated
based on the actual predictions of classes rather than model predicted
probabilities.</p><p>For virtual screening<sup><xref ref-type="bibr" rid="ref305">305</xref></sup> (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>a), what
matters most for ML
models is prioritizing compounds from hit triage toward validation.
From an evaluation perspective, in this setting a model needs to be
better at early detection (high sensitivity at low false positive
rates), and the modeler needs to determine the threshold for prediction
according to the practical use case, such as the number of compounds
that can be selected for experimental testing.<sup><xref ref-type="bibr" rid="ref306">306</xref></sup> There are metrics, such as the Enrichment Factor, designed
to emphasize the early recognition compared to the larger set of compounds
considered in the ROC curve.<sup><xref ref-type="bibr" rid="ref307">307</xref></sup> Enrichment
factor refers to the ratio between the proportion of true positives
among the top-ranked candidates and the proportion in the full screening
set for some number or fraction of top-ranked candidates. A higher
enrichment factor indicates that the model is effective at early detection,
identifying active compounds among the top-ranked candidates. From
an AUC-ROC perspective, the enrichment factor is primarily dependent
on the initial segment of the curve. It is often more practical to
work with absolute numbers, such as selecting 100,000 compounds for
testing (or screening 100 &#x000d7; 96-well plates), to align with the
specific capacity or resources available. Another way to achieve these
objectives is by analyzing the regions of the PRC and ROC curves.
For example, ranking the top 1% of compounds predicted correctly as
active (true positives), one could identify the region of the PRC
curve where the highest precision is achieved, while recall is relatively
able to capture 1% of positives. Typically, the top 1% of compounds
would be at the beginning of the PRC (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>a), typically at the top left of the curve,
where the model makes predictions with the highest precision because
the model is most confident about these predictions. Since it is often
hard to determine what parts of the PR or ROC curves map to percentage
of compounds predicted active, another way to evaluate models for
prioritizing compounds would be to plot precision as a function of
the percentage of compounds predicted active (with exact numbers tested
on a secondary axis).<sup><xref ref-type="bibr" rid="ref308">308</xref></sup> Overall, we would
want to identify a set of chemically diverse compounds, while a model
that has high precision. To do so, modelers could choose a threshold
that has acceptable precision and that is large enough to perform
diversity selection.</p><p>Deselection involves setting a threshold
on the ROC curve to correctly
identify a large proportion of undesired compounds as true negatives
while retaining as many desired compounds as true positives as possible
(<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>b). To ensure
a high recall of the undesired class (e.g., 90%), we aim to maximize
true negative rate specifically subject to this constraint.</p><p>Prioritizing (or ranking) compounds based on their likelihood of
being true positives involves analyzing the Precision-Recall Curve
(PRC) to determine where precision and recall maximize the true positive
rate (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>c). The
goal is to identify a set of compounds that is sufficiently large
to support a selection of the desired size while also ensuring a high
confirmation rate. This selection typically occurs in a region of
the PRC where the model maintains good precision while recalling a
significant number of true positives. An alternative way to evaluate
the model&#x02019;s ability to rank compounds is to plot precision
as a function of the number of compounds predicted to be positive
(<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>), which is
often easier to interpret.<sup><xref ref-type="bibr" rid="ref308">308</xref></sup> For finer
granularity, a rank-based metric such as Kendall&#x02019;s tau can
also be useful.</p><p>For toxicity prediction tasks, when the goal
is often to flag compounds
with likely toxicity, prioritizing a higher recall of toxic compounds
is often more appropriate, even if it results in lower precision,
which is associated with more false positives (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>d), because advancing toxic compounds is
highly costly. This approach is related to a deselection setting,
where we aim for a high recall of desired compunds. On the other hand,
if the model is used to deselect compounds, a high true negative rate
(removing <italic>mostly</italic> toxic compounds) is desirable to
preserve as many safe compounds as possible. It can be seen that models
present a trade-off, and not all that is desirable can be obtained
at the same time; being able to, say, have a higher recall of desired
compounds comes at the cost of more false-positive predictions, etc.
This underlines the importance of choosing a suitable performance
metric and classification threshold for a particular use case, as
opposed to trying to find a generic answer to the problem.</p><p>Models
should also be compared with baseline models (such as majority
class or average predictor or randomly shuffled labels using Y-Scrambling<sup><xref ref-type="bibr" rid="ref309">309</xref></sup>), in order to establish how much value the
proposed model provides. Baseline models can provide surprisingly
good performance in many cases, such as on imbalanced data sets (where
one can predict the majority class), or otherwise biased data sets,
where the baseline classifier just picks up the underlying bias of
the data set.<sup><xref ref-type="bibr" rid="ref310">310</xref></sup></p><p>For classification
models, it is necessary to compare models to
chance prediction and baseline models, in particular, given that even
baseline models can obtain surprisingly good performance. Cohen&#x02019;s
Kappa measures the agreement between actual and predicted values,
adjusted for agreement occurring by chance.<sup><xref ref-type="bibr" rid="ref304">304</xref>,<xref ref-type="bibr" rid="ref311">311</xref></sup> In terms of applications, Cohen&#x02019;s Kappa was used as the metric
to identify the optimal decision threshold that maximizes the balanced
accuracy of the classifier predicting structure&#x02013;activity data
from 138 public data sets corresponding to pharmaceutical targets,
addressing the issue of class imbalance, where the model may overpredict
the majority class and underpredict the minority class.<sup><xref ref-type="bibr" rid="ref312">312</xref></sup> The authors found that optimizing thresholds
significantly enhances prediction outcomes for inhibitors of Tau fibril
formation, particularly when the initial model is already well-predictive
(as measured by AUC-ROC). This optimization improved the True Positive
Rate (TPR, also known as recall and sensitivity) from 4% to 43% and
Cohen&#x02019;s Kappa from 0.06 to 0.4. However, for predicting inhibitors
of Marburg virus binding or entry into cells, where the initial model
had lower predictive power, the improvements were more modest, with
TPR increasing from 0.1% to 5% and Cohen&#x02019;s Kappa from 0.002
to 0.08. Where there are several classes to predict (such as low,
medium, and high solubility), Kappa can be used to rank classification
models; this was used in recent Kaggle solubility challenge.<sup><xref ref-type="bibr" rid="ref313">313</xref></sup> Overall, Kappa-based optimization is recommended
for machine learning classification models in toxicity prediction,
particularly when the initial model performance is strong.</p><p>Overall,
the threshold chosen to generate definitive model predictions
from model-predicted probabilities is context-dependent for each task.
The final model should be chosen based on the desired balance between
the performance metric most relevant for a particular use case.</p><p>To evaluate a regression model, it is essential to check at least
three aspects of the prediction: (a) correlation&#x02014;how well the
model captures the relationship between the real target values and
predicted data, (b) goodness of fit&#x02014;how well the model fits
the data overall and how much of the variance in the output variable
is explained by the model, and (c) dispersion of errors&#x02014;how
close the predicted values are to the actual target values. Distribution-
and point-based metrics are generally used to evaluate regression
models.</p><p>The simplest way to evaluate a regression model is by
measuring
correlation, which tells us about the strength and direction of the
relationship between the model&#x02019;s predictions and the actual
values. A common metric for this purpose is the Pearson correlation
coefficient (<italic>r</italic>), which ranges from &#x02212;1 to 1.
If <italic>r</italic> is close to 1, it indicates a strong positive
relationship, meaning that the model&#x02019;s predictions closely
match the actual target values. A value close to 0 (or negative) suggests
little to no linear relationship or even an inverse relationship,
indicating that the model may not effectively capture the trend in
the data. The squared Pearson correlation (<italic>r</italic><sup>2</sup>) measures the proportion of the variance in the actual values
that is predictable from the model&#x02019;s predictions. Another useful
correlation metric is Spearman correlation, which is used when we
are more interested in the ranking of values rather than their exact
predicted values. Unlike Pearson correlation, Spearman correlation
focuses on the rank order of the predictions compared to the actual
values and is thus less sensitive to outlier values. This makes Spearman
correlation useful for nonlinear relationships between predictions
and actual target values, and in practice it can be a very useful
metric to establish the ability to prioritize, e.g., compounds to
be tested experimentally in an assay, where the number of compounds
to select is fixed (and only depends on the ordered list of model
output).</p><p>The second aspect of model evaluation is assessing
the goodness
of fit, which tells us how well the regression model fits the data
points. There are multiple metrics commonly used to evaluate goodness
of fit such as coefficient of determination (<italic>R</italic><sup>2</sup>), coefficient of determination on regression through the
origin (<italic>R</italic><sub arrange="stack"><italic>o</italic></sub><sup arrange="stack">2</sup>), and modified <italic>R</italic><sup>2</sup> (<italic>R</italic><sub arrange="stack"><italic>m</italic></sub><sup arrange="stack">2</sup>).<sup><xref ref-type="bibr" rid="ref314">314</xref>,<xref ref-type="bibr" rid="ref315">315</xref></sup> An <italic>R</italic><sup>2</sup> value closer to 1 indicates that the model
explains a large percentage of the variability in the data, suggesting
a good fit. It is well established that regression through the origin
(<italic>R</italic><sub arrange="stack"><italic>o</italic></sub><sup arrange="stack">2</sup>) is of less significance to predictive ML
models, where we wish to compare observed versus predicted values.
Global metrics like <italic>R</italic><sup>2</sup> are often less
informative because they are not measures of the decisional impact;
often, errors near the decisional boundary are most important instead
of equally weighting everywhere. Alexander et al. demonstrate that <italic>R</italic><sup>2</sup> (as defined in equation below), defined as
the proportion of total variability explained by the model (the ratio
of explained variability to total variability, subtracted from unity),
is practically useful, particularly when the goal is to minimize residuals
between model predictions and actual values.<sup><xref ref-type="bibr" rid="ref316">316</xref></sup><disp-formula id="ueq6"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_m006" position="anchor"/></disp-formula>where <italic>y</italic> is the observed response
variable, <italic><overline>y</overline></italic> is its mean, and <italic>&#x00177;</italic> is the corresponding predicted value.</p><p>While <italic>r</italic><sup>2</sup> and <italic>R</italic><sup>2</sup> are sometimes
equivalent, they are not always the same. The
key difference arises when the mean of the model&#x02019;s predictions
does not match the mean of the real data. In such cases, <italic>R</italic><sup>2</sup> will decrease because the model&#x02019;s predictions
are biased, either systematically overestimating or underestimating
the targets. In contrast, <italic>r</italic><sup>2</sup> remains unaffected
by this bias as it only captures the strength of the linear relationship
between the predictions and targets. Therefore, <italic>r</italic><sup>2</sup> may still be high even if the model&#x02019;s predictions
are consistently offset. Whether to prioritize <italic>R</italic><sup>2</sup> or <italic>r</italic><sup>2</sup> depends on the goal of
the model. If the primary interest is in capturing the underlying
trends without regard to systematic bias, <italic>r</italic><sup>2</sup> may be more informative. However, if the exact accuracy of predictions
is critical, <italic>R</italic><sup>2</sup> is more appropriate as
it penalizes bias.</p><p>While metrics like the coefficient of determination
(<italic>R</italic><sup>2</sup>) are standard for evaluating how well
a regression model
captures the overall trend and variance of the data distribution (measure
of distribution), Alexander et al. suggest that it is also important
to assess the accuracy of predictions at individual data points (measure
of dispersion).<sup><xref ref-type="bibr" rid="ref316">316</xref></sup><italic>R</italic><sup>2</sup> measures how well the predicted values replicate the variability
of the true data but does not detect point-wise deviations where predictions
are systematically higher or lower than actual values.</p><p>To capture
these point-wise deviations, point-based error metrics
are used that are, when it comes to anticipating the error of a prediction
in future use cases, at least as important as the above distribution-based
metrics. Studies often use Mean Absolute Error (MAE), which measures
the average magnitude of the errors without considering their direction,
offering a straightforward measure of how much, on average, the predictions
deviate from the true values at each point.<disp-formula id="ueq7"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_m007" position="anchor"/></disp-formula>where for <italic>n</italic> predictions from
a sample of <italic>n</italic> data points, <italic>Y</italic><sub><italic>i</italic></sub> is the observed value of the variable being
predicted, and <italic>&#x00176;</italic><sub><italic>i</italic></sub> is the predicted value.</p><p>The most common metrics used is the
Mean Squared Error (MSE), which
calculates the average of the squared differences between predicted
and actual values at each data point. A lower MSE indicates that the
model&#x02019;s predictions are generally close to the actual values
on a point-by-point basis.<disp-formula id="ueq8"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_m008" position="anchor"/></disp-formula>where for <italic>n</italic> predictions from
a sample of <italic>n</italic> data points, <italic>Y</italic><sub><italic>i</italic></sub> is the observed value of the variable being
predicted, and <italic>&#x00176;</italic><sub><italic>i</italic></sub> is the predicted value.</p><p>The Root-Mean-Square Error (RMSE)
is the square root of the MSE
and provides an error measure in the same units as the target variable,
enhancing interpretability.<disp-formula id="ueq9"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_m009" position="anchor"/></disp-formula>where for <italic>n</italic> predictions from
a sample of <italic>n</italic> data points, <italic>Y</italic><sub><italic>i</italic></sub> is the observed value of the variable being
predicted, and <italic>&#x00176;</italic><sub><italic>i</italic></sub> is the predicted value.</p><p>In some regression tasks, it can be
useful to evaluate model performance
using classification metrics by converting continuous targets into
binary labels based on a threshold. For instance, if the target values
are bimodal or contain a small fraction of extreme values, we can
convert them into binary or multiclass labels and compare the actual
data to the predicted labels. Also in case of data with large experimental
error, such as microsomal stability assays, categorical predictions
based on a regression model can be useful.<sup><xref ref-type="bibr" rid="ref317">317</xref></sup> Metrics such as accuracy, precision, recall, and F1 score can then
be used to assess the model&#x02019;s ability to correctly classify
target values. This approach is particularly helpful when the continuous
target values are noisy within each mode, and the primary focus is
on accurately making a binary decision: identifying high-risk or high-value
cases.</p><p>From the perspective of ML models in toxicity prediction,
a model
with a low <italic>R</italic><sup>2</sup> may still be helpful in
practical drug discovery if the measure of dispersion, such as the
Root-Mean-Square Error (RMSE), is low and acceptable for the intended
use. For example, <italic>in vivo</italic> pharmacokinetic parameters
are organism-level data that are considered difficult to model using
chemical descriptors: models usually have a low <italic>R</italic><sup>2</sup>.<sup><xref ref-type="bibr" rid="ref124">124</xref>,<xref ref-type="bibr" rid="ref125">125</xref></sup> Yet, such models where the RMSE
is deemed within acceptable thresholds are used internally in pharmaceutical
companies. In predictive <italic>in vivo</italic> PK property models,
the number of compounds predicted within 2- or 3-fold error (prediction
fold error) is a common evaluation metric.<sup><xref ref-type="bibr" rid="ref318">318</xref></sup> This level of &#x02018;error&#x02019; is acceptable due to the significant
inherent variability in biological systems, as well as differences
in the output variable that span multiple orders of magnitude, meaning
that even the experimental data can exhibit substantial variability
between individuals, and predictions falling within a 2- to 3-fold
range of observed values are considered reasonable in PK prediction,
as the model&#x02019;s performance aligns with the actual variability
in the data.<sup><xref ref-type="bibr" rid="ref319">319</xref>,<xref ref-type="bibr" rid="ref320">320</xref></sup></p><p>Overall, we recommend
measures of dispersion like RMSE and Mean/Median
Absolute Error (MAE) along with fit-to-data-distribution metrics like
(<italic>R</italic><sup>2</sup>) as metrics in evaluating toxicity
models for real-world applications. (For a more detailed of those
aspects, see ref (<xref ref-type="bibr" rid="ref33">33</xref>).) In addition, it is important to keep in mind that the impact of
experimental assay error should not be overlooked in the pursuit of
achieving the &#x02018;best&#x02019; performance and that model error
needs to be seen in context of experimental error. Once a model reaches
the known theoretical accuracy (and error) of the experimental method
(the data from which the model was built on), the model could be considered
as good as the underlying experiment.<sup><xref ref-type="bibr" rid="ref321">321</xref></sup> Striving for performance beyond that point, on the same test set,
may only reflect the error and noise inherent in the data and hence
lead to model overfitting (which indeed seems to be the case for several
published models<sup><xref ref-type="bibr" rid="ref322">322</xref></sup>).</p></sec><sec id="sec26"><title>Retrospective Model Validation</title><p>In order to optimize
hyperparameters of models, as well as to obtain
an estimate of future performance, models must be validated on compounds
not seen during model training before real-world use (see <xref rid="box2-fo" ref-type="chart">Box 2</xref> for details on validation
strategies). Models are typically validated by splitting the data
to create train, validation and test sets (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig">10</xref></xref>), where the primary purpose of the training set is to fit
model parameters; the validation set is used to optmise hyperparameters
(however, preoptimized hyperparameters can also suffer from overfitting<sup><xref ref-type="bibr" rid="ref323">323</xref></sup>) and the test set is used to estimate future
model performance.</p><fig id="box2-fo" position="float"><label>Chart Box 2</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_0016" id="fx16" position="float"/></fig><fig id="fig10" position="float"><label>Figure 10</label><caption><p>Comparative overview of model validation techniques for
ML models
in chemical space for toxicity prediction: Internal validation methods
include (a) cross-validation, ensuring model reliability through repetitive
training and testing on different data segments, (b) leave-one-cluster-out,
assessing generalization across similar compound groups, (c) held-out
test set, evaluating unseen data held-out from the data set; and (d)
nested cross-validation, optimizing model parameters while preventing
overfitting. External validation techniques comprise (e) a posthoc
test set, providing an unbiased assessment of completely new experimental
data; (f) an out-of-distribution set, testing model robustness against
novel compound distributions such as new class compounds; and (g)
prospective validation, confirming real-world applicability on future
projects. Note: This figure offers an oversimplified representation
of chemical space. While the 2D space can be visualized on two axes,
chemical space is multidimensional, underpopulated, and behaves differently
in every area. Thus, validation in chemical space is more complex
than visualized here, and this figure is intended for illustrative
purposes only.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_0010" id="gr10" position="float"/></fig><p>More specifically, cross-validation is often used
to provide a
better performance estimate than that given by a single train-test
split and to estimate the uncertainty in this performance estimate.
Cross-validation (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig">10</xref></xref>a) involves dividing the data set into multiple subsets and
systematically training and validating the model across different
combinations of these subsets.<sup><xref ref-type="bibr" rid="ref234">234</xref></sup> In each
iteration, one subset of the data is used for training, and the remaining
subset of the data is used for testing. Performance metrics are each
averaged across splits to provide an estimate of the model&#x02019;s
performance, and the variance of each metric across splits is used
to provide error bars for this performance estimate. If there is no
need to select and optimize hyperparameters for an algorithm, then
a cross-validation is sufficient. However, when optimizing parameters,
a simple cross-validation often leads to an overestimation of model
performance.<sup><xref ref-type="bibr" rid="ref324">324</xref></sup> In any case, the caveat
remains that performance of the model is still evaluated only on the
chemistry contained in the test set, which may not represent future
use cases. Hence, nested cross-validation (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig">10</xref></xref>d) extends this concept by incorporating
an inner loop for hyperparameter tuning (&#x02018;validation set&#x02019;)
and an outer loop for model performance assessment (&#x02018;test set&#x02019;).
This approach aims to prevent overfitting by ensuring that hyperparameter
tuning does not bias the model&#x02019;s performance evaluation. Once
a model has been optimized with respect to hyperparameters, it is
typically retrained on all training data and validated on held-out
data retrospectively (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig">10</xref></xref>c). A held-out (&#x02018;external&#x02019;) test set is where
a part of the original data set is reserved only for testing a single
time, ensuring that the model was never exposed to it during prior
steps (such as feature selection, model selection/training, nested-cross
validation, etc.). Holding out test compounds from the same source
data, however, means the test data is being drawn from the same underlying
distribution as the training data, which can represent &#x02018;data
leakage&#x02019; (given that similar compounds are present in training
and test set) and lead to an overestimation of model performance.
If a model performs similar across different folds of the (nested)
cross-validation it can be seen as &#x02018;stable&#x02019;, and if
it performs well on a held-out test set, the model can be considered
reliable <italic>in the respective chemical space and conditions covered
by this test set</italic> (which may or may not be predictive for
future use cases, particularly if the training set and test set contained
highly similar compounds, allowing information leakage, but future
use cases do not). Given future use cases are generally unknown, it
is difficult to obtain a reliable estimate of model performance for
this situation.</p><p>There are different approaches for data splitting,
which impact
how the training and test sets are formed.<sup><xref ref-type="bibr" rid="ref325">325</xref></sup> The simplest is randomized data splitting, which assigns each data
point randomly to training or test sets. Although this often still
being used, it poses dangers: training data sets may differ in distribution
from the data seen during model deployment&#x02014;for example, the
training set may contain clusters of compounds from the same chemical
series, whereas the data the model is deployed on may include novel
series&#x02014;and thus other strategies would more realistically reflect
expected model performance in real-world use.<sup><xref ref-type="bibr" rid="ref326">326</xref>&#x02212;<xref ref-type="bibr" rid="ref328">328</xref></sup> For instance, &#x0201c;scaffold splitting&#x0201d; groups compounds
based on their molecular scaffolds&#x02014;the core structures of molecules
without side chains.<sup><xref ref-type="bibr" rid="ref326">326</xref></sup> By ensuring that
compounds with the same scaffold are all in either the training or
test set, metrics evaluated with this train-test split measure the
model&#x02019;s ability to generalize to new chemical scaffolds not
seen during training. While this is conceptually valid, &#x02018;new
chemical scaffolds&#x02019; may still be more similar, or less similar,
in the test set compared to the training set relative to future use
cases. Related approaches split data based on other methods of clustering
molecules based on various measures of similarity to avoid information
leakage from training to test. A more stringent variant of data split
is leave-one-cluster-out (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig">10</xref></xref>b) validation, where each <italic>cluster</italic> forms
a separate test split. In effect, this splitting strategy carves out
whole <italic>areas</italic> of chemical space for the test set. A
temporal (time) split, on the other hand, involves dividing the data
based on the time of data acquisition or compound synthesis. The model
is trained on older data and tested on newer data, simulating real-world
scenarios where models are applied to future compounds, designed based
on measured properties of past compounds.<sup><xref ref-type="bibr" rid="ref328">328</xref></sup> This method evaluates the model&#x02019;s predictive performance
over time and can reveal if model performance suffers due to the underlying
data distribution changing over time. This approach is meant to measure
model performance on &#x02018;new project compounds&#x02019;; however,
given that &#x02018;new project compounds&#x02019; may still be located
in very different areas of chemical space, this may or may not resemble
future applications of the model. Step-forward splits are another
approach of model validation, where data are split based on an ordering
based on a molecular property, which could be a physicochemical property
like logD or molecular weight. Molecules falling within some range
of the property (often the highest or lowest values) are held out
from training and are used for testing.<sup><xref ref-type="bibr" rid="ref327">327</xref>,<xref ref-type="bibr" rid="ref329">329</xref></sup> This strategy mimics the application of a model to data that may
have different properties to the training set (for example, molecules
in different ranges of physicochemical space) and can thus help in
understanding how the model will perform in practical, forward-looking
applications. It can be summarized that various data splitting strategies
for model training exist; but due to the size of chemical space and
unknown future use cases, obtaining a reliable model performance estimate
is difficult in practice.</p></sec><sec id="sec27"><title>Prospective Model Validation on Relevant Chemical Space</title><p>While the above retrospective data splitting strategies can give
some estimate of performance in future use cases, the real proof of
applicability of a model rests in <italic>prospective</italic> applications;
after all, it is always easier to predict the past, than to predict
the future. Prospective validation involves testing the model&#x02019;s
predictions against new, unseen data on future projects or compounds,
to confirm their reliability in the chemical space required for the
project. While some of such cases are represented to model applications
in true future projects, also some &#x02018;mixed&#x02019; approaches
are possible. A posthoc test set (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig">10</xref></xref>e) consists of validation of predictions
for molecules (say, newly synthesized compounds) that the model has
never encountered during any stage of its development. These molecules
should be kept hidden from the model developers until the final evaluation
phase. An out-of-distribution validation (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig">10</xref></xref>f) includes compounds that are significantly
different from the training data distribution&#x02014;such as new classes
of compounds, novel scaffolds, or data obtained under different experimental
conditions. The difference to retrospective validation is here fluent
in a way, and artificially &#x02018;difficult&#x02019; retrospective
cases can be more difficult for the model to handle than, e.g., close
analogues in a true prospective set. Finally, prospective validation
on future projects (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig">10</xref></xref>g) would involve applying the model to predict outcomes in
future projects or compounds synthesized after the model&#x02019;s
development, to test the model&#x02019;s predictive power in live scenarios,
reflecting its utility in actual practice. And this, in combination
with what is described in the next pillar, is actually what matters
in reality: Not whether a validation is &#x02018;retrospective&#x02019;
or &#x02018;prospective&#x02019;, but rather whether we can improve
decision making (which of course will then usually be in the prospective
domain).</p><p>The overall process of model training and validation
is explained
by using a hypothetical case here: Take for example, a model aiming
to predict mitochondrial membrane depolarization, which will be applied
in a discovery project for a novel class of chemical compounds, synthetic
cannabinoids. An ML model could have been trained and internally validated
using nested cross-validation on a data set for small molecules and
associated mitochondrial membrane depolarization readouts (a toxicity
measure); this set of compounds could include some known cannabinoids.
The nesting can leave one-cluster-out to ensure that the optimization
results in a model that can generalize across different subclasses
of compounds, including cannabinoids. Once optimized, the fitted model
should be validated retrospectively using a held-out test set, including
some novel synthetic cannabinoids that were not part of the training
data (out-of-distribution) to assess its predictive accuracy in the
particular chemical space. If the performance is acceptable for practical
application, the model could be applied to a drug discovery project
targeting the development of cannabinoid-based therapeutics. A prospective
validation would be attempted against experimental data from the new
cannabinoid compounds developed during the project. Such prospective
validation assesses whether the models perform as expected in practical
project applications.</p><p>Once validated, a model can be retrained
on all available data,
including the test data, before it is deployed again. This should
expand the model&#x02019;s coverage of the chemical space since more
data are included for model training. Given that the test set typically
represents a small addition to a much larger training data set and
the optimized model parameters remain the same as the before, the
inclusion of the test data in the retraining now is unlikely to significantly
alter predictions in other areas of the chemical space. Instead, it
primarily enhances the model&#x02019;s accuracy within the newly added
chemical space. On the other hand, using the test data in training
the final deployed model means that further performance evaluation
of the model is difficult unless new test data becomes available.
Thus, as new data become available from experiments, the model is
retrained, re-evaluated, updated if suitable, and deployed for use.
This process is particularly important in the case of project work,
where information about the chemical space of current interest can
greatly increase model performance. For an example of implementation
of suitable validation protocols, see OCHEM (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ochem.eu">https://ochem.eu</uri>), a platform developed
more than 15 years ago.</p></sec><sec id="sec28"><title>Defining the Applicability Domain</title><p>Optimizing a model
for a given evaluation metric needs to be complemented
with a measure how well the model is able to predict for future uses
cases - similar to experiments, which result, e.g., in a mean and
an associated standard deviation, predictions need to come with a
prediction value, and an associated confidence measure into this prediction.<sup><xref ref-type="bibr" rid="ref330">330</xref></sup> Models must, therefore, balance optimizing
the performance metric with the so-called &#x02018;Applicability Domain&#x02019;
(AD). The AD defines the range of input/output values or conditions
under which the model&#x02019;s predictions are considered reliable
and valid. It essentially sets the boundaries within which the model
can be expected to perform accurately (to various quantitative degrees),
based on the data it was trained on and the model training and validation
process used. Models trained on a smaller data set of more project-relevant
compounds may outperform those trained on larger data sets; this was
observed in the context of virtual screening, where removing half
of the molecules with the lowest applicability scores indeed <italic>improved</italic> performance.<sup><xref ref-type="bibr" rid="ref331">331</xref></sup> One
approach to evaluating performance with respect to the applicability
domain involves using test sets split into distance bins (where distance
refers to structural similarity to the training compounds) to monitor
performance. Furthermore, bins representing chemical space with poor
performance suggest new experiments, whose data might improve the
model performance in that space. Various alternatives have been explored
to define AD in chemical space (<xref rid="tbl9" ref-type="other">Table <xref rid="tbl9" ref-type="other">8</xref></xref>), each catering to particular scenarios.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> It should be noted that while a large number
of such approaches exist, given the size of chemical space and that
it behaves very differently locally, it is very difficult to come
with reliable error (and applicability domain) estimates in practice.</p><table-wrap id="tbl9" position="float"><label>Table 8</label><caption><title>Methods to Estimate the Applicability
Domain of a Predictive Model for Small Molecule Compound Properties<sup><xref ref-type="bibr" rid="ref331">331</xref></sup></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">Method</th><th style="border:none;" align="center">Description</th><th style="border:none;" align="center">When to Use</th><th style="border:none;" align="center">When Not to
Use</th><th style="border:none;" align="center">Reference</th></tr></thead><tbody><tr><td style="border:none;" align="left">Range-based methods</td><td style="border:none;" align="left">Define boundaries based
on the range of descriptor values in
the training set</td><td style="border:none;" align="left">When the descriptor values are well-defined
and bounded within
a specific range</td><td style="border:none;" align="left">When the data contains many outliers</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref40">40</xref>)</td></tr><tr><td style="border:none;" align="left">Convex
hull methods</td><td style="border:none;" align="left">Establish a geometric boundary around training
data points</td><td style="border:none;" align="left">When the data points form a well-defined
area in the descriptor
space</td><td style="border:none;" align="left">When the data is multidimensional, sparse, or
irregularly distributed</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref332">332</xref>)</td></tr><tr><td style="border:none;" align="left">Distance-based methods</td><td style="border:none;" align="left">Measure
the distance between a query molecule and the closest
training data points</td><td style="border:none;" align="left">When the distances between data
points in the descriptor space
are meaningful and consistent</td><td style="border:none;" align="left">When the descriptor space
is a binary vector or too high-dimensional</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref333">333</xref>)</td></tr><tr><td style="border:none;" align="left">Density-related methods</td><td style="border:none;" align="left">Evaluate the density of data points around a query molecule</td><td style="border:none;" align="left">When data consists of a few chemical series, the density of
data points around a query molecule indicates prediction reliability</td><td style="border:none;" align="left">When the data is uniformly distributed or lacks significant
density variations</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref40">40</xref>)</td></tr><tr><td style="border:none;" align="left">One-class SVM</td><td style="border:none;" align="left">Train a model to identify
the region in the descriptor space
occupied by the training set</td><td style="border:none;" align="left">Identifying whether a query
point belongs to the same distribution
as the training set</td><td style="border:none;" align="left">When the training data is highly
heterogeneous or contains
multiple clusters</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref334">334</xref>)</td></tr><tr><td style="border:none;" align="left">Uncertainty quantification and confidence estimation</td><td style="border:none;" align="left">Assess prediction confidence by analyzing model outputs</td><td style="border:none;" align="left">Report the confidence of the model&#x02019;s predictions</td><td style="border:none;" align="left">When the computational cost of uncertainty estimation is prohibitively
high</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref335">335</xref>,<xref ref-type="bibr" rid="ref336">336</xref>)</td></tr><tr><td style="border:none;" align="left">Reliability-density
neighborhood approaches</td><td style="border:none;" align="left">Combine density and distance
metrics to define AD</td><td style="border:none;" align="left">Combining density and distance
metrics can provide a more nuanced
definition of AD</td><td style="border:none;" align="left">When the data lacks sufficient density
or distance information
to make reliable assessments</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref337">337</xref>)</td></tr></tbody></table></table-wrap></sec><sec id="sec29"><title>Pillar 5: Translating to Decision-Making</title><p>As we have
seen, improving ML models for molecular toxicity prediction
relies on data, chemical representation, model architectures, and
validation. However, improving drug discovery (as a process) involves
translating the outcomes of ML models into actionable follow-up decisions,
such as prioritization of one compound over another, which assay to
run next, etc.<sup><xref ref-type="bibr" rid="ref300">300</xref></sup> (<xref rid="fig11" ref-type="fig">Figure <xref rid="fig11" ref-type="fig">11</xref></xref>; see <xref rid="box3-fo" ref-type="chart">Box 3</xref> for critical
takeaways on moving ML predictions toward actionable drug discovery
decisions). It can be seen that a machine learning model (and its
application) is only a tool, an ability&#x02014;when used, it is embedded
into a <italic>context</italic>, and that context is frequently insufficiently
considered when only focusing on &#x02018;model metrics&#x02019;. However,
a machine learning model is not a purpose in itself; the purpose of
a model is to be applied in a context.</p><fig id="box3-fo" position="float"><label>Chart Box 3</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_0017" id="fx17" position="float"/></fig><fig id="fig11" position="float"><label>Figure 11</label><caption><p>Influence on ML predictions in hypothetical project contexts
depends
on the availability of assays and validation on a subset of compounds.
Interpreting and understanding predictions from ML models.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_0011" id="gr11" position="float"/></fig><p>Many ML models for toxicity in the industry are
used as an alert
for potential risk or for prioritization and not necessarily as a
go/no-go decision. Those decisions depend highly on PK/ADME, dose,
exposure, etc., conditions that an ML model usually does not capture.
In terms of machine learning, this represents an &#x02018;underspecification&#x02019;
of the task the model is trained on<sup><xref ref-type="bibr" rid="ref338">338</xref></sup>&#x02014;and
hence the model output cannot be directly translated to decision making.
For example, acetaminophen (paracetamol) is generally safe at therapeutic
doses but becomes toxic at higher doses due to its metabolism into
a harmful compound called N-acetyl-p-benzoquinone imine (NAPQI).<sup><xref ref-type="bibr" rid="ref339">339</xref></sup> Machine learning models predicting toxicity
solely on the basis of molecular structure might not flag this risk
because they rarely account for dose-dependent effects, metabolic
pathways, or individual variations in drug metabolism (PK/ADME factors).
PK parameters are needed for human-relevant decision making in safety.<sup><xref ref-type="bibr" rid="ref340">340</xref></sup> For example, predicting <italic>in vivo</italic> pharmacokinetic parameters (which cover drug absorption, distribution,
and clearance in humans) could reveal unsuitable drug characteristics
(such as bioavailability), informing the next iteration of drug design
as part of a Design&#x02013;Make&#x02013;Test&#x02013;Analyze cycle to
optimize compounds in development.<sup><xref ref-type="bibr" rid="ref341">341</xref>,<xref ref-type="bibr" rid="ref342">342</xref></sup> Overall,
ML models for efficacy, toxicity, and PK/ADME can only translate to
human-relevant decision-making if all three are considered in parallel.</p><p>To a small extent computational methods have already impacted regulatory
processes, such as the adoption of the ICH M7 guidelines (International
Council for Harmonisation of Technical Requirements for Pharmaceuticals
for Human Use).<sup><xref ref-type="bibr" rid="ref343">343</xref></sup> These guidelines provide
a framework for using computational methods, including ML, to predict
the mutagenic potential of pharmaceutical impurities. The ICH M7 guidelines
emphasize the importance of (Q)SAR (Quantitative Structure&#x02013;Activity
Relationship) methodologies, recommending two complementary approaches
for this purpose, namely, an expert rule-based system and a statistics-based
system. Expert rule-based systems apply established toxicological
rules to identify certain molecular fragments, known as structural
alerts, associated with mutagenicity, while statistical (ML) models
leverage large data sets to detect patterns and predict outcomes.
Where both methodologies indicate no structural alerts for mutagenicity,
the guidelines deem the negative <italic>in silico</italic> results
as sufficient evidence to conclude that the impurity is not of mutagenic
concern, eliminating the need for further experimental testing. This
is one concrete example of computational toxicology replacing laboratory
experiments, which, however, is limited to a relatively narrow range:
to <italic>impurities</italic> (so compounds present at relatively
low concentration), in the genotoxicity area, and only when two methods
are employed in parallel. In another example, French health authorities&#x02019;
request for toxicity data on cyamemazine was satisfactorily answered
with an <italic>in silico</italic> assessment of target organ toxicity.<sup><xref ref-type="bibr" rid="ref344">344</xref></sup> The <italic>in silico</italic> models used
for hazard assessment covered toxicity end points such as mutagenicity,
hepatotoxicity, nephrotoxicity, cardiotoxicity, etc., including two
complementary models, namely expert alert and statistical QSAR models.
It can be seen that model predictions can <italic>contribute to</italic> decision making, but having a model does not represent &#x02018;having
the answer&#x02019; by itself.</p><p>Machine learning models are increasingly
being applied in real-world
projects in drug discovery to uncover mechanisms of action, predict
toxicity, and assess off-target risks early in the development process.
Predictive assays for hepatotoxicity and cardiotoxicity have also
been an essential part of the early toxicology strategy.<sup><xref ref-type="bibr" rid="ref345">345</xref></sup> Recently, a virtual enhanced cross-screen panel
(vEXP) used ML models to predict 67 off-target activities, aiming
to provide early warnings about potential adverse drug reactions.<sup><xref ref-type="bibr" rid="ref346">346</xref></sup> The authors reported that the vEXP panel effectively
identified potential off-target activities, aiding in the early prioritization
and risk assessment of drug candidates&#x02014;for targets with well-balanced
data sets and sufficient data points, the models demonstrated strong
predictive performance, many exceeding the thresholds set for acceptable
performance (e.g., Kappa &#x02265; 0.4, ROC-AUC &#x02265; 0.7). The
authors suggested that the vEXP panel be integrated into various stages
of the drug discovery process&#x02014;to rank hit compounds based on
their predicted off-target profiles, identify systematic risks associated
with specific chemical series or functional groups, and ensure that
late-stage optimization efforts do not inadvertently introduce new
off-target activities. This example represents a case where computational
models can complement experimental approaches to achieve <italic>higher
efficiency</italic> as a result.</p><p>Extending beyond animal experiments,
Next Generation Risk Assessment
(NGRA) combines <italic>in silico</italic> models and <italic>in vitro</italic> assays to evaluate chemical safety without relying on animal data.
For instance, an industry study on coumarin in cosmetic products integrated
mathematical models, <italic>in vitro</italic> NAMs, an <italic>in
vitro</italic> cell stress panel, high-throughput transcriptomics,
and <italic>in silico</italic> alerts for genotoxicity.<sup><xref ref-type="bibr" rid="ref347">347</xref></sup> The authors demonstrated that <italic>in silico</italic> methods can complement experimental data to provide sufficient evidence
for safety evaluations in a regulatory context. Similarly, Ouedraogo
et al. used a 10-step framework of read-across and NAMs with propylparaben,
demonstrating the practical application of integrating exposure assessment, <italic>in silico</italic> methods, and bioactivity data to inform reproductive
toxicity alerts.<sup><xref ref-type="bibr" rid="ref348">348</xref></sup> Overall, these approaches
highlight the value of combining multiple data sources and methodologies
to enhance the accuracy, efficiency, and regulatory acceptance of
risk assessments. Overall, <italic>in silico</italic> models used
in drug (or here compound) discovery, development, and safety assessment
can, to some extent, reduce the experimental burden in real-world
settings.</p><p>A final key to improving the translation of ML models
in the real
world involves a suitable understanding of the use case and user,
hence setting up a system that enables adoption in real-world projects.
Aspects such as understanding the need for retraining (on project-specific
data), the type of model developed (regression vs two/three/four-class
classification), the output of prediction confidence (and potentially
a nearest neighbor/concrete experimental data point for the user to
gain trust into the model), suitable interfaces with databases and
other software systems, design of the user interface, run time, etc.
are important considerations in creating an impactful system in practice.<sup><xref ref-type="bibr" rid="ref349">349</xref></sup> Several publicly available ADMET models are
commonly used (<xref rid="tbl10" ref-type="other">Table <xref rid="tbl10" ref-type="other">9</xref></xref>), some with web-based portals and a graphical user interface. Their
ability to show feature importance, structural alerts, and other interpretive
insights, where present, enhances their transparency and usability.
The reader is encouraged to use these (and other available) tools
to gain hands-on experience, and to see which approaches are useful
in the context of their own work.</p><table-wrap id="tbl10" position="float"><label>Table 9</label><caption><title>Open-Source or Freely Accessible ML
Models for Toxicity Prediction, with Server or Local Implementation</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">Tool Name</th><th style="border:none;" align="center">Web Site</th><th style="border:none;" align="center">Description</th><th style="border:none;" align="center">Reference</th></tr></thead><tbody><tr><td style="border:none;" align="left">ADMETLab 3.0</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://admetlab3.scbdd.com">admetlab3.scbdd.com</uri></td><td style="border:none;" align="left">Predicts ADME-Tox properties using advanced machine learning
models</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref350">350</xref>)</td></tr><tr><td style="border:none;" align="left">QSARdb</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://qsardb.org">qsardb.org</uri></td><td style="border:none;" align="left">Models for human health effects, toxicokinetics, etc.
for evaluating
chemical and environmental risk</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref352">352</xref>)</td></tr><tr><td style="border:none;" align="left">OCHEM</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ochem.eu">ochem.eu</uri></td><td style="border:none;" align="left">Models with environmental
and health related end-points, Tox21,
etc.</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref353">353</xref>)</td></tr><tr><td style="border:none;" align="left">CPSign</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://github.com/arosbio/cpsign">github.com/arosbio/cpsign</uri></td><td style="border:none;" align="left">Conformal prediction
for valid prediction intervals on a per-compound
basis</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref302">302</xref>)</td></tr><tr><td style="border:none;" align="left">Danish QSAR Database</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://qsar.food.dtu.dk">qsar.food.dtu.dk</uri></td><td style="border:none;" align="left">Database of QSAR models for predicting toxicological end points,
especially for regulatory purposes</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref354">354</xref>)</td></tr><tr><td style="border:none;" align="left">DILIPredictor</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://broad.io/DILIPredictor">broad.io/DILIPredictor</uri></td><td style="border:none;" align="left">Predicts human and animal-relevant liver injury and proxy liver
injury end points</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref355">355</xref>)</td></tr><tr><td style="border:none;" align="left">EPI Suite</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://epa.gov/tsca-screening-tools/epi-suitetm-estimation-program-interface">epa.gov/tsca-screening-tools/epi-suitetm-estimation-program-interface</uri></td><td style="border:none;" align="left">A suite of physical/chemical property and environmental
fate
estimation programs</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref356">356</xref>)</td></tr><tr><td style="border:none;" align="left">EMolTox</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://xundrug.cn/moltox">xundrug.cn/moltox</uri></td><td style="border:none;" align="left">Web Server for the prediction of toxicity for safety analysis
in drug development</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref357">357</xref>)</td></tr><tr><td style="border:none;" align="left">OECD QSAR Toolbox</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://qsartoolbox.org">qsartoolbox.org</uri></td><td style="border:none;" align="left">Provides tools for grouping chemicals into categories and predicting
their toxicological properties</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref358">358</xref>)</td></tr><tr><td style="border:none;" align="left">OPERA</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://github.com/NIEHS/OPERA">github.com/NIEHS/OPERA</uri></td><td style="border:none;" align="left">A suite of QSAR models to predict physicochemical properties,
environmental fate, ADME and toxicity end points</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref238">238</xref>)</td></tr><tr><td style="border:none;" align="left">pkCSM</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://biosig.lab.uq.edu.au/pkcsm/prediction">biosig.lab.uq.edu.au/pkcsm/prediction</uri></td><td style="border:none;" align="left">Predicts pharmacokinetic properties of small molecules
using
graph-based signatures</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref359">359</xref>)</td></tr><tr><td style="border:none;" align="left">PKSmart</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://broad.io/PKSmart">broad.io/PKSmart</uri></td><td style="border:none;" align="left">Predicts human and animal pharmacokinetic parameters</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref125">125</xref>)</td></tr><tr><td style="border:none;" align="left">ProTox 3.0</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://tox.charite.de/protox3/">tox.charite.de/protox3/</uri></td><td style="border:none;" align="left">Virtual lab for predicting toxicities of small molecules
using
various predictive models</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref360">360</xref>)</td></tr><tr><td style="border:none;" align="left">SwissADME</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://swissadme.ch">swissadme.ch</uri></td><td style="border:none;" align="left">Predicts
ADME properties of small molecules using free web
tools provided by the Swiss Institute of Bioinformatics</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref361">361</xref>)</td></tr><tr><td style="border:none;" align="left">Toxtree</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://toxtree.sourceforge.net/">toxtree.sourceforge.net</uri></td><td style="border:none;" align="left">Open-source application for the estimation of toxic
hazards
based on decision tree approaches</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref362">362</xref>)</td></tr><tr><td style="border:none;" align="left">VEGA-QSAR</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://vegahub.eu/portfolio-item/vega-qsar">vegahub.eu/portfolio-item/vega-qsar</uri></td><td style="border:none;" align="left">Provides models for predicting toxicological end points
using
Quantitative Structure&#x02013;Activity Relationship (QSAR) models</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref363">363</xref>)</td></tr><tr><td style="border:none;" align="left">VenomPred
2.0</td><td style="border:none;" align="left"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://mmvsl.it/wp/venompred2">mmvsl.it/wp/venompred2</uri></td><td style="border:none;" align="left">Evaluate the toxicological profile of small molecules
and features
that contribute to predictions to derive a structural toxicophore</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref364">364</xref>)</td></tr></tbody></table></table-wrap><table-wrap id="tbl11" position="float"><label>Table 10</label><caption><title>Commonly Used Feature/Model Importance
Methods to Assess Model Performance</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">Method</th><th style="border:none;" align="center">Description</th><th style="border:none;" align="center">Advantages</th><th style="border:none;" align="center">Disadvantages</th><th style="border:none;" align="center">Source</th></tr></thead><tbody><tr><td style="border:none;" align="left">Permutation Importance</td><td style="border:none;" align="left">Measures the increase in the
model&#x02019;s prediction error
when a feature&#x02019;s values are randomly shuffled</td><td style="border:none;" align="left">Easy to understand and implement; can be used in combination
with any modeling method in principle</td><td style="border:none;" align="left">Computationally
intensive and can be misleading if features
are correlated</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref375">375</xref>)</td></tr><tr><td style="border:none;" align="left">Shapley (SHAP) Value</td><td style="border:none;" align="left">Assigns each
feature an important value based on Shapley values
from cooperative game theory</td><td style="border:none;" align="left">Provides consistent and
interpretable results</td><td style="border:none;" align="left">Computationally expensive, especially
for complex models; can
be misleading if features are correlated</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref156">156</xref>)</td></tr><tr><td style="border:none;" align="left">LIME (Local Interpretable
Model-agnostic Explanations)</td><td style="border:none;" align="left">Approximates the model
locally with an interpretable model
to explain predictions</td><td style="border:none;" align="left">Model-agnostic and provides local
explanations</td><td style="border:none;" align="left">Can be unstable and sensitive to the choice
of local region</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref376">376</xref>)</td></tr><tr><td style="border:none;" align="left">Feature Importance from Tree-based Models</td><td style="border:none;" align="left">Measures the importance of a feature by the average gain of
the splits in which it is used. Can be based on permutation feature
importance or mean decrease in impurity</td><td style="border:none;" align="left">Directly available
in tree-based models like Random Forest
and XGBoost</td><td style="border:none;" align="left">Biased toward features with many categories</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref377">377</xref>)</td></tr><tr><td style="border:none;" align="left">Coefficient
Magnitude in Linear Models</td><td style="border:none;" align="left">Uses the magnitude of the
coefficients in linear models to
determine feature importance</td><td style="border:none;" align="left">Straightforward to compute
and interpret</td><td style="border:none;" align="left">Only applicable to linear models and assumes
linear relationships</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref378">378</xref>)</td></tr><tr><td style="border:none;" align="left">Mutual Information</td><td style="border:none;" align="left">Measures the reduction
in uncertainty about one variable given
knowledge of another variable</td><td style="border:none;" align="left">Nonparametric and captures
nonlinear relationships</td><td style="border:none;" align="left">Requires discretization for
continuous variables and can be
computationally expensive</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref379">379</xref>)</td></tr><tr><td style="border:none;" align="left">Attention Mechanisms</td><td style="border:none;" align="left">Uses
the attention weights in attention-based models to determine
feature importance</td><td style="border:none;" align="left">Naturally integrated into models
like transformers. Allows
focusing on relevant parts of the input sequence when making predictions
(captures dependencies)</td><td style="border:none;" align="left">Limited to models that use attention
mechanisms</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref289">289</xref>)</td></tr><tr><td style="border:none;" align="left">Counterfactual Explanations</td><td style="border:none;" align="left">Determines feature
importance by analyzing how changing feature
values affects the prediction outcome</td><td style="border:none;" align="left">Highlights specific
changes needed to alter predictions</td><td style="border:none;" align="left">May generate unrealistic
or nonfeasible changes</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref380">380</xref>)</td></tr><tr><td style="border:none;" align="left">Partial Dependence Plots (PDP)</td><td style="border:none;" align="left">Illustrates the impact of a feature on the predicted outcome
by averaging the effects of all other features.</td><td style="border:none;" align="left">Easy
to interpret and visualize</td><td style="border:none;" align="left">Assumes independence of features
and can be misleading if features
are correlated</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref381">381</xref>)</td></tr><tr><td style="border:none;" align="left">Prediction-Driven Molecular Matched Pairs</td><td style="border:none;" align="left">Examines pairs of similar molecules to identify transformations
affecting specific properties.</td><td style="border:none;" align="left">Overcomes the data limitation
problem and allows interpreting
the model itself and not the experimental data</td><td style="border:none;" align="left">Limited
number of molecules can be checked in this transformation-driven
approach</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref382">382</xref>)</td></tr></tbody></table></table-wrap><p>Interpreting and hence, to an extent, &#x02018;understanding&#x02019;
ML models, in terms of their underlying basis for predictions, can
make predictions more trustworthy and help detect biases in the model,
as well as ensure the model recovers previous knowledge (e.g., known
structural alerts). Suitable feature spaces and modeling architectures
need to be used to interpret models, which can lead to novel understanding
of the model (and problem) at hand. Feature importance measures (<xref rid="tbl11" ref-type="other">Table <xref rid="tbl11" ref-type="other">10</xref></xref>) can be used to
estimate the contribution of individual features, particularly where
the features are interpretable, e.g., specific molecular targets,
such as proteins, or chemical substructures associated with toxicity,
etc. For example, mutagenicity and skin sensitization are often concerns
in drug development that can be interpreted from chemical features.
Specific structural alerts&#x02014;such as nitroaromatic groups for
mutagenicity,<sup><xref ref-type="bibr" rid="ref365">365</xref></sup> or electrophilic groups
like &#x003b1;,&#x003b2;-unsaturated carbonyls (Michael acceptors) for
skin sensitization<sup><xref ref-type="bibr" rid="ref366">366</xref></sup>&#x02014;are associated
with these toxicities; predictive models can identify these fragments
and enable medicinal chemists to modify molecules by eliminating or
altering these groups to reduce the risk (although modifying a few
fragments with the highest contribution in the model does not necessarily
resolve toxicity completely<sup><xref ref-type="bibr" rid="ref355">355</xref>,<xref ref-type="bibr" rid="ref367">367</xref></sup>).</p><p>However, interpretations
are not always straightforward, especially
when it comes to predictions based on the chemical structure. Misinterpretations
are common for data sets with high bias in chemical space, which is
often the case due to project, synthesis, and analogue bias, etc.
For example, a previous study by one of the authors found that <italic>sugar</italic> rings were associated with the <italic>bitterness</italic> of compounds, a result that does not make sense at face value. In
this case, the confounding factor was that natural products are frequently
glycosylated <italic>and</italic> tend to be bitter. The model then
proposed this <italic>confounding factor</italic> (and bias) in the
model as a correlation when it was not, in fact, the <italic>causation</italic>.<sup><xref ref-type="bibr" rid="ref368">368</xref></sup> This example shows that while feature
importance measures can provide actionable insights, their application
in real-world drug discovery must account for potential biases in
the input data.</p><p>Mechanistic insights can also be gained by interpreting
ML models.
For example, fuzzy rules are a set of &#x0201c;if&#x02013;then&#x0201d;
statements based on fuzzy logic.<sup><xref ref-type="bibr" rid="ref369">369</xref></sup> Unlike
traditional binary logic that deals strictly with true or false values,
fuzzy logic allows for reasoning with uncertain or imprecise information
by accommodating degrees of truth. For example, a rule might state,
&#x0201c;If the daily dose of an oral medication is high and the lipophilicity
is high, then the probability of hepatotoxicity is high&#x0201d;,<sup><xref ref-type="bibr" rid="ref370">370</xref></sup> where the term &#x0201c;high&#x0201d; is not
an exact value but a linguistic variable represented by membership
functions in a fuzzy set. After training an ML model, fuzzy set rules
can be developed based on how certain input features influence the
model&#x02019;s predictions. For example, converting decision tree
rules or clustering results into fuzzy rules can make them more interpretable.
For example, Friederichs et al. were able to cluster 90 environmental
compounds using fuzzy clustering based on physicochemical parameters,
reasoning why compounds in specific clusters exhibit aquatic toxicity
(volatility, hydrolysis, etc.).<sup><xref ref-type="bibr" rid="ref371">371</xref></sup> Fuzzy
rule sets are usually based on well-defined and interpretable variables
(such as molecular weight, logD, etc.). They can help elucidate the
fundamental properties contributing to toxicity and guide the design
of safer compounds, where interpretability from a medicinal chemistry
perspective drives decision-making.<sup><xref ref-type="bibr" rid="ref372">372</xref>&#x02212;<xref ref-type="bibr" rid="ref374">374</xref></sup></p><p>When interpreting
model predictions, however, correlation must
not be confused with causation; the most-contributing features used
by the model are only meaningful if they represent the underlying
cause (which is often unknown), and in practice, feature importance
often suffers from a &#x02018;long tail&#x02019; distribution, where
a large number of features are associated with a prediction; this
complicates interpretation (many features contribute &#x02018;somewhat&#x02019;
to the end point the model predicts). Moreover, feature importance
is a local property for nonlinear models, while global for linear
models. Combining modeling and computational analysis with expert
knowledge is, hence, key. For example, pathway enrichment analysis
involves mapping important features, such as genes and proteins, to
known biological pathways using tools like KEGG, Reactome or Ingenuity
Pathways Analysis (IPA); for example, Antazak et al. identified 21
molecular pathways differentially modulated in response to nephrotoxic
vs nontoxic compounds.<sup><xref ref-type="bibr" rid="ref383">383</xref></sup> They identified
the three main functional categories of pathways for nephrotoxicity&#x02014;metabolic
pathways (e.g., Glycerophospholipid metabolism), signaling pathways
(e.g., Parkinson&#x02019;s disease), and cell communication pathways
(e.g., cell communication). Network analysis can extend mechanistic
analysis by constructing and analyzing biological networks, such as
Protein&#x02013;Protein Interaction (PPI) networks, to pinpoint key
nodes and modules. For example, IPA has very specific features to
evaluate protein&#x02013;protein interactions, such as upstream regulator
analysis, mechanistic networks, causal network analysis, and downstream
effects analysis.<sup><xref ref-type="bibr" rid="ref384">384</xref></sup> A study using IPA
revealed a novel antitumor mechanism for MK886, a leukotriene antagonist,
involving cytoskeleton-induced alteration of chromatin structure,
revealing unknown aspects of the action and safety.<sup><xref ref-type="bibr" rid="ref385">385</xref></sup> Another study used PPI networks to determine targets for
cardiac disorders and found protein ERBB4 interacting with known drug
targets.<sup><xref ref-type="bibr" rid="ref386">386</xref></sup> Although ERBB4 was not a known
drug target for cardiac failure at the time (according to Huang et
al.<sup><xref ref-type="bibr" rid="ref386">386</xref></sup>), there is considerable work now
on using ERBB4 agonists for treating heart failure.<sup><xref ref-type="bibr" rid="ref387">387</xref></sup> Overall, pathway enrichment analysis and PPI networks can
highlight important proteins or groups of proteins that may contribute
to specific properties, yielding a deeper understanding of the complex
biological interactions involved. In the cases discussed here, prior
knowledge (in terms of biological pathways) was combined with data
(from the models) to arrive at an interpretable model output.</p><p>Another related approach to interpretable predictions is to use
causal and mathematical mechanistic models to directly establish cause-and-effect
relationships rather than correlations captured by ML models. Causal
inference methods have been applied directly to transcriptional data
and PPI networks to distinguish correlation from causation and infer
potential mechanisms of actions that drive toxicity. For example,
these methods were shown to recapitulate specific pathways downstream
of the molecular targets, providing a systems-level view of the drug&#x02019;s
mechanism.<sup><xref ref-type="bibr" rid="ref388">388</xref>,<xref ref-type="bibr" rid="ref389">389</xref></sup></p><p>Overall, understanding
the features involved in the predictions
of ML models can provide both insight and confidence into the predictions
being made.</p></sec><sec id="sec30"><title>Pharmacokinetics in Decision-Making</title><p>Toxicity is not
a simple &#x02018;yes&#x02019; or &#x02018;no&#x02019;
question&#x02014;even water can be toxic at &#x02018;too high a dose&#x02019;.<sup><xref ref-type="bibr" rid="ref390">390</xref></sup> Concentration and exposure (and PK in general)
are absolutely critical for assessing safety and toxicity but are
relatively neglected in the ML community.</p><p>Pharmacokinetics is
a critical aspect of drug development and clinical
decision-making because it provides detailed insights into how a drug
is absorbed, distributed, metabolized, and eliminated within the body.<sup><xref ref-type="bibr" rid="ref391">391</xref></sup> This information is essential for determining
the optimal dosage and administration schedule to achieve therapeutic
efficacy without causing harm. By studying pharmacokinetics, researchers
can establish the time it takes for a drug to reach therapeutic levels,
how long it remains effective, and the dynamics of its elimination.
This knowledge ensures that drug regimens are optimized for maximum
benefit while minimizing the risk of adverse effects. Analogous considerations
apply to compound toxicity.</p><p>Pharmacokinetics also plays a central
role in balancing efficacy
and safety by informing the therapeutic index (TI),<sup><xref ref-type="bibr" rid="ref340">340</xref></sup> a critical parameter derived from pharmacokinetics and
pharmacodynamic (PD) studies and defined as the ratio between the
toxic dose and the effective dose of a drug:<disp-formula id="ueq10"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_m010" position="anchor"/></disp-formula>where <italic>TD50</italic> is the dose that
produces toxicity in 50% of the population, and <italic>ED50</italic> is the dose that is effective in 50% of the population.<sup><xref ref-type="bibr" rid="ref340">340</xref></sup> A higher TI indicates a greater margin of safety
between therapeutic and toxic doses. Accurate PK modeling helps to
determine the TI more precisely, aiding in optimizing dosing regimens
to maximize efficacy while minimizing toxicity.</p><p>While physiologically
based Pharmacokinetics (PBPK) models have
been used in drug discovery for a number of years, they require tailoring
to the particular compound properties at hand. On the other hand,
in recent years approaches have become popular to predict <italic>in vivo</italic> PK directly based on chemical structure,<sup><xref ref-type="bibr" rid="ref392">392</xref></sup> owing to the availability of suitable data
sets. Machine Learning models have recently been integrated with mechanistic
models to enhance the predictive accuracy. Tools that predict pharmacokinetics
parameters using ML algorithms, such as PKSmart,<sup><xref ref-type="bibr" rid="ref125">125</xref></sup> can process large data sets to predict the pharmacokinetics
parameters that can then be used as input parameters to a compartment
model.<sup><xref ref-type="bibr" rid="ref393">393</xref>&#x02212;<xref ref-type="bibr" rid="ref396">396</xref></sup> This hybrid approach combines the strengths of data-driven ML models
with the interpretability of the mechanistic models.</p></sec><sec id="sec31"><title>Optimizing ML Strategies in Various Stages of Drug Discovery</title><p>Using ML for QSAR/QSPR models is common practice in drug discovery,
where finding the right balance between cost, speed, and predictivity
of a method at a given stage of the drug discovery process is critical
(see <xref rid="tbl12" ref-type="other">Table <xref rid="tbl12" ref-type="other">11</xref></xref>). It
is important to recognize that different industries may adopt varying
approaches to using ML models, both within drug discovery and development
and in other industries such as consumer goods or agrochemistry. In
these contexts, different properties of data sets, representations,
models, validation methods, and evaluation metrics may hold varying
degrees of importance. Some projects might favor a balanced approach
between recall and precision, while in other cases one or the other
might be more important.<sup><xref ref-type="bibr" rid="ref397">397</xref></sup> Others may
tailor their model optimization strategies (or loss functions) to
particular aspects of model performance, specific therapeutic areas,
the types of compounds being studied, or the technologies employed.<sup><xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref398">398</xref></sup> A typical use of models along the early and late drug discovery
stages follows.</p><table-wrap id="tbl12" position="float"><label>Table 11</label><caption><title>Different Priorities and Criteria
Are Used in ML Models to Balance Efficacy, Toxicity, and Selection
(e.g., on-target activity, efficacy) or Deselection (e.g., toxicity
alert models) in Early- and Late-Stage Drug Discovery</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">Focus</th><th style="border:none;" align="center">Early Stage Exploratory/Discovery (usually qualitative)</th><th style="border:none;" align="center">Late Stage Refinement/Development (usually quantitative:
exposure, PK, etc.)</th></tr></thead><tbody><tr><td style="border:none;" align="left">ML models
for selection (e.g., on-target activity, efficacy)</td><td style="border:none;" align="left">Broad
selection, high recall. Include as many potential compounds
fitting the target product profile as possible.</td><td style="border:none;" align="left">Narrow
selection, high specificity. Only compounds that meet
strict efficacy and safety criteria are selected for further development.</td></tr><tr><td style="border:none;" align="left">ML models for deselection (e.g., toxicity alert
models)</td><td style="border:none;" align="left">Low impact of compounds incorrectly predicted
as toxic (false
positives). It is acceptable to have some false positive predictions.</td><td style="border:none;" align="left">High precision is desired in ML models to minimize compounds
incorrectly predicted as nontoxic (false negatives), avoiding resource
wastage on failing compounds.</td></tr></tbody></table></table-wrap><p>For early stage virtual screening of compounds across
a range of
targets, discovery phases are exploratory, often targeting novel or
less well-understood pathways. Given that on-target effects are crucial
for compound selection (after a target has been selected), ideal ML
models would find many hits with a high precision (i.e., with a high
confidence that the compounds selected are indeed hitting the target
the project is working on).<sup><xref ref-type="bibr" rid="ref399">399</xref></sup> On the other
hand, from a toxicity prediction perspective, early discovery phases
also need to <italic>minimize compounds incorrectly predicted as nontoxic</italic> (&#x02018;false negatives&#x02019;, where toxicity is seen as the
&#x02018;positive&#x02019; label, from the modeling perspective).<sup><xref ref-type="bibr" rid="ref345">345</xref></sup> The above decisions depend on the project context&#x02014;for
example, when the project aims at conditions with limited patient
survival (e.g., advance stage oncology or rare diseases), toxicity
concerns may not be a major roadblock.<sup><xref ref-type="bibr" rid="ref400">400</xref></sup> Instead, other factors such as the compound&#x02019;s pharmacokinetic
profile (if distribution to target organs such as the brain is required)
may take center stage. One possible strategy for using data and machine
learning in a drug discovery project is visualized in <xref rid="box4-fo" ref-type="chart">Box 4</xref>. Variations need
to be applied according to project needs in a given concrete situation.</p><fig id="box4-fo" position="float"><label>Chart Box 4</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00033_0018" id="fx18" position="float"/></fig><p>Me-too/Me-better drugs share the same mechanism
of action or target
as the existing drugs. Projects focused on identifying me-too drugs
generally have a lower human safety risk profile because their mechanisms
of action and on-target toxicity are often already known. Still, off-target
toxicity may present challenges, where the adverse reactions are not
caused by the therapeutic class.<sup><xref ref-type="bibr" rid="ref401">401</xref></sup> The
opportunity also lies in finding incremental improvements in therapeutic
action and/or safety. Projects focusing on me-too/follow-on drugs
usually demand fewer resources to develop<sup><xref ref-type="bibr" rid="ref402">402</xref></sup> and thus ML models could be optimized on minimizing compounds incorrectly
predicted as inactive (false negatives) among the known target (in
line with the practice of revisiting prior screening data and &#x02018;rescuing&#x02019;
false negatives).<sup><xref ref-type="bibr" rid="ref401">401</xref></sup> To ensure competitiveness
in the market, these projects would likely want to find all possible
molecules in the early stage (high recall), advancing the most promising
ones to development and keeping the others as backup in case the molecule
fails in the preclinical or clinical stage.<sup><xref ref-type="bibr" rid="ref403">403</xref>,<xref ref-type="bibr" rid="ref404">404</xref></sup></p><p>By contrast, first-in-class drugs have a new and unique mechanism
of action that could yield greater efficacy than existing treatments,
but carry a higher risk due to unproven mechanisms that may not work
as expected, or may have unforeseen side effects or consequences.<sup><xref ref-type="bibr" rid="ref405">405</xref></sup> That said, a study by Health Canada considering
drugs that were approved and later withdrawn found that first-in-class
drugs do not exhibit a higher concern for safety compared to nonfirst-in-class
drugs.<sup><xref ref-type="bibr" rid="ref406">406</xref></sup> Projects aiming for a first-in-class
drug also offer higher rewards, with market exclusivity initially,
and in later years increased market share when other pharmaceuticals
enter the space (even when new molecules may have benefits).<sup><xref ref-type="bibr" rid="ref402">402</xref></sup> First-in-class drugs have limited or no data
in the chemical space and therefore rely more on chemical space exploration.
ML models employed in early discovery would ideally need to rank compounds
with the desired target profile (efficacy) and low toxicity (at human
exposure levels) for experimental validation.<sup><xref ref-type="bibr" rid="ref306">306</xref></sup></p><p>In the early screening paradigm, <italic>in vitro</italic> end
points are relatively inexpensive to test; lead compounds that are
predicted positive could be screened in those assays to detect false
positives. False negatives may not get tested as they were deemed
&#x0201c;safe&#x0201d; and carried forward an unidentified liability.
ML models thus need to have a lower tolerance for false negatives;
we would like to flag compounds if they are toxic. As a project progresses
to late-stage discovery, the focus shifts to precision to ensure that
only the most promising, efficacious, and safe compounds are pursued
from the pool of candidates.</p><p>In summary, to translate the benefits
of toxicity models to decision-making,
they must consider a number of aspects in the context of the project-relevant
data, suitable representations, proper validation, reliable interpretation.<sup><xref ref-type="bibr" rid="ref127">127</xref></sup> Given the complexity of the task, the lack
of data in many domains, and the variability of the biological systems
many end points are measured in, it is not trivial to get all of those
aspects right.</p></sec><sec id="sec32"><title>Conclusion</title><p>This review summarizes key challenges and
considerations in translating
machine learning models into decision-making tools for real-world
drug discovery projects, in particular, related to compound toxicity
and safety. This includes making choices about data, modeling, validation,
model metrics, and applying the <italic>model</italic> thus obtained
to the <italic>process</italic> of drug discovery. We hope that the
reader finds this review useful and that it helps this translation
from concept to practice.</p></sec></body><back><notes notes-type="" id="notes1"><title>Author Contributions</title><p>All
authors
have approved the final version of the manuscript. The views expressed
in this work are from a collaborative effort, with conceptualization
by S. Seal and A.B. Throughout the process, all authors engaged in
critical discussions, review, and editing, ensuring the work was comprehensive
in articulating the current state and future directions of understanding
ML models for molecular toxicity prediction. CRediT: <bold>Srijit
Seal</bold> conceptualization, data curation, formal analysis, funding
acquisition, investigation, methodology, project administration, resources,
software, supervision, validation, visualization, writing - original
draft, writing - review &#x00026; editing; <bold>Layla Hosseini-Gerami</bold> writing - review &#x00026; editing; <bold>Alex Beatson</bold> writing
- review &#x00026; editing; <bold>Caroline Weis</bold> writing - review
&#x00026; editing; <bold>Arash Mehrjou</bold> writing - review &#x00026; editing; <bold>Rhiannon Lowe</bold> writing - review &#x00026; editing; <bold>Falgun
Shah</bold> writing - original draft; <bold>Bjarki Johannesson</bold> writing - original draft, writing - review &#x00026; editing; <bold>Patrick Schwab</bold> writing - review &#x00026; editing; <bold>Nicola
Richmond</bold> writing - review &#x00026; editing; <bold>Christos A Nicolaou</bold> writing - review &#x00026; editing; <bold>Carolin Schramm</bold> writing
- review &#x00026; editing; <bold>Deidre Dalmas Wilk</bold> writing -
review &#x00026; editing; <bold>Ola Spjuth</bold> conceptualization, funding
acquisition, supervision, writing - original draft, writing - review
&#x00026; editing; <bold>Anne E. Carpenter</bold> conceptualization, funding
acquisition, supervision, writing - original draft, writing - review
&#x00026; editing; <bold>Andreas Bender</bold> conceptualization, supervision,
writing - original draft, writing - review &#x00026; editing; <bold>Manas
Mahale</bold> writing - review &#x00026; editing; <bold>Miguel Garc&#x000ed;a-Orteg&#x000f3;n</bold> writing - review &#x00026; editing; <bold>Chaitanya K. Joshi</bold> writing
- review &#x00026; editing; <bold>Matthew Greenig</bold> writing - review
&#x00026; editing; <bold>Mrinal Shekhar</bold> writing - review &#x00026;
editing; <bold>Arijit Patra</bold> writing - review &#x00026; editing; <bold>Adrien Badr&#x000e9;</bold> writing - review &#x00026; editing; <bold>Brianna Paisley</bold> writing - review &#x00026; editing; <bold>Shantanu
Singh</bold> writing - review &#x00026; editing; <bold>Dominic Williams</bold> writing - review &#x00026; editing; <bold>David Rouqui&#x000e9;</bold> writing - review &#x00026; editing; <bold>Djork-Arn&#x000e9; Clevert</bold> writing - review &#x00026; editing; <bold>Raymond J. Gonzalez</bold> writing - review &#x00026; editing; <bold>Russell Naven</bold> writing
- review &#x00026; editing; <bold>Lewis R. Vidler</bold> writing - review
&#x00026; editing; <bold>Kamel Mansouri</bold> writing - review &#x00026;
editing; <bold>W. Patrick Walters</bold> writing - review &#x00026; editing.</p></notes><notes notes-type="funding-statement" id="notes2"><p>S. Seal
acknowledges
funding from the Cambridge Centre for Data-Driven Discovery (C2D3)
and Accelerate Programme for Scientific Discovery. The Broad Institute
authors acknowledge funding from the National Institutes of Health
(R35 GM122547 to A.E.C.) and the OASIS Consortium members, which is
partially supported by a grant from the Massachusetts Life Sciences
Center Bits to Bytes Capital Call program (to S. Singh). O.S. acknowledges
funding from the Swedish Research Council (Grants 2020-03731 and 2020-01865),
FORMAS (Grant 2022-00940), and Swedish Cancer Foundation (22 2412
Pj 03 H).</p></notes><notes notes-type="COI-statement" id="notes3"><p>The authors
declare the following competing financial interest(s): S. Singh and
A.E.C. serve as scientific advisors for companies that use image-based
profiling and Cell Painting (A.E.C.: Recursion, SyzOnc, Quiver Bioscience,
S. Singh: Waypoint Bio, Dewpoint Therapeutics, Deepcell) and receive
honoraria for occasional scientific visits to pharmaceutical and biotechnology
companies. O.S. declares ownership in Phenaros Pharmaceuticals and
Aros Bio. A.B. is an advisor to Ignota Labs and a consultant or advisor
to various biotech companies. L.H.G. is an employee and shareholder
of Ignota Labs. All other authors declare no competing interests.</p></notes><bio id="BIO-d14e4119-autogenerated" rid="ath1"><p>Srijit Seal specializes in machine
learning and cheminformatics.
His research focuses on developing machine learning algorithms for
drug discovery, particularly in toxicity prediction. He is also a
Fellow of the Cambridge Philosophical Society and serves on the Board
of Directors of the American Society for Cellular and Computational
Toxicology (ASCCT). Seal received his PhD at the University of Cambridge
and previously was a postdoctoral associate at the Broad Institute
of MIT and Harvard.</p></bio><bio id="BIO-d14e4121-autogenerated" rid="ath2"><p>Manas Mahale is an
undergraduate at Bombay College of Pharmacy,
University of Mumbai. His research focuses on using cheminformatics
and data science to analyze chemical data.</p></bio><bio id="BIO-d14e4123-autogenerated" rid="ath3"><p>Miguel Garc&#x000ed;a Orteg&#x000f3;n is a researcher specializing
in probabilistic machine learning for drug discovery. With a PhD from
the University of Cambridge, his expertise includes Gaussian processes,
Bayesian optimization, and graph neural networks. Miguel has interned
at Microsoft and CRG, contributing to generative modeling and machine
learning projects.</p></bio><bio id="BIO-d14e4125-autogenerated" rid="ath4"><p>Chaitanya K. Joshi
is a PhD student at the Department of Computer
Science and Technology, University of Cambridge. His research explores
the intersection of Geometric Deep Learning and Graph Neural Networks
for applications in biomolecule modeling and design.</p></bio><bio id="BIO-d14e4127-autogenerated" rid="ath5"><p>Layla Hosseini-Gerami is the Chief Data Science Officer
and cofounder
of Ignota Laboratories, a TechBio startup specializing in <italic>in silico</italic> toxicity prediction. With a PhD from the University
of Cambridge in Bioinformatics and Machine Learning, she has extensive
experience in developing AI-driven solutions for drug discovery and
toxicity mitigation.</p></bio><bio id="BIO-d14e4132-autogenerated" rid="ath6"><p>Alex Beatson is a
cofounder of Axiom Bio, which builds AI for drug
toxicity risk assessment. Axiom generates high throughput, high content
vitro data and trains AI models across in vitro and clinical data
to predict toxicity risk from molecular structure. Alex received a
PhD working on deep learning at Princeton University and built ML
platforms for virtual screening and generative molecular design at
Genesis Therapeutics and Redesign Science.</p></bio><bio id="BIO-d14e4134-autogenerated" rid="ath7"><p>Matthew Greenig is a PhD student at the University of Cambridge,
where he applies deep learning techniques to antibody discovery and
engineering. Matt&#x02019;s work combines ideas from fragment-based
protein design with modern geometric deep learning approaches to engineer
binding affinity in antibodies.</p></bio><bio id="BIO-d14e4136-autogenerated" rid="ath8"><p>Mrinal
Shekhar is a Group Leader in the Data Sciences and Computational
Chemistry group at the Center for the Development of Therapeutics
(CDoT), Broad Institute. His group employs computational chemistry,
biophysics, and computational structural biology methodologies for
drug discovery projects at various stages in the drug discovery pipeline,
including hit identification and validation.</p></bio><bio id="BIO-d14e4138-autogenerated" rid="ath9"><p>Arijit Patra is a Senior Principal Scientist at UCB Biopharma UK,
where he focuses on building a new generation of AI systems for drug
safety workflows for rare diseases. Previously, he was also associated
with AstraZeneca, where he contributed to several initiatives pertinent
to the development of novel therapeutic candidates. He holds a PhD
in machine learning for obstetric ultrasound from the University of
Oxford, where he was a Rhodes Scholar. Arijit has authored several
publications around machine learning and medical imaging and has delivered
multiple invited talks around the theme of Artificial Intelligence
for Healthcare around the globe.</p></bio><bio id="BIO-d14e4140-autogenerated" rid="ath10"><p>Caroline
Weis is a Senior AI/ML Engineer and Team Lead for Clinical
Biomedical AI at GSK.ai. With a PhD in Machine Learning for Healthcare
from ETH Zurich, her contributions focusedshe focuses on antimicrobial
resistance prediction, personalized medicine, and topological data
analysis. Caroline&#x02019;s expertise lies in developing advanced
machine learning models to improve healthcare outcomes.</p></bio><bio id="BIO-d14e4142-autogenerated" rid="ath11"><p>Arash Mehrjou is a researcher at ETH Z&#x000fc;rich,
specializing
in making sense of complexities using mathematics, machine learning,
and artificial intelligence. His work spans nature and abstract concepts,
including probabilistic ML, Gaussian processes, and Bayesian optimization.
Arash has also contributed to various projects at Google DeepMind,
Max Planck Society, and GSK.</p></bio><bio id="BIO-d14e4145-autogenerated" rid="ath12"><p>Adrien Badr&#x000e9;
is a data scientist at Novartis Institute for
Biomedical Research in Preclinical Safety. With a strong background
in computer science and machine learning, his expertise lies in developing
data analysis and machine learning workflows for preclinical safety.
He earned his Ph.D. from the University of Oklahoma.</p></bio><bio id="BIO-d14e4147-autogenerated" rid="ath13"><p>Brianna Paisley is an Advisor Toxicologist that has
been in Toxinformatics
at Eli Lilly and Company for 13 years. Her background is in chemistry,
pharmacology, statistics and bioinformatics. She focuses on identification
of structure-mediated and off-target toxicology liabilities for small
molecules and genetic medicines by leveraging machine learning and
genomics.</p></bio><bio id="BIO-d14e4149-autogenerated" rid="ath14"><p>Rhiannon Lowe is a UKRT, ERT
registered toxicologist and FRSB with
over 20 years of experience in nonclinical safety within the pharmaceutical
and biotech industries. As Associate Director at Relation, she leads
nonclinical safety studies for drug discovery and target safety assessment
across multiple modalities and disease indications.</p></bio><bio id="BIO-d14e4151-autogenerated" rid="ath15"><p>Shantanu Singh coleads the Carpenter-Singh lab at the
Broad Institute,
applying computer vision, machine learning, and bioimaging to understand
human diseases and accelerate drug discovery.</p></bio><bio id="BIO-d14e4153-autogenerated" rid="ath16"><p>Falgun Shah is the Director of Data Science and Computational Toxicology
at Merck Research Laboratories, specializing in applying cheminformatics
and machine learning approaches to rapidly advancing better molecules.
Falgun has a PhD in Medicinal Chemistry from the University of Mississippi
and a Master of Pharmaceutical Sciences from the University of Mumbai,
India.</p></bio><bio id="BIO-d14e4155-autogenerated" rid="ath17"><p>Bjarki Johannesson is a Director
within Safety Innovation at AstraZeneca&#x02019;s
department of Clinical Pharmacology and Safety Sciences (CPSS). Within
his role Bjarki leads efforts to combine AI and Cell Painting for
improved and accelerated drug safety predictions. Prior to this, Bjarki
led a cross-functional R&#x00026;D research team at the New York Stem
Cell Foundation focused on automated high-throughput differentiation
of pluripotent stem cells and AI-driven HCI-based disease modeling.
Bjarki completed his PhD in 2010 at EMBL in Heidelberg, Germany.</p></bio><bio id="BIO-d14e4157-autogenerated" rid="ath18"><p>Dominic Williams leads the preclinical Hepatic
Safety team at AstraZeneca,
specializing in bespoke hepatic safety assays and integrating AI/ML,
drug metabolism, and 3D models. With over 15 years of academic experience,
he has authored 150+ publications and actively participates in various
EU initiatives for drug safety improvement.</p></bio><bio id="BIO-d14e4159-autogenerated" rid="ath19"><p>David Rouquie, Head of Toxicology Data Science at Bayer, specializes
in digital transformation, early toxicology, and predictive toxicology.
With a PhD in Molecular Biology, he leads innovative strategies in
chemical safety, integrates AI, and manages interdisciplinary teams.
David actively collaborates with internal and external partners, driving
impactful safety assessments.</p></bio><bio id="BIO-d14e4161-autogenerated" rid="ath20"><p>Djork-Arn&#x000e9;
Clevert holds the position of Vice President
at Pfizer, where he is in charge of the Machine Learning Research
group. He concentrates his research on the development of machine
learning methods that span the entire continuum of drug discovery
projects.</p></bio><bio id="BIO-d14e4163-autogenerated" rid="ath21"><p>Patrick Schwab is Senior Director
of Machine Learning and Artificial
Intelligence and Head of the Biomedical AI group at GSK.ai. His work
aims to advance personalized medicine using machine learning, computational
systems biology methods and large-scale health data, such as genetics,
multiomics, cell-based assays, and continuous measurements from smart
devices and electronic health records, to better understand and treat
complex diseases.</p></bio><bio id="BIO-d14e4165-autogenerated" rid="ath22"><p>Nicola Richmond is
Chief Scientist, AI at Recursion where she leads
the Data Science and AI organisation and oversees Recursion&#x02019;s
Industrialisation of drug discovery with AI. Prior to joining Recursion,
Nicola led the AI function at BenevolentAI with a focus on explainable
LLMs for target discovery. The majority of Nicola&#x02019;s career
was spent at GlaxoSmithKline where she built numerous tech solutions
to advance small molecule and therapeutic antibody drug discovery.
Nicola trained as a pure mathematician, completing a PhD in Algebra
and Algebraic Geometry at the University of Leeds, before transitioning
to cheminformatics as a post doctoral fellow. Her cheminformatics
research focussed on developing novel approaches to 3D pharmacophore
design, working with Peter Willett in the Department of Information
Studies at the University of Sheffield.</p></bio><bio id="BIO-d14e4168-autogenerated" rid="ath23"><p>Christos A. Nicolaou has been working in the small molecule digital
chemistry field for over two decades. He has a background in Computer
Science (BSc/MSc Florida State University, PhD University of Cyprus)
and has contributed to the development of multiple proprietary and
commercial cheminformatics software packages. In his most recent role
as Senior Director, Digital Chemistry at Novo Nordisk, he is involved
in the development and implementation of the small molecule research
strategy and leads the Digital Chemistry department. Prior to that
he led the establishment of the Digital Chemistry group at Recursion
and spent over a decade at the Computational Chemistry and Cheminformatics
group of Eli Lilly, Discovery Chemistry and Research Technologies
department. Christos has led efforts to map and exploit virtual synthesizable
chemistry spaces, mine big pharmaceutical data including chemical
reactions, advance machine learning and artificial intelligence research
for predictive and generative modeling and, implement model-driven
drug discovery.</p></bio><bio id="BIO-d14e4170-autogenerated" rid="ath24"><p>Raymond J. Gonzalez is
Executive Director in Investigative Toxicology
at Merck, with over 20 years in the pharmaceutical industry. He leads
a multidisciplinary team focused on systems, immunotoxic, computational,
in vitro, and analytical toxicology to drive drug discovery and development.
Gonzalez collaborates with research, regulatory affairs, and external
partners to integrate toxicology assessments for drug development
and mentors team members, fostering innovation and continuous professional
growth. He holds a PhD in Pharmacology and Toxicology from the University
of the Sciences in Philadelphia.</p></bio><bio id="BIO-d14e4172-autogenerated" rid="ath25"><p>Russell
Naven is Head of the Predictive Safety Data Exploration
Group in the Preclinical Safety Department of Novartis. With a strong
background in Medicinal Chemistry and Predictive Toxicology, his expertise
is in the application of Data Science techniques to support the development
and validation of predictive safety tools that inspire better drug
design and selection. Russ earned his B. Sc. from Manchester University
and his PhD in Organic Chemistry from the University of Nottingham
in the UK.</p></bio><bio id="BIO-d14e4174-autogenerated" rid="ath26"><p>Carolin Schramm is a Nonclinical
Safety Expert at Sanofi with a
background in drug discovery and development, molecular toxicology,
and nonclinical strategy development.</p></bio><bio id="BIO-d14e4176-autogenerated" rid="ath27"><p>Dr. Lewis Vidler is a Senior Director of Structure Based Drug Design
at Eli Lilly and Company. He achieved a first-class chemistry degree
at the University of Oxford and subsequently a PhD in Computational
Medicinal Chemistry at the Institute of Cancer research in London.
He joined Eli Lilly that year and spent an initial duration of 7 years
there. Following shorter stints as a computational medicinal chemist
at UCB and Amphista Therapeutics, he returned to Lilly in 2023, to
further progress his career. Bridging computational and medicinal
chemistry he has deep expertise in leveraging computational tools
to drive drug discovery programs towards meeting their milestones.</p></bio><bio id="BIO-d14e4178-autogenerated" rid="ath28"><p>Kamel Mansouri, a computational chemist,
earned his Ph.D. in computational
chemistry from the University of Milano Bicocca, Italy, as a Marie
Curie fellow. Since 2020, he has spearheaded computational chemistry
endeavors at the NTP Interagency Center for the Evaluation of Alternative
Toxicological Methods (NICEATM) within the U.S. National Institute
of Environmental Health Sciences (NIEHS). His focus includes QSAR
modeling, cheminformatics, and computational toxicology, with a reputation
for fostering international collaborations and leading scientific
consortia.</p></bio><bio id="BIO-d14e4180-autogenerated" rid="ath29"><p>W. Patrick Walters is Chief
Data Officer at Relay Therapeutics
in Cambridge, MA, applying statistics, machine learning, cheminformatics,
and computational chemistry to a range of drug discovery projects.</p></bio><bio id="BIO-d14e4182-autogenerated" rid="ath30"><p>Deidre Dalmas is a Director of Investigative
Toxicology and Nonclinical
Safety Expert within the pharmaceutical industry. She specializes
in investigative mechanistic toxicology, toxicogenomics, and generation/application
of cutting-edge capabilities to predict drug-induced toxicity and
identify safety biomarkers that aid in selection and advancement of
safe medicines from discovery through development. Deidre is the Pharmaceutical
Industry Chair for the Health Environment and Safety (HESI) - Emerging
Systems in Toxicology for Risk Assessment (e-STAR) Consortium and
Co-Chair of the Critical Path Institute Predictive Safety Testing
Consortium (CPATH-PSTC) Drug-Induced Vascular Injury Working Group.</p></bio><bio id="BIO-d14e4184-autogenerated" rid="ath31"><p>Ola Spjuth is Professor at Uppsala University
with research focus
on AI and automation in drug discovery. He is also CEO of Phenaros
Pharmaceuticals where the aim is to accelerate drug discovery with
AI and automation.</p></bio><bio id="BIO-d14e4186-autogenerated" rid="ath32"><p>Anne E. Carpenter
is an Institute Scientist at the Broad Institute
of MIT and Harvard, where she is also Senior Director of the Imaging
Platform. She is a coinventor of the open-source bioimage analysis
software CellProfiler and the Cell Painting assay. With a background
in cell biology, microscopy, and computational biology, her expertise
is in applying methods leveraging the quantitative information in
biological images, especially in large-scale experiments. Carpenter
earned her BS from Purdue University and her PhD from the University
of Illinois at Urbana&#x02013;Champaign.</p></bio><bio id="BIO-d14e4188-autogenerated" rid="ath33"><p>Andreas Bender is a Professor of Molecular Informatics at the University
of Cambridge, focusing on using chemical and biological data combined
with machine learning methods to predict safety- and efficacy-related
end points. He is also the Chief Informatics and Technology Officer
(CITO) of Pangea Bio, which employs historical information about traditional
medicines to increase the probability of success of drug discovery
projects in clinical phases. Bender received his PhD from the University
of Cambridge and previously worked for Novartis, Leiden University,
and AstraZeneca.</p></bio><ack><title>Acknowledgments</title><p>Cartoons in all figures were created with DALLEv2
(<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://openai.com/dall-e-2">https://openai.com/dall-e-2</uri>), Microsoft Designer (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://designer.microsoft.com/">https://designer.microsoft.com/</uri>), and Bioicons (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bioicons.com">https://bioicons.com</uri>), which compiled
images from the Database Centre for the life sciences/TogoTV (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://togotv.dbcls.jp">https://togotv.dbcls.jp</uri>) and
Servier (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://smart.servier.com">https://smart.servier.com</uri>). The authors thank Nigel Greene (Recursion) and Nichloas Coltman
(Apconix) for helpful comments on an earlier version of the manuscript.
S. Seal thanks Elsa Lawrence (University of Cambridge), Adit Shah
(UC Berkeley College of Engineering), James Bradshaw (Ignota Lab),
Matthew Wilkinson (Ignota Lab), and Adham El Shazly (University of
Cambridge) for helpful comments on an earlier version of the paper.
S. Seal thanks Jeremy R. Ash (Johnson &#x00026; Johnson Innovative Medicine)
for helpful comments on Pillar 4, Validation of predictive models.
GSK is committed to the replacement, reduction, and refinement of
animal studies (3Rs). Nonanimal models and alternative technologies
are part of the strategy in GSK and are employed where possible. GSK
states that when animals are required, application of robust study
design principles and peer review minimizes animal use, reduces harm,
and improves benefit in studies. The views and conclusions presented
in this manuscript are those of the contributing authors and do not
necessarily reflect the representative affiliation or individual company&#x02019;s
or organization&#x02019;s position of the authors on the subject.</p></ack><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Shen</surname><given-names>J.</given-names></name>; <name><surname>Nicolaou</surname><given-names>C. A.</given-names></name>
<article-title>Molecular Property Prediction: Recent Trends in the
Era of Artificial Intelligence</article-title>. <source>Drug Discovery
Today Technol.</source>
<year>2019</year>, <volume>32&#x02013;33</volume>, <fpage>29</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddtec.2020.05.001</pub-id>.</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Schuhmacher</surname><given-names>A.</given-names></name>; <name><surname>Hinder</surname><given-names>M.</given-names></name>; <name><surname>von Stegmann Und Stein</surname><given-names>A.</given-names></name>; <name><surname>Hartl</surname><given-names>D.</given-names></name>; <name><surname>Gassmann</surname><given-names>O.</given-names></name>
<article-title>Analysis of Pharma R&#x00026;D Productivity
- a New Perspective
Needed</article-title>. <source>Drug Discovery Today</source>
<year>2023</year>, <volume>28</volume> (<issue>10</issue>), <fpage>103726</fpage><pub-id pub-id-type="doi">10.1016/j.drudis.2023.103726</pub-id>.<pub-id pub-id-type="pmid">37506762</pub-id>
</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Sun</surname><given-names>D.</given-names></name>; <name><surname>Gao</surname><given-names>W.</given-names></name>; <name><surname>Hu</surname><given-names>H.</given-names></name>; <name><surname>Zhou</surname><given-names>S.</given-names></name>
<article-title>Why 90% of Clinical Drug Development
Fails and How to Improve It?</article-title>. <source>Acta Pharm. Sin
B</source>
<year>2022</year>, <volume>12</volume> (<issue>7</issue>), <fpage>3049</fpage>&#x02013;<lpage>3062</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2022.02.002</pub-id>.<pub-id pub-id-type="pmid">35865092</pub-id>
</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Rudmann</surname><given-names>D. G.</given-names></name>
<article-title>On-Target
and off-Target-Based Toxicologic Effects</article-title>. <source>Toxicol.
Pathol.</source>
<year>2013</year>, <volume>41</volume> (<issue>2</issue>), <fpage>310</fpage>&#x02013;<lpage>314</lpage>. <pub-id pub-id-type="doi">10.1177/0192623312464311</pub-id>.<pub-id pub-id-type="pmid">23085982</pub-id>
</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Liu</surname><given-names>A.</given-names></name>; <name><surname>Seal</surname><given-names>S.</given-names></name>; <name><surname>Yang</surname><given-names>H.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>
<article-title>Using Chemical and
Biological Data to Predict Drug Toxicity</article-title>. <source>SLAS
Discov</source>
<year>2023</year>, <volume>28</volume> (<issue>3</issue>), <fpage>53</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.slasd.2022.12.003</pub-id>.<pub-id pub-id-type="pmid">36639032</pub-id>
</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><person-group person-group-type="allauthors"><name><surname>Bilodeau</surname><given-names>C.</given-names></name>; <name><surname>Jin</surname><given-names>W.</given-names></name>; <name><surname>Jaakkola</surname><given-names>T.</given-names></name>; <name><surname>Barzilay</surname><given-names>R.</given-names></name>; <name><surname>Jensen</surname><given-names>K. F.</given-names></name></person-group><article-title>Generative Models for Molecular
Discovery: Recent Advances and Challenges</article-title>. <source>Wiley Interdiscip. Rev. Comput. Mol. Sci.</source><year>2022</year>, <volume>12</volume> ( (<issue>5</issue>), ).<pub-id pub-id-type="doi">10.1002/wcms.1608</pub-id>.</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Wei</surname><given-names>F.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name>; <name><surname>Gou</surname><given-names>X.</given-names></name>
<article-title>A Review for
Cell-Based Screening
Methods in Drug Discovery</article-title>. <source>Biophys Rep</source>
<year>2021</year>, <volume>7</volume> (<issue>6</issue>), <fpage>504</fpage>&#x02013;<lpage>516</lpage>. <pub-id pub-id-type="doi">10.52601/bpr.2021.210042</pub-id>.<pub-id pub-id-type="pmid">37288368</pub-id>
</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Eder</surname><given-names>J.</given-names></name>; <name><surname>Sedrani</surname><given-names>R.</given-names></name>; <name><surname>Wiesmann</surname><given-names>C.</given-names></name>
<article-title>The Discovery of First-in-Class Drugs:
Origins and Evolution</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2014</year>, <volume>13</volume> (<issue>8</issue>), <fpage>577</fpage>&#x02013;<lpage>587</lpage>. <pub-id pub-id-type="doi">10.1038/nrd4336</pub-id>.<pub-id pub-id-type="pmid">25033734</pub-id>
</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Sadri</surname><given-names>A.</given-names></name>
<article-title>Is Target-Based
Drug Discovery Efficient? Discovery and &#x0201c;Off-Target&#x0201d;
Mechanisms of All Drugs</article-title>. <source>J. Med. Chem.</source>
<year>2023</year>, <volume>66</volume> (<issue>18</issue>), <fpage>12651</fpage>&#x02013;<lpage>12677</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c01737</pub-id>.<pub-id pub-id-type="pmid">37672650</pub-id>
</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Jenkinson</surname><given-names>S.</given-names></name>; <name><surname>Schmidt</surname><given-names>F.</given-names></name>; <name><surname>Rosenbrier Ribeiro</surname><given-names>L.</given-names></name>; <name><surname>Delaunois</surname><given-names>A.</given-names></name>; <name><surname>Valentin</surname><given-names>J.-P.</given-names></name>
<article-title>A Practical Guide to Secondary Pharmacology in Drug
Discovery</article-title>. <source>J. Pharmacol. Toxicol. Methods</source>
<year>2020</year>, <volume>105</volume>, <fpage>106869</fpage><pub-id pub-id-type="doi">10.1016/j.vascn.2020.106869</pub-id>.<pub-id pub-id-type="pmid">32302774</pub-id>
</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Bowes</surname><given-names>J.</given-names></name>; <name><surname>Brown</surname><given-names>A. J.</given-names></name>; <name><surname>Hamon</surname><given-names>J.</given-names></name>; <name><surname>Jarolimek</surname><given-names>W.</given-names></name>; <name><surname>Sridhar</surname><given-names>A.</given-names></name>; <name><surname>Waldron</surname><given-names>G.</given-names></name>; <name><surname>Whitebread</surname><given-names>S.</given-names></name>
<article-title>Reducing Safety-Related
Drug Attrition: The Use of in Vitro Pharmacological Profiling</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2012</year>, <volume>11</volume> (<issue>12</issue>), <fpage>909</fpage>&#x02013;<lpage>922</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3845</pub-id>.<pub-id pub-id-type="pmid">23197038</pub-id>
</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Xu</surname><given-names>J. J.</given-names></name>; <name><surname>Henstock</surname><given-names>P. V.</given-names></name>; <name><surname>Dunn</surname><given-names>M. C.</given-names></name>; <name><surname>Smith</surname><given-names>A. R.</given-names></name>; <name><surname>Chabot</surname><given-names>J. R.</given-names></name>; <name><surname>de Graaf</surname><given-names>D.</given-names></name>
<article-title>Cellular Imaging Predictions
of Clinical Drug-Induced
Liver Injury</article-title>. <source>Toxicol. Sci.</source>
<year>2008</year>, <volume>105</volume> (<issue>1</issue>), <fpage>97</fpage>&#x02013;<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfn109</pub-id>.<pub-id pub-id-type="pmid">18524759</pub-id>
</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><person-group person-group-type="allauthors"><name><surname>Hartung</surname><given-names>T.</given-names></name></person-group><article-title>The (misleading)
Role of Animal Models in Drug Development</article-title>. <source>Front. Drug Des. Discovery</source><year>2024</year>, <volume>4</volume>. <pub-id pub-id-type="doi">10.3389/fddsv.2024.1355044</pub-id>.</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Shanks</surname><given-names>N.</given-names></name>; <name><surname>Greek</surname><given-names>R.</given-names></name>; <name><surname>Greek</surname><given-names>J.</given-names></name>
<article-title>Are Animal Models Predictive
for
Humans?</article-title>. <source>Philos. Ethics Humanit. Med.</source>
<year>2009</year>, <volume>4</volume>, <fpage>2</fpage><pub-id pub-id-type="doi">10.1186/1747-5341-4-2</pub-id>.<pub-id pub-id-type="pmid">19146696</pub-id>
</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Van
Norman</surname><given-names>G. A.</given-names></name>
<article-title>Limitations of Animal Studies for Predicting Toxicity
in Clinical Trials: Is It Time to Rethink Our Current Approach?</article-title>. <source>JACC Basic Transl Sci.</source>
<year>2019</year>, <volume>4</volume> (<issue>7</issue>), <fpage>845</fpage>&#x02013;<lpage>854</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacbts.2019.10.008</pub-id>.<pub-id pub-id-type="pmid">31998852</pub-id>
</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Olson</surname><given-names>H.</given-names></name>; <name><surname>Betton</surname><given-names>G.</given-names></name>; <name><surname>Robinson</surname><given-names>D.</given-names></name>; <name><surname>Thomas</surname><given-names>K.</given-names></name>; <name><surname>Monro</surname><given-names>A.</given-names></name>; <name><surname>Kolaja</surname><given-names>G.</given-names></name>; <name><surname>Lilly</surname><given-names>P.</given-names></name>; <name><surname>Sanders</surname><given-names>J.</given-names></name>; <name><surname>Sipes</surname><given-names>G.</given-names></name>; <name><surname>Bracken</surname><given-names>W.</given-names></name>; <name><surname>Dorato</surname><given-names>M.</given-names></name>; <name><surname>Van Deun</surname><given-names>K.</given-names></name>; <name><surname>Smith</surname><given-names>P.</given-names></name>; <name><surname>Berger</surname><given-names>B.</given-names></name>; <name><surname>Heller</surname><given-names>A.</given-names></name>
<article-title>Concordance
of the Toxicity of Pharmaceuticals
in Humans and in Animals</article-title>. <source>Regul. Toxicol. Pharmacol.</source>
<year>2000</year>, <volume>32</volume> (<issue>1</issue>), <fpage>56</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1006/rtph.2000.1399</pub-id>.<pub-id pub-id-type="pmid">11029269</pub-id>
</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Ekert</surname><given-names>J. E.</given-names></name>; <name><surname>Deakyne</surname><given-names>J.</given-names></name>; <name><surname>Pribul-Allen</surname><given-names>P.</given-names></name>; <name><surname>Terry</surname><given-names>R.</given-names></name>; <name><surname>Schofield</surname><given-names>C.</given-names></name>; <name><surname>Jeong</surname><given-names>C. G.</given-names></name>; <name><surname>Storey</surname><given-names>J.</given-names></name>; <name><surname>Mohamet</surname><given-names>L.</given-names></name>; <name><surname>Francis</surname><given-names>J.</given-names></name>; <name><surname>Naidoo</surname><given-names>A.</given-names></name>; <name><surname>Amador</surname><given-names>A.</given-names></name>; <name><surname>Klein</surname><given-names>J.-L.</given-names></name>; <name><surname>Rowan</surname><given-names>W.</given-names></name>
<article-title>Recommended
Guidelines for Developing, Qualifying, and Implementing Complex In
Vitro Models (CIVMs) for Drug Discovery</article-title>. <source>SLAS
Discov</source>
<year>2020</year>, <volume>25</volume> (<issue>10</issue>), <fpage>1174</fpage>&#x02013;<lpage>1190</lpage>. <pub-id pub-id-type="doi">10.1177/2472555220923332</pub-id>.<pub-id pub-id-type="pmid">32495689</pub-id>
</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><person-group person-group-type="allauthors"><name><surname>Zushin</surname><given-names>P.-J. H.</given-names></name>; <name><surname>Mukherjee</surname><given-names>S.</given-names></name>; <name><surname>Wu</surname><given-names>J. C.</given-names></name></person-group><article-title>FDA Modernization
Act 2.0:
Transitioning beyond Animal Models with Human Cells, Organoids, and
AI/ML-Based Approaches</article-title>. <source>J. Clin. Invest.</source><year>2023</year>, <volume>133</volume> ( (<issue>21</issue>), ).<pub-id pub-id-type="doi">10.1172/JCI175824</pub-id>.</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Han</surname><given-names>J. J.</given-names></name>
<article-title>FDA Modernization
Act 2.0 Allows for Alternatives to Animal Testing</article-title>. <source>Artif. Organs</source>
<year>2023</year>, <volume>47</volume> (<issue>3</issue>), <fpage>449</fpage>&#x02013;<lpage>450</lpage>. <pub-id pub-id-type="doi">10.1111/aor.14503</pub-id>.<pub-id pub-id-type="pmid">36762462</pub-id>
</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Schmeisser</surname><given-names>S.</given-names></name>; <name><surname>Miccoli</surname><given-names>A.</given-names></name>; <name><surname>von Bergen</surname><given-names>M.</given-names></name>; <name><surname>Berggren</surname><given-names>E.</given-names></name>; <name><surname>Braeuning</surname><given-names>A.</given-names></name>; <name><surname>Busch</surname><given-names>W.</given-names></name>; <name><surname>Desaintes</surname><given-names>C.</given-names></name>; <name><surname>Gourmelon</surname><given-names>A.</given-names></name>; <name><surname>Grafstr&#x000f6;m</surname><given-names>R.</given-names></name>; <name><surname>Harrill</surname><given-names>J.</given-names></name>; <name><surname>Hartung</surname><given-names>T.</given-names></name>; <name><surname>Herzler</surname><given-names>M.</given-names></name>; <name><surname>Kass</surname><given-names>G. E. N.</given-names></name>; <name><surname>Kleinstreuer</surname><given-names>N.</given-names></name>; <name><surname>Leist</surname><given-names>M.</given-names></name>; <name><surname>Luijten</surname><given-names>M.</given-names></name>; <name><surname>Marx-Stoelting</surname><given-names>P.</given-names></name>; <name><surname>Poetz</surname><given-names>O.</given-names></name>; <name><surname>van Ravenzwaay</surname><given-names>B.</given-names></name>; <name><surname>Roggeband</surname><given-names>R.</given-names></name>; <name><surname>Rogiers</surname><given-names>V.</given-names></name>; <name><surname>Roth</surname><given-names>A.</given-names></name>; <name><surname>Sanders</surname><given-names>P.</given-names></name>; <name><surname>Thomas</surname><given-names>R. S.</given-names></name>; <name><surname>Marie Vinggaard</surname><given-names>A.</given-names></name>; <name><surname>Vinken</surname><given-names>M.</given-names></name>; <name><surname>van de Water</surname><given-names>B.</given-names></name>; <name><surname>Luch</surname><given-names>A.</given-names></name>; <name><surname>Tralau</surname><given-names>T.</given-names></name>
<article-title>New Approach Methodologies in Human
Regulatory Toxicology - Not If, but How and When!</article-title>. <source>Environ. Int.</source>
<year>2023</year>, <volume>178</volume>, <fpage>108082</fpage><pub-id pub-id-type="doi">10.1016/j.envint.2023.108082</pub-id>.<pub-id pub-id-type="pmid">37422975</pub-id>
</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Anth&#x000e9;rieu</surname><given-names>S.</given-names></name>; <name><surname>Chesn&#x000e9;</surname><given-names>C.</given-names></name>; <name><surname>Li</surname><given-names>R.</given-names></name>; <name><surname>Guguen-Guillouzo</surname><given-names>C.</given-names></name>; <name><surname>Guillouzo</surname><given-names>A.</given-names></name>
<article-title>Optimization of the HepaRG Cell Model for Drug Metabolism
and Toxicity Studies</article-title>. <source>Toxicol. In Vitro</source>
<year>2012</year>, <volume>26</volume> (<issue>8</issue>), <fpage>1278</fpage>&#x02013;<lpage>1285</lpage>. <pub-id pub-id-type="doi">10.1016/j.tiv.2012.05.008</pub-id>.<pub-id pub-id-type="pmid">22643240</pub-id>
</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>F&#x000e4;s</surname><given-names>L.</given-names></name>; <name><surname>Chen</surname><given-names>M.</given-names></name>; <name><surname>Tong</surname><given-names>W.</given-names></name>; <name><surname>Wenz</surname><given-names>F.</given-names></name>; <name><surname>Hewitt</surname><given-names>N. J.</given-names></name>; <name><surname>Tu</surname><given-names>M.</given-names></name>; <name><surname>Sanchez</surname><given-names>K.</given-names></name>; <name><surname>Zapi&#x000f3;rkowska-Blumer</surname><given-names>N.</given-names></name>; <name><surname>Varga</surname><given-names>H.</given-names></name>; <name><surname>Kaczmarska</surname><given-names>K.</given-names></name>; <name><surname>Colombo</surname><given-names>M. V.</given-names></name>; <name><surname>Filippi</surname><given-names>B. G. H.</given-names></name>
<article-title>Physiological
Liver Microtissue 384-Well Microplate System for Preclinical Hepatotoxicity
Assessment of Therapeutic Small Molecule Drugs</article-title>. <source>Toxicol. Sci.</source>
<year>2025</year>, <volume>203</volume> (<issue>1</issue>), <fpage>79</fpage><pub-id pub-id-type="doi">10.1093/toxsci/kfae123</pub-id>.<pub-id pub-id-type="pmid">39397666</pub-id>
</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="weblink" id="cit23"><source>Alternative Methods Accepted by US Agencies</source>; <publisher-name>National Toxicology Program</publisher-name>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ntp.niehs.nih.gov/whatwestudy/niceatm/accept-methods">https://ntp.niehs.nih.gov/whatwestudy/niceatm/accept-methods</uri> (accessed 2025-01-18).</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Namdari</surname><given-names>R.</given-names></name>; <name><surname>Jones</surname><given-names>K.</given-names></name>; <name><surname>Chuang</surname><given-names>S. S.</given-names></name>; <name><surname>Van Cruchten</surname><given-names>S.</given-names></name>; <name><surname>Dincer</surname><given-names>Z.</given-names></name>; <name><surname>Downes</surname><given-names>N.</given-names></name>; <name><surname>Mikkelsen</surname><given-names>L. F.</given-names></name>; <name><surname>Harding</surname><given-names>J.</given-names></name>; <name><surname>J&#x000e4;ckel</surname><given-names>S.</given-names></name>; <name><surname>Jacobsen</surname><given-names>B.</given-names></name>; <name><surname>Kinyamu-Akunda</surname><given-names>J.</given-names></name>; <name><surname>Lortie</surname><given-names>A.</given-names></name>; <name><surname>Mhedhbi</surname><given-names>S.</given-names></name>; <name><surname>Mohr</surname><given-names>S.</given-names></name>; <name><surname>Schmitt</surname><given-names>M. W.</given-names></name>; <name><surname>Prior</surname><given-names>H.</given-names></name>
<article-title>Species Selection for Nonclinical Safety Assessment of Drug Candidates:
Examples of Current Industry Practice</article-title>. <source>Regul.
Toxicol. Pharmacol.</source>
<year>2021</year>, <volume>126</volume>, <fpage>105029</fpage><pub-id pub-id-type="doi">10.1016/j.yrtph.2021.105029</pub-id>.<pub-id pub-id-type="pmid">34455009</pub-id>
</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Scannell</surname><given-names>J. W.</given-names></name>; <name><surname>Bosley</surname><given-names>J.</given-names></name>; <name><surname>Hickman</surname><given-names>J. A.</given-names></name>; <name><surname>Dawson</surname><given-names>G. R.</given-names></name>; <name><surname>Truebel</surname><given-names>H.</given-names></name>; <name><surname>Ferreira</surname><given-names>G. S.</given-names></name>; <name><surname>Richards</surname><given-names>D.</given-names></name>; <name><surname>Treherne</surname><given-names>J. M.</given-names></name>
<article-title>Predictive Validity
in Drug Discovery: What It Is, Why It Matters and How to Improve It</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2022</year>, <volume>21</volume> (<issue>12</issue>), <fpage>915</fpage>&#x02013;<lpage>931</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-022-00552-x</pub-id>.<pub-id pub-id-type="pmid">36195754</pub-id>
</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Brubaker</surname><given-names>D. K.</given-names></name>; <name><surname>Lauffenburger</surname><given-names>D. A.</given-names></name>
<article-title>Translating
Preclinical Models to Humans</article-title>. <source>Science</source>
<year>2020</year>, <volume>367</volume> (<issue>6479</issue>), <fpage>742</fpage>&#x02013;<lpage>743</lpage>. <pub-id pub-id-type="doi">10.1126/science.aay8086</pub-id>.<pub-id pub-id-type="pmid">32054749</pub-id>
</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Butler</surname><given-names>L. D.</given-names></name>; <name><surname>Guzzie-Peck</surname><given-names>P.</given-names></name>; <name><surname>Hartke</surname><given-names>J.</given-names></name>; <name><surname>Bogdanffy</surname><given-names>M. S.</given-names></name>; <name><surname>Will</surname><given-names>Y.</given-names></name>; <name><surname>Diaz</surname><given-names>D.</given-names></name>; <name><surname>Mortimer-Cassen</surname><given-names>E.</given-names></name>; <name><surname>Derzi</surname><given-names>M.</given-names></name>; <name><surname>Greene</surname><given-names>N.</given-names></name>; <name><surname>DeGeorge</surname><given-names>J. J.</given-names></name>
<article-title>Current Nonclinical
Testing Paradigms in Support of Safe Clinical Trials: An IQ Consortium
DruSafe Perspective</article-title>. <source>Regul. Toxicol. Pharmacol.</source>
<year>2017</year>, <volume>87</volume> (<issue>Suppl 3</issue>), <fpage>S1</fpage>&#x02013;<lpage>S15</lpage>. <pub-id pub-id-type="doi">10.1016/j.yrtph.2017.05.009</pub-id>.</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Russo</surname><given-names>D. P.</given-names></name>; <name><surname>Aleksunes</surname><given-names>L. M.</given-names></name>; <name><surname>Goyak</surname><given-names>K.</given-names></name>; <name><surname>Qian</surname><given-names>H.</given-names></name>; <name><surname>Zhu</surname><given-names>H.</given-names></name>
<article-title>Integrating
Concentration-Dependent Toxicity Data and Toxicokinetics To Inform
Hepatotoxicity Response Pathways</article-title>. <source>Environ. Sci.
Technol.</source>
<year>2023</year>, <volume>57</volume> (<issue>33</issue>), <fpage>12291</fpage>&#x02013;<lpage>12301</lpage>. <pub-id pub-id-type="doi">10.1021/acs.est.3c02792</pub-id>.<pub-id pub-id-type="pmid">37566783</pub-id>
</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Rusyn</surname><given-names>I.</given-names></name>; <name><surname>Chiu</surname><given-names>W. A.</given-names></name>; <name><surname>Wright</surname><given-names>F. A.</given-names></name>
<article-title>Model Systems and Organisms for Addressing
Inter- and Intra-Species Variability in Risk Assessment</article-title>. <source>Regul. Toxicol. Pharmacol.</source>
<year>2022</year>, <volume>132</volume>, <fpage>105197</fpage><pub-id pub-id-type="doi">10.1016/j.yrtph.2022.105197</pub-id>.<pub-id pub-id-type="pmid">35636685</pub-id>
</mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Barber</surname><given-names>C.</given-names></name>; <name><surname>Heghes</surname><given-names>C.</given-names></name>; <name><surname>Johnston</surname><given-names>L.</given-names></name>
<article-title>A Framework to Support
the Application
of the OECD Guidance Documents on (Q)SAR Model Validation and Prediction
Assessment for Regulatory Decisions</article-title>. <source>Computational
Toxicology</source>
<year>2024</year>, <volume>30</volume>, <fpage>100305</fpage><pub-id pub-id-type="doi">10.1016/j.comtox.2024.100305</pub-id>.</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="book" id="cit31"><person-group person-group-type="allauthors"><collab>OECD</collab></person-group>. <source>QSAR Assessment Framework: Guidance for
the Regulatory
Assessment of (Quantitative) Structure Activity Relationship Models
and Predictions</source>; <publisher-name>OECD</publisher-name>, <year>2023</year>.</mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Rich</surname><given-names>A. S.</given-names></name>; <name><surname>Chan</surname><given-names>Y. H.</given-names></name>; <name><surname>Birnbaum</surname><given-names>B.</given-names></name>; <name><surname>Haider</surname><given-names>K.</given-names></name>; <name><surname>Haimson</surname><given-names>J.</given-names></name>; <name><surname>Hale</surname><given-names>M.</given-names></name>; <name><surname>Han</surname><given-names>Y.</given-names></name>; <name><surname>Hickman</surname><given-names>W.</given-names></name>; <name><surname>Hoeflich</surname><given-names>K. P.</given-names></name>; <name><surname>Ortwine</surname><given-names>D.</given-names></name>; <name><surname>Ozen</surname><given-names>A.</given-names></name>; <name><surname>Belanger</surname><given-names>D.</given-names></name>
<article-title>Machine Learning ADME
Models in Practice: Four Guidelines from a Successful Lead Optimization
Case Study</article-title>. <source>ACS Med. Chem. Lett.</source>
<year>2024</year>, <volume>15</volume>, <fpage>1169</fpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.4c00290</pub-id>.<pub-id pub-id-type="pmid">39140048</pub-id>
</mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>Schneider</surname><given-names>N.</given-names></name>; <name><surname>Segler</surname><given-names>M.</given-names></name>; <name><surname>Patrick Walters</surname><given-names>W.</given-names></name>; <name><surname>Engkvist</surname><given-names>O.</given-names></name>; <name><surname>Rodrigues</surname><given-names>T.</given-names></name>
<article-title>Evaluation
Guidelines for Machine
Learning Tools in the Chemical Sciences</article-title>. <source>Nat.
Rev. Chem.</source>
<year>2022</year>, <volume>6</volume> (<issue>6</issue>), <fpage>428</fpage>&#x02013;<lpage>442</lpage>. <pub-id pub-id-type="doi">10.1038/s41570-022-00391-9</pub-id>.<pub-id pub-id-type="pmid">37117429</pub-id>
</mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="conf-proc" id="cit34"><person-group person-group-type="allauthors"><name><surname>Sculley</surname><given-names>D.</given-names></name>; <name><surname>Brodley</surname><given-names>C. E.</given-names></name></person-group><article-title>Compression
and Machine Learning: A New Perspective on Feature Space Vectors</article-title>. In <source>Data Compression Conference (DCC&#x02019;06)</source>; <publisher-name>IEEE</publisher-name>, <year>2006</year>; pp <fpage>332</fpage>&#x02013;<lpage>341</lpage>.</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Haghighatlari</surname><given-names>M.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Heidar-Zadeh</surname><given-names>F.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Guan</surname><given-names>X.</given-names></name>; <name><surname>Head-Gordon</surname><given-names>T.</given-names></name>
<article-title>Learning to
Make Chemical Predictions: The Interplay of Feature Representation,
Data, and Machine Learning Methods</article-title>. <source>Chem.</source>
<year>2020</year>, <volume>6</volume> (<issue>7</issue>), <fpage>1527</fpage>&#x02013;<lpage>1542</lpage>. <pub-id pub-id-type="doi">10.1016/j.chempr.2020.05.014</pub-id>.<pub-id pub-id-type="pmid">32695924</pub-id>
</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="book" id="cit36"><person-group person-group-type="allauthors"><name><surname>Kirkpatrick</surname><given-names>P.</given-names></name>; <name><surname>Ellis</surname><given-names>C.</given-names></name></person-group><source>Chemical space</source>; <publisher-name>Nature Publishing Group UK</publisher-name>.<pub-id pub-id-type="doi">10.1038/432823a</pub-id>.</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Hawkins</surname><given-names>D.
M.</given-names></name>
<article-title>The Problem
of Overfitting</article-title>. <source>J. Chem. Inf. Comput. Sci.</source>
<year>2004</year>, <volume>44</volume> (<issue>1</issue>), <fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1021/ci0342472</pub-id>.<pub-id pub-id-type="pmid">14741005</pub-id>
</mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Sushko</surname><given-names>I.</given-names></name>; <name><surname>Novotarskyi</surname><given-names>S.</given-names></name>; <name><surname>K&#x000f6;rner</surname><given-names>R.</given-names></name>; <name><surname>Pandey</surname><given-names>A. K.</given-names></name>; <name><surname>Kovalishyn</surname><given-names>V. V.</given-names></name>; <name><surname>Prokopenko</surname><given-names>V. V.</given-names></name>; <name><surname>Tetko</surname><given-names>I. V.</given-names></name>
<article-title>Applicability Domain for in Silico
Models to Achieve Accuracy of Experimental Measurements</article-title>. <source>J. Chemom.</source>
<year>2010</year>, <volume>24</volume> (<issue>3&#x02013;4</issue>), <fpage>202</fpage>&#x02013;<lpage>208</lpage>. <pub-id pub-id-type="doi">10.1002/cem.1296</pub-id>.</mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Dragos</surname><given-names>H.</given-names></name>; <name><surname>Gilles</surname><given-names>M.</given-names></name>; <name><surname>Alexandre</surname><given-names>V.</given-names></name>
<article-title>Predicting
the Predictability: A
Unified Approach to the Applicability Domain Problem of QSAR Models</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2009</year>, <volume>49</volume> (<issue>7</issue>), <fpage>1762</fpage>&#x02013;<lpage>1776</lpage>. <pub-id pub-id-type="doi">10.1021/ci9000579</pub-id>.<pub-id pub-id-type="pmid">19530661</pub-id>
</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Sahigara</surname><given-names>F.</given-names></name>; <name><surname>Mansouri</surname><given-names>K.</given-names></name>; <name><surname>Ballabio</surname><given-names>D.</given-names></name>; <name><surname>Mauri</surname><given-names>A.</given-names></name>; <name><surname>Consonni</surname><given-names>V.</given-names></name>; <name><surname>Todeschini</surname><given-names>R.</given-names></name>
<article-title>Comparison
of Different Approaches to Define the Applicability
Domain of QSAR Models</article-title>. <source>Molecules</source>
<year>2012</year>, <volume>17</volume> (<issue>5</issue>), <fpage>4791</fpage>&#x02013;<lpage>4810</lpage>. <pub-id pub-id-type="doi">10.3390/molecules17054791</pub-id>.<pub-id pub-id-type="pmid">22534664</pub-id>
</mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Fang</surname><given-names>C.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Grater</surname><given-names>R.</given-names></name>; <name><surname>Kapadnis</surname><given-names>S.</given-names></name>; <name><surname>Black</surname><given-names>C.</given-names></name>; <name><surname>Trapa</surname><given-names>P.</given-names></name>; <name><surname>Sciabola</surname><given-names>S.</given-names></name>
<article-title>Prospective Validation of Machine
Learning Algorithms for Absorption, Distribution, Metabolism, and
Excretion Prediction: An Industrial Perspective</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2023</year>, <volume>63</volume> (<issue>11</issue>), <fpage>3263</fpage>&#x02013;<lpage>3274</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.3c00160</pub-id>.<pub-id pub-id-type="pmid">37216672</pub-id>
</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Mathai</surname><given-names>N.</given-names></name>; <name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Kirchmair</surname><given-names>J.</given-names></name>
<article-title>Validation
Strategies for Target
Prediction Methods</article-title>. <source>Brief. Bioinform.</source>
<year>2020</year>, <volume>21</volume> (<issue>3</issue>), <fpage>791</fpage>&#x02013;<lpage>802</lpage>. <pub-id pub-id-type="doi">10.1093/bib/bbz026</pub-id>.<pub-id pub-id-type="pmid">31220208</pub-id>
</mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>Jain</surname><given-names>S.</given-names></name>; <name><surname>Siramshetty</surname><given-names>V. B.</given-names></name>; <name><surname>Alves</surname><given-names>V. M.</given-names></name>; <name><surname>Muratov</surname><given-names>E. N.</given-names></name>; <name><surname>Kleinstreuer</surname><given-names>N.</given-names></name>; <name><surname>Tropsha</surname><given-names>A.</given-names></name>; <name><surname>Nicklaus</surname><given-names>M. C.</given-names></name>; <name><surname>Simeonov</surname><given-names>A.</given-names></name>; <name><surname>Zakharov</surname><given-names>A. V.</given-names></name>
<article-title>Large-Scale
Modeling of Multispecies Acute Toxicity End Points Using Consensus
of Multitask Deep Learning Methods</article-title>. <source>J. Chem.
Inf. Model.</source>
<year>2021</year>, <volume>61</volume> (<issue>2</issue>), <fpage>653</fpage>&#x02013;<lpage>663</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.0c01164</pub-id>.<pub-id pub-id-type="pmid">33533614</pub-id>
</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Sosnin</surname><given-names>S.</given-names></name>; <name><surname>Karlov</surname><given-names>D.</given-names></name>; <name><surname>Tetko</surname><given-names>I. V.</given-names></name>; <name><surname>Fedorov</surname><given-names>M. V.</given-names></name>
<article-title>Comparative
Study
of Multitask Toxicity Modeling on a Broad Chemical Space</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2019</year>, <volume>59</volume> (<issue>3</issue>), <fpage>1062</fpage>&#x02013;<lpage>1072</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.8b00685</pub-id>.<pub-id pub-id-type="pmid">30589269</pub-id>
</mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Davis</surname><given-names>R. L.</given-names></name>
<article-title>Mechanism
of Action and Target Identification: A Matter of Timing in Drug Discovery</article-title>. <source>iScience</source>
<year>2020</year>, <volume>23</volume> (<issue>9</issue>), <fpage>101487</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2020.101487</pub-id>.<pub-id pub-id-type="pmid">32891054</pub-id>
</mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Pognan</surname><given-names>F.</given-names></name>; <name><surname>Beilmann</surname><given-names>M.</given-names></name>; <name><surname>Boonen</surname><given-names>H. C. M.</given-names></name>; <name><surname>Czich</surname><given-names>A.</given-names></name>; <name><surname>Dear</surname><given-names>G.</given-names></name>; <name><surname>Hewitt</surname><given-names>P.</given-names></name>; <name><surname>Mow</surname><given-names>T.</given-names></name>; <name><surname>Oinonen</surname><given-names>T.</given-names></name>; <name><surname>Roth</surname><given-names>A.</given-names></name>; <name><surname>Steger-Hartmann</surname><given-names>T.</given-names></name>; <name><surname>Valentin</surname><given-names>J.-P.</given-names></name>; <name><surname>Van Goethem</surname><given-names>F.</given-names></name>; <name><surname>Weaver</surname><given-names>R. J.</given-names></name>; <name><surname>Newham</surname><given-names>P.</given-names></name>
<article-title>The Evolving Role of Investigative
Toxicology in the Pharmaceutical Industry</article-title>. <source>Nat.
Rev. Drug Discovery</source>
<year>2023</year>, <volume>22</volume> (<issue>4</issue>), <fpage>317</fpage>&#x02013;<lpage>335</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-022-00633-x</pub-id>.<pub-id pub-id-type="pmid">36781957</pub-id>
</mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name><surname>Priest</surname><given-names>B. T.</given-names></name>; <name><surname>Bell</surname><given-names>I. M.</given-names></name>; <name><surname>Garcia</surname><given-names>M. L.</given-names></name>
<article-title>Role of hERG Potassium
Channel Assays
in Drug Development</article-title>. <source>Channels</source>
<year>2008</year>, <volume>2</volume> (<issue>2</issue>), <fpage>87</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.4161/chan.2.2.6004</pub-id>.<pub-id pub-id-type="pmid">18849661</pub-id>
</mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name><surname>Sakamuru</surname><given-names>S.</given-names></name>; <name><surname>Attene-Ramos</surname><given-names>M. S.</given-names></name>; <name><surname>Xia</surname><given-names>M.</given-names></name>
<article-title>Mitochondrial Membrane Potential
Assay</article-title>. <source>Methods Mol. Biol.</source>
<year>2016</year>, <volume>1473</volume>, <fpage>17</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-6346-1_2</pub-id>.<pub-id pub-id-type="pmid">27518619</pub-id>
</mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name><surname>Seal</surname><given-names>S.</given-names></name>; <name><surname>Carreras-Puigvert</surname><given-names>J.</given-names></name>; <name><surname>Trapotsi</surname><given-names>M.-A.</given-names></name>; <name><surname>Yang</surname><given-names>H.</given-names></name>; <name><surname>Spjuth</surname><given-names>O.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>
<article-title>Integrating
Cell Morphology with Gene Expression and
Chemical Structure to Aid Mitochondrial Toxicity Detection</article-title>. <source>Commun. Biol.</source>
<year>2022</year>, <volume>5</volume> (<issue>1</issue>), <fpage>858</fpage><pub-id pub-id-type="doi">10.1016/j.yrtph.2017.05.009</pub-id>.<pub-id pub-id-type="pmid">35999457</pub-id>
</mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>Cort&#x000e9;s-Ciriano</surname><given-names>I.</given-names></name>
<article-title>Artificial Intelligence
in Drug Discovery:
What Is Realistic, What Are Illusions? Part 1: Ways to Make an Impact,
and Why We Are Not There yet</article-title>. <source>Drug Discovery
Today</source>
<year>2021</year>, <volume>26</volume> (<issue>2</issue>), <fpage>511</fpage>&#x02013;<lpage>524</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2020.12.009</pub-id>.<pub-id pub-id-type="pmid">33346134</pub-id>
</mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal" id="cit51"><name><surname>Hoffmann</surname><given-names>P.</given-names></name>; <name><surname>Warner</surname><given-names>B.</given-names></name>
<article-title>Are hERG Channel Inhibition and QT
Interval Prolongation
All There Is in Drug-Induced Torsadogenesis? A Review of Emerging
Trends</article-title>. <source>J. Pharmacol. Toxicol. Methods</source>
<year>2006</year>, <volume>53</volume> (<issue>2</issue>), <fpage>87</fpage>&#x02013;<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1016/j.vascn.2005.07.003</pub-id>.<pub-id pub-id-type="pmid">16289936</pub-id>
</mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name><surname>Gintant</surname><given-names>G.</given-names></name>
<article-title>An Evaluation
of hERG Current Assay Performance: Translating Preclinical Safety
Studies to Clinical QT Prolongation</article-title>. <source>Pharmacol.
Ther.</source>
<year>2011</year>, <volume>129</volume> (<issue>2</issue>), <fpage>109</fpage>&#x02013;<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2010.08.008</pub-id>.<pub-id pub-id-type="pmid">20807552</pub-id>
</mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal" id="cit53"><name><surname>European
Union</surname></name>
<article-title>Regulation (EC) No
1223/2009 of the European Parliament and of the Council</article-title>. <source>Official Journal of the European Union L</source>
<year>2009</year>, <volume>342</volume>, <fpage>59</fpage>.</mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="report" id="cit54"><article-title>Test Guideline
No. 442C In Chemico Skin Sensitisation Assays Addressing
the Adverse Outcome Pathway Key Event on Covalent Binding to Proteins</article-title>. <year>2022</year>.</mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal" id="cit55"><name><surname>Brennan</surname><given-names>R.
J.</given-names></name>; <name><surname>Jenkinson</surname><given-names>S.</given-names></name>; <name><surname>Brown</surname><given-names>A.</given-names></name>; <name><surname>Delaunois</surname><given-names>A.</given-names></name>; <name><surname>Dumotier</surname><given-names>B.</given-names></name>; <name><surname>Pannirselvam</surname><given-names>M.</given-names></name>; <name><surname>Rao</surname><given-names>M.</given-names></name>; <name><surname>Ribeiro</surname><given-names>L. R.</given-names></name>; <name><surname>Schmidt</surname><given-names>F.</given-names></name>; <name><surname>Sibony</surname><given-names>A.</given-names></name>; <name><surname>Timsit</surname><given-names>Y.</given-names></name>; <name><surname>Sales</surname><given-names>V. T.</given-names></name>; <name><surname>Armstrong</surname><given-names>D.</given-names></name>; <name><surname>Lagrutta</surname><given-names>A.</given-names></name>; <name><surname>Mittlestadt</surname><given-names>S. W.</given-names></name>; <name><surname>Naven</surname><given-names>R.</given-names></name>; <name><surname>Peri</surname><given-names>R.</given-names></name>; <name><surname>Roberts</surname><given-names>S.</given-names></name>; <name><surname>Vergis</surname><given-names>J. M.</given-names></name>; <name><surname>Valentin</surname><given-names>J.-P.</given-names></name>
<article-title>The State of the Art in Secondary Pharmacology and
Its Impact on the Safety of New Medicines</article-title>. <source>Nat.
Rev. Drug Discovery</source>
<year>2024</year>, <volume>23</volume> (<issue>7</issue>), <fpage>525</fpage>&#x02013;<lpage>545</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-024-00942-3</pub-id>.<pub-id pub-id-type="pmid">38773351</pub-id>
</mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal" id="cit56"><name><surname>Vo</surname><given-names>A. H.</given-names></name>; <name><surname>Van Vleet</surname><given-names>T. R.</given-names></name>; <name><surname>Gupta</surname><given-names>R. R.</given-names></name>; <name><surname>Liguori</surname><given-names>M. J.</given-names></name>; <name><surname>Rao</surname><given-names>M. S.</given-names></name>
<article-title>An Overview
of Machine Learning and Big Data for Drug Toxicity Evaluation</article-title>. <source>Chem. Res. Toxicol.</source>
<year>2020</year>, <volume>33</volume> (<issue>1</issue>), <fpage>20</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.9b00227</pub-id>.<pub-id pub-id-type="pmid">31625725</pub-id>
</mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal" id="cit57"><name><surname>Cavasotto</surname><given-names>C. N.</given-names></name>; <name><surname>Scardino</surname><given-names>V.</given-names></name>
<article-title>Machine Learning Toxicity
Prediction: Latest Advances
by Toxicity End Point</article-title>. <source>ACS Omega</source>
<year>2022</year>, <volume>7</volume> (<issue>51</issue>), <fpage>47536</fpage>&#x02013;<lpage>47546</lpage>. <pub-id pub-id-type="doi">10.1021/acsomega.2c05693</pub-id>.<pub-id pub-id-type="pmid">36591139</pub-id>
</mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal" id="cit58"><person-group person-group-type="allauthors"><name><surname>Huang</surname><given-names>K.</given-names></name>; <name><surname>Fu</surname><given-names>T.</given-names></name>; <name><surname>Gao</surname><given-names>W.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Roohani</surname><given-names>Y.</given-names></name>; <name><surname>Leskovec</surname><given-names>J.</given-names></name>; <name><surname>Coley</surname><given-names>C. W.</given-names></name>; <name><surname>Xiao</surname><given-names>C.</given-names></name>; <name><surname>Sun</surname><given-names>J.</given-names></name>; <name><surname>Zitnik</surname><given-names>M.</given-names></name></person-group><article-title>Therapeutics
Data Commons: Machine Learning Datasets and Tasks for Drug Discovery
and Development</article-title>. <source>arXiv [cs.LG]</source><year>2021</year>,<pub-id pub-id-type="doi">10.48550/arXiv.2102.09548</pub-id>.</mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal" id="cit59"><name><surname>Schapin</surname><given-names>N.</given-names></name>; <name><surname>Majewski</surname><given-names>M.</given-names></name>; <name><surname>Varela-Rial</surname><given-names>A.</given-names></name>; <name><surname>Arroniz</surname><given-names>C.</given-names></name>; <name><surname>Fabritiis</surname><given-names>G. D.</given-names></name>
<article-title>Machine
Learning Small Molecule Properties in Drug Discovery</article-title>. <source>Artificial Intelligence Chemistry</source>
<year>2023</year>, <volume>1</volume> (<issue>2</issue>), <fpage>100020</fpage><pub-id pub-id-type="doi">10.1016/j.aichem.2023.100020</pub-id>.</mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal" id="cit60"><person-group person-group-type="allauthors"><name><surname>Walters</surname><given-names>P.</given-names></name></person-group><article-title>We need better
benchmarks for machine learning in drug discovery</article-title>. <source>Practical Cheminformatics</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://practicalcheminformatics.blogspot.com/2023/08/we-need-better-benchmarks-for-machine.html">https://practicalcheminformatics.blogspot.com/2023/08/we-need-better-benchmarks-for-machine.html</uri> (accessed 2024-07-12), <year>2023</year>.</mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal" id="cit61"><name><surname>Sutherland</surname><given-names>J. J.</given-names></name>; <name><surname>Yonchev</surname><given-names>D.</given-names></name>; <name><surname>Fekete</surname><given-names>A.</given-names></name>; <name><surname>Urban</surname><given-names>L.</given-names></name>
<article-title>A Preclinical Secondary
Pharmacology Resource Illuminates Target-Adverse Drug Reaction Associations
of Marketed Drugs</article-title>. <source>Nat. Commun.</source>
<year>2023</year>, <volume>14</volume> (<issue>1</issue>), <fpage>4323</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-40064-9</pub-id>.<pub-id pub-id-type="pmid">37468498</pub-id>
</mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal" id="cit62"><name><surname>Shimizu</surname><given-names>Y.</given-names></name>; <name><surname>Sasaki</surname><given-names>T.</given-names></name>; <name><surname>Yonekawa</surname><given-names>E.</given-names></name>; <name><surname>Yamazaki</surname><given-names>H.</given-names></name>; <name><surname>Ogura</surname><given-names>R.</given-names></name>; <name><surname>Watanabe</surname><given-names>M.</given-names></name>; <name><surname>Hosaka</surname><given-names>T.</given-names></name>; <name><surname>Shizu</surname><given-names>R.</given-names></name>; <name><surname>Takeshita</surname><given-names>J.-I.</given-names></name>; <name><surname>Yoshinari</surname><given-names>K.</given-names></name>
<article-title>Association
of CYP1A1 and CYP1B1 Inhibition in in Vitro
Assays with Drug-Induced Liver Injury</article-title>. <source>J. Toxicol.
Sci.</source>
<year>2021</year>, <volume>46</volume> (<issue>4</issue>), <fpage>167</fpage>&#x02013;<lpage>176</lpage>. <pub-id pub-id-type="doi">10.2131/jts.46.167</pub-id>.<pub-id pub-id-type="pmid">33814510</pub-id>
</mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="weblink" id="cit63"><person-group person-group-type="allauthors"><collab>PubChem</collab></person-group>. <source>AID 1207781 - Human HepG2 cell viability assay in 384 well
format - PubChem.</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1207781">https://pubchem.ncbi.nlm.nih.gov/bioassay/1207781</uri> (accessed 2024-02-20).</mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal" id="cit64"><name><surname>Veith</surname><given-names>H.</given-names></name>; <name><surname>Southall</surname><given-names>N.</given-names></name>; <name><surname>Huang</surname><given-names>R.</given-names></name>; <name><surname>James</surname><given-names>T.</given-names></name>; <name><surname>Fayne</surname><given-names>D.</given-names></name>; <name><surname>Artemenko</surname><given-names>N.</given-names></name>; <name><surname>Shen</surname><given-names>M.</given-names></name>; <name><surname>Inglese</surname><given-names>J.</given-names></name>; <name><surname>Austin</surname><given-names>C. P.</given-names></name>; <name><surname>Lloyd</surname><given-names>D. G.</given-names></name>; <name><surname>Auld</surname><given-names>D. S.</given-names></name>
<article-title>Comprehensive Characterization of
Cytochrome P450 Isozyme Selectivity across Chemical Libraries</article-title>. <source>Nat. Biotechnol.</source>
<year>2009</year>, <volume>27</volume> (<issue>11</issue>), <fpage>1050</fpage>&#x02013;<lpage>1055</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.1581</pub-id>.<pub-id pub-id-type="pmid">19855396</pub-id>
</mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal" id="cit65"><person-group person-group-type="allauthors"><name><surname>Narkar</surname><given-names>A.</given-names></name>; <name><surname>Willard</surname><given-names>J. M.</given-names></name>; <name><surname>Blinova</surname><given-names>K.</given-names></name></person-group><article-title>Chronic Cardiotoxicity
Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
(hiPSC-CMs)</article-title>. <source>Int. J. Mol. Sci.</source><year>2022</year>, <volume>23</volume> ( (<issue>6</issue>), ). <fpage>3199</fpage><pub-id pub-id-type="doi">10.3390/ijms23063199</pub-id>.<pub-id pub-id-type="pmid">35328619</pub-id>
</mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="weblink" id="cit66"><person-group person-group-type="allauthors"><collab>PubChem</collab></person-group>. <source>AID 720551 - qHTS for Inhibitors of KCHN2
3.1: Wildtype
qHTS - PubChem.</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/bioassay/720551">https://pubchem.ncbi.nlm.nih.gov/bioassay/720551</uri> (accessed 2024&#x02013;02&#x02013;20).</mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal" id="cit67"><name><surname>Du</surname><given-names>F.</given-names></name>; <name><surname>Yu</surname><given-names>H.</given-names></name>; <name><surname>Zou</surname><given-names>B.</given-names></name>; <name><surname>Babcock</surname><given-names>J.</given-names></name>; <name><surname>Long</surname><given-names>S.</given-names></name>; <name><surname>Li</surname><given-names>M.</given-names></name>
<article-title>hERGCentral:
A Large Database to Store, Retrieve, and Analyze Compound-Human Ether-&#x000e0;-Go-Go
Related Gene Channel Interactions to Facilitate Cardiotoxicity Assessment
in Drug Development</article-title>. <source>Assay Drug Dev. Technol.</source>
<year>2011</year>, <volume>9</volume> (<issue>6</issue>), <fpage>580</fpage>&#x02013;<lpage>588</lpage>. <pub-id pub-id-type="doi">10.1089/adt.2011.0425</pub-id>.<pub-id pub-id-type="pmid">22149888</pub-id>
</mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal" id="cit68"><name><surname>Jing</surname><given-names>B.</given-names></name>; <name><surname>Yan</surname><given-names>L.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Luo</surname><given-names>P.</given-names></name>; <name><surname>Ai</surname><given-names>X.</given-names></name>; <name><surname>Tu</surname><given-names>P.</given-names></name>
<article-title>Functional
Evaluation and Nephrotoxicity Assessment of Human Renal Proximal Tubule
Cells on a Chip</article-title>. <source>Biosensors</source>
<year>2022</year>, <volume>12</volume> (<issue>9</issue>), <fpage>718</fpage><pub-id pub-id-type="doi">10.3390/bios12090718</pub-id>.<pub-id pub-id-type="pmid">36140103</pub-id>
</mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal" id="cit69"><name><surname>Wu</surname><given-names>Y.</given-names></name>; <name><surname>Connors</surname><given-names>D.</given-names></name>; <name><surname>Barber</surname><given-names>L.</given-names></name>; <name><surname>Jayachandra</surname><given-names>S.</given-names></name>; <name><surname>Hanumegowda</surname><given-names>U. M.</given-names></name>; <name><surname>Adams</surname><given-names>S. P.</given-names></name>
<article-title>Multiplexed Assay
Panel of Cytotoxicity
in HK-2 Cells for Detection of Renal Proximal Tubule Injury Potential
of Compounds</article-title>. <source>Toxicol. In Vitro</source>
<year>2009</year>, <volume>23</volume> (<issue>6</issue>), <fpage>1170</fpage>&#x02013;<lpage>1178</lpage>. <pub-id pub-id-type="doi">10.1016/j.tiv.2009.06.003</pub-id>.<pub-id pub-id-type="pmid">19523510</pub-id>
</mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal" id="cit70"><name><surname>Qiu</surname><given-names>X.</given-names></name>; <name><surname>Zhou</surname><given-names>X.</given-names></name>; <name><surname>Miao</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>B.</given-names></name>
<article-title>An in Vitro Method
for Nephrotoxicity Evaluation Using HK-2 Human Kidney Epithelial Cells
Combined with Biomarkers of Nephrotoxicity</article-title>. <source>Toxicol. Res.</source>
<year>2018</year>, <volume>7</volume> (<issue>6</issue>), <fpage>1205</fpage>&#x02013;<lpage>1213</lpage>. <pub-id pub-id-type="doi">10.1039/C8TX00095F</pub-id>.</mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal" id="cit71"><person-group person-group-type="allauthors"><name><surname>Aras</surname><given-names>M. A.</given-names></name>; <name><surname>Hartnett</surname><given-names>K. A.</given-names></name>; <name><surname>Aizenman</surname><given-names>E.</given-names></name></person-group><article-title>Assessment of
Cell Viability in Primary Neuronal Cultures</article-title>. <source>Curr. Protoc. Neurosci.</source><year>2008</year>, <volume>44</volume>, Unit 7.18.<pub-id pub-id-type="doi">10.1002/0471142301.ns0718s44</pub-id>.</mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal" id="cit72"><person-group person-group-type="allauthors"><name><surname>Filous</surname><given-names>A. R.</given-names></name>; <name><surname>Silver</surname><given-names>J.</given-names></name></person-group><article-title>Neurite Outgrowth
Assay</article-title>. <source>Bio Protoc</source><year>2016</year>, <volume>6</volume> ( (<issue>1</issue>), ).<pub-id pub-id-type="doi">10.21769/BioProtoc.1694</pub-id>.</mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal" id="cit73"><person-group person-group-type="allauthors"><name><surname>Bryant</surname><given-names>S. D.</given-names></name>; <name><surname>Langer</surname><given-names>T.</given-names></name></person-group><source>NeuroDeRisk In Silico
Toolbox: De-Risking Neurotoxicity and 3D-Pharmacophores</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://infochim.u-strasbg.fr/CS3_2024/Abstracts_Posters/P_42_BryantSD_Abstract-CS3-2024.pdf">https://infochim.u-strasbg.fr/CS3_2024/Abstracts_Posters/P_42_BryantSD_Abstract-CS3-2024.pdf</uri> (accessed 2024-07-18).</mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal" id="cit74"><name><surname>Adams</surname><given-names>D. J.</given-names></name>; <name><surname>Barlas</surname><given-names>B.</given-names></name>; <name><surname>McIntyre</surname><given-names>R. E.</given-names></name>; <name><surname>Salguero</surname><given-names>I.</given-names></name>; <name><surname>van der
Weyden</surname><given-names>L.</given-names></name>; <name><surname>Barros</surname><given-names>A.</given-names></name>; <name><surname>Vicente</surname><given-names>J. R.</given-names></name>; <name><surname>Karimpour</surname><given-names>N.</given-names></name>; <name><surname>Haider</surname><given-names>A.</given-names></name>; <name><surname>Ranzani</surname><given-names>M.</given-names></name>; <name><surname>Turner</surname><given-names>G.</given-names></name>; <name><surname>Thompson</surname><given-names>N. A.</given-names></name>; <name><surname>Harle</surname><given-names>V.</given-names></name>; <name><surname>Olvera-Le&#x000f3;n</surname><given-names>R.</given-names></name>; <name><surname>Robles-Espinoza</surname><given-names>C. D.</given-names></name>; <name><surname>Speak</surname><given-names>A. O.</given-names></name>; <name><surname>Geisler</surname><given-names>N.</given-names></name>; <name><surname>Weninger</surname><given-names>W. J.</given-names></name>; <name><surname>Geyer</surname><given-names>S. H.</given-names></name>; <name><surname>Hewinson</surname><given-names>J.</given-names></name>; <name><surname>Karp</surname><given-names>N. A.</given-names></name>; <name><surname>Fu</surname><given-names>B.</given-names></name>; <name><surname>Yang</surname><given-names>F.</given-names></name>; <name><surname>Kozik</surname><given-names>Z.</given-names></name>; <name><surname>Choudhary</surname><given-names>J.</given-names></name>; <name><surname>Yu</surname><given-names>L.</given-names></name>; <name><surname>van Ruiten</surname><given-names>M. S.</given-names></name>; <name><surname>Rowland</surname><given-names>B. D.</given-names></name>; <name><surname>Lelliott</surname><given-names>C. J.</given-names></name>; <name><surname>Del Castillo Velasco-Herrera</surname><given-names>M.</given-names></name>; <name><surname>Verstraten</surname><given-names>R.</given-names></name>; <name><surname>Bruckner</surname><given-names>L.</given-names></name>; <name><surname>Henssen</surname><given-names>A. G.</given-names></name>; <name><surname>Rooimans</surname><given-names>M. A.</given-names></name>; <name><surname>de Lange</surname><given-names>J.</given-names></name>; <name><surname>Mohun</surname><given-names>T. J.</given-names></name>; <name><surname>Arends</surname><given-names>M. J.</given-names></name>; <name><surname>Kentistou</surname><given-names>K. A.</given-names></name>; <name><surname>Coelho</surname><given-names>P. A.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Zecchini</surname><given-names>H.</given-names></name>; <name><surname>Perry</surname><given-names>J. R. B.</given-names></name>; <name><surname>Jackson</surname><given-names>S. P.</given-names></name>; <name><surname>Balmus</surname><given-names>G.</given-names></name>; et al. <article-title>Genetic Determinants
of Micronucleus Formation in Vivo</article-title>. <source>Nature</source>
<year>2024</year>, <volume>627</volume> (<issue>8002</issue>), <fpage>130</fpage>&#x02013;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-023-07009-0</pub-id>.<pub-id pub-id-type="pmid">38355793</pub-id>
</mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="journal" id="cit75"><name><surname>Hayashi</surname><given-names>M.</given-names></name>
<article-title>The Micronucleus
Test-Most Widely Used in Vivo Genotoxicity Test</article-title>. <source>Genes Environ</source>
<year>2016</year>, <volume>38</volume>, <fpage>18</fpage><pub-id pub-id-type="doi">10.1186/s41021-016-0044-x</pub-id>.<pub-id pub-id-type="pmid">27733885</pub-id>
</mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal" id="cit76"><name><surname>Vijay</surname><given-names>U.</given-names></name>; <name><surname>Gupta</surname><given-names>S.</given-names></name>; <name><surname>Mathur</surname><given-names>P.</given-names></name>; <name><surname>Suravajhala</surname><given-names>P.</given-names></name>; <name><surname>Bhatnagar</surname><given-names>P.</given-names></name>
<article-title>Microbial Mutagenicity Assay: Ames
Test</article-title>. <source>Bio Protoc</source>
<year>2018</year>, <volume>8</volume> (<issue>6</issue>), <elocation-id>e2763</elocation-id><pub-id pub-id-type="doi">10.21769/BioProtoc.2763</pub-id>.</mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="journal" id="cit77"><name><surname>Cordelli</surname><given-names>E.</given-names></name>; <name><surname>Bignami</surname><given-names>M.</given-names></name>; <name><surname>Pacchierotti</surname><given-names>F.</given-names></name>
<article-title>Comet Assay:
A Versatile but Complex
Tool in Genotoxicity Testing</article-title>. <source>Toxicol. Res.</source>
<year>2021</year>, <volume>10</volume> (<issue>1</issue>), <fpage>68</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1093/toxres/tfaa093</pub-id>.</mixed-citation></ref><ref id="ref78"><mixed-citation publication-type="journal" id="cit78"><name><surname>Creton</surname><given-names>S.</given-names></name>; <name><surname>Aardema</surname><given-names>M. J.</given-names></name>; <name><surname>Carmichael</surname><given-names>P. L.</given-names></name>; <name><surname>Harvey</surname><given-names>J. S.</given-names></name>; <name><surname>Martin</surname><given-names>F. L.</given-names></name>; <name><surname>Newbold</surname><given-names>R. F.</given-names></name>; <name><surname>O&#x02019;Donovan</surname><given-names>M. R.</given-names></name>; <name><surname>Pant</surname><given-names>K.</given-names></name>; <name><surname>Poth</surname><given-names>A.</given-names></name>; <name><surname>Sakai</surname><given-names>A.</given-names></name>; <name><surname>Sasaki</surname><given-names>K.</given-names></name>; <name><surname>Scott</surname><given-names>A. D.</given-names></name>; <name><surname>Schechtman</surname><given-names>L. M.</given-names></name>; <name><surname>Shen</surname><given-names>R. R.</given-names></name>; <name><surname>Tanaka</surname><given-names>N.</given-names></name>; <name><surname>Yasaei</surname><given-names>H.</given-names></name>
<article-title>Cell Transformation
Assays for Prediction of Carcinogenic Potential: State of the Science
and Future Research Needs</article-title>. <source>Mutagenesis</source>
<year>2012</year>, <volume>27</volume> (<issue>1</issue>), <fpage>93</fpage>&#x02013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1093/mutage/ger053</pub-id>.<pub-id pub-id-type="pmid">21852270</pub-id>
</mixed-citation></ref><ref id="ref79"><mixed-citation publication-type="journal" id="cit79"><name><surname>Kuo</surname><given-names>B.</given-names></name>; <name><surname>Beal</surname><given-names>M. A.</given-names></name>; <name><surname>Wills</surname><given-names>J. W.</given-names></name>; <name><surname>White</surname><given-names>P. A.</given-names></name>; <name><surname>Marchetti</surname><given-names>F.</given-names></name>; <name><surname>Nong</surname><given-names>A.</given-names></name>; <name><surname>Barton-Maclaren</surname><given-names>T. S.</given-names></name>; <name><surname>Houck</surname><given-names>K.</given-names></name>; <name><surname>Yauk</surname><given-names>C. L.</given-names></name>
<article-title>Comprehensive
Interpretation of in Vitro Micronucleus Test Results for 292 Chemicals:
From Hazard Identification to Risk Assessment Application</article-title>. <source>Arch. Toxicol.</source>
<year>2022</year>, <volume>96</volume> (<issue>7</issue>), <fpage>2067</fpage>&#x02013;<lpage>2085</lpage>. <pub-id pub-id-type="doi">10.1007/s00204-022-03286-2</pub-id>.<pub-id pub-id-type="pmid">35445829</pub-id>
</mixed-citation></ref><ref id="ref80"><mixed-citation publication-type="journal" id="cit80"><name><surname>Xu</surname><given-names>C.</given-names></name>; <name><surname>Cheng</surname><given-names>F.</given-names></name>; <name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>Du</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>W.</given-names></name>; <name><surname>Liu</surname><given-names>G.</given-names></name>; <name><surname>Lee</surname><given-names>P. W.</given-names></name>; <name><surname>Tang</surname><given-names>Y.</given-names></name>
<article-title>In Silico
Prediction of Chemical
Ames Mutagenicity</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2012</year>, <volume>52</volume> (<issue>11</issue>), <fpage>2840</fpage>&#x02013;<lpage>2847</lpage>. <pub-id pub-id-type="doi">10.1021/ci300400a</pub-id>.<pub-id pub-id-type="pmid">23030379</pub-id>
</mixed-citation></ref><ref id="ref81"><mixed-citation publication-type="weblink" id="cit81"><person-group person-group-type="allauthors"><collab>PubChem</collab></person-group>. <source>Chemical Carcinogenesis Research Information System (CCRIS)
- PubChem. Data Source</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/source/22070">https://pubchem.ncbi.nlm.nih.gov/source/22070</uri> (accessed 2024-02-21).</mixed-citation></ref><ref id="ref82"><mixed-citation publication-type="journal" id="cit82"><name><surname>Shanle</surname><given-names>E.
K.</given-names></name>; <name><surname>Xu</surname><given-names>W.</given-names></name>
<article-title>Endocrine
Disrupting Chemicals Targeting Estrogen Receptor Signaling:
Identification and Mechanisms of Action</article-title>. <source>Chem.
Res. Toxicol.</source>
<year>2011</year>, <volume>24</volume> (<issue>1</issue>), <fpage>6</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1021/tx100231n</pub-id>.<pub-id pub-id-type="pmid">21053929</pub-id>
</mixed-citation></ref><ref id="ref83"><mixed-citation publication-type="journal" id="cit83"><name><surname>Tinwell</surname><given-names>H.</given-names></name>; <name><surname>Karmaus</surname><given-names>A.</given-names></name>; <name><surname>Gaskell</surname><given-names>V.</given-names></name>; <name><surname>Gomes</surname><given-names>C.</given-names></name>; <name><surname>Grant</surname><given-names>C.</given-names></name>; <name><surname>Holmes</surname><given-names>T.</given-names></name>; <name><surname>Jonas</surname><given-names>A.</given-names></name>; <name><surname>Kellum</surname><given-names>S.</given-names></name>; <name><surname>Kr&#x000fc;ger</surname><given-names>K.</given-names></name>; <name><surname>Malley</surname><given-names>L.</given-names></name>; <name><surname>Melching-Kollmuss</surname><given-names>S.</given-names></name>; <name><surname>Mercier</surname><given-names>O.</given-names></name>; <name><surname>Pandya</surname><given-names>H.</given-names></name>; <name><surname>Placke</surname><given-names>T.</given-names></name>; <name><surname>Settivari</surname><given-names>R.</given-names></name>; <name><surname>De Waen</surname><given-names>B.</given-names></name>
<article-title>Evaluating H295R Steroidogenesis
Assay Data for Robust Interpretation</article-title>. <source>Regul.
Toxicol. Pharmacol.</source>
<year>2023</year>, <volume>143</volume>, <fpage>105461</fpage><pub-id pub-id-type="doi">10.1016/j.yrtph.2023.105461</pub-id>.<pub-id pub-id-type="pmid">37490962</pub-id>
</mixed-citation></ref><ref id="ref84"><mixed-citation publication-type="report" id="cit84"><person-group person-group-type="allauthors"><collab>US EPA</collab></person-group>. <source>Exploring ToxCast Data</source>; <publisher-name>US EPA</publisher-name>, <year>2017</year>.</mixed-citation></ref><ref id="ref85"><mixed-citation publication-type="journal" id="cit85"><name><surname>Gerberick</surname><given-names>G. F.</given-names></name>; <name><surname>Ryan</surname><given-names>C. A.</given-names></name>; <name><surname>Dearman</surname><given-names>R. J.</given-names></name>; <name><surname>Kimber</surname><given-names>I.</given-names></name>
<article-title>Local Lymph Node Assay
(LLNA) for Detection of Sensitization Capacity of Chemicals</article-title>. <source>Methods</source>
<year>2007</year>, <volume>41</volume> (<issue>1</issue>), <fpage>54</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymeth.2006.07.006</pub-id>.<pub-id pub-id-type="pmid">16938465</pub-id>
</mixed-citation></ref><ref id="ref86"><mixed-citation publication-type="journal" id="cit86"><name><surname>Wang</surname><given-names>C.-C.</given-names></name>; <name><surname>Lin</surname><given-names>Y.-C.</given-names></name>; <name><surname>Wang</surname><given-names>S.-S.</given-names></name>; <name><surname>Shih</surname><given-names>C.</given-names></name>; <name><surname>Lin</surname><given-names>Y.-H.</given-names></name>; <name><surname>Tung</surname><given-names>C.-W.</given-names></name>
<article-title>SkinSensDB: A Curated Database for
Skin Sensitization
Assays</article-title>. <source>J. Cheminform.</source>
<year>2017</year>, <volume>9</volume>, <fpage>5</fpage><pub-id pub-id-type="doi">10.1186/s13321-017-0194-2</pub-id>.<pub-id pub-id-type="pmid">28194231</pub-id>
</mixed-citation></ref><ref id="ref87"><mixed-citation publication-type="journal" id="cit87"><name><surname>Barile</surname><given-names>F. A.</given-names></name>
<article-title>Validating
and Troubleshooting Ocular in Vitro Toxicology Tests</article-title>. <source>J. Pharmacol. Toxicol. Methods</source>
<year>2010</year>, <volume>61</volume> (<issue>2</issue>), <fpage>136</fpage>&#x02013;<lpage>145</lpage>. <pub-id pub-id-type="doi">10.1016/j.vascn.2010.01.001</pub-id>.<pub-id pub-id-type="pmid">20096797</pub-id>
</mixed-citation></ref><ref id="ref88"><mixed-citation publication-type="journal" id="cit88"><name><surname>Zhou</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name>; <name><surname>Huang</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>W.</given-names></name>; <name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Yu</surname><given-names>X.</given-names></name>; <name><surname>Tang</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>G.</given-names></name>
<article-title>In Silico
Prediction of Ocular Toxicity
of Compounds Using Explainable Machine Learning and Deep Learning
Approaches</article-title>. <source>J. Appl. Toxicol.</source>
<year>2024</year>, <volume>44</volume>, <fpage>892</fpage><pub-id pub-id-type="doi">10.1002/jat.4586</pub-id>.<pub-id pub-id-type="pmid">38329145</pub-id>
</mixed-citation></ref><ref id="ref89"><mixed-citation publication-type="journal" id="cit89"><name><surname>van
Tilborg</surname><given-names>D.</given-names></name>; <name><surname>Alenicheva</surname><given-names>A.</given-names></name>; <name><surname>Grisoni</surname><given-names>F.</given-names></name>
<article-title>Exposing the Limitations
of Molecular Machine Learning with Activity Cliffs</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2022</year>, <volume>62</volume> (<issue>23</issue>), <fpage>5938</fpage>&#x02013;<lpage>5951</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.2c01073</pub-id>.<pub-id pub-id-type="pmid">36456532</pub-id>
</mixed-citation></ref><ref id="ref90"><mixed-citation publication-type="journal" id="cit90"><person-group person-group-type="allauthors"><name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Zhao</surname><given-names>B.</given-names></name>; <name><surname>Xie</surname><given-names>A.</given-names></name>; <name><surname>Bian</surname><given-names>Y.</given-names></name>; <name><surname>Zhou</surname><given-names>S.</given-names></name></person-group><article-title>Activity Cliff Prediction: Dataset
and Benchmark</article-title>. <source>arXiv [q-bio.BM]</source><year>2023</year>,<pub-id pub-id-type="doi">10.48550/arXiv.2302.07541</pub-id>.</mixed-citation></ref><ref id="ref91"><mixed-citation publication-type="journal" id="cit91"><name><surname>Dablander</surname><given-names>M.</given-names></name>; <name><surname>Hanser</surname><given-names>T.</given-names></name>; <name><surname>Lambiotte</surname><given-names>R.</given-names></name>; <name><surname>Morris</surname><given-names>G. M.</given-names></name>
<article-title>Exploring QSAR Models
for Activity-Cliff Prediction</article-title>. <source>J. Cheminform.</source>
<year>2023</year>, <volume>15</volume> (<issue>1</issue>), <fpage>47</fpage><pub-id pub-id-type="doi">10.1186/s13321-023-00708-w</pub-id>.<pub-id pub-id-type="pmid">37069675</pub-id>
</mixed-citation></ref><ref id="ref92"><mixed-citation publication-type="weblink" id="cit92"><source>Document: Experimental in vitro DMPK and physicochemical
data on
a set of publicly disclosed compounds</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebi.ac.uk/chembl/document_report_card/CHEMBL3301361/">https://www.ebi.ac.uk/chembl/document_report_card/CHEMBL3301361/</uri> (accessed 2024-07-12).</mixed-citation></ref><ref id="ref93"><mixed-citation publication-type="weblink" id="cit93"><source>U.S. environmental protection
agency - evaluation of existing QSAR
models and structural alerts and development of new ensemble models
for genotoxicity using a newly compiled experimental dataset</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://catalog.data.gov/dataset/evaluation-of-existing-qsar-models-and-structural-alerts-and-development-of-new-ensemble-m">https://catalog.data.gov/dataset/evaluation-of-existing-qsar-models-and-structural-alerts-and-development-of-new-ensemble-m</uri> (accessed 2024-07-12).</mixed-citation></ref><ref id="ref94"><mixed-citation publication-type="journal" id="cit94"><name><surname>Madia</surname><given-names>F.</given-names></name>; <name><surname>Kirkland</surname><given-names>D.</given-names></name>; <name><surname>Morita</surname><given-names>T.</given-names></name>; <name><surname>White</surname><given-names>P.</given-names></name>; <name><surname>Asturiol</surname><given-names>D.</given-names></name>; <name><surname>Corvi</surname><given-names>R.</given-names></name>
<article-title>EURL ECVAM Genotoxicity
and Carcinogenicity Database of Substances
Eliciting Negative Results in the Ames Test: Construction of the Database</article-title>. <source>Mutat Res. Genet Toxicol Environ. Mutagen</source>
<year>2020</year>, <volume>854&#x02013;855</volume>, <fpage>503199</fpage><pub-id pub-id-type="doi">10.1016/j.mrgentox.2020.503199</pub-id>.</mixed-citation></ref><ref id="ref95"><mixed-citation publication-type="journal" id="cit95"><person-group person-group-type="allauthors"><name><surname>Corvi</surname><given-names>R.</given-names></name>; <name><surname>Madia</surname><given-names>F.</given-names></name></person-group><article-title>Eurl
ECVAM Genotoxicity and
Carcinogenicity Consolidated Database of Ames Positive Chemicals</article-title>. <source>Eur. Comm. Jt. Res. Cent. [Dataset]</source><year>2018</year>.</mixed-citation></ref><ref id="ref96"><mixed-citation publication-type="journal" id="cit96"><person-group person-group-type="allauthors"><name><surname>Mart&#x000ed;nez</surname><given-names>M. J.</given-names></name></person-group>; <etal/><source>Ames Mutagenicity Dataset for Multi-Task
Learning</source><year>2022</year>,<pub-id pub-id-type="doi">10.17632/KTC6GBFSBH.2</pub-id>.</mixed-citation></ref><ref id="ref97"><mixed-citation publication-type="journal" id="cit97"><name><surname>Hansen</surname><given-names>K.</given-names></name>; <name><surname>Mika</surname><given-names>S.</given-names></name>; <name><surname>Schroeter</surname><given-names>T.</given-names></name>; <name><surname>Sutter</surname><given-names>A.</given-names></name>; <name><surname>ter Laak</surname><given-names>A.</given-names></name>; <name><surname>Steger-Hartmann</surname><given-names>T.</given-names></name>; <name><surname>Heinrich</surname><given-names>N.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>K.-R.</given-names></name>
<article-title>Benchmark
Data Set for in Silico Prediction of Ames Mutagenicity</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2009</year>, <volume>49</volume> (<issue>9</issue>), <fpage>2077</fpage>&#x02013;<lpage>2081</lpage>. <pub-id pub-id-type="doi">10.1021/ci900161g</pub-id>.<pub-id pub-id-type="pmid">19702240</pub-id>
</mixed-citation></ref><ref id="ref98"><mixed-citation publication-type="journal" id="cit98"><name><surname>Ciallella</surname><given-names>H. L.</given-names></name>; <name><surname>Russo</surname><given-names>D. P.</given-names></name>; <name><surname>Sharma</surname><given-names>S.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Sloter</surname><given-names>E.</given-names></name>; <name><surname>Sweet</surname><given-names>L.</given-names></name>; <name><surname>Huang</surname><given-names>H.</given-names></name>; <name><surname>Zhu</surname><given-names>H.</given-names></name>
<article-title>Predicting
Prenatal
Developmental Toxicity Based On the Combination of Chemical Structures
and Biological Data</article-title>. <source>Environ. Sci. Technol.</source>
<year>2022</year>, <volume>56</volume> (<issue>9</issue>), <fpage>5984</fpage>&#x02013;<lpage>5998</lpage>. <pub-id pub-id-type="doi">10.1021/acs.est.2c01040</pub-id>.<pub-id pub-id-type="pmid">35451820</pub-id>
</mixed-citation></ref><ref id="ref99"><mixed-citation publication-type="journal" id="cit99"><name><surname>Yuan</surname><given-names>H.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Cheng</surname><given-names>Y.</given-names></name>
<article-title>Local and Global Quantitative Structure-Activity
Relationship Modeling and Prediction for the Baseline Toxicity</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2007</year>, <volume>47</volume> (<issue>1</issue>), <fpage>159</fpage>&#x02013;<lpage>169</lpage>. <pub-id pub-id-type="doi">10.1021/ci600299j</pub-id>.<pub-id pub-id-type="pmid">17238261</pub-id>
</mixed-citation></ref><ref id="ref100"><mixed-citation publication-type="journal" id="cit100"><name><surname>Di Lascio</surname><given-names>E.</given-names></name>; <name><surname>Gerebtzoff</surname><given-names>G.</given-names></name>; <name><surname>Rodr&#x000ed;guez-P&#x000e9;rez</surname><given-names>R.</given-names></name>
<article-title>Systematic
Evaluation of Local and Global Machine Learning Models for the Prediction
of ADME Properties</article-title>. <source>Mol. Pharmaceutics</source>
<year>2023</year>, <volume>20</volume> (<issue>3</issue>), <fpage>1758</fpage>&#x02013;<lpage>1767</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.2c00962</pub-id>.</mixed-citation></ref><ref id="ref101"><mixed-citation publication-type="journal" id="cit101"><name><surname>Enoch</surname><given-names>S. J.</given-names></name>; <name><surname>Cronin</surname><given-names>M. T. D.</given-names></name>; <name><surname>Schultz</surname><given-names>T. W.</given-names></name>; <name><surname>Madden</surname><given-names>J. C.</given-names></name>
<article-title>An Evaluation
of Global QSAR Models for the Prediction of the Toxicity of Phenols
to Tetrahymena Pyriformis</article-title>. <source>Chemosphere</source>
<year>2008</year>, <volume>71</volume> (<issue>7</issue>), <fpage>1225</fpage>&#x02013;<lpage>1232</lpage>. <pub-id pub-id-type="doi">10.1016/j.chemosphere.2007.12.011</pub-id>.<pub-id pub-id-type="pmid">18261763</pub-id>
</mixed-citation></ref><ref id="ref102"><mixed-citation publication-type="journal" id="cit102"><name><surname>Cumming</surname><given-names>J. G.</given-names></name>; <name><surname>Davis</surname><given-names>A. M.</given-names></name>; <name><surname>Muresan</surname><given-names>S.</given-names></name>; <name><surname>Haeberlein</surname><given-names>M.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>
<article-title>Chemical Predictive Modelling to Improve Compound Quality</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2013</year>, <volume>12</volume> (<issue>12</issue>), <fpage>948</fpage>&#x02013;<lpage>962</lpage>. <pub-id pub-id-type="doi">10.1038/nrd4128</pub-id>.<pub-id pub-id-type="pmid">24287782</pub-id>
</mixed-citation></ref><ref id="ref103"><mixed-citation publication-type="journal" id="cit103"><name><surname>Gomis-Tena</surname><given-names>J.</given-names></name>; <name><surname>Brown</surname><given-names>B. M.</given-names></name>; <name><surname>Cano</surname><given-names>J.</given-names></name>; <name><surname>Trenor</surname><given-names>B.</given-names></name>; <name><surname>Yang</surname><given-names>P.-C.</given-names></name>; <name><surname>Saiz</surname><given-names>J.</given-names></name>; <name><surname>Clancy</surname><given-names>C. E.</given-names></name>; <name><surname>Romero</surname><given-names>L.</given-names></name>
<article-title>When Does
the IC50 Accurately Assess the Blocking Potency of a Drug?</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2020</year>, <volume>60</volume> (<issue>3</issue>), <fpage>1779</fpage>&#x02013;<lpage>1790</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.9b01085</pub-id>.<pub-id pub-id-type="pmid">32105478</pub-id>
</mixed-citation></ref><ref id="ref104"><mixed-citation publication-type="journal" id="cit104"><name><surname>Aronov</surname><given-names>A. M.</given-names></name>
<article-title>Common Pharmacophores for Uncharged
Human Ether-a-Go-Go-Related
Gene (hERG) Blockers</article-title>. <source>J. Med. Chem.</source>
<year>2006</year>, <volume>49</volume> (<issue>23</issue>), <fpage>6917</fpage>&#x02013;<lpage>6921</lpage>. <pub-id pub-id-type="doi">10.1021/jm060500o</pub-id>.<pub-id pub-id-type="pmid">17154521</pub-id>
</mixed-citation></ref><ref id="ref105"><mixed-citation publication-type="journal" id="cit105"><name><surname>Creanza</surname><given-names>T.
M.</given-names></name>; <name><surname>Delre</surname><given-names>P.</given-names></name>; <name><surname>Ancona</surname><given-names>N.</given-names></name>; <name><surname>Lentini</surname><given-names>G.</given-names></name>; <name><surname>Saviano</surname><given-names>M.</given-names></name>; <name><surname>Mangiatordi</surname><given-names>G. F.</given-names></name>
<article-title>Structure-Based
Prediction of hERG-Related
Cardiotoxicity: A Benchmark Study</article-title>. <source>J. Chem.
Inf. Model.</source>
<year>2021</year>, <volume>61</volume> (<issue>9</issue>), <fpage>4758</fpage>&#x02013;<lpage>4770</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.1c00744</pub-id>.<pub-id pub-id-type="pmid">34506150</pub-id>
</mixed-citation></ref><ref id="ref106"><mixed-citation publication-type="journal" id="cit106"><name><surname>G&#x000f6;ller</surname><given-names>A. H.</given-names></name>; <name><surname>Kuhnke</surname><given-names>L.</given-names></name>; <name><surname>Montanari</surname><given-names>F.</given-names></name>; <name><surname>Bonin</surname><given-names>A.</given-names></name>; <name><surname>Schneckener</surname><given-names>S.</given-names></name>; <name><surname>Ter Laak</surname><given-names>A.</given-names></name>; <name><surname>Wichard</surname><given-names>J.</given-names></name>; <name><surname>Lobell</surname><given-names>M.</given-names></name>; <name><surname>Hillisch</surname><given-names>A.</given-names></name>
<article-title>Bayer&#x02019;s in Silico ADMET Platform:
A Journey of Machine Learning over the Past Two Decades</article-title>. <source>Drug Discovery Today</source>
<year>2020</year>, <volume>25</volume> (<issue>9</issue>), <fpage>1702</fpage>&#x02013;<lpage>1709</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2020.07.001</pub-id>.<pub-id pub-id-type="pmid">32652309</pub-id>
</mixed-citation></ref><ref id="ref107"><mixed-citation publication-type="journal" id="cit107"><name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Xiong</surname><given-names>J.</given-names></name>; <name><surname>Xiao</surname><given-names>F.</given-names></name>; <name><surname>Zhang</surname><given-names>W.</given-names></name>; <name><surname>Cheng</surname><given-names>K.</given-names></name>; <name><surname>Rao</surname><given-names>J.</given-names></name>; <name><surname>Niu</surname><given-names>B.</given-names></name>; <name><surname>Tong</surname><given-names>X.</given-names></name>; <name><surname>Qu</surname><given-names>N.</given-names></name>; <name><surname>Zhang</surname><given-names>R.</given-names></name>; <name><surname>Wang</surname><given-names>D.</given-names></name>; <name><surname>Chen</surname><given-names>K.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Zheng</surname><given-names>M.</given-names></name>
<article-title>LogD7.4 Prediction
Enhanced by Transferring Knowledge from Chromatographic
Retention Time, Microscopic pKa and logP</article-title>. <source>J.
Cheminform.</source>
<year>2023</year>, <volume>15</volume> (<issue>1</issue>), <fpage>76</fpage><pub-id pub-id-type="doi">10.1186/s13321-023-00754-4</pub-id>.<pub-id pub-id-type="pmid">37670374</pub-id>
</mixed-citation></ref><ref id="ref108"><mixed-citation publication-type="journal" id="cit108"><name><surname>Mannhold</surname><given-names>R.</given-names></name>; <name><surname>Poda</surname><given-names>G. I.</given-names></name>; <name><surname>Ostermann</surname><given-names>C.</given-names></name>; <name><surname>Tetko</surname><given-names>I. V.</given-names></name>
<article-title>Calculation of Molecular
Lipophilicity: State-of-the-Art
and Comparison of Log P Methods on More than 96,000 Compounds</article-title>. <source>J. Pharm. Sci.</source>
<year>2009</year>, <volume>98</volume> (<issue>3</issue>), <fpage>861</fpage>&#x02013;<lpage>893</lpage>. <pub-id pub-id-type="doi">10.1002/jps.21494</pub-id>.<pub-id pub-id-type="pmid">18683876</pub-id>
</mixed-citation></ref><ref id="ref109"><mixed-citation publication-type="journal" id="cit109"><name><surname>Mansouri</surname><given-names>K.</given-names></name>; <name><surname>Moreira-Filho</surname><given-names>J. T.</given-names></name>; <name><surname>Lowe</surname><given-names>C. N.</given-names></name>; <name><surname>Charest</surname><given-names>N.</given-names></name>; <name><surname>Martin</surname><given-names>T.</given-names></name>; <name><surname>Tkachenko</surname><given-names>V.</given-names></name>; <name><surname>Judson</surname><given-names>R.</given-names></name>; <name><surname>Conway</surname><given-names>M.</given-names></name>; <name><surname>Kleinstreuer</surname><given-names>N. C.</given-names></name>; <name><surname>Williams</surname><given-names>A. J.</given-names></name>
<article-title>Free and Open-Source QSAR-Ready Workflow
for Automated Standardization of Chemical Structures in Support of
QSAR Modeling</article-title>. <source>J. Cheminform.</source>
<year>2024</year>, <volume>16</volume> (<issue>1</issue>), <fpage>19</fpage><pub-id pub-id-type="doi">10.1186/s13321-024-00814-3</pub-id>.<pub-id pub-id-type="pmid">38378618</pub-id>
</mixed-citation></ref><ref id="ref110"><mixed-citation publication-type="journal" id="cit110"><name><surname>DeVane</surname><given-names>C. L.</given-names></name>; <name><surname>Boulton</surname><given-names>D. W.</given-names></name>
<article-title>Great Expectations
in Stereochemistry:
Focus on Antidepressants</article-title>. <source>CNS Spectr.</source>
<year>2002</year>, <volume>7</volume> (<issue>S1</issue>), <fpage>28</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1017/S1092852900028571</pub-id>.<pub-id pub-id-type="pmid">15131490</pub-id>
</mixed-citation></ref><ref id="ref111"><mixed-citation publication-type="journal" id="cit111"><name><surname>McConathy</surname><given-names>J.</given-names></name>; <name><surname>Owens</surname><given-names>M. J.</given-names></name>
<article-title>Stereochemistry in Drug Action</article-title>. <source>Prim. Care Companion J. Clin. Psychiatry</source>
<year>2003</year>, <volume>5</volume> (<issue>2</issue>), <fpage>70</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.4088/PCC.v05n0202</pub-id>.<pub-id pub-id-type="pmid">15156233</pub-id>
</mixed-citation></ref><ref id="ref112"><mixed-citation publication-type="journal" id="cit112"><name><surname>Gal</surname><given-names>J.</given-names></name>
<article-title>Molecular Chirality in Chemistry
and Biology: Historical Milestones</article-title>. <source>Helv. Chim.
Acta</source>
<year>2013</year>, <volume>96</volume> (<issue>9</issue>), <fpage>1617</fpage>&#x02013;<lpage>1657</lpage>. <pub-id pub-id-type="doi">10.1002/hlca.201300300</pub-id>.</mixed-citation></ref><ref id="ref113"><mixed-citation publication-type="journal" id="cit113"><name><surname>Heller</surname><given-names>S. R.</given-names></name>; <name><surname>McNaught</surname><given-names>A.</given-names></name>; <name><surname>Pletnev</surname><given-names>I.</given-names></name>; <name><surname>Stein</surname><given-names>S.</given-names></name>; <name><surname>Tchekhovskoi</surname><given-names>D.</given-names></name>
<article-title>InChI, the IUPAC International Chemical Identifier</article-title>. <source>J. Cheminform.</source>
<year>2015</year>, <volume>7</volume> (<issue>1</issue>), <fpage>23</fpage><pub-id pub-id-type="doi">10.1186/s13321-015-0068-4</pub-id>.<pub-id pub-id-type="pmid">26136848</pub-id>
</mixed-citation></ref><ref id="ref114"><mixed-citation publication-type="journal" id="cit114"><name><surname>H&#x000e4;hnke</surname><given-names>V. D.</given-names></name>; <name><surname>Kim</surname><given-names>S.</given-names></name>; <name><surname>Bolton</surname><given-names>E. E.</given-names></name>
<article-title>PubChem
Chemical
Structure Standardization</article-title>. <source>J. Cheminform.</source>
<year>2018</year>, <volume>10</volume> (<issue>1</issue>), <fpage>36</fpage><pub-id pub-id-type="doi">10.1186/s13321-018-0293-8</pub-id>.<pub-id pub-id-type="pmid">30097821</pub-id>
</mixed-citation></ref><ref id="ref115"><mixed-citation publication-type="journal" id="cit115"><name><surname>Bento</surname><given-names>A. P.</given-names></name>; <name><surname>Hersey</surname><given-names>A.</given-names></name>; <name><surname>F&#x000e9;lix</surname><given-names>E.</given-names></name>; <name><surname>Landrum</surname><given-names>G.</given-names></name>; <name><surname>Gaulton</surname><given-names>A.</given-names></name>; <name><surname>Atkinson</surname><given-names>F.</given-names></name>; <name><surname>Bellis</surname><given-names>L. J.</given-names></name>; <name><surname>De Veij</surname><given-names>M.</given-names></name>; <name><surname>Leach</surname><given-names>A. R.</given-names></name>
<article-title>An Open Source Chemical Structure
Curation Pipeline Using RDKit</article-title>. <source>J. Cheminform.</source>
<year>2020</year>, <volume>12</volume> (<issue>1</issue>), <fpage>51</fpage><pub-id pub-id-type="doi">10.1186/s13321-020-00456-1</pub-id>.<pub-id pub-id-type="pmid">33431044</pub-id>
</mixed-citation></ref><ref id="ref116"><mixed-citation publication-type="journal" id="cit116"><name><surname>Sayle</surname><given-names>R. A.</given-names></name>
<article-title>So You Think You Understand Tautomerism?</article-title>. <source>J. Comput. Aided Mol. Des.</source>
<year>2010</year>, <volume>24</volume> (<issue>6&#x02013;7</issue>), <fpage>485</fpage>&#x02013;<lpage>496</lpage>. <pub-id pub-id-type="doi">10.1007/s10822-010-9329-5</pub-id>.<pub-id pub-id-type="pmid">20309607</pub-id>
</mixed-citation></ref><ref id="ref117"><mixed-citation publication-type="journal" id="cit117"><name><surname>Robello</surname><given-names>M.</given-names></name>; <name><surname>Barresi</surname><given-names>E.</given-names></name>; <name><surname>Baglini</surname><given-names>E.</given-names></name>; <name><surname>Salerno</surname><given-names>S.</given-names></name>; <name><surname>Taliani</surname><given-names>S.</given-names></name>; <name><surname>Settimo</surname><given-names>F. D.</given-names></name>
<article-title>The Alpha Keto Amide
Moiety as a
Privileged Motif in Medicinal Chemistry: Current Insights and Emerging
Opportunities</article-title>. <source>J. Med. Chem.</source>
<year>2021</year>, <volume>64</volume> (<issue>7</issue>), <fpage>3508</fpage>&#x02013;<lpage>3545</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c01808</pub-id>.<pub-id pub-id-type="pmid">33764065</pub-id>
</mixed-citation></ref><ref id="ref118"><mixed-citation publication-type="journal" id="cit118"><name><surname>Dhaked</surname><given-names>D. K.</given-names></name>; <name><surname>Ihlenfeldt</surname><given-names>W.-D.</given-names></name>; <name><surname>Patel</surname><given-names>H.</given-names></name>; <name><surname>Delann&#x000e9;e</surname><given-names>V.</given-names></name>; <name><surname>Nicklaus</surname><given-names>M. C.</given-names></name>
<article-title>Toward a Comprehensive
Treatment of Tautomerism in
Chemoinformatics Including in InChI V2</article-title>. <source>J. Chem.
Inf. Model.</source>
<year>2020</year>, <volume>60</volume> (<issue>3</issue>), <fpage>1253</fpage>&#x02013;<lpage>1275</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.9b01080</pub-id>.<pub-id pub-id-type="pmid">32043883</pub-id>
</mixed-citation></ref><ref id="ref119"><mixed-citation publication-type="journal" id="cit119"><name><surname>Guasch</surname><given-names>L.</given-names></name>; <name><surname>Yapamudiyansel</surname><given-names>W.</given-names></name>; <name><surname>Peach</surname><given-names>M. L.</given-names></name>; <name><surname>Kelley</surname><given-names>J. A.</given-names></name>; <name><surname>Barchi</surname><given-names>J. J.</given-names><suffix>Jr</suffix></name>; <name><surname>Nicklaus</surname><given-names>M. C.</given-names></name>
<article-title>Experimental and
Chemoinformatics Study of Tautomerism in a Database of Commercially
Available Screening Samples</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2016</year>, <volume>56</volume> (<issue>11</issue>), <fpage>2149</fpage>&#x02013;<lpage>2161</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.6b00338</pub-id>.<pub-id pub-id-type="pmid">27669079</pub-id>
</mixed-citation></ref><ref id="ref120"><mixed-citation publication-type="journal" id="cit120"><name><surname>Sitzmann</surname><given-names>M.</given-names></name>; <name><surname>Ihlenfeldt</surname><given-names>W.-D.</given-names></name>; <name><surname>Nicklaus</surname><given-names>M. C.</given-names></name>
<article-title>Tautomerism in Large
Databases</article-title>. <source>J. Comput. Aided Mol. Des.</source>
<year>2010</year>, <volume>24</volume> (<issue>6&#x02013;7</issue>), <fpage>521</fpage>&#x02013;<lpage>551</lpage>. <pub-id pub-id-type="doi">10.1007/s10822-010-9346-4</pub-id>.<pub-id pub-id-type="pmid">20512400</pub-id>
</mixed-citation></ref><ref id="ref121"><mixed-citation publication-type="journal" id="cit121"><name><surname>Dhaked</surname><given-names>D. K.</given-names></name>; <name><surname>Nicklaus</surname><given-names>M. C.</given-names></name>
<article-title>Tautomeric Conflicts in Forty Small-Molecule
Databases</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2024</year>, <volume>64</volume> (<issue>19</issue>), <fpage>7409</fpage>&#x02013;<lpage>7421</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.4c00700</pub-id>.<pub-id pub-id-type="pmid">39314089</pub-id>
</mixed-citation></ref><ref id="ref122"><mixed-citation publication-type="journal" id="cit122"><name><surname>P&#x000e9;rez-Isidoro</surname><given-names>R.</given-names></name>; <name><surname>Sierra-Valdez</surname><given-names>F. J.</given-names></name>; <name><surname>Ruiz-Su&#x000e1;rez</surname><given-names>J.
C.</given-names></name>
<article-title>Anesthetic
Diffusion through Lipid Membranes Depends on the Protonation Rate</article-title>. <source>Sci. Rep.</source>
<year>2014</year>, <volume>4</volume>, <fpage>7534</fpage><pub-id pub-id-type="doi">10.1038/srep07534</pub-id>.<pub-id pub-id-type="pmid">25520016</pub-id>
</mixed-citation></ref><ref id="ref123"><mixed-citation publication-type="journal" id="cit123"><name><surname>Shin</surname><given-names>J. M.</given-names></name>; <name><surname>Sachs</surname><given-names>G.</given-names></name>
<article-title>Pharmacology of Proton
Pump Inhibitors</article-title>. <source>Curr. Gastroenterol. Rep.</source>
<year>2008</year>, <volume>10</volume> (<issue>6</issue>), <fpage>528</fpage>&#x02013;<lpage>534</lpage>. <pub-id pub-id-type="doi">10.1007/s11894-008-0098-4</pub-id>.<pub-id pub-id-type="pmid">19006606</pub-id>
</mixed-citation></ref><ref id="ref124"><mixed-citation publication-type="journal" id="cit124"><name><surname>Miljkovi&#x00107;</surname><given-names>F.</given-names></name>; <name><surname>Martinsson</surname><given-names>A.</given-names></name>; <name><surname>Obrezanova</surname><given-names>O.</given-names></name>; <name><surname>Williamson</surname><given-names>B.</given-names></name>; <name><surname>Johnson</surname><given-names>M.</given-names></name>; <name><surname>Sykes</surname><given-names>A.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>Greene</surname><given-names>N.</given-names></name>
<article-title>Machine Learning
Models for Human In Vivo Pharmacokinetic
Parameters with In-House Validation</article-title>. <source>Mol. Pharmaceutics</source>
<year>2021</year>, <volume>18</volume> (<issue>12</issue>), <fpage>4520</fpage>&#x02013;<lpage>4530</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.1c00718</pub-id>.</mixed-citation></ref><ref id="ref125"><mixed-citation publication-type="journal" id="cit125"><name><surname>Seal</surname><given-names>S.</given-names></name>; <name><surname>Trapotsi</surname><given-names>M.-A.</given-names></name>; <name><surname>Subramanian</surname><given-names>V.</given-names></name>; <name><surname>Spjuth</surname><given-names>O.</given-names></name>; <name><surname>Greene</surname><given-names>N.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>
<article-title>PKSmart: An Open-Source
Computational Model to Predict in Vivo Pharmacokinetics of Small Molecules</article-title>. <source>bioRxiv</source>
<year>2024</year>, <pub-id pub-id-type="doi">10.1101/2024.02.02.578658</pub-id>.</mixed-citation></ref><ref id="ref126"><mixed-citation publication-type="journal" id="cit126"><name><surname>Zheng</surname><given-names>J.</given-names></name>; <name><surname>Leito</surname><given-names>I.</given-names></name>; <name><surname>Green</surname><given-names>W.</given-names></name>
<article-title>Widespread Misinterpretation
of pKa Terminology for Zwitterionic Compounds and Its Consequences</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2024</year>, <volume>64</volume>, <fpage>8838</fpage><pub-id pub-id-type="doi">10.1021/acs.jcim.4c01420</pub-id>.<pub-id pub-id-type="pmid">39560282</pub-id>
</mixed-citation></ref><ref id="ref127"><mixed-citation publication-type="journal" id="cit127"><name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>Cortes-Ciriano</surname><given-names>I.</given-names></name>
<article-title>Artificial Intelligence in Drug Discovery:
What Is Realistic, What Are Illusions? Part 2: A Discussion of Chemical
and Biological Data</article-title>. <source>Drug Discovery Today</source>
<year>2021</year>, <volume>26</volume> (<issue>4</issue>), <fpage>1040</fpage>&#x02013;<lpage>1052</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2020.11.037</pub-id>.<pub-id pub-id-type="pmid">33508423</pub-id>
</mixed-citation></ref><ref id="ref128"><mixed-citation publication-type="journal" id="cit128"><name><surname>Xu</surname><given-names>W.</given-names></name>; <name><surname>Hou</surname><given-names>Y.</given-names></name>; <name><surname>Hung</surname><given-names>Y. S.</given-names></name>; <name><surname>Zou</surname><given-names>Y.</given-names></name>
<article-title>A Comparative Analysis
of Spearman&#x02019;s Rho and Kendall&#x02019;s Tau in Normal and Contaminated
Normal Models</article-title>. <source>Signal Processing</source>
<year>2013</year>, <volume>93</volume> (<issue>1</issue>), <fpage>261</fpage>&#x02013;<lpage>276</lpage>. <pub-id pub-id-type="doi">10.1016/j.sigpro.2012.08.005</pub-id>.</mixed-citation></ref><ref id="ref129"><mixed-citation publication-type="journal" id="cit129"><name><surname>Landrum</surname><given-names>G. A.</given-names></name>; <name><surname>Riniker</surname><given-names>S.</given-names></name>
<article-title>Combining IC50 or Ki
Values from
Different Sources Is a Source of Significant Noise</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2024</year>, <volume>64</volume> (<issue>5</issue>), <fpage>1560</fpage>&#x02013;<lpage>1567</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.4c00049</pub-id>.<pub-id pub-id-type="pmid">38394344</pub-id>
</mixed-citation></ref><ref id="ref130"><mixed-citation publication-type="journal" id="cit130"><person-group person-group-type="allauthors"><name><surname>Dawson</surname><given-names>R.</given-names></name></person-group><article-title>How Significant
Is a Boxplot Outlier?</article-title><source>J. Stat. Educ.</source><year>2011</year>, <volume>19</volume> ( (<issue>2</issue>), ).<pub-id pub-id-type="doi">10.1080/10691898.2011.11889610</pub-id>.</mixed-citation></ref><ref id="ref131"><mixed-citation publication-type="journal" id="cit131"><name><surname>Kalliokoski</surname><given-names>T.</given-names></name>; <name><surname>Kramer</surname><given-names>C.</given-names></name>; <name><surname>Vulpetti</surname><given-names>A.</given-names></name>; <name><surname>Gedeck</surname><given-names>P.</given-names></name>
<article-title>Comparability
of Mixed IC<sub>50</sub> Data - a Statistical Analysis</article-title>. <source>PLoS One</source>
<year>2013</year>, <volume>8</volume> (<issue>4</issue>), <elocation-id>e61007</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0061007</pub-id>.<pub-id pub-id-type="pmid">23613770</pub-id>
</mixed-citation></ref><ref id="ref132"><mixed-citation publication-type="journal" id="cit132"><name><surname>Escher</surname><given-names>B. I.</given-names></name>; <name><surname>Henneberger</surname><given-names>L.</given-names></name>; <name><surname>K&#x000f6;nig</surname><given-names>M.</given-names></name>; <name><surname>Schlichting</surname><given-names>R.</given-names></name>; <name><surname>Fischer</surname><given-names>F. C.</given-names></name>
<article-title>Cytotoxicity Burst? Differentiating
Specific from Nonspecific Effects in Tox21 in Vitro Reporter Gene
Assays</article-title>. <source>Environ. Health Perspect.</source>
<year>2020</year>, <volume>128</volume> (<issue>7</issue>), <fpage>77007</fpage><pub-id pub-id-type="doi">10.1289/EHP6664</pub-id>.<pub-id pub-id-type="pmid">32700975</pub-id>
</mixed-citation></ref><ref id="ref133"><mixed-citation publication-type="journal" id="cit133"><name><surname>Seal</surname><given-names>S.</given-names></name>; <name><surname>Yang</surname><given-names>H.</given-names></name>; <name><surname>Vollmers</surname><given-names>L.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>
<article-title>Comparison
of Cellular Morphological Descriptors and Molecular Fingerprints for
the Prediction of Cytotoxicity- and Proliferation-Related Assays</article-title>. <source>Chem. Res. Toxicol.</source>
<year>2021</year>, <volume>34</volume> (<issue>2</issue>), <fpage>422</fpage>&#x02013;<lpage>437</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.0c00303</pub-id>.<pub-id pub-id-type="pmid">33522793</pub-id>
</mixed-citation></ref><ref id="ref134"><mixed-citation publication-type="journal" id="cit134"><name><surname>Azqueta</surname><given-names>A.</given-names></name>; <name><surname>Stopper</surname><given-names>H.</given-names></name>; <name><surname>Zegura</surname><given-names>B.</given-names></name>; <name><surname>Dusinska</surname><given-names>M.</given-names></name>; <name><surname>M&#x000f8;ller</surname><given-names>P.</given-names></name>
<article-title>Do Cytotoxicity and Cell Death Cause
False Positive
Results in the in Vitro Comet Assay?</article-title>. <source>Mutat
Res. Genet Toxicol Environ. Mutagen</source>
<year>2022</year>, <volume>881</volume>, <fpage>503520</fpage><pub-id pub-id-type="doi">10.1016/j.mrgentox.2022.503520</pub-id>.<pub-id pub-id-type="pmid">36031332</pub-id>
</mixed-citation></ref><ref id="ref135"><mixed-citation publication-type="journal" id="cit135"><name><surname>Owen</surname><given-names>A.</given-names></name>
<article-title>A Robust Hybrid of Lasso and Ridge
Regression</article-title>. <source>Prediction and Discovery</source>
<year>2007</year>, <volume>443</volume>, <fpage>59</fpage><pub-id pub-id-type="doi">10.1090/conm/443/08555</pub-id>.</mixed-citation></ref><ref id="ref136"><mixed-citation publication-type="weblink" id="cit136"><person-group person-group-type="allauthors"><name><surname>Lewinson</surname><given-names>E.</given-names></name></person-group><source>3 Robust Linear Regression
Models to Handle Outliers</source>. <publisher-name>NVIDIA Technical
Blog</publisher-name>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://developer.nvidia.com/blog/dealing-with-outliers-using-three-robust-linear-regression-models/">https://developer.nvidia.com/blog/dealing-with-outliers-using-three-robust-linear-regression-models/</uri> (accessed 2025-03-22).</mixed-citation></ref><ref id="ref137"><mixed-citation publication-type="book" id="cit137"><person-group person-group-type="allauthors"><name><surname>Mohebali</surname><given-names>B.</given-names></name>; <name><surname>Tahmassebi</surname><given-names>A.</given-names></name>; <name><surname>Meyer-Baese</surname><given-names>A.</given-names></name>; <name><surname>Gandomi</surname><given-names>A. H.</given-names></name></person-group><article-title>Probabilistic
Neural Networks</article-title>. In <source>Handbook of Probabilistic
Models</source>; <person-group person-group-type="editor"><name><surname>Samui</surname><given-names>P.</given-names></name>, <name><surname>Tien
Bui</surname><given-names>D.</given-names></name>, <name><surname>Chakraborty</surname><given-names>S.</given-names></name>; <name><surname>Deo</surname><given-names>R. C.</given-names></name></person-group>, Eds.; <publisher-name>Elsevier</publisher-name>, <year>2020</year>; pp <fpage>347</fpage>&#x02013;<lpage>367</lpage>.</mixed-citation></ref><ref id="ref138"><mixed-citation publication-type="journal" id="cit138"><name><surname>Grandjean</surname><given-names>P.</given-names></name>
<article-title>Paracelsus Revisited: The Dose Concept
in a Complex
World</article-title>. <source>Basic Clin. Pharmacol. Toxicol.</source>
<year>2016</year>, <volume>119</volume> (<issue>2</issue>), <fpage>126</fpage>&#x02013;<lpage>132</lpage>. <pub-id pub-id-type="doi">10.1111/bcpt.12622</pub-id>.<pub-id pub-id-type="pmid">27214290</pub-id>
</mixed-citation></ref><ref id="ref139"><mixed-citation publication-type="journal" id="cit139"><name><surname>Smit</surname><given-names>I. A.</given-names></name>; <name><surname>Afzal</surname><given-names>A. M.</given-names></name>; <name><surname>Allen</surname><given-names>C. H. G.</given-names></name>; <name><surname>Svensson</surname><given-names>F.</given-names></name>; <name><surname>Hanser</surname><given-names>T.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>
<article-title>Systematic Analysis of Protein Targets
Associated with Adverse Events of Drugs from Clinical Trials and Postmarketing
Reports</article-title>. <source>Chem. Res. Toxicol.</source>
<year>2021</year>, <volume>34</volume> (<issue>2</issue>), <fpage>365</fpage>&#x02013;<lpage>384</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.0c00294</pub-id>.<pub-id pub-id-type="pmid">33351593</pub-id>
</mixed-citation></ref><ref id="ref140"><mixed-citation publication-type="journal" id="cit140"><name><surname>Lafront</surname><given-names>C.</given-names></name>; <name><surname>Germain</surname><given-names>L.</given-names></name>; <name><surname>Weidmann</surname><given-names>C.</given-names></name>; <name><surname>Audet-Walsh</surname><given-names>&#x000c9;.</given-names></name>
<article-title>A Systematic
Study of the Impact of Estrogens and Selective Estrogen Receptor Modulators
on Prostate Cancer Cell Proliferation</article-title>. <source>Sci.
Rep.</source>
<year>2020</year>, <volume>10</volume> (<issue>1</issue>), <fpage>4024</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-60844-3</pub-id>.<pub-id pub-id-type="pmid">32132580</pub-id>
</mixed-citation></ref><ref id="ref141"><mixed-citation publication-type="journal" id="cit141"><name><surname>Mervin</surname><given-names>L. H.</given-names></name>; <name><surname>Trapotsi</surname><given-names>M.-A.</given-names></name>; <name><surname>Afzal</surname><given-names>A. M.</given-names></name>; <name><surname>Barrett</surname><given-names>I. P.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>Engkvist</surname><given-names>O.</given-names></name>
<article-title>Probabilistic Random
Forest Improves
Bioactivity Predictions close to the Classification Threshold by Taking
into Account Experimental Uncertainty</article-title>. <source>J. Cheminform.</source>
<year>2021</year>, <volume>13</volume> (<issue>1</issue>), <fpage>62</fpage><pub-id pub-id-type="doi">10.1186/s13321-021-00539-7</pub-id>.<pub-id pub-id-type="pmid">34412708</pub-id>
</mixed-citation></ref><ref id="ref142"><mixed-citation publication-type="journal" id="cit142"><name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>Glen</surname><given-names>R. C.</given-names></name>
<article-title>Molecular Similarity:
A Key Technique
in Molecular Informatics</article-title>. <source>Org. Biomol. Chem.</source>
<year>2004</year>, <volume>2</volume> (<issue>22</issue>), <fpage>3204</fpage>&#x02013;<lpage>3218</lpage>. <pub-id pub-id-type="doi">10.1039/b409813g</pub-id>.<pub-id pub-id-type="pmid">15534697</pub-id>
</mixed-citation></ref><ref id="ref143"><mixed-citation publication-type="book" id="cit143"><person-group person-group-type="allauthors"><name><surname>Todeschini</surname><given-names>R.</given-names></name>; <name><surname>Consonni</surname><given-names>V.</given-names></name></person-group><source>Molecular
Descriptors for Chemoinformatics, 2 Vol. Set: Vol. I: Alphabetical
Listing/Vol. II: Appendices, References</source>; <publisher-name>Wiley</publisher-name>, <year>2009</year>.</mixed-citation></ref><ref id="ref144"><mixed-citation publication-type="journal" id="cit144"><name><surname>Brown</surname><given-names>N.</given-names></name>; <name><surname>Ertl</surname><given-names>P.</given-names></name>; <name><surname>Lewis</surname><given-names>R.</given-names></name>; <name><surname>Luksch</surname><given-names>T.</given-names></name>; <name><surname>Reker</surname><given-names>D.</given-names></name>; <name><surname>Schneider</surname><given-names>N.</given-names></name>
<article-title>Artificial Intelligence in Chemistry
and Drug Design</article-title>. <source>J. Comput. Aided Mol. Des.</source>
<year>2020</year>, <volume>34</volume> (<issue>7</issue>), <fpage>709</fpage>&#x02013;<lpage>715</lpage>. <pub-id pub-id-type="doi">10.1007/s10822-020-00317-x</pub-id>.<pub-id pub-id-type="pmid">32468207</pub-id>
</mixed-citation></ref><ref id="ref145"><mixed-citation publication-type="journal" id="cit145"><name><surname>Ruddigkeit</surname><given-names>L.</given-names></name>; <name><surname>van Deursen</surname><given-names>R.</given-names></name>; <name><surname>Blum</surname><given-names>L. C.</given-names></name>; <name><surname>Reymond</surname><given-names>J.-L.</given-names></name>
<article-title>Enumeration
of 166 Billion Organic Small Molecules in the Chemical Universe Database
GDB-17</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2012</year>, <volume>52</volume> (<issue>11</issue>), <fpage>2864</fpage>&#x02013;<lpage>2875</lpage>. <pub-id pub-id-type="doi">10.1021/ci300415d</pub-id>.<pub-id pub-id-type="pmid">23088335</pub-id>
</mixed-citation></ref><ref id="ref146"><mixed-citation publication-type="journal" id="cit146"><name><surname>Seal</surname><given-names>S.</given-names></name>; <name><surname>Trapotsi</surname><given-names>M.-A.</given-names></name>; <name><surname>Spjuth</surname><given-names>O.</given-names></name>; <name><surname>Singh</surname><given-names>S.</given-names></name>; <name><surname>Carreras-Puigvert</surname><given-names>J.</given-names></name>; <name><surname>Greene</surname><given-names>N.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>Carpenter</surname><given-names>A. E.</given-names></name>
<article-title>A Decade
in a Systematic Review: The Evolution and Impact of Cell Painting</article-title>. <source>bioRxiv</source>
<year>2024</year>, <pub-id pub-id-type="doi">10.1101/2024.05.04.592531</pub-id>.</mixed-citation></ref><ref id="ref147"><mixed-citation publication-type="journal" id="cit147"><name><surname>Moriwaki</surname><given-names>H.</given-names></name>; <name><surname>Tian</surname><given-names>Y.-S.</given-names></name>; <name><surname>Kawashita</surname><given-names>N.</given-names></name>; <name><surname>Takagi</surname><given-names>T.</given-names></name>
<article-title>Mordred: A Molecular
Descriptor Calculator</article-title>. <source>J. Cheminform.</source>
<year>2018</year>, <volume>10</volume> (<issue>1</issue>), <fpage>4</fpage><pub-id pub-id-type="doi">10.1186/s13321-018-0258-y</pub-id>.<pub-id pub-id-type="pmid">29411163</pub-id>
</mixed-citation></ref><ref id="ref148"><mixed-citation publication-type="journal" id="cit148"><person-group person-group-type="allauthors"><name><surname>Ewald</surname><given-names>J. D.</given-names></name>; <name><surname>Titterton</surname><given-names>K. L.</given-names></name>; <name><surname>B&#x000e4;uerle</surname><given-names>A.</given-names></name>; <name><surname>Beatson</surname><given-names>A.</given-names></name>; <name><surname>Boiko</surname><given-names>D.
A.</given-names></name>; <name><surname>Cabrera</surname><given-names>&#x000c1;. A.</given-names></name>; <name><surname>Cheah</surname><given-names>J.</given-names></name>; <name><surname>Cimini</surname><given-names>B. A.</given-names></name>; <name><surname>Gorissen</surname><given-names>B.</given-names></name>; <name><surname>Jones</surname><given-names>T.</given-names></name>; <name><surname>Karczewski</surname><given-names>K. J.</given-names></name>; <name><surname>Rouquie</surname><given-names>D.</given-names></name>; <name><surname>Seal</surname><given-names>S.</given-names></name>; <name><surname>Weisbart</surname><given-names>E.</given-names></name>; <name><surname>White</surname><given-names>B.</given-names></name>; <name><surname>Carpenter</surname><given-names>A. E.</given-names></name>; <name><surname>Singh</surname><given-names>S.</given-names></name></person-group><article-title>Cell Painting for Cytotoxicity and Mode-of-Action
Analysis in Primary Human Hepatocytes</article-title>. <source>bioRxiv</source><year>2025</year>.<pub-id pub-id-type="doi">10.1101/2025.01.22.634152</pub-id>.</mixed-citation></ref><ref id="ref149"><mixed-citation publication-type="journal" id="cit149"><name><surname>Pruteanu</surname><given-names>L.-L.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>
<article-title>Using Transcriptomics and Cell Morphology
Data in Drug Discovery: The Long Road to Practice</article-title>. <source>ACS Med. Chem. Lett.</source>
<year>2023</year>, <volume>14</volume> (<issue>4</issue>), <fpage>386</fpage>&#x02013;<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1021/acsmedchemlett.3c00015</pub-id>.<pub-id pub-id-type="pmid">37077392</pub-id>
</mixed-citation></ref><ref id="ref150"><mixed-citation publication-type="journal" id="cit150"><name><surname>Chandrasekaran</surname><given-names>S. N.</given-names></name>; <name><surname>Ceulemans</surname><given-names>H.</given-names></name>; <name><surname>Boyd</surname><given-names>J. D.</given-names></name>; <name><surname>Carpenter</surname><given-names>A. E.</given-names></name>
<article-title>Image-Based
Profiling for Drug Discovery: Due for a Machine-Learning Upgrade?</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2021</year>, <volume>20</volume> (<issue>2</issue>), <fpage>145</fpage>&#x02013;<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-020-00117-w</pub-id>.<pub-id pub-id-type="pmid">33353986</pub-id>
</mixed-citation></ref><ref id="ref151"><mixed-citation publication-type="journal" id="cit151"><name><surname>Boldini</surname><given-names>D.</given-names></name>; <name><surname>Ballabio</surname><given-names>D.</given-names></name>; <name><surname>Consonni</surname><given-names>V.</given-names></name>; <name><surname>Todeschini</surname><given-names>R.</given-names></name>; <name><surname>Grisoni</surname><given-names>F.</given-names></name>; <name><surname>Sieber</surname><given-names>S. A.</given-names></name>
<article-title>Effectiveness of
Molecular Fingerprints
for Exploring the Chemical Space of Natural Products</article-title>. <source>J. Cheminform.</source>
<year>2024</year>, <volume>16</volume> (<issue>1</issue>), <fpage>35</fpage><pub-id pub-id-type="doi">10.1186/s13321-024-00830-3</pub-id>.<pub-id pub-id-type="pmid">38528548</pub-id>
</mixed-citation></ref><ref id="ref152"><mixed-citation publication-type="journal" id="cit152"><name><surname>Gao</surname><given-names>K.</given-names></name>; <name><surname>Nguyen</surname><given-names>D. D.</given-names></name>; <name><surname>Sresht</surname><given-names>V.</given-names></name>; <name><surname>Mathiowetz</surname><given-names>A. M.</given-names></name>; <name><surname>Tu</surname><given-names>M.</given-names></name>; <name><surname>Wei</surname><given-names>G.-W.</given-names></name>
<article-title>Are 2D Fingerprints Still Valuable for Drug Discovery?</article-title>. <source>Phys. Chem. Chem. Phys.</source>
<year>2020</year>, <volume>22</volume> (<issue>16</issue>), <fpage>8373</fpage>&#x02013;<lpage>8390</lpage>. <pub-id pub-id-type="doi">10.1039/D0CP00305K</pub-id>.<pub-id pub-id-type="pmid">32266895</pub-id>
</mixed-citation></ref><ref id="ref153"><mixed-citation publication-type="journal" id="cit153"><name><surname>David</surname><given-names>L.</given-names></name>; <name><surname>Thakkar</surname><given-names>A.</given-names></name>; <name><surname>Mercado</surname><given-names>R.</given-names></name>; <name><surname>Engkvist</surname><given-names>O.</given-names></name>
<article-title>Molecular
Representations in AI-Driven Drug Discovery: A Review and Practical
Guide</article-title>. <source>J. Cheminform.</source>
<year>2020</year>, <volume>12</volume> (<issue>1</issue>), <fpage>56</fpage><pub-id pub-id-type="doi">10.1186/s13321-020-00460-5</pub-id>.<pub-id pub-id-type="pmid">33431035</pub-id>
</mixed-citation></ref><ref id="ref154"><mixed-citation publication-type="journal" id="cit154"><name><surname>Venkatraman</surname><given-names>V.</given-names></name>
<article-title>FP-ADMET: A Compendium of Fingerprint-Based
ADMET Prediction
Models</article-title>. <source>J. Cheminform.</source>
<year>2021</year>, <volume>13</volume> (<issue>1</issue>), <fpage>75</fpage><pub-id pub-id-type="doi">10.1186/s13321-021-00557-5</pub-id>.<pub-id pub-id-type="pmid">34583740</pub-id>
</mixed-citation></ref><ref id="ref155"><mixed-citation publication-type="journal" id="cit155"><name><surname>Durant</surname><given-names>J. L.</given-names></name>; <name><surname>Leland</surname><given-names>B. A.</given-names></name>; <name><surname>Henry</surname><given-names>D. R.</given-names></name>; <name><surname>Nourse</surname><given-names>J. G.</given-names></name>
<article-title>Reoptimization
of MDL Keys for Use in Drug Discovery</article-title>. <source>J. Chem.
Inf. Comput. Sci.</source>
<year>2002</year>, <volume>42</volume> (<issue>6</issue>), <fpage>1273</fpage>&#x02013;<lpage>1280</lpage>. <pub-id pub-id-type="doi">10.1021/ci010132r</pub-id>.<pub-id pub-id-type="pmid">12444722</pub-id>
</mixed-citation></ref><ref id="ref156"><mixed-citation publication-type="journal" id="cit156"><name><surname>Lundberg</surname><given-names>S. M.</given-names></name>; <name><surname>Lee</surname><given-names>S.-I.</given-names></name>
<article-title>A Unified Approach
to Interpreting
Model Predictions</article-title>. <source>Adv. Neural Inf. Process.
Syst.</source>
<year>2017</year>, <fpage>4765</fpage>&#x02013;<lpage>4774</lpage>.</mixed-citation></ref><ref id="ref157"><mixed-citation publication-type="conf-proc" id="cit157"><person-group person-group-type="allauthors"><name><surname>Ribeiro</surname><given-names>M. T.</given-names></name>; <name><surname>Singh</surname><given-names>S.</given-names></name>; <name><surname>Guestrin</surname><given-names>C.</given-names></name></person-group><article-title>&#x0201c;Why
Should
I Trust You?&#x0201d;: Explaining the Predictions of Any Classifier</article-title>. In <source>Proceedings of the 22nd ACM SIGKDD International Conference
on Knowledge Discovery and Data Mining</source>; <publisher-name>KDD
&#x02019;16; Association for Computing Machinery</publisher-name>: <publisher-loc>New York, NY, USA</publisher-loc>, <year>2016</year>; pp <fpage>1135</fpage>&#x02013;<lpage>1144</lpage>.</mixed-citation></ref><ref id="ref158"><mixed-citation publication-type="journal" id="cit158"><name><surname>Glem</surname><given-names>R. C.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>Arnby</surname><given-names>C. H.</given-names></name>; <name><surname>Carlsson</surname><given-names>L.</given-names></name>; <name><surname>Boyer</surname><given-names>S.</given-names></name>; <name><surname>Smith</surname><given-names>J.</given-names></name>
<article-title>Circular Fingerprints: Flexible Molecular
Descriptors with Applications from Physical Chemistry to ADME</article-title>. <source>IDrugs</source>
<year>2006</year>, <volume>9</volume> (<issue>3</issue>), <fpage>199</fpage>&#x02013;<lpage>204</lpage>.<pub-id pub-id-type="pmid">16523386</pub-id>
</mixed-citation></ref><ref id="ref159"><mixed-citation publication-type="weblink" id="cit159"><source>FingerprintGenerator
tutorial - RDKit blog</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://greglandrum.github.io/rdkit-blog/posts/2023-01-18-fingerprint-generator-tutorial.html">https://greglandrum.github.io/rdkit-blog/posts/2023-01-18-fingerprint-generator-tutorial.html</uri> (accessed 2025-01-18).</mixed-citation></ref><ref id="ref160"><mixed-citation publication-type="journal" id="cit160"><name><surname>G&#x000fc;tlein</surname><given-names>M.</given-names></name>; <name><surname>Kramer</surname><given-names>S.</given-names></name>
<article-title>Filtered Circular
Fingerprints Improve
Either Prediction or Runtime Performance While Retaining Interpretability</article-title>. <source>J. Cheminform.</source>
<year>2016</year>, <volume>8</volume>, <fpage>60</fpage><pub-id pub-id-type="doi">10.1186/s13321-016-0173-z</pub-id>.<pub-id pub-id-type="pmid">27853484</pub-id>
</mixed-citation></ref><ref id="ref161"><mixed-citation publication-type="journal" id="cit161"><name><surname>Rogers</surname><given-names>D.</given-names></name>; <name><surname>Hahn</surname><given-names>M.</given-names></name>
<article-title>Extended-Connectivity Fingerprints</article-title>. <source>J. Chem.
Inf. Model.</source>
<year>2010</year>, <volume>50</volume> (<issue>5</issue>), <fpage>742</fpage>&#x02013;<lpage>754</lpage>. <pub-id pub-id-type="doi">10.1021/ci100050t</pub-id>.<pub-id pub-id-type="pmid">20426451</pub-id>
</mixed-citation></ref><ref id="ref162"><mixed-citation publication-type="journal" id="cit162"><name><surname>Prasanna</surname><given-names>S.</given-names></name>; <name><surname>Doerksen</surname><given-names>R. J.</given-names></name>
<article-title>Topological Polar Surface Area: A
Useful Descriptor in 2D-QSAR</article-title>. <source>Curr. Med. Chem.</source>
<year>2009</year>, <volume>16</volume> (<issue>1</issue>), <fpage>21</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.2174/092986709787002817</pub-id>.<pub-id pub-id-type="pmid">19149561</pub-id>
</mixed-citation></ref><ref id="ref163"><mixed-citation publication-type="journal" id="cit163"><name><surname>Kier</surname><given-names>L. B.</given-names></name>; <name><surname>Hall</surname><given-names>L. H.</given-names></name>
<article-title>An Electrotopological-State Index
for Atoms in Molecules</article-title>. <source>Pharm. Res.</source>
<year>1990</year>, <volume>7</volume> (<issue>8</issue>), <fpage>801</fpage>&#x02013;<lpage>807</lpage>. <pub-id pub-id-type="doi">10.1023/A:1015952613760</pub-id>.<pub-id pub-id-type="pmid">2235877</pub-id>
</mixed-citation></ref><ref id="ref164"><mixed-citation publication-type="journal" id="cit164"><name><surname>Yukawa</surname><given-names>T.</given-names></name>; <name><surname>Naven</surname><given-names>R.</given-names></name>
<article-title>Utility of Physicochemical
Properties
for the Prediction of Toxicological Outcomes: Takeda Perspective</article-title>. <source>ACS Med. Chem. Lett.</source>
<year>2020</year>, <volume>11</volume> (<issue>2</issue>), <fpage>203</fpage>&#x02013;<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1021/acsmedchemlett.9b00536</pub-id>.<pub-id pub-id-type="pmid">32071689</pub-id>
</mixed-citation></ref><ref id="ref165"><mixed-citation publication-type="journal" id="cit165"><name><surname>Seal</surname><given-names>S.</given-names></name>; <name><surname>Spjuth</surname><given-names>O.</given-names></name>; <name><surname>Hosseini-Gerami</surname><given-names>L.</given-names></name>; <name><surname>Garc&#x000ed;a-Orteg&#x000f3;n</surname><given-names>M.</given-names></name>; <name><surname>Singh</surname><given-names>S.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>Carpenter</surname><given-names>A. E.</given-names></name>
<article-title>Insights into Drug Cardiotoxicity from Biological and
Chemical Data: The First Public Classifiers for FDA Drug-Induced Cardiotoxicity
Rank</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2024</year>, <volume>64</volume>, <fpage>1172</fpage><pub-id pub-id-type="doi">10.1021/acs.jcim.3c01834</pub-id>.<pub-id pub-id-type="pmid">38300851</pub-id>
</mixed-citation></ref><ref id="ref166"><mixed-citation publication-type="journal" id="cit166"><name><surname>Hong</surname><given-names>H.</given-names></name>; <name><surname>Xie</surname><given-names>Q.</given-names></name>; <name><surname>Ge</surname><given-names>W.</given-names></name>; <name><surname>Qian</surname><given-names>F.</given-names></name>; <name><surname>Fang</surname><given-names>H.</given-names></name>; <name><surname>Shi</surname><given-names>L.</given-names></name>; <name><surname>Su</surname><given-names>Z.</given-names></name>; <name><surname>Perkins</surname><given-names>R.</given-names></name>; <name><surname>Tong</surname><given-names>W.</given-names></name>
<article-title>Mold(2), Molecular Descriptors from 2D Structures for Chemoinformatics
and Toxicoinformatics</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2008</year>, <volume>48</volume> (<issue>7</issue>), <fpage>1337</fpage>&#x02013;<lpage>1344</lpage>. <pub-id pub-id-type="doi">10.1021/ci800038f</pub-id>.<pub-id pub-id-type="pmid">18564836</pub-id>
</mixed-citation></ref><ref id="ref167"><mixed-citation publication-type="journal" id="cit167"><name><surname>Anighoro</surname><given-names>A.</given-names></name>; <name><surname>Bajorath</surname><given-names>J.</given-names></name>
<article-title>Three-Dimensional
Similarity in Molecular
Docking: Prioritizing Ligand Poses on the Basis of Experimental Binding
Modes</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2016</year>, <volume>56</volume> (<issue>3</issue>), <fpage>580</fpage>&#x02013;<lpage>587</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.5b00745</pub-id>.<pub-id pub-id-type="pmid">26918284</pub-id>
</mixed-citation></ref><ref id="ref168"><mixed-citation publication-type="journal" id="cit168"><name><surname>Nettles</surname><given-names>J. H.</given-names></name>; <name><surname>Jenkins</surname><given-names>J. L.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>Deng</surname><given-names>Z.</given-names></name>; <name><surname>Davies</surname><given-names>J. W.</given-names></name>; <name><surname>Glick</surname><given-names>M.</given-names></name>
<article-title>Bridging Chemical and
Biological
Space: &#x0201c;Target Fishing&#x0201d; Using 2D and 3D Molecular Descriptors</article-title>. <source>J. Med. Chem.</source>
<year>2006</year>, <volume>49</volume> (<issue>23</issue>), <fpage>6802</fpage>&#x02013;<lpage>6810</lpage>. <pub-id pub-id-type="doi">10.1021/jm060902w</pub-id>.<pub-id pub-id-type="pmid">17154510</pub-id>
</mixed-citation></ref><ref id="ref169"><mixed-citation publication-type="journal" id="cit169"><person-group person-group-type="allauthors"><name><surname>Zankov</surname><given-names>D.</given-names></name>; <name><surname>Madzhidov</surname><given-names>T.</given-names></name>; <name><surname>Varnek</surname><given-names>A.</given-names></name>; <name><surname>Polishchuk</surname><given-names>P.</given-names></name></person-group><article-title>Chemical Complexity
Challenge: Is Multi-instance Machine Learning a Solution?</article-title><source>Wiley Interdiscip. Rev. Comput. Mol. Sci.</source><year>2024</year>, <volume>14</volume> ( (<issue>1</issue>), ).<pub-id pub-id-type="doi">10.1002/wcms.1698</pub-id>.</mixed-citation></ref><ref id="ref170"><mixed-citation publication-type="journal" id="cit170"><person-group person-group-type="allauthors"><name><surname>Moon</surname><given-names>K.</given-names></name>; <name><surname>Im</surname><given-names>H.-J.</given-names></name>; <name><surname>Kwon</surname><given-names>S.</given-names></name></person-group><article-title>3D Graph Contrastive Learning for
Molecular Property Prediction</article-title>. <source>Bioinformatics</source><year>2023</year>, <volume>39</volume> ( (<issue>6</issue>), ).<pub-id pub-id-type="doi">10.1093/bioinformatics/btad371</pub-id>.</mixed-citation></ref><ref id="ref171"><mixed-citation publication-type="journal" id="cit171"><name><surname>Bahia</surname><given-names>M. S.</given-names></name>; <name><surname>Kaspi</surname><given-names>O.</given-names></name>; <name><surname>Touitou</surname><given-names>M.</given-names></name>; <name><surname>Binayev</surname><given-names>I.</given-names></name>; <name><surname>Dhail</surname><given-names>S.</given-names></name>; <name><surname>Spiegel</surname><given-names>J.</given-names></name>; <name><surname>Khazanov</surname><given-names>N.</given-names></name>; <name><surname>Yosipof</surname><given-names>A.</given-names></name>; <name><surname>Senderowitz</surname><given-names>H.</given-names></name>
<article-title>A Comparison between 2D and 3D Descriptors in QSAR
Modeling Based on Bio-Active Conformations</article-title>. <source>Mol. Inform.</source>
<year>2023</year>, <volume>42</volume> (<issue>4</issue>), <elocation-id>e2200186</elocation-id><pub-id pub-id-type="doi">10.1002/minf.202200186</pub-id>.<pub-id pub-id-type="pmid">36617991</pub-id>
</mixed-citation></ref><ref id="ref172"><mixed-citation publication-type="journal" id="cit172"><name><surname>Mapari</surname><given-names>S.</given-names></name>; <name><surname>Camarda</surname><given-names>K. V.</given-names></name>
<article-title>Use of Three-Dimensional Descriptors
in Molecular Design for Biologically Active Compounds</article-title>. <source>Curr. Opin. Chem. Eng.</source>
<year>2020</year>, <volume>27</volume>, <fpage>60</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.coche.2019.11.011</pub-id>.</mixed-citation></ref><ref id="ref173"><mixed-citation publication-type="journal" id="cit173"><name><surname>Devinyak</surname><given-names>O.</given-names></name>; <name><surname>Havrylyuk</surname><given-names>D.</given-names></name>; <name><surname>Lesyk</surname><given-names>R.</given-names></name>
<article-title>3D-MoRSE Descriptors
Explained</article-title>. <source>J. Mol. Graph. Model.</source>
<year>2014</year>, <volume>54</volume>, <fpage>194</fpage>&#x02013;<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmgm.2014.10.006</pub-id>.<pub-id pub-id-type="pmid">25459771</pub-id>
</mixed-citation></ref><ref id="ref174"><mixed-citation publication-type="journal" id="cit174"><name><surname>Katritzky</surname><given-names>A. R.</given-names></name>; <name><surname>Mu</surname><given-names>L.</given-names></name>; <name><surname>Lobanov</surname><given-names>V. S.</given-names></name>; <name><surname>Karelson</surname><given-names>M.</given-names></name>
<article-title>Correlation
of Boiling Points with Molecular Structure. 1. A Training Set of 298
Diverse Organics and a Test Set of 9 Simple Inorganics</article-title>. <source>J. Phys. Chem.</source>
<year>1996</year>, <volume>100</volume> (<issue>24</issue>), <fpage>10400</fpage>&#x02013;<lpage>10407</lpage>. <pub-id pub-id-type="doi">10.1021/jp953224q</pub-id>.</mixed-citation></ref><ref id="ref175"><mixed-citation publication-type="journal" id="cit175"><name><surname>Sliwoski</surname><given-names>G.</given-names></name>; <name><surname>Mendenhall</surname><given-names>J.</given-names></name>; <name><surname>Meiler</surname><given-names>J.</given-names></name>
<article-title>Autocorrelation Descriptor
Improvements for QSAR: 2DA_Sign and 3DA_Sign</article-title>. <source>J. Comput. Aided Mol. Des.</source>
<year>2016</year>, <volume>30</volume> (<issue>3</issue>), <fpage>209</fpage>&#x02013;<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1007/s10822-015-9893-9</pub-id>.<pub-id pub-id-type="pmid">26721261</pub-id>
</mixed-citation></ref><ref id="ref176"><mixed-citation publication-type="journal" id="cit176"><name><surname>Beglari</surname><given-names>M.</given-names></name>; <name><surname>Goudarzi</surname><given-names>N.</given-names></name>; <name><surname>Shahsavani</surname><given-names>D.</given-names></name>; <name><surname>Arab Chamjangali</surname><given-names>M.</given-names></name>; <name><surname>Mozafari</surname><given-names>Z.</given-names></name>
<article-title>Combination of Radial Distribution
Functions as Structural Descriptors with Ligand-Receptor Interaction
Information in the QSAR Study of Some 4-Anilinoquinazoline Derivatives
as Potent EGFR Inhibitors</article-title>. <source>Struct. Chem.</source>
<year>2020</year>, <volume>31</volume> (<issue>4</issue>), <fpage>1481</fpage>&#x02013;<lpage>1491</lpage>. <pub-id pub-id-type="doi">10.1007/s11224-020-01505-z</pub-id>.</mixed-citation></ref><ref id="ref177"><mixed-citation publication-type="journal" id="cit177"><name><surname>Gramatica</surname><given-names>P.</given-names></name>
<article-title>WHIM Descriptors
of Shape</article-title>. <source>QSAR
Comb. Sci.</source>
<year>2006</year>, <volume>25</volume> (<issue>4</issue>), <fpage>327</fpage>&#x02013;<lpage>332</lpage>. <pub-id pub-id-type="doi">10.1002/qsar.200510159</pub-id>.</mixed-citation></ref><ref id="ref178"><mixed-citation publication-type="journal" id="cit178"><name><surname>von Korff</surname><given-names>M.</given-names></name>; <name><surname>Freyss</surname><given-names>J.</given-names></name>; <name><surname>Sander</surname><given-names>T.</given-names></name>
<article-title>Flexophore, a New Versatile
3D Pharmacophore Descriptor That Considers Molecular Flexibility</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2008</year>, <volume>48</volume> (<issue>4</issue>), <fpage>797</fpage>&#x02013;<lpage>810</lpage>. <pub-id pub-id-type="doi">10.1021/ci700359j</pub-id>.<pub-id pub-id-type="pmid">18393490</pub-id>
</mixed-citation></ref><ref id="ref179"><mixed-citation publication-type="conf-proc" id="cit179"><person-group person-group-type="allauthors"><name><surname>Gilmer</surname><given-names>J.</given-names></name>; <name><surname>Schoenholz</surname><given-names>S. S.</given-names></name>; <name><surname>Riley</surname><given-names>P. F.</given-names></name>; <name><surname>Vinyals</surname><given-names>O.</given-names></name>; <name><surname>Dahl</surname><given-names>G.
E.</given-names></name></person-group><article-title>Neural Message
Passing for Quantum Chemistry</article-title>. In <source>Proceedings
of the 34th International Conference on Machine Learning</source>; <person-group person-group-type="editor"><name><surname>Precup</surname><given-names>D.</given-names></name>, <name><surname>Teh</surname><given-names>Y.
W.</given-names></name></person-group>, Eds.; <publisher-name>Proceedings
of Machine Learning Research; PMLR</publisher-name>, 06&#x02013;11
Aug <year>2017</year>; Vol. <volume>70</volume>, pp <fpage>1263</fpage>&#x02013;<lpage>1272</lpage>.</mixed-citation></ref><ref id="ref180"><mixed-citation publication-type="journal" id="cit180"><name><surname>Heid</surname><given-names>E.</given-names></name>; <name><surname>Greenman</surname><given-names>K. P.</given-names></name>; <name><surname>Chung</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>S.-C.</given-names></name>; <name><surname>Graff</surname><given-names>D. E.</given-names></name>; <name><surname>Vermeire</surname><given-names>F. H.</given-names></name>; <name><surname>Wu</surname><given-names>H.</given-names></name>; <name><surname>Green</surname><given-names>W. H.</given-names></name>; <name><surname>McGill</surname><given-names>C. J.</given-names></name>
<article-title>Chemprop:
A Machine Learning Package for Chemical Property
Prediction</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2024</year>, <volume>64</volume> (<issue>1</issue>), <fpage>9</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.3c01250</pub-id>.<pub-id pub-id-type="pmid">38147829</pub-id>
</mixed-citation></ref><ref id="ref181"><mixed-citation publication-type="report" id="cit181"><person-group person-group-type="allauthors"><name><surname>Joshi</surname><given-names>C. K.</given-names></name></person-group><source>Transformers are Graph
Neural Networks</source>. The Gradient. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://thegradient.pub/transformers-are-graph-neural-networks/">https://thegradient.pub/transformers-are-graph-neural-networks/</uri> (accessed 2024-10-05), <year>2020</year>.</mixed-citation></ref><ref id="ref182"><mixed-citation publication-type="journal" id="cit182"><name><surname>M&#x000e9;ndez-Lucio</surname><given-names>O.</given-names></name>; <name><surname>Nicolaou</surname><given-names>C. A.</given-names></name>; <name><surname>Earnshaw</surname><given-names>B.</given-names></name>
<article-title>MolE: A Foundation
Model for Molecular Graphs Using Disentangled Attention</article-title>. <source>Nat. Commun.</source>
<year>2024</year>, <volume>15</volume> (<issue>1</issue>), <fpage>9431</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-53751-y</pub-id>.<pub-id pub-id-type="pmid">39532853</pub-id>
</mixed-citation></ref><ref id="ref183"><mixed-citation publication-type="journal" id="cit183"><name><surname>Jiang</surname><given-names>D.</given-names></name>; <name><surname>Wu</surname><given-names>Z.</given-names></name>; <name><surname>Hsieh</surname><given-names>C.-Y.</given-names></name>; <name><surname>Chen</surname><given-names>G.</given-names></name>; <name><surname>Liao</surname><given-names>B.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name>; <name><surname>Shen</surname><given-names>C.</given-names></name>; <name><surname>Cao</surname><given-names>D.</given-names></name>; <name><surname>Wu</surname><given-names>J.</given-names></name>; <name><surname>Hou</surname><given-names>T.</given-names></name>
<article-title>Could Graph Neural Networks Learn Better Molecular
Representation for Drug Discovery? A Comparison Study of Descriptor-Based
and Graph-Based Models</article-title>. <source>J. Cheminform.</source>
<year>2021</year>, <volume>13</volume> (<issue>1</issue>), <fpage>12</fpage><pub-id pub-id-type="doi">10.1186/s13321-020-00479-8</pub-id>.<pub-id pub-id-type="pmid">33597034</pub-id>
</mixed-citation></ref><ref id="ref184"><mixed-citation publication-type="journal" id="cit184"><name><surname>Moshkov</surname><given-names>N.</given-names></name>; <name><surname>Becker</surname><given-names>T.</given-names></name>; <name><surname>Yang</surname><given-names>K.</given-names></name>; <name><surname>Horvath</surname><given-names>P.</given-names></name>; <name><surname>Dancik</surname><given-names>V.</given-names></name>; <name><surname>Wagner</surname><given-names>B. K.</given-names></name>; <name><surname>Clemons</surname><given-names>P. A.</given-names></name>; <name><surname>Singh</surname><given-names>S.</given-names></name>; <name><surname>Carpenter</surname><given-names>A. E.</given-names></name>; <name><surname>Caicedo</surname><given-names>J. C.</given-names></name>
<article-title>Predicting Compound
Activity from
Phenotypic Profiles and Chemical Structures</article-title>. <source>Nat. Commun.</source>
<year>2023</year>, <volume>14</volume> (<issue>1</issue>), <fpage>1967</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-37570-1</pub-id>.<pub-id pub-id-type="pmid">37031208</pub-id>
</mixed-citation></ref><ref id="ref185"><mixed-citation publication-type="journal" id="cit185"><name><surname>Myung</surname><given-names>Y.</given-names></name>; <name><surname>de S&#x000e1;</surname><given-names>A. G. C.</given-names></name>; <name><surname>Ascher</surname><given-names>D. B.</given-names></name>
<article-title>Deep-PK: Deep Learning
for Small Molecule Pharmacokinetic and Toxicity Prediction</article-title>. <source>Nucleic Acids Res.</source>
<year>2024</year>, <volume>52</volume> (<issue>W1</issue>), <fpage>W469</fpage>&#x02013;<lpage>W475</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkae254</pub-id>.<pub-id pub-id-type="pmid">38634808</pub-id>
</mixed-citation></ref><ref id="ref186"><mixed-citation publication-type="conf-proc" id="cit186"><person-group person-group-type="allauthors"><name><surname>Satorras</surname><given-names>V. G.</given-names></name>; <name><surname>Hoogeboom</surname><given-names>E.</given-names></name>; <name><surname>Welling</surname><given-names>M.</given-names></name></person-group><article-title>E(n) Equivariant
Graph Neural Networks</article-title>. In <source>Proceedings of the
38th International Conference on Machine Learning</source>; <person-group person-group-type="editor"><name><surname>Meila</surname><given-names>M.</given-names></name>, <name><surname>Zhang</surname><given-names>T.</given-names></name></person-group>, Eds.; Proceedings of Machine Learning Research;
PMLR, 18&#x02013;24 Jul <year>2021</year>; Vol. <volume>139</volume>, pp <fpage>9323</fpage>&#x02013;<lpage>9332</lpage>.</mixed-citation></ref><ref id="ref187"><mixed-citation publication-type="journal" id="cit187"><person-group person-group-type="allauthors"><name><surname>Thomas</surname><given-names>N.</given-names></name>; <name><surname>Smidt</surname><given-names>T.</given-names></name>; <name><surname>Kearnes</surname><given-names>S.</given-names></name>; <name><surname>Yang</surname><given-names>L.</given-names></name>; <name><surname>Li</surname><given-names>L.</given-names></name>; <name><surname>Kohlhoff</surname><given-names>K.</given-names></name>; <name><surname>Riley</surname><given-names>P.</given-names></name></person-group><article-title>Tensor Field Networks: Rotation- and Translation-Equivariant
Neural Networks for 3D Point Clouds</article-title>. <source>arXiv
[cs.LG]</source><year>2018</year>,<pub-id pub-id-type="doi">10.48550/arXiv.1802.08219</pub-id>.</mixed-citation></ref><ref id="ref188"><mixed-citation publication-type="journal" id="cit188"><person-group person-group-type="allauthors"><name><surname>Duval</surname><given-names>A.</given-names></name>; <name><surname>Mathis</surname><given-names>S. V.</given-names></name>; <name><surname>Joshi</surname><given-names>C. K.</given-names></name>; <name><surname>Schmidt</surname><given-names>V.</given-names></name>; <name><surname>Miret</surname><given-names>S.</given-names></name>; <name><surname>Malliaros</surname><given-names>F. D.</given-names></name>; <name><surname>Cohen</surname><given-names>T.</given-names></name>; <name><surname>Lio</surname><given-names>P.</given-names></name>; <name><surname>Bengio</surname><given-names>Y.</given-names></name>; <name><surname>Bronstein</surname><given-names>M.</given-names></name></person-group><article-title>A Hitchhiker&#x02019;s Guide to Geometric GNNs for
3D Atomic Systems</article-title>. <source>arXiv [cs.LG]</source><year>2023</year>,<pub-id pub-id-type="doi">10.48550/arXiv.2312.07511</pub-id>.</mixed-citation></ref><ref id="ref189"><mixed-citation publication-type="journal" id="cit189"><name><surname>Hendrychov&#x000e1;</surname><given-names>T.</given-names></name>; <name><surname>Anzenbacherov&#x000e1;</surname><given-names>E.</given-names></name>; <name><surname>Hude&#x0010d;ek</surname><given-names>J.</given-names></name>; <name><surname>Skopal&#x000ed;k</surname><given-names>J.</given-names></name>; <name><surname>Lange</surname><given-names>R.</given-names></name>; <name><surname>Hildebrandt</surname><given-names>P.</given-names></name>; <name><surname>Otyepka</surname><given-names>M.</given-names></name>; <name><surname>Anzenbacher</surname><given-names>P.</given-names></name>
<article-title>Flexibility of Human Cytochrome P450
Enzymes: Molecular Dynamics and Spectroscopy Reveal Important Function-Related
Variations</article-title>. <source>Biochim. Biophys. Acta</source>
<year>2011</year>, <volume>1814</volume> (<issue>1</issue>), <fpage>58</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbapap.2010.07.017</pub-id>.<pub-id pub-id-type="pmid">20656072</pub-id>
</mixed-citation></ref><ref id="ref190"><mixed-citation publication-type="journal" id="cit190"><name><surname>Jumper</surname><given-names>J.</given-names></name>; <name><surname>Evans</surname><given-names>R.</given-names></name>; <name><surname>Pritzel</surname><given-names>A.</given-names></name>; <name><surname>Green</surname><given-names>T.</given-names></name>; <name><surname>Figurnov</surname><given-names>M.</given-names></name>; <name><surname>Ronneberger</surname><given-names>O.</given-names></name>; <name><surname>Tunyasuvunakool</surname><given-names>K.</given-names></name>; <name><surname>Bates</surname><given-names>R.</given-names></name>; <name><surname>&#x0017d;&#x000ed;dek</surname><given-names>A.</given-names></name>; <name><surname>Potapenko</surname><given-names>A.</given-names></name>; <name><surname>Bridgland</surname><given-names>A.</given-names></name>; <name><surname>Meyer</surname><given-names>C.</given-names></name>; <name><surname>Kohl</surname><given-names>S. A. A.</given-names></name>; <name><surname>Ballard</surname><given-names>A. J.</given-names></name>; <name><surname>Cowie</surname><given-names>A.</given-names></name>; <name><surname>Romera-Paredes</surname><given-names>B.</given-names></name>; <name><surname>Nikolov</surname><given-names>S.</given-names></name>; <name><surname>Jain</surname><given-names>R.</given-names></name>; <name><surname>Adler</surname><given-names>J.</given-names></name>; <name><surname>Back</surname><given-names>T.</given-names></name>; <name><surname>Petersen</surname><given-names>S.</given-names></name>; <name><surname>Reiman</surname><given-names>D.</given-names></name>; <name><surname>Clancy</surname><given-names>E.</given-names></name>; <name><surname>Zielinski</surname><given-names>M.</given-names></name>; <name><surname>Steinegger</surname><given-names>M.</given-names></name>; <name><surname>Pacholska</surname><given-names>M.</given-names></name>; <name><surname>Berghammer</surname><given-names>T.</given-names></name>; <name><surname>Bodenstein</surname><given-names>S.</given-names></name>; <name><surname>Silver</surname><given-names>D.</given-names></name>; <name><surname>Vinyals</surname><given-names>O.</given-names></name>; <name><surname>Senior</surname><given-names>A. W.</given-names></name>; <name><surname>Kavukcuoglu</surname><given-names>K.</given-names></name>; <name><surname>Kohli</surname><given-names>P.</given-names></name>; <name><surname>Hassabis</surname><given-names>D.</given-names></name>
<article-title>Highly Accurate Protein
Structure
Prediction with AlphaFold</article-title>. <source>Nature</source>
<year>2021</year>, <volume>596</volume> (<issue>7873</issue>), <fpage>583</fpage>&#x02013;<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id>.<pub-id pub-id-type="pmid">34265844</pub-id>
</mixed-citation></ref><ref id="ref191"><mixed-citation publication-type="journal" id="cit191"><name><surname>Baek</surname><given-names>M.</given-names></name>; <name><surname>DiMaio</surname><given-names>F.</given-names></name>; <name><surname>Anishchenko</surname><given-names>I.</given-names></name>; <name><surname>Dauparas</surname><given-names>J.</given-names></name>; <name><surname>Ovchinnikov</surname><given-names>S.</given-names></name>; <name><surname>Lee</surname><given-names>G. R.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Cong</surname><given-names>Q.</given-names></name>; <name><surname>Kinch</surname><given-names>L. N.</given-names></name>; <name><surname>Schaeffer</surname><given-names>R. D.</given-names></name>; <name><surname>Mill&#x000e1;n</surname><given-names>C.</given-names></name>; <name><surname>Park</surname><given-names>H.</given-names></name>; <name><surname>Adams</surname><given-names>C.</given-names></name>; <name><surname>Glassman</surname><given-names>C. R.</given-names></name>; <name><surname>DeGiovanni</surname><given-names>A.</given-names></name>; <name><surname>Pereira</surname><given-names>J. H.</given-names></name>; <name><surname>Rodrigues</surname><given-names>A. V.</given-names></name>; <name><surname>van Dijk</surname><given-names>A. A.</given-names></name>; <name><surname>Ebrecht</surname><given-names>A. C.</given-names></name>; <name><surname>Opperman</surname><given-names>D. J.</given-names></name>; <name><surname>Sagmeister</surname><given-names>T.</given-names></name>; <name><surname>Buhlheller</surname><given-names>C.</given-names></name>; <name><surname>Pavkov-Keller</surname><given-names>T.</given-names></name>; <name><surname>Rathinaswamy</surname><given-names>M. K.</given-names></name>; <name><surname>Dalwadi</surname><given-names>U.</given-names></name>; <name><surname>Yip</surname><given-names>C. K.</given-names></name>; <name><surname>Burke</surname><given-names>J. E.</given-names></name>; <name><surname>Garcia</surname><given-names>K. C.</given-names></name>; <name><surname>Grishin</surname><given-names>N. V.</given-names></name>; <name><surname>Adams</surname><given-names>P. D.</given-names></name>; <name><surname>Read</surname><given-names>R. J.</given-names></name>; <name><surname>Baker</surname><given-names>D.</given-names></name>
<article-title>Accurate Prediction
of Protein Structures and Interactions Using a Three-Track Neural
Network</article-title>. <source>Science</source>
<year>2021</year>, <volume>373</volume> (<issue>6557</issue>), <fpage>871</fpage>&#x02013;<lpage>876</lpage>. <pub-id pub-id-type="doi">10.1126/science.abj8754</pub-id>.<pub-id pub-id-type="pmid">34282049</pub-id>
</mixed-citation></ref><ref id="ref192"><mixed-citation publication-type="journal" id="cit192"><name><surname>Smith</surname><given-names>S. W.</given-names></name>
<article-title>Chiral Toxicology: It&#x02019;s the
Same Thing&#x000b7;&#x000b7;&#x000b7;only
Different</article-title>. <source>Toxicol. Sci.</source>
<year>2009</year>, <volume>110</volume> (<issue>1</issue>), <fpage>4</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfp097</pub-id>.<pub-id pub-id-type="pmid">19414517</pub-id>
</mixed-citation></ref><ref id="ref193"><mixed-citation publication-type="journal" id="cit193"><name><surname>Lin</surname><given-names>M.-C.</given-names></name>; <name><surname>Hwang</surname><given-names>M.-T.</given-names></name>; <name><surname>Chang</surname><given-names>H.-G.</given-names></name>; <name><surname>Lin</surname><given-names>C.-S.</given-names></name>; <name><surname>Lin</surname><given-names>G.</given-names></name>
<article-title>Benzene-1,2-, 1,3-, and 1,4-Di-N-Substituted
Carbamates as Conformationally
Constrained Inhibitors of Acetylcholinesterase</article-title>. <source>J. Biochem. Mol. Toxicol.</source>
<year>2007</year>, <volume>21</volume> (<issue>6</issue>), <fpage>348</fpage>&#x02013;<lpage>353</lpage>. <pub-id pub-id-type="doi">10.1002/jbt.20202</pub-id>.<pub-id pub-id-type="pmid">17994573</pub-id>
</mixed-citation></ref><ref id="ref194"><mixed-citation publication-type="journal" id="cit194"><name><surname>Vistoli</surname><given-names>G.</given-names></name>; <name><surname>Pedretti</surname><given-names>A.</given-names></name>; <name><surname>Testa</surname><given-names>B.</given-names></name>; <name><surname>Matucci</surname><given-names>R.</given-names></name>
<article-title>The Conformational
and Property Space of Acetylcholine Bound to Muscarinic Receptors:
An Entropy Component Accounts for the Subtype Selectivity of Acetylcholine</article-title>. <source>Arch. Biochem. Biophys.</source>
<year>2007</year>, <volume>464</volume> (<issue>1</issue>), <fpage>112</fpage>&#x02013;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/j.abb.2007.04.022</pub-id>.<pub-id pub-id-type="pmid">17544360</pub-id>
</mixed-citation></ref><ref id="ref195"><mixed-citation publication-type="journal" id="cit195"><name><surname>Sokouti</surname><given-names>B.</given-names></name>; <name><surname>Hamzeh-Mivehroud</surname><given-names>M.</given-names></name>
<article-title>6D-QSAR for
Predicting Biological
Activity of Human Aldose Reductase Inhibitors Using Quasar Receptor
Surface Modeling</article-title>. <source>BMC Chem. Biol.</source>
<year>2023</year>, <volume>17</volume> (<issue>1</issue>), <fpage>63</fpage><pub-id pub-id-type="doi">10.1186/s13065-023-00970-x</pub-id>.</mixed-citation></ref><ref id="ref196"><mixed-citation publication-type="journal" id="cit196"><name><surname>Senese</surname><given-names>C. L.</given-names></name>; <name><surname>Duca</surname><given-names>J.</given-names></name>; <name><surname>Pan</surname><given-names>D.</given-names></name>; <name><surname>Hopfinger</surname><given-names>A. J.</given-names></name>; <name><surname>Tseng</surname><given-names>Y. J.</given-names></name>
<article-title>4D-Fingerprints, Universal QSAR and
QSPR Descriptors</article-title>. <source>J. Chem. Inf. Comput. Sci.</source>
<year>2004</year>, <volume>44</volume> (<issue>5</issue>), <fpage>1526</fpage>&#x02013;<lpage>1539</lpage>. <pub-id pub-id-type="doi">10.1021/ci049898s</pub-id>.<pub-id pub-id-type="pmid">15446810</pub-id>
</mixed-citation></ref><ref id="ref197"><mixed-citation publication-type="journal" id="cit197"><name><surname>Teramoto</surname><given-names>R.</given-names></name>; <name><surname>Kashima</surname><given-names>H.</given-names></name>
<article-title>Prediction
of Protein-Ligand Binding
Affinities Using Multiple Instance Learning</article-title>. <source>J. Mol. Graph. Model.</source>
<year>2010</year>, <volume>29</volume> (<issue>3</issue>), <fpage>492</fpage>&#x02013;<lpage>497</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmgm.2010.09.006</pub-id>.<pub-id pub-id-type="pmid">20965757</pub-id>
</mixed-citation></ref><ref id="ref198"><mixed-citation publication-type="journal" id="cit198"><name><surname>Zankov</surname><given-names>D. V.</given-names></name>; <name><surname>Matveieva</surname><given-names>M.</given-names></name>; <name><surname>Nikonenko</surname><given-names>A. V.</given-names></name>; <name><surname>Nugmanov</surname><given-names>R. I.</given-names></name>; <name><surname>Baskin</surname><given-names>I. I.</given-names></name>; <name><surname>Varnek</surname><given-names>A.</given-names></name>; <name><surname>Polishchuk</surname><given-names>P.</given-names></name>; <name><surname>Madzhidov</surname><given-names>T. I.</given-names></name>
<article-title>QSAR Modeling Based on Conformation
Ensembles Using
a Multi-Instance Learning Approach</article-title>. <source>J. Chem.
Inf. Model.</source>
<year>2021</year>, <volume>61</volume> (<issue>10</issue>), <fpage>4913</fpage>&#x02013;<lpage>4923</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.1c00692</pub-id>.<pub-id pub-id-type="pmid">34554736</pub-id>
</mixed-citation></ref><ref id="ref199"><mixed-citation publication-type="journal" id="cit199"><name><surname>Wu</surname><given-names>Z.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Du</surname><given-names>H.</given-names></name>; <name><surname>Jiang</surname><given-names>D.</given-names></name>; <name><surname>Kang</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>D.</given-names></name>; <name><surname>Pan</surname><given-names>P.</given-names></name>; <name><surname>Deng</surname><given-names>Y.</given-names></name>; <name><surname>Cao</surname><given-names>D.</given-names></name>; <name><surname>Hsieh</surname><given-names>C.-Y.</given-names></name>; <name><surname>Hou</surname><given-names>T.</given-names></name>
<article-title>Chemistry-Intuitive Explanation of
Graph Neural Networks for Molecular
Property Prediction with Substructure Masking</article-title>. <source>Nat. Commun.</source>
<year>2023</year>, <volume>14</volume> (<issue>1</issue>), <fpage>2585</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-38192-3</pub-id>.<pub-id pub-id-type="pmid">37142585</pub-id>
</mixed-citation></ref><ref id="ref200"><mixed-citation publication-type="journal" id="cit200"><name><surname>W&#x000f3;jcikowski</surname><given-names>M.</given-names></name>; <name><surname>Kukie&#x00142;ka</surname><given-names>M.</given-names></name>; <name><surname>Stepniewska-Dziubinska</surname><given-names>M. M.</given-names></name>; <name><surname>Siedlecki</surname><given-names>P.</given-names></name>
<article-title>Development
of a Protein-Ligand Extended Connectivity
(PLEC) Fingerprint and Its Application for Binding Affinity Predictions</article-title>. <source>Bioinformatics</source>
<year>2019</year>, <volume>35</volume> (<issue>8</issue>), <fpage>1334</fpage>&#x02013;<lpage>1341</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bty757</pub-id>.<pub-id pub-id-type="pmid">30202917</pub-id>
</mixed-citation></ref><ref id="ref201"><mixed-citation publication-type="journal" id="cit201"><name><surname>Cang</surname><given-names>Z.</given-names></name>; <name><surname>Mu</surname><given-names>L.</given-names></name>; <name><surname>Wei</surname><given-names>G.-W.</given-names></name>
<article-title>Representability
of Algebraic Topology for Biomolecules in Machine Learning Based Scoring
and Virtual Screening</article-title>. <source>PLoS Comput. Biol.</source>
<year>2018</year>, <volume>14</volume> (<issue>1</issue>), <elocation-id>e1005929</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1005929</pub-id>.<pub-id pub-id-type="pmid">29309403</pub-id>
</mixed-citation></ref><ref id="ref202"><mixed-citation publication-type="journal" id="cit202"><person-group person-group-type="allauthors"><name><surname>Townshend</surname><given-names>R. J. L.</given-names></name>; <name><surname>V&#x000f6;gele</surname><given-names>M.</given-names></name>; <name><surname>Suriana</surname><given-names>P.</given-names></name>; <name><surname>Derry</surname><given-names>A.</given-names></name>; <name><surname>Powers</surname><given-names>A.</given-names></name>; <name><surname>Laloudakis</surname><given-names>Y.</given-names></name>; <name><surname>Balachandar</surname><given-names>S.</given-names></name>; <name><surname>Jing</surname><given-names>B.</given-names></name>; <name><surname>Anderson</surname><given-names>B.</given-names></name>; <name><surname>Eismann</surname><given-names>S.</given-names></name>; <name><surname>Kondor</surname><given-names>R.</given-names></name>; <name><surname>Altman</surname><given-names>R. B.</given-names></name>; <name><surname>Dror</surname><given-names>R. O.</given-names></name></person-group><article-title>ATOM3D: Tasks On Molecules
in Three Dimensions</article-title>. <source>arXiv [cs.LG]</source><year>2020</year>,<pub-id pub-id-type="doi">10.48550/arXiv.2012.04035</pub-id>.</mixed-citation></ref><ref id="ref203"><mixed-citation publication-type="journal" id="cit203"><name><surname>Cremer</surname><given-names>J.</given-names></name>; <name><surname>Medrano Sandonas</surname><given-names>L.</given-names></name>; <name><surname>Tkatchenko</surname><given-names>A.</given-names></name>; <name><surname>Clevert</surname><given-names>D.-A.</given-names></name>; <name><surname>De Fabritiis</surname><given-names>G.</given-names></name>
<article-title>Equivariant
Graph Neural Networks
for Toxicity Prediction</article-title>. <source>Chem. Res. Toxicol.</source>
<year>2023</year>, <volume>36</volume> (<issue>10</issue>), <fpage>1561</fpage>&#x02013;<lpage>1573</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.3c00032</pub-id>.<pub-id pub-id-type="pmid">37690056</pub-id>
</mixed-citation></ref><ref id="ref204"><mixed-citation publication-type="journal" id="cit204"><name><surname>Wieder</surname><given-names>O.</given-names></name>; <name><surname>Kohlbacher</surname><given-names>S.</given-names></name>; <name><surname>Kuenemann</surname><given-names>M.</given-names></name>; <name><surname>Garon</surname><given-names>A.</given-names></name>; <name><surname>Ducrot</surname><given-names>P.</given-names></name>; <name><surname>Seidel</surname><given-names>T.</given-names></name>; <name><surname>Langer</surname><given-names>T.</given-names></name>
<article-title>A Compact
Review of Molecular Property Prediction with Graph Neural Networks</article-title>. <source>Drug Discovery Today Technol.</source>
<year>2020</year>, <volume>37</volume>, <fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddtec.2020.11.009</pub-id>.</mixed-citation></ref><ref id="ref205"><mixed-citation publication-type="journal" id="cit205"><name><surname>Dias</surname><given-names>A. L.</given-names></name>; <name><surname>Bustillo</surname><given-names>L.</given-names></name>; <name><surname>Rodrigues</surname><given-names>T.</given-names></name>
<article-title>Limitations
of Representation Learning in Small Molecule Property Prediction</article-title>. <source>Nat. Commun.</source>
<year>2023</year>, <volume>14</volume> (<issue>1</issue>), <fpage>6394</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-41967-3</pub-id>.<pub-id pub-id-type="pmid">37833279</pub-id>
</mixed-citation></ref><ref id="ref206"><mixed-citation publication-type="journal" id="cit206"><name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Cao</surname><given-names>Z.</given-names></name>; <name><surname>Barati Farimani</surname><given-names>A.</given-names></name>
<article-title>Molecular
Contrastive Learning of Representations via Graph Neural Networks</article-title>. <source>Nature Machine Intelligence</source>
<year>2022</year>, <volume>4</volume> (<issue>3</issue>), <fpage>279</fpage>&#x02013;<lpage>287</lpage>. <pub-id pub-id-type="doi">10.1038/s42256-022-00447-x</pub-id>.</mixed-citation></ref><ref id="ref207"><mixed-citation publication-type="journal" id="cit207"><name><surname>Winter</surname><given-names>R.</given-names></name>; <name><surname>Montanari</surname><given-names>F.</given-names></name>; <name><surname>No&#x000e9;</surname><given-names>F.</given-names></name>; <name><surname>Clevert</surname><given-names>D.-A.</given-names></name>
<article-title>Learning Continuous and Data-Driven
Molecular Descriptors
by Translating Equivalent Chemical Representations</article-title>. <source>Chem. Sci.</source>
<year>2019</year>, <volume>10</volume> (<issue>6</issue>), <fpage>1692</fpage>&#x02013;<lpage>1701</lpage>. <pub-id pub-id-type="doi">10.1039/C8SC04175J</pub-id>.<pub-id pub-id-type="pmid">30842833</pub-id>
</mixed-citation></ref><ref id="ref208"><mixed-citation publication-type="journal" id="cit208"><name><surname>Moshkov</surname><given-names>N.</given-names></name>; <name><surname>Bornholdt</surname><given-names>M.</given-names></name>; <name><surname>Benoit</surname><given-names>S.</given-names></name>; <name><surname>Smith</surname><given-names>M.</given-names></name>; <name><surname>McQuin</surname><given-names>C.</given-names></name>; <name><surname>Goodman</surname><given-names>A.</given-names></name>; <name><surname>Senft</surname><given-names>R. A.</given-names></name>; <name><surname>Han</surname><given-names>Y.</given-names></name>; <name><surname>Babadi</surname><given-names>M.</given-names></name>; <name><surname>Horvath</surname><given-names>P.</given-names></name>; <name><surname>Cimini</surname><given-names>B. A.</given-names></name>; <name><surname>Carpenter</surname><given-names>A. E.</given-names></name>; <name><surname>Singh</surname><given-names>S.</given-names></name>; <name><surname>Caicedo</surname><given-names>J. C.</given-names></name>
<article-title>Learning
Representations for Image-Based
Profiling of Perturbations</article-title>. <source>Nat. Commun.</source>
<year>2024</year>, <volume>15</volume> (<issue>1</issue>), <fpage>1594</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-45999-1</pub-id>.<pub-id pub-id-type="pmid">38383513</pub-id>
</mixed-citation></ref><ref id="ref209"><mixed-citation publication-type="journal" id="cit209"><person-group person-group-type="allauthors"><name><surname>Liu</surname><given-names>G.</given-names></name>; <name><surname>Seal</surname><given-names>S.</given-names></name>; <name><surname>Arevalo</surname><given-names>J.</given-names></name>; <name><surname>Liang</surname><given-names>Z.</given-names></name>; <name><surname>Carpenter</surname><given-names>A. E.</given-names></name>; <name><surname>Jiang</surname><given-names>M.</given-names></name>; <name><surname>Singh</surname><given-names>S.</given-names></name></person-group><article-title>Learning Molecular Representation
in a Cell</article-title>. <source>ArXiv [cs.LG]</source><year>2024</year>,<pub-id pub-id-type="doi">10.48550/arXiv.2406.12056</pub-id>.</mixed-citation></ref><ref id="ref210"><mixed-citation publication-type="journal" id="cit210"><name><surname>Sanchez-Fernandez</surname><given-names>A.</given-names></name>; <name><surname>Rumetshofer</surname><given-names>E.</given-names></name>; <name><surname>Hochreiter</surname><given-names>S.</given-names></name>; <name><surname>Klambauer</surname><given-names>G.</given-names></name>
<article-title>CLOOME: Contrastive Learning Unlocks
Bioimaging Databases
for Queries with Chemical Structures</article-title>. <source>Nat. Commun.</source>
<year>2023</year>, <volume>14</volume> (<issue>1</issue>), <fpage>7339</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-42328-w</pub-id>.<pub-id pub-id-type="pmid">37957207</pub-id>
</mixed-citation></ref><ref id="ref211"><mixed-citation publication-type="journal" id="cit211"><person-group person-group-type="allauthors"><name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Gupta</surname><given-names>S.</given-names></name>; <name><surname>Uhler</surname><given-names>C.</given-names></name>; <name><surname>Jaakkola</surname><given-names>T.</given-names></name></person-group><article-title>Removing Biases
from Molecular Representations
via Information Maximization</article-title>. <source>arXiv [cs.LG]</source><year>2023</year>,<pub-id pub-id-type="doi">10.48550/arXiv.2312.00718</pub-id>.</mixed-citation></ref><ref id="ref212"><mixed-citation publication-type="journal" id="cit212"><name><surname>Trunk</surname><given-names>G. V.</given-names></name>
<article-title>A Problem
of Dimensionality: A Simple Example</article-title>. <source>IEEE Trans.
Pattern Anal. Mach. Intell.</source>
<year>1979</year>, <volume>PAMI-1</volume> (<issue>3</issue>), <fpage>306</fpage>&#x02013;<lpage>307</lpage>. <pub-id pub-id-type="doi">10.1109/TPAMI.1979.4766926</pub-id>.</mixed-citation></ref><ref id="ref213"><mixed-citation publication-type="journal" id="cit213"><name><surname>Munson</surname><given-names>M. A.</given-names></name>; <name><surname>Caruana</surname><given-names>R.</given-names></name>
<article-title>On Feature Selection,
Bias-Variance,
and Bagging</article-title>. <source>Machine Learning and Knowledge
Discovery in Databases</source>
<year>2009</year>, <volume>5782</volume>, <fpage>144</fpage>&#x02013;<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-642-04174-7_10</pub-id>.</mixed-citation></ref><ref id="ref214"><mixed-citation publication-type="journal" id="cit214"><name><surname>Yu</surname><given-names>L.</given-names></name>; <name><surname>Liu</surname><given-names>H.</given-names></name>
<article-title>Efficient Feature Selection via Analysis
of Relevance
and Redundancy</article-title>. <source>J. Mach. Learn. Res.</source>
<year>2004</year>, <volume>5</volume>, <fpage>1205</fpage>&#x02013;<lpage>1224</lpage>.</mixed-citation></ref><ref id="ref215"><mixed-citation publication-type="journal" id="cit215"><person-group person-group-type="allauthors"><name><surname>Tetko</surname><given-names>I.</given-names></name>; <name><surname>Baskin</surname><given-names>I. I.</given-names></name>; <name><surname>Varnek</surname><given-names>A.</given-names></name></person-group> . Unpublished 2008. <source>Tutorial
on Machine Learning. Part 2. Descriptor Selection Bias</source><year>2008</year><pub-id pub-id-type="doi">10.13140/RG.2.2.26353.43361</pub-id>.</mixed-citation></ref><ref id="ref216"><mixed-citation publication-type="journal" id="cit216"><name><surname>Tetko</surname><given-names>I. V.</given-names></name>; <name><surname>Sushko</surname><given-names>I.</given-names></name>; <name><surname>Pandey</surname><given-names>A. K.</given-names></name>; <name><surname>Zhu</surname><given-names>H.</given-names></name>; <name><surname>Tropsha</surname><given-names>A.</given-names></name>; <name><surname>Papa</surname><given-names>E.</given-names></name>; <name><surname>Oberg</surname><given-names>T.</given-names></name>; <name><surname>Todeschini</surname><given-names>R.</given-names></name>; <name><surname>Fourches</surname><given-names>D.</given-names></name>; <name><surname>Varnek</surname><given-names>A.</given-names></name>
<article-title>Critical Assessment of QSAR Models
of Environmental Toxicity against Tetrahymena Pyriformis: Focusing
on Applicability Domain and Overfitting by Variable Selection</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2008</year>, <volume>48</volume> (<issue>9</issue>), <fpage>1733</fpage>&#x02013;<lpage>1746</lpage>. <pub-id pub-id-type="doi">10.1021/ci800151m</pub-id>.<pub-id pub-id-type="pmid">18729318</pub-id>
</mixed-citation></ref><ref id="ref217"><mixed-citation publication-type="journal" id="cit217"><name><surname>Pudjihartono</surname><given-names>N.</given-names></name>; <name><surname>Fadason</surname><given-names>T.</given-names></name>; <name><surname>Kempa-Liehr</surname><given-names>A. W.</given-names></name>; <name><surname>O&#x02019;Sullivan</surname><given-names>J. M.</given-names></name>
<article-title>A Review of Feature Selection Methods for Machine Learning-Based
Disease Risk Prediction</article-title>. <source>Front. Bioinform.</source>
<year>2022</year>, <volume>2</volume>, <fpage>927312</fpage><pub-id pub-id-type="doi">10.3389/fbinf.2022.927312</pub-id>.<pub-id pub-id-type="pmid">36304293</pub-id>
</mixed-citation></ref><ref id="ref218"><mixed-citation publication-type="journal" id="cit218"><name><surname>Radovic</surname><given-names>M.</given-names></name>; <name><surname>Ghalwash</surname><given-names>M.</given-names></name>; <name><surname>Filipovic</surname><given-names>N.</given-names></name>; <name><surname>Obradovic</surname><given-names>Z.</given-names></name>
<article-title>Minimum Redundancy Maximum Relevance Feature Selection
Approach for Temporal Gene Expression Data</article-title>. <source>BMC Bioinformatics</source>
<year>2017</year>, <volume>18</volume> (<issue>1</issue>), <fpage>9</fpage><pub-id pub-id-type="doi">10.1186/s12859-016-1423-9</pub-id>.<pub-id pub-id-type="pmid">28049413</pub-id>
</mixed-citation></ref><ref id="ref219"><mixed-citation publication-type="journal" id="cit219"><name><surname>Guyon</surname><given-names>I.</given-names></name>; <name><surname>Weston</surname><given-names>J.</given-names></name>; <name><surname>Barnhill</surname><given-names>S.</given-names></name>; <name><surname>Vapnik</surname><given-names>V.</given-names></name>
<article-title>Gene Selection
for Cancer Classification Using Support Vector Machines</article-title>. <source>Mach. Learn.</source>
<year>2002</year>, <volume>46</volume> (<issue>1</issue>), <fpage>389</fpage>&#x02013;<lpage>422</lpage>. <pub-id pub-id-type="doi">10.1023/A:1012487302797</pub-id>.</mixed-citation></ref><ref id="ref220"><mixed-citation publication-type="journal" id="cit220"><name><surname>&#x0010c;melo</surname><given-names>I.</given-names></name>; <name><surname>Vor&#x00161;il&#x000e1;k</surname><given-names>M.</given-names></name>; <name><surname>Svozil</surname><given-names>D.</given-names></name>
<article-title>Profiling
and Analysis of Chemical Compounds Using Pointwise Mutual Information</article-title>. <source>J. Cheminform.</source>
<year>2021</year>, <volume>13</volume> (<issue>1</issue>), <fpage>3</fpage><pub-id pub-id-type="doi">10.1186/s13321-020-00483-y</pub-id>.<pub-id pub-id-type="pmid">33423694</pub-id>
</mixed-citation></ref><ref id="ref221"><mixed-citation publication-type="journal" id="cit221"><name><surname>Kursa</surname><given-names>M. B.</given-names></name>; <name><surname>Rudnicki</surname><given-names>W. R.</given-names></name>
<article-title>Feature Selection with the Boruta
Package</article-title>. <source>J. Stat. Softw.</source>
<year>2010</year>, <volume>36</volume>, <fpage>1</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.18637/jss.v036.i11</pub-id>.</mixed-citation></ref><ref id="ref222"><mixed-citation publication-type="journal" id="cit222"><name><surname>Tibshirani</surname><given-names>R.</given-names></name>
<article-title>Regression Shrinkage and Selection
via the Lasso</article-title>. <source>J. R. Stat. Soc. Series B Stat.
Methodol.</source>
<year>1996</year>, <volume>58</volume> (<issue>1</issue>), <fpage>267</fpage>&#x02013;<lpage>288</lpage>. <pub-id pub-id-type="doi">10.1111/j.2517-6161.1996.tb02080.x</pub-id>.</mixed-citation></ref><ref id="ref223"><mixed-citation publication-type="conf-proc" id="cit223"><person-group person-group-type="allauthors"><name><surname>Song</surname><given-names>F.</given-names></name>; <name><surname>Guo</surname><given-names>Z.</given-names></name>; <name><surname>Mei</surname><given-names>D.</given-names></name></person-group><article-title>Feature Selection
Using Principal
Component Analysis</article-title>. In <source>2010 International
Conference on System Science, Engineering Design and Manufacturing
Informatization</source>; <publisher-name>IEEE</publisher-name>, <year>2010</year>; Vol. <volume>1</volume>, pp <fpage>27</fpage>&#x02013;<lpage>30</lpage>.</mixed-citation></ref><ref id="ref224"><mixed-citation publication-type="book" id="cit224"><person-group person-group-type="allauthors"><name><surname>Jovi&#x00107;</surname><given-names>A.</given-names></name>; <name><surname>Brki&#x00107;</surname><given-names>K.</given-names></name>; <name><surname>Bogunovi&#x00107;</surname><given-names>N.</given-names></name></person-group><article-title>A
Review of Feature Selection Methods with Applications</article-title>. In <source>2015 38th International Convention on Information and
Communication Technology, Electronics and Microelectronics (MIPRO)</source>; <publisher-name>IEEE</publisher-name>, <year>2015</year>; pp <fpage>1200</fpage>&#x02013;<lpage>1205</lpage>.</mixed-citation></ref><ref id="ref225"><mixed-citation publication-type="journal" id="cit225"><name><surname>Kraskov</surname><given-names>A.</given-names></name>; <name><surname>St&#x000f6;gbauer</surname><given-names>H.</given-names></name>; <name><surname>Grassberger</surname><given-names>P.</given-names></name>
<article-title>Estimating
Mutual Information</article-title>. <source>Phys. Rev. E Stat. Nonlin.
Soft Matter Phys.</source>
<year>2004</year>, <volume>69</volume> (<issue>6 Pt 2</issue>), <fpage>066138</fpage><pub-id pub-id-type="doi">10.1103/PhysRevE.69.066138</pub-id>.<pub-id pub-id-type="pmid">15244698</pub-id>
</mixed-citation></ref><ref id="ref226"><mixed-citation publication-type="journal" id="cit226"><name><surname>Zou</surname><given-names>H.</given-names></name>; <name><surname>Hastie</surname><given-names>T.</given-names></name>
<article-title>Regularization and Variable Selection
Via the Elastic
Net</article-title>. <source>J. R. Stat. Soc. Series B Stat. Methodol.</source>
<year>2005</year>, <volume>67</volume> (<issue>2</issue>), <fpage>301</fpage>&#x02013;<lpage>320</lpage>. <pub-id pub-id-type="doi">10.1111/j.1467-9868.2005.00503.x</pub-id>.</mixed-citation></ref><ref id="ref227"><mixed-citation publication-type="journal" id="cit227"><name><surname>Eklund</surname><given-names>M.</given-names></name>; <name><surname>Norinder</surname><given-names>U.</given-names></name>; <name><surname>Boyer</surname><given-names>S.</given-names></name>; <name><surname>Carlsson</surname><given-names>L.</given-names></name>
<article-title>Choosing Feature
Selection and Learning Algorithms in QSAR</article-title>. <source>J.
Chem. Inf. Model.</source>
<year>2014</year>, <volume>54</volume> (<issue>3</issue>), <fpage>837</fpage>&#x02013;<lpage>843</lpage>. <pub-id pub-id-type="doi">10.1021/ci400573c</pub-id>.<pub-id pub-id-type="pmid">24460242</pub-id>
</mixed-citation></ref><ref id="ref228"><mixed-citation publication-type="book" id="cit228"><person-group person-group-type="allauthors"><name><surname>Labjar</surname><given-names>H.</given-names></name>; <name><surname>Labjar</surname><given-names>N.</given-names></name>; <name><surname>Kissi</surname><given-names>M.</given-names></name></person-group><article-title>QSAR Anti-HIV Feature Selection
and Prediction for Drug Discovery Using Genetic Algorithm and Machine
Learning Algorithms</article-title>. In <source>Computational Intelligence
in Recent Communication Networks</source>; <person-group person-group-type="editor"><name><surname>Ouaissa</surname><given-names>M.</given-names></name>, <name><surname>Boulouard</surname><given-names>Z.</given-names></name>, <name><surname>Ouaissa</surname><given-names>M.</given-names></name>, <name><surname>Guermah</surname><given-names>B.</given-names></name></person-group>, Eds.; <publisher-name>Springer
International Publishing</publisher-name>: <publisher-loc>Cham</publisher-loc>, <year>2022</year>; pp <fpage>191</fpage>&#x02013;<lpage>204</lpage>.</mixed-citation></ref><ref id="ref229"><mixed-citation publication-type="journal" id="cit229"><name><surname>Mitchell</surname><given-names>J. B. O.</given-names></name>
<article-title>Machine Learning Methods in Chemoinformatics</article-title>. <source>Wiley Interdiscip. Rev. Comput. Mol. Sci.</source>
<year>2014</year>, <volume>4</volume> (<issue>5</issue>), <fpage>468</fpage>&#x02013;<lpage>481</lpage>. <pub-id pub-id-type="doi">10.1002/wcms.1183</pub-id>.<pub-id pub-id-type="pmid">25285160</pub-id>
</mixed-citation></ref><ref id="ref230"><mixed-citation publication-type="journal" id="cit230"><name><surname>Lavecchia</surname><given-names>A.</given-names></name>
<article-title>Machine-Learning Approaches in Drug
Discovery: Methods
and Applications</article-title>. <source>Drug Discovery Today</source>
<year>2015</year>, <volume>20</volume> (<issue>3</issue>), <fpage>318</fpage>&#x02013;<lpage>331</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2014.10.012</pub-id>.<pub-id pub-id-type="pmid">25448759</pub-id>
</mixed-citation></ref><ref id="ref231"><mixed-citation publication-type="journal" id="cit231"><name><surname>Hornik</surname><given-names>K.</given-names></name>; <name><surname>Stinchcombe</surname><given-names>M.</given-names></name>; <name><surname>White</surname><given-names>H.</given-names></name>
<article-title>Multilayer Feedforward
Networks Are Universal Approximators</article-title>. <source>Neural
Netw.</source>
<year>1989</year>, <volume>2</volume> (<issue>5</issue>), <fpage>359</fpage>&#x02013;<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1016/0893-6080(89)90020-8</pub-id>.</mixed-citation></ref><ref id="ref232"><mixed-citation publication-type="journal" id="cit232"><name><surname>Belkin</surname><given-names>M.</given-names></name>; <name><surname>Hsu</surname><given-names>D.</given-names></name>; <name><surname>Ma</surname><given-names>S.</given-names></name>; <name><surname>Mandal</surname><given-names>S.</given-names></name>
<article-title>Reconciling
Modern Machine-Learning Practice and the Classical Bias-Variance Trade-Off</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2019</year>, <volume>116</volume> (<issue>32</issue>), <fpage>15849</fpage>&#x02013;<lpage>15854</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1903070116</pub-id>.<pub-id pub-id-type="pmid">31341078</pub-id>
</mixed-citation></ref><ref id="ref233"><mixed-citation publication-type="journal" id="cit233"><person-group person-group-type="allauthors"><name><surname>Curth</surname><given-names>A.</given-names></name>; <name><surname>Jeffares</surname><given-names>A.</given-names></name>; <name><surname>van der Schaar</surname><given-names>M.</given-names></name></person-group><article-title>Why
Do Random
Forests Work? Understanding Tree Ensembles as Self-Regularizing Adaptive
Smoothers</article-title>. <source>arXiv [stat.ML]</source><year>2024</year>,<pub-id pub-id-type="doi">10.48550/arXiv.2402.01502</pub-id>.</mixed-citation></ref><ref id="ref234"><mixed-citation publication-type="journal" id="cit234"><name><surname>Carracedo-Reboredo</surname><given-names>P.</given-names></name>; <name><surname>Li&#x000f1;ares-Blanco</surname><given-names>J.</given-names></name>; <name><surname>Rodr&#x000ed;guez-Fern&#x000e1;ndez</surname><given-names>N.</given-names></name>; <name><surname>Cedr&#x000f3;n</surname><given-names>F.</given-names></name>; <name><surname>Novoa</surname><given-names>F. J.</given-names></name>; <name><surname>Carballal</surname><given-names>A.</given-names></name>; <name><surname>Maojo</surname><given-names>V.</given-names></name>; <name><surname>Pazos</surname><given-names>A.</given-names></name>; <name><surname>Fernandez-Lozano</surname><given-names>C.</given-names></name>
<article-title>A Review on
Machine Learning Approaches and Trends in Drug Discovery</article-title>. <source>Comput. Struct. Biotechnol. J.</source>
<year>2021</year>, <volume>19</volume>, <fpage>4538</fpage>&#x02013;<lpage>4558</lpage>. <pub-id pub-id-type="doi">10.1016/j.csbj.2021.08.011</pub-id>.<pub-id pub-id-type="pmid">34471498</pub-id>
</mixed-citation></ref><ref id="ref235"><mixed-citation publication-type="journal" id="cit235"><name><surname>Nakkiran</surname><given-names>P.</given-names></name>; <name><surname>Kaplun</surname><given-names>G.</given-names></name>; <name><surname>Bansal</surname><given-names>Y.</given-names></name>; <name><surname>Yang</surname><given-names>T.</given-names></name>; <name><surname>Barak</surname><given-names>B.</given-names></name>; <name><surname>Sutskever</surname><given-names>I.</given-names></name>
<article-title>Deep Double
Descent: Where Bigger
Models and More Data Hurt</article-title>. <source>J. Stat. Mech.</source>
<year>2021</year>, <volume>2021</volume> (<issue>12</issue>), <fpage>124003</fpage><pub-id pub-id-type="doi">10.1088/1742-5468/ac3a74</pub-id>.</mixed-citation></ref><ref id="ref236"><mixed-citation publication-type="journal" id="cit236"><person-group person-group-type="allauthors"><name><surname>Curth</surname><given-names>A.</given-names></name>; <name><surname>Jeffares</surname><given-names>A.</given-names></name>; <name><surname>van der Schaar</surname><given-names>M.</given-names></name></person-group><article-title>A
U-Turn on Double
Descent: Rethinking Parameter Counting in Statistical Learning</article-title>. <source>arXiv [stat.ML]</source><year>2023</year>,<pub-id pub-id-type="doi">10.48550/arXiv.2310.18988</pub-id>.</mixed-citation></ref><ref id="ref237"><mixed-citation publication-type="journal" id="cit237"><name><surname>Sha</surname><given-names>C. M.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Dokholyan</surname><given-names>N. V.</given-names></name>
<article-title>NeuralDock:
Rapid and Conformation-Agnostic Docking of Small Molecules</article-title>. <source>Front Mol. Biosci</source>
<year>2022</year>, <volume>9</volume>, <fpage>867241</fpage><pub-id pub-id-type="doi">10.3389/fmolb.2022.867241</pub-id>.<pub-id pub-id-type="pmid">35392534</pub-id>
</mixed-citation></ref><ref id="ref238"><mixed-citation publication-type="journal" id="cit238"><name><surname>Mansouri</surname><given-names>K.</given-names></name>; <name><surname>Grulke</surname><given-names>C. M.</given-names></name>; <name><surname>Judson</surname><given-names>R. S.</given-names></name>; <name><surname>Williams</surname><given-names>A. J.</given-names></name>
<article-title>OPERA Models
for Predicting Physicochemical Properties and Environmental Fate Endpoints</article-title>. <source>J. Cheminform.</source>
<year>2018</year>, <volume>10</volume> (<issue>1</issue>), <fpage>10</fpage><pub-id pub-id-type="doi">10.1186/s13321-018-0263-1</pub-id>.<pub-id pub-id-type="pmid">29520515</pub-id>
</mixed-citation></ref><ref id="ref239"><mixed-citation publication-type="journal" id="cit239"><name><surname>Klambauer</surname><given-names>G.</given-names></name>; <name><surname>Clevert</surname><given-names>D.-A.</given-names></name>; <name><surname>Shah</surname><given-names>I.</given-names></name>; <name><surname>Benfenati</surname><given-names>E.</given-names></name>; <name><surname>Tetko</surname><given-names>I. V.</given-names></name>
<article-title>Introduction to the Special Issue: AI Meets Toxicology</article-title>. <source>Chem. Res. Toxicol.</source>
<year>2023</year>, <volume>36</volume> (<issue>8</issue>), <fpage>1163</fpage>&#x02013;<lpage>1167</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.3c00217</pub-id>.<pub-id pub-id-type="pmid">37599584</pub-id>
</mixed-citation></ref><ref id="ref240"><mixed-citation publication-type="journal" id="cit240"><name><surname>Eytcheson</surname><given-names>S. A.</given-names></name>; <name><surname>Tetko</surname><given-names>I. V.</given-names></name>
<article-title>Which Modern AI
Methods Provide Accurate
Predictions of Toxicological Endpoints? Analysis of Tox24 Challenge
Results</article-title>. <source>ChemRxiv</source>
<year>2025</year>, <pub-id pub-id-type="doi">10.26434/chemrxiv-2025-7k7x3</pub-id>.</mixed-citation></ref><ref id="ref241"><mixed-citation publication-type="journal" id="cit241"><name><surname>Ekins</surname><given-names>S.</given-names></name>
<article-title>Progress in Computational Toxicology</article-title>. <source>J. Pharmacol.
Toxicol. Methods</source>
<year>2014</year>, <volume>69</volume> (<issue>2</issue>), <fpage>115</fpage>&#x02013;<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1016/j.vascn.2013.12.003</pub-id>.<pub-id pub-id-type="pmid">24361690</pub-id>
</mixed-citation></ref><ref id="ref242"><mixed-citation publication-type="journal" id="cit242"><name><surname>Raies</surname><given-names>A. B.</given-names></name>; <name><surname>Bajic</surname><given-names>V. B.</given-names></name>
<article-title>In Silico Toxicology: Computational
Methods for the Prediction of Chemical Toxicity</article-title>. <source>Wiley Interdiscip. Rev. Comput. Mol. Sci.</source>
<year>2016</year>, <volume>6</volume> (<issue>2</issue>), <fpage>147</fpage>&#x02013;<lpage>172</lpage>. <pub-id pub-id-type="doi">10.1002/wcms.1240</pub-id>.<pub-id pub-id-type="pmid">27066112</pub-id>
</mixed-citation></ref><ref id="ref243"><mixed-citation publication-type="book" id="cit243"><person-group person-group-type="allauthors"><name><surname>Baskin</surname><given-names>I. I.</given-names></name></person-group><article-title>Machine Learning
Methods in Computational Toxicology</article-title>. In <source>Computational
Toxicology: Methods and Protocols</source>; <person-group person-group-type="editor"><name><surname>Nicolotti</surname><given-names>O.</given-names></name></person-group>, Ed.; <publisher-name>Springer
New York</publisher-name>: <publisher-loc>New York, NY</publisher-loc>, <year>2018</year>; pp <fpage>119</fpage>&#x02013;<lpage>139</lpage>.</mixed-citation></ref><ref id="ref244"><mixed-citation publication-type="journal" id="cit244"><name><surname>Yang</surname><given-names>H.</given-names></name>; <name><surname>Sun</surname><given-names>L.</given-names></name>; <name><surname>Li</surname><given-names>W.</given-names></name>; <name><surname>Liu</surname><given-names>G.</given-names></name>; <name><surname>Tang</surname><given-names>Y.</given-names></name>
<article-title>In Silico Prediction of Chemical Toxicity for Drug
Design Using Machine
Learning Methods and Structural Alerts</article-title>. <source>Front
Chem.</source>
<year>2018</year>, <volume>6</volume>, <fpage>30</fpage><pub-id pub-id-type="doi">10.3389/fchem.2018.00030</pub-id>.<pub-id pub-id-type="pmid">29515993</pub-id>
</mixed-citation></ref><ref id="ref245"><mixed-citation publication-type="journal" id="cit245"><name><surname>Vamathevan</surname><given-names>J.</given-names></name>; <name><surname>Clark</surname><given-names>D.</given-names></name>; <name><surname>Czodrowski</surname><given-names>P.</given-names></name>; <name><surname>Dunham</surname><given-names>I.</given-names></name>; <name><surname>Ferran</surname><given-names>E.</given-names></name>; <name><surname>Lee</surname><given-names>G.</given-names></name>; <name><surname>Li</surname><given-names>B.</given-names></name>; <name><surname>Madabhushi</surname><given-names>A.</given-names></name>; <name><surname>Shah</surname><given-names>P.</given-names></name>; <name><surname>Spitzer</surname><given-names>M.</given-names></name>; <name><surname>Zhao</surname><given-names>S.</given-names></name>
<article-title>Applications
of Machine Learning in Drug Discovery and Development</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2019</year>, <volume>18</volume> (<issue>6</issue>), <fpage>463</fpage>&#x02013;<lpage>477</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-019-0024-5</pub-id>.<pub-id pub-id-type="pmid">30976107</pub-id>
</mixed-citation></ref><ref id="ref246"><mixed-citation publication-type="journal" id="cit246"><name><surname>Ciallella</surname><given-names>H. L.</given-names></name>; <name><surname>Zhu</surname><given-names>H.</given-names></name>
<article-title>Advancing Computational
Toxicology
in the Big Data Era by Artificial Intelligence: Data-Driven and Mechanism-Driven
Modeling for Chemical Toxicity</article-title>. <source>Chem. Res. Toxicol.</source>
<year>2019</year>, <volume>32</volume> (<issue>4</issue>), <fpage>536</fpage>&#x02013;<lpage>547</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.8b00393</pub-id>.<pub-id pub-id-type="pmid">30907586</pub-id>
</mixed-citation></ref><ref id="ref247"><mixed-citation publication-type="journal" id="cit247"><name><surname>Jim&#x000e9;nez-Luna</surname><given-names>J.</given-names></name>; <name><surname>Grisoni</surname><given-names>F.</given-names></name>; <name><surname>Schneider</surname><given-names>G.</given-names></name>
<article-title>Drug Discovery
with Explainable Artificial Intelligence</article-title>. <source>Nature
Machine Intelligence</source>
<year>2020</year>, <volume>2</volume> (<issue>10</issue>), <fpage>573</fpage>&#x02013;<lpage>584</lpage>. <pub-id pub-id-type="doi">10.1038/s42256-020-00236-4</pub-id>.</mixed-citation></ref><ref id="ref248"><mixed-citation publication-type="journal" id="cit248"><name><surname>Wang</surname><given-names>M. W. H.</given-names></name>; <name><surname>Goodman</surname><given-names>J. M.</given-names></name>; <name><surname>Allen</surname><given-names>T. E. H.</given-names></name>
<article-title>Machine
Learning
in Predictive Toxicology: Recent Applications and Future Directions
for Classification Models</article-title>. <source>Chem. Res. Toxicol.</source>
<year>2021</year>, <volume>34</volume> (<issue>2</issue>), <fpage>217</fpage>&#x02013;<lpage>239</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.0c00316</pub-id>.<pub-id pub-id-type="pmid">33356168</pub-id>
</mixed-citation></ref><ref id="ref249"><mixed-citation publication-type="journal" id="cit249"><name><surname>Dara</surname><given-names>S.</given-names></name>; <name><surname>Dhamercherla</surname><given-names>S.</given-names></name>; <name><surname>Jadav</surname><given-names>S. S.</given-names></name>; <name><surname>Babu</surname><given-names>C. M.</given-names></name>; <name><surname>Ahsan</surname><given-names>M. J.</given-names></name>
<article-title>Machine
Learning in Drug Discovery: A Review</article-title>. <source>Artif
Intell Rev.</source>
<year>2022</year>, <volume>55</volume> (<issue>3</issue>), <fpage>1947</fpage>&#x02013;<lpage>1999</lpage>. <pub-id pub-id-type="doi">10.1007/s10462-021-10058-4</pub-id>.<pub-id pub-id-type="pmid">34393317</pub-id>
</mixed-citation></ref><ref id="ref250"><mixed-citation publication-type="journal" id="cit250"><name><surname>Van Tran</surname><given-names>T. T.</given-names></name>; <name><surname>Surya Wibowo</surname><given-names>A.</given-names></name>; <name><surname>Tayara</surname><given-names>H.</given-names></name>; <name><surname>Chong</surname><given-names>K. T.</given-names></name>
<article-title>Artificial
Intelligence in Drug Toxicity Prediction: Recent Advances, Challenges,
and Future Perspectives</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2023</year>, <volume>63</volume> (<issue>9</issue>), <fpage>2628</fpage>&#x02013;<lpage>2643</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.3c00200</pub-id>.<pub-id pub-id-type="pmid">37125780</pub-id>
</mixed-citation></ref><ref id="ref251"><mixed-citation publication-type="journal" id="cit251"><name><surname>Guo</surname><given-names>W.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Dong</surname><given-names>F.</given-names></name>; <name><surname>Song</surname><given-names>M.</given-names></name>; <name><surname>Li</surname><given-names>Z.</given-names></name>; <name><surname>Khan</surname><given-names>M. K. H.</given-names></name>; <name><surname>Patterson</surname><given-names>T. A.</given-names></name>; <name><surname>Hong</surname><given-names>H.</given-names></name>
<article-title>Review of Machine Learning
and Deep Learning Models for Toxicity Prediction</article-title>. <source>Exp. Biol. Med.</source>
<year>2023</year>, <volume>248</volume> (<issue>21</issue>), <fpage>1952</fpage>&#x02013;<lpage>1973</lpage>. <pub-id pub-id-type="doi">10.1177/15353702231209421</pub-id>.</mixed-citation></ref><ref id="ref252"><mixed-citation publication-type="journal" id="cit252"><person-group person-group-type="allauthors"><name><surname>Tonoyan</surname><given-names>L.</given-names></name>; <name><surname>Siraki</surname><given-names>A. G.</given-names></name></person-group><article-title>Machine Learning
in Toxicological Sciences: Opportunities for Assessing Drug Toxicity</article-title>. <source>Front. Drug Discovery (Lausanne)</source><year>2024</year>, <volume>4</volume>.<pub-id pub-id-type="doi">10.3389/fddsv.2024.1336025</pub-id>.</mixed-citation></ref><ref id="ref253"><mixed-citation publication-type="journal" id="cit253"><name><surname>Kovarich</surname><given-names>S.</given-names></name>; <name><surname>Ceriani</surname><given-names>L.</given-names></name>; <name><surname>Fuart Gatnik</surname><given-names>M.</given-names></name>; <name><surname>Bassan</surname><given-names>A.</given-names></name>; <name><surname>Pavan</surname><given-names>M.</given-names></name>
<article-title>Filling Data Gaps by Read-across:
A Mini Review on Its Application, Developments and Challenges</article-title>. <source>Mol. Inform.</source>
<year>2019</year>, <volume>38</volume> (<issue>8&#x02013;9</issue>), <elocation-id>e1800121</elocation-id><pub-id pub-id-type="doi">10.1002/minf.201800121</pub-id>.<pub-id pub-id-type="pmid">30977298</pub-id>
</mixed-citation></ref><ref id="ref254"><mixed-citation publication-type="journal" id="cit254"><name><surname>Lester</surname><given-names>C. C.</given-names></name>; <name><surname>Yan</surname><given-names>G.</given-names></name>
<article-title>A Matched Molecular
Pair (MMP) Approach
for Selecting Analogs Suitable for Structure Activity Relationship
(SAR)-Based Read across</article-title>. <source>Regul. Toxicol. Pharmacol.</source>
<year>2021</year>, <volume>124</volume>, <fpage>104966</fpage><pub-id pub-id-type="doi">10.1016/j.yrtph.2021.104966</pub-id>.<pub-id pub-id-type="pmid">34044089</pub-id>
</mixed-citation></ref><ref id="ref255"><mixed-citation publication-type="journal" id="cit255"><name><surname>Yang</surname><given-names>Y.</given-names></name>; <name><surname>Wu</surname><given-names>Z.</given-names></name>; <name><surname>Yao</surname><given-names>X.</given-names></name>; <name><surname>Kang</surname><given-names>Y.</given-names></name>; <name><surname>Hou</surname><given-names>T.</given-names></name>; <name><surname>Hsieh</surname><given-names>C.-Y.</given-names></name>; <name><surname>Liu</surname><given-names>H.</given-names></name>
<article-title>Exploring
Low-Toxicity Chemical Space
with Deep Learning for Molecular Generation</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2022</year>, <volume>62</volume> (<issue>13</issue>), <fpage>3191</fpage>&#x02013;<lpage>3199</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.2c00671</pub-id>.<pub-id pub-id-type="pmid">35713712</pub-id>
</mixed-citation></ref><ref id="ref256"><mixed-citation publication-type="journal" id="cit256"><name><surname>Anstine</surname><given-names>D. M.</given-names></name>; <name><surname>Isayev</surname><given-names>O.</given-names></name>
<article-title>Generative Models as
an Emerging
Paradigm in the Chemical Sciences</article-title>. <source>J. Am. Chem.
Soc.</source>
<year>2023</year>, <volume>145</volume> (<issue>16</issue>), <fpage>8736</fpage>&#x02013;<lpage>8750</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.2c13467</pub-id>.<pub-id pub-id-type="pmid">37052978</pub-id>
</mixed-citation></ref><ref id="ref257"><mixed-citation publication-type="journal" id="cit257"><name><surname>Wang</surname><given-names>M.</given-names></name>; <name><surname>Li</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>O.</given-names></name>; <name><surname>Du</surname><given-names>H.</given-names></name>; <name><surname>Jiang</surname><given-names>D.</given-names></name>; <name><surname>Wu</surname><given-names>Z.</given-names></name>; <name><surname>Deng</surname><given-names>Y.</given-names></name>; <name><surname>Kang</surname><given-names>Y.</given-names></name>; <name><surname>Pan</surname><given-names>P.</given-names></name>; <name><surname>Li</surname><given-names>D.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Yao</surname><given-names>X.</given-names></name>; <name><surname>Hou</surname><given-names>T.</given-names></name>; <name><surname>Hsieh</surname><given-names>C.-Y.</given-names></name>
<article-title>ClickGen: Directed Exploration of Synthesizable Chemical
Space via Modular Reactions and Reinforcement Learning</article-title>. <source>Nat. Commun.</source>
<year>2024</year>, <volume>15</volume> (<issue>1</issue>), <fpage>10127</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-54456-y</pub-id>.<pub-id pub-id-type="pmid">39578485</pub-id>
</mixed-citation></ref><ref id="ref258"><mixed-citation publication-type="journal" id="cit258"><name><surname>Thomas</surname><given-names>M.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>de Graaf</surname><given-names>C.</given-names></name>
<article-title>Integrating Structure-Based
Approaches in Generative Molecular Design</article-title>. <source>Curr.
Opin. Struct. Biol.</source>
<year>2023</year>, <volume>79</volume>, <fpage>102559</fpage><pub-id pub-id-type="doi">10.1016/j.sbi.2023.102559</pub-id>.<pub-id pub-id-type="pmid">36870277</pub-id>
</mixed-citation></ref><ref id="ref259"><mixed-citation publication-type="journal" id="cit259"><person-group person-group-type="allauthors"><name><surname>Kingma</surname><given-names>D. P.</given-names></name>; <name><surname>Welling</surname><given-names>M.</given-names></name></person-group><article-title>Auto-Encoding
Variational Bayes</article-title>. <source>arXiv [stat.ML]</source><year>2013</year>,<pub-id pub-id-type="doi">10.48550/arXiv.1312.6114</pub-id>.</mixed-citation></ref><ref id="ref260"><mixed-citation publication-type="journal" id="cit260"><name><surname>G&#x000f3;mez-Bombarelli</surname><given-names>R.</given-names></name>; <name><surname>Wei</surname><given-names>J. N.</given-names></name>; <name><surname>Duvenaud</surname><given-names>D.</given-names></name>; <name><surname>Hern&#x000e1;ndez-Lobato</surname><given-names>J. M.</given-names></name>; <name><surname>S&#x000e1;nchez-Lengeling</surname><given-names>B.</given-names></name>; <name><surname>Sheberla</surname><given-names>D.</given-names></name>; <name><surname>Aguilera-Iparraguirre</surname><given-names>J.</given-names></name>; <name><surname>Hirzel</surname><given-names>T. D.</given-names></name>; <name><surname>Adams</surname><given-names>R. P.</given-names></name>; <name><surname>Aspuru-Guzik</surname><given-names>A.</given-names></name>
<article-title>Automatic
Chemical Design Using a
Data-Driven Continuous Representation of Molecules</article-title>. <source>ACS Cent Sci.</source>
<year>2018</year>, <volume>4</volume> (<issue>2</issue>), <fpage>268</fpage>&#x02013;<lpage>276</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.7b00572</pub-id>.<pub-id pub-id-type="pmid">29532027</pub-id>
</mixed-citation></ref><ref id="ref261"><mixed-citation publication-type="journal" id="cit261"><person-group person-group-type="allauthors"><name><surname>Kusner</surname><given-names>M. J.</given-names></name>; <name><surname>Paige</surname><given-names>B.</given-names></name>; <name><surname>Hern&#x000e1;ndez-Lobato</surname><given-names>J. M.</given-names></name></person-group><article-title>Grammar Variational Autoencoder</article-title>. <source>arXiv [stat.ML]</source><year>2017</year>,<pub-id pub-id-type="doi">10.48550/arXiv.1703.01925</pub-id>.</mixed-citation></ref><ref id="ref262"><mixed-citation publication-type="journal" id="cit262"><name><surname>Ciepli&#x00144;ski</surname><given-names>T.</given-names></name>; <name><surname>Danel</surname><given-names>T.</given-names></name>; <name><surname>Podlewska</surname><given-names>S.</given-names></name>; <name><surname>Jastrz&#x00229;bski</surname><given-names>S.</given-names></name>
<article-title>Generative
Models Should at Least Be Able to Design
Molecules That Dock Well: A New Benchmark</article-title>. <source>J.
Chem. Inf. Model.</source>
<year>2023</year>, <volume>63</volume> (<issue>11</issue>), <fpage>3238</fpage>&#x02013;<lpage>3247</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.2c01355</pub-id>.<pub-id pub-id-type="pmid">37224003</pub-id>
</mixed-citation></ref><ref id="ref263"><mixed-citation publication-type="conf-proc" id="cit263"><person-group person-group-type="allauthors"><name><surname>Garc&#x000ed;a-Orteg&#x000f3;n</surname><given-names>M.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>Rasmussen</surname><given-names>C. E.</given-names></name>; <name><surname>Kajino</surname><given-names>H.</given-names></name>; <name><surname>Bacallado</surname><given-names>S.</given-names></name></person-group><article-title>Combining
Variational Autoencoder Representations with Structural Descriptors
Improves Prediction of Docking Scores</article-title>. <source>Machine
Learning for Structural Biology Workshop, NeurIPS 2020, Vancouver,
Canada</source>, <year>2020</year>.</mixed-citation></ref><ref id="ref264"><mixed-citation publication-type="journal" id="cit264"><person-group person-group-type="allauthors"><name><surname>Jin</surname><given-names>W.</given-names></name>; <name><surname>Barzilay</surname><given-names>R.</given-names></name>; <name><surname>Jaakkola</surname><given-names>T.</given-names></name></person-group><article-title>Junction Tree
Variational Autoencoder for Molecular Graph Generation</article-title>. <source>arXiv [cs.LG]</source><year>2018</year>. ,<pub-id pub-id-type="doi">10.48550/arXiv.1802.04364</pub-id>.</mixed-citation></ref><ref id="ref265"><mixed-citation publication-type="journal" id="cit265"><name><surname>Kang</surname><given-names>S.</given-names></name>; <name><surname>Cho</surname><given-names>K.</given-names></name>
<article-title>Conditional Molecular
Design with
Deep Generative Models</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2019</year>, <volume>59</volume> (<issue>1</issue>), <fpage>43</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.8b00263</pub-id>.<pub-id pub-id-type="pmid">30016587</pub-id>
</mixed-citation></ref><ref id="ref266"><mixed-citation publication-type="journal" id="cit266"><name><surname>Chow</surname><given-names>Y. L.</given-names></name>; <name><surname>Singh</surname><given-names>S.</given-names></name>; <name><surname>Carpenter</surname><given-names>A. E.</given-names></name>; <name><surname>Way</surname><given-names>G. P.</given-names></name>
<article-title>Predicting Drug
Polypharmacology from Cell Morphology
Readouts Using Variational Autoencoder Latent Space Arithmetic</article-title>. <source>PLoS Comput. Biol.</source>
<year>2022</year>, <volume>18</volume> (<issue>2</issue>), <elocation-id>e1009888</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1009888</pub-id>.<pub-id pub-id-type="pmid">35213530</pub-id>
</mixed-citation></ref><ref id="ref267"><mixed-citation publication-type="journal" id="cit267"><name><surname>Goodfellow</surname><given-names>I. J.</given-names></name>; <name><surname>Pouget-Abadie</surname><given-names>J.</given-names></name>; <name><surname>Mirza</surname><given-names>M.</given-names></name>; <name><surname>Xu</surname><given-names>B.</given-names></name>; <name><surname>Warde-Farley</surname><given-names>D.</given-names></name>; <name><surname>Ozair</surname><given-names>S.</given-names></name>; <name><surname>Courville</surname><given-names>A.</given-names></name>; <name><surname>Bengio</surname><given-names>Y.</given-names></name>
<article-title>Generative Adversarial
Networks</article-title>. <source>Commun. ACM</source>
<year>2014</year>, <volume>63</volume>, <fpage>139</fpage><pub-id pub-id-type="doi">10.1145/3422622</pub-id>.</mixed-citation></ref><ref id="ref268"><mixed-citation publication-type="journal" id="cit268"><name><surname>Macedo</surname><given-names>B.</given-names></name>; <name><surname>Ribeiro Vaz</surname><given-names>I.</given-names></name>; <name><surname>Taveira Gomes</surname><given-names>T.</given-names></name>
<article-title>MedGAN: Optimized
Generative Adversarial Network with Graph Convolutional Networks for
Novel Molecule Design</article-title>. <source>Sci. Rep.</source>
<year>2024</year>, <volume>14</volume> (<issue>1</issue>), <fpage>1212</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-50834-6</pub-id>.<pub-id pub-id-type="pmid">38216614</pub-id>
</mixed-citation></ref><ref id="ref269"><mixed-citation publication-type="journal" id="cit269"><name><surname>Richard</surname><given-names>A. M.</given-names></name>; <name><surname>Huang</surname><given-names>R.</given-names></name>; <name><surname>Waidyanatha</surname><given-names>S.</given-names></name>; <name><surname>Shinn</surname><given-names>P.</given-names></name>; <name><surname>Collins</surname><given-names>B. J.</given-names></name>; <name><surname>Thillainadarajah</surname><given-names>I.</given-names></name>; <name><surname>Grulke</surname><given-names>C. M.</given-names></name>; <name><surname>Williams</surname><given-names>A. J.</given-names></name>; <name><surname>Lougee</surname><given-names>R. R.</given-names></name>; <name><surname>Judson</surname><given-names>R. S.</given-names></name>; <name><surname>Houck</surname><given-names>K. A.</given-names></name>; <name><surname>Shobair</surname><given-names>M.</given-names></name>; <name><surname>Yang</surname><given-names>C.</given-names></name>; <name><surname>Rathman</surname><given-names>J. F.</given-names></name>; <name><surname>Yasgar</surname><given-names>A.</given-names></name>; <name><surname>Fitzpatrick</surname><given-names>S. C.</given-names></name>; <name><surname>Simeonov</surname><given-names>A.</given-names></name>; <name><surname>Thomas</surname><given-names>R. S.</given-names></name>; <name><surname>Crofton</surname><given-names>K. M.</given-names></name>; <name><surname>Paules</surname><given-names>R. S.</given-names></name>; <name><surname>Bucher</surname><given-names>J. R.</given-names></name>; <name><surname>Austin</surname><given-names>C. P.</given-names></name>; <name><surname>Kavlock</surname><given-names>R. J.</given-names></name>; <name><surname>Tice</surname><given-names>R. R.</given-names></name>
<article-title>The Tox21 10K Compound Library: Collaborative
Chemistry Advancing Toxicology</article-title>. <source>Chem. Res. Toxicol.</source>
<year>2021</year>, <volume>34</volume> (<issue>2</issue>), <fpage>189</fpage>&#x02013;<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.0c00264</pub-id>.<pub-id pub-id-type="pmid">33140634</pub-id>
</mixed-citation></ref><ref id="ref270"><mixed-citation publication-type="journal" id="cit270"><name><surname>Chen</surname><given-names>X.</given-names></name>; <name><surname>Roberts</surname><given-names>R.</given-names></name>; <name><surname>Tong</surname><given-names>W.</given-names></name>; <name><surname>Liu</surname><given-names>Z.</given-names></name>
<article-title>Tox-GAN: An
Artificial Intelligence Approach Alternative to Animal Studies-A Case
Study With Toxicogenomics</article-title>. <source>Toxicol. Sci.</source>
<year>2022</year>, <volume>186</volume> (<issue>2</issue>), <fpage>242</fpage>&#x02013;<lpage>259</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfab157</pub-id>.<pub-id pub-id-type="pmid">34971401</pub-id>
</mixed-citation></ref><ref id="ref271"><mixed-citation publication-type="journal" id="cit271"><name><surname>Li</surname><given-names>T.</given-names></name>; <name><surname>Roberts</surname><given-names>R.</given-names></name>; <name><surname>Liu</surname><given-names>Z.</given-names></name>; <name><surname>Tong</surname><given-names>W.</given-names></name>
<article-title>TransOrGAN: An Artificial
Intelligence Mapping of Rat Transcriptomic Profiles between Organs,
Ages, and Sexes</article-title>. <source>Chem. Res. Toxicol.</source>
<year>2023</year>, <volume>36</volume> (<issue>6</issue>), <fpage>916</fpage>&#x02013;<lpage>925</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.3c00037</pub-id>.<pub-id pub-id-type="pmid">37200521</pub-id>
</mixed-citation></ref><ref id="ref272"><mixed-citation publication-type="journal" id="cit272"><name><surname>Urbina</surname><given-names>F.</given-names></name>; <name><surname>Lentzos</surname><given-names>F.</given-names></name>; <name><surname>Invernizzi</surname><given-names>C.</given-names></name>; <name><surname>Ekins</surname><given-names>S.</given-names></name>
<article-title>Dual Use of Artificial
Intelligence-Powered Drug Discovery</article-title>. <source>Nat. Mach
Intell</source>
<year>2022</year>, <volume>4</volume> (<issue>3</issue>), <fpage>189</fpage>&#x02013;<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1038/s42256-022-00465-9</pub-id>.<pub-id pub-id-type="pmid">36211133</pub-id>
</mixed-citation></ref><ref id="ref273"><mixed-citation publication-type="journal" id="cit273"><name><surname>Alakhdar</surname><given-names>A.</given-names></name>; <name><surname>Poczos</surname><given-names>B.</given-names></name>; <name><surname>Washburn</surname><given-names>N.</given-names></name>
<article-title>Diffusion Models in
DE Novo Drug Design</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2024</year>, <volume>64</volume> (<issue>19</issue>), <fpage>7238</fpage>&#x02013;<lpage>7256</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.4c01107</pub-id>.<pub-id pub-id-type="pmid">39322943</pub-id>
</mixed-citation></ref><ref id="ref274"><mixed-citation publication-type="journal" id="cit274"><person-group person-group-type="allauthors"><name><surname>Sohl-Dickstein</surname><given-names>J.</given-names></name>; <name><surname>Weiss</surname><given-names>E. A.</given-names></name>; <name><surname>Maheswaranathan</surname><given-names>N.</given-names></name>; <name><surname>Ganguli</surname><given-names>S.</given-names></name></person-group><article-title>Deep
Unsupervised Learning Using Nonequilibrium Thermodynamics</article-title>. <source>arXiv [cs.LG]</source><year>2015</year>,<pub-id pub-id-type="doi">10.48550/arXiv.1503.03585</pub-id>.</mixed-citation></ref><ref id="ref275"><mixed-citation publication-type="journal" id="cit275"><person-group person-group-type="allauthors"><name><surname>Song</surname><given-names>Y.</given-names></name>; <name><surname>Ermon</surname><given-names>S.</given-names></name></person-group><article-title>Generative
Modeling by Estimating
Gradients of the Data Distribution</article-title>. <source>arXiv
[cs.LG]</source><year>2019</year>,<pub-id pub-id-type="doi">10.48550/arXiv.1907.05600</pub-id>.</mixed-citation></ref><ref id="ref276"><mixed-citation publication-type="journal" id="cit276"><person-group person-group-type="allauthors"><name><surname>Vignac</surname><given-names>C.</given-names></name>; <name><surname>Krawczuk</surname><given-names>I.</given-names></name>; <name><surname>Siraudin</surname><given-names>A.</given-names></name>; <name><surname>Wang</surname><given-names>B.</given-names></name>; <name><surname>Cevher</surname><given-names>V.</given-names></name>; <name><surname>Frossard</surname><given-names>P.</given-names></name></person-group><article-title>DiGress: Discrete Denoising
Diffusion for Graph Generation</article-title>. <source>arXiv [cs.LG]</source><year>2022</year>,<pub-id pub-id-type="doi">10.48550/arXiv.2209.14734</pub-id>.</mixed-citation></ref><ref id="ref277"><mixed-citation publication-type="journal" id="cit277"><person-group person-group-type="allauthors"><name><surname>Jing</surname><given-names>B.</given-names></name>; <name><surname>Corso</surname><given-names>G.</given-names></name>; <name><surname>Chang</surname><given-names>J.</given-names></name>; <name><surname>Barzilay</surname><given-names>R.</given-names></name>; <name><surname>Jaakkola</surname><given-names>T.</given-names></name></person-group><article-title>Torsional Diffusion for Molecular
Conformer Generation</article-title>. <source>arXiv [physics.chem-ph]</source><year>2022</year>,<pub-id pub-id-type="doi">10.48550/arXiv.2206.01729</pub-id>.</mixed-citation></ref><ref id="ref278"><mixed-citation publication-type="journal" id="cit278"><person-group person-group-type="allauthors"><name><surname>Corso</surname><given-names>G.</given-names></name>; <name><surname>St&#x000e4;rk</surname><given-names>H.</given-names></name>; <name><surname>Jing</surname><given-names>B.</given-names></name>; <name><surname>Barzilay</surname><given-names>R.</given-names></name>; <name><surname>Jaakkola</surname><given-names>T.</given-names></name></person-group><article-title>DiffDock: Diffusion Steps,
Twists, and Turns for Molecular Docking</article-title>. <source>arXiv
[q-bio.BM]</source><year>2022</year>,<pub-id pub-id-type="doi">10.48550/arXiv.2210.01776</pub-id>.</mixed-citation></ref><ref id="ref279"><mixed-citation publication-type="journal" id="cit279"><person-group person-group-type="allauthors"><name><surname>Hoogeboom</surname><given-names>E.</given-names></name>; <name><surname>Satorras</surname><given-names>V. G.</given-names></name>; <name><surname>Vignac</surname><given-names>C.</given-names></name>; <name><surname>Welling</surname><given-names>M.</given-names></name></person-group><article-title>Equivariant Diffusion
for Molecule Generation in 3D</article-title>. <source>arXiv [cs.LG]</source><bold>2022</bold>,<pub-id pub-id-type="doi">10.48550/arXiv.2203.17003</pub-id>.</mixed-citation></ref><ref id="ref280"><mixed-citation publication-type="journal" id="cit280"><name><surname>Huang</surname><given-names>L.</given-names></name>; <name><surname>Xu</surname><given-names>T.</given-names></name>; <name><surname>Yu</surname><given-names>Y.</given-names></name>; <name><surname>Zhao</surname><given-names>P.</given-names></name>; <name><surname>Chen</surname><given-names>X.</given-names></name>; <name><surname>Han</surname><given-names>J.</given-names></name>; <name><surname>Xie</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Zhong</surname><given-names>W.</given-names></name>; <name><surname>Wong</surname><given-names>K.-C.</given-names></name>; <name><surname>Zhang</surname><given-names>H.</given-names></name>
<article-title>A Dual Diffusion
Model
Enables 3D Molecule Generation and Lead Optimization Based on Target
Pockets</article-title>. <source>Nat. Commun.</source>
<year>2024</year>, <volume>15</volume> (<issue>1</issue>), <fpage>2657</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-46569-1</pub-id>.<pub-id pub-id-type="pmid">38531837</pub-id>
</mixed-citation></ref><ref id="ref281"><mixed-citation publication-type="report" id="cit281"><person-group person-group-type="allauthors"><name><surname>Radford</surname><given-names>A.</given-names></name>; <name><surname>Narasimhan</surname><given-names>K.</given-names></name></person-group><source>Improving Language Understanding
by Generative Pre-Training</source>; <publisher-name>OpenAI</publisher-name>, <year>2018</year>.</mixed-citation></ref><ref id="ref282"><mixed-citation publication-type="report" id="cit282"><person-group person-group-type="allauthors"><collab>OpenAI</collab></person-group>; <person-group person-group-type="allauthors"><name><surname>Achiam</surname><given-names>J.</given-names></name>; <name><surname>Adler</surname><given-names>S.</given-names></name>; <name><surname>Agarwal</surname><given-names>S.</given-names></name>; <name><surname>Ahmad</surname><given-names>L.</given-names></name>; <name><surname>Akkaya</surname><given-names>I.</given-names></name>; <name><surname>Aleman</surname><given-names>F. L.</given-names></name>; <name><surname>Almeida</surname><given-names>D.</given-names></name>; <name><surname>Altenschmidt</surname><given-names>J.</given-names></name>; <name><surname>Altman</surname><given-names>S.</given-names></name>; <name><surname>Anadkat</surname><given-names>S.</given-names></name>; <name><surname>Avila</surname><given-names>R.</given-names></name>; <name><surname>Babuschkin</surname><given-names>I.</given-names></name>; <name><surname>Balaji</surname><given-names>S.</given-names></name>; <name><surname>Balcom</surname><given-names>V.</given-names></name>; <name><surname>Baltescu</surname><given-names>P.</given-names></name>; <name><surname>Bao</surname><given-names>H.</given-names></name>; <name><surname>Bavarian</surname><given-names>M.</given-names></name>; <name><surname>Belgum</surname><given-names>J.</given-names></name>; <name><surname>Bello</surname><given-names>I.</given-names></name>; <name><surname>Berdine</surname><given-names>J.</given-names></name>; <name><surname>Bernadett-Shapiro</surname><given-names>G.</given-names></name>; <name><surname>Berner</surname><given-names>C.</given-names></name>; <name><surname>Bogdonoff</surname><given-names>L.</given-names></name>; <name><surname>Boiko</surname><given-names>O.</given-names></name>; <name><surname>Boyd</surname><given-names>M.</given-names></name>; <name><surname>Brakman</surname><given-names>A.-L.</given-names></name>; <name><surname>Brockman</surname><given-names>G.</given-names></name>; <name><surname>Brooks</surname><given-names>T.</given-names></name>; <name><surname>Brundage</surname><given-names>M.</given-names></name>; <name><surname>Button</surname><given-names>K.</given-names></name>; <name><surname>Cai</surname><given-names>T.</given-names></name>; <name><surname>Campbell</surname><given-names>R.</given-names></name>; <name><surname>Cann</surname><given-names>A.</given-names></name>; <name><surname>Carey</surname><given-names>B.</given-names></name>; <name><surname>Carlson</surname><given-names>C.</given-names></name>; <name><surname>Carmichael</surname><given-names>R.</given-names></name>; <name><surname>Chan</surname><given-names>B.</given-names></name>; <name><surname>Chang</surname><given-names>C.</given-names></name>; <name><surname>Chantzis</surname><given-names>F.</given-names></name>; <name><surname>Chen</surname><given-names>D.</given-names></name>; <name><surname>Chen</surname><given-names>S.</given-names></name>; <name><surname>Chen</surname><given-names>R.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>M.</given-names></name>; <name><surname>Chess</surname><given-names>B.</given-names></name>; <name><surname>Cho</surname><given-names>C.</given-names></name>; <name><surname>Chu</surname><given-names>C.</given-names></name>; <name><surname>Chung</surname><given-names>H. W.</given-names></name>; <name><surname>Cummings</surname><given-names>D.</given-names></name>; <name><surname>Currier</surname><given-names>J.</given-names></name>; <name><surname>Dai</surname><given-names>Y.</given-names></name>; <name><surname>Decareaux</surname><given-names>C.</given-names></name>; <name><surname>Degry</surname><given-names>T.</given-names></name>; <name><surname>Deutsch</surname><given-names>N.</given-names></name>; <name><surname>Deville</surname><given-names>D.</given-names></name>; <name><surname>Dhar</surname><given-names>A.</given-names></name>; <name><surname>Dohan</surname><given-names>D.</given-names></name>; <name><surname>Dowling</surname><given-names>S.</given-names></name>; <name><surname>Dunning</surname><given-names>S.</given-names></name>; <name><surname>Ecoffet</surname><given-names>A.</given-names></name>; <name><surname>Eleti</surname><given-names>A.</given-names></name>; <name><surname>Eloundou</surname><given-names>T.</given-names></name>; <name><surname>Farhi</surname><given-names>D.</given-names></name>; <name><surname>Fedus</surname><given-names>L.</given-names></name>; <name><surname>Felix</surname><given-names>N.</given-names></name>; <name><surname>Fishman</surname><given-names>S. P.</given-names></name>; <name><surname>Forte</surname><given-names>J.</given-names></name>; <name><surname>Fulford</surname><given-names>I.</given-names></name>; <name><surname>Gao</surname><given-names>L.</given-names></name>; <name><surname>Georges</surname><given-names>E.</given-names></name>; <name><surname>Gibson</surname><given-names>C.</given-names></name>; <name><surname>Goel</surname><given-names>V.</given-names></name>; <name><surname>Gogineni</surname><given-names>T.</given-names></name>; <name><surname>Goh</surname><given-names>G.</given-names></name>; <name><surname>Gontijo-Lopes</surname><given-names>R.</given-names></name>; <name><surname>Gordon</surname><given-names>J.</given-names></name>; <name><surname>Grafstein</surname><given-names>M.</given-names></name>; <name><surname>Gray</surname><given-names>S.</given-names></name>; <name><surname>Greene</surname><given-names>R.</given-names></name>; <name><surname>Gross</surname><given-names>J.</given-names></name>; <name><surname>Gu</surname><given-names>S. S.</given-names></name>; <name><surname>Guo</surname><given-names>Y.</given-names></name>; <name><surname>Hallacy</surname><given-names>C.</given-names></name>; <name><surname>Han</surname><given-names>J.</given-names></name>; <name><surname>Harris</surname><given-names>J.</given-names></name>; <name><surname>He</surname><given-names>Y.</given-names></name>; <name><surname>Heaton</surname><given-names>M.</given-names></name>; <name><surname>Heidecke</surname><given-names>J.</given-names></name>; <name><surname>Hesse</surname><given-names>C.</given-names></name>; <name><surname>Hickey</surname><given-names>A.</given-names></name>; <name><surname>Hickey</surname><given-names>W.</given-names></name>; <name><surname>Hoeschele</surname><given-names>P.</given-names></name>; <name><surname>Houghton</surname><given-names>B.</given-names></name>; <name><surname>Hsu</surname><given-names>K.</given-names></name>; <name><surname>Hu</surname><given-names>S.</given-names></name>; <name><surname>Hu</surname><given-names>X.</given-names></name>; <name><surname>Huizinga</surname><given-names>J.</given-names></name>; <name><surname>Jain</surname><given-names>S.</given-names></name>; <name><surname>Jain</surname><given-names>S.</given-names></name>; <name><surname>Jang</surname><given-names>J.</given-names></name>; <name><surname>Jiang</surname><given-names>A.</given-names></name>; <name><surname>Jiang</surname><given-names>R.</given-names></name>; <name><surname>Jin</surname><given-names>H.</given-names></name>; <name><surname>Jin</surname><given-names>D.</given-names></name>; <name><surname>Jomoto</surname><given-names>S.</given-names></name>; <name><surname>Jonn</surname><given-names>B.</given-names></name>; <name><surname>Jun</surname><given-names>H.</given-names></name>; <name><surname>Kaftan</surname><given-names>T.</given-names></name>; <name><surname>Kaiser</surname><given-names>&#x00141;.</given-names></name>; <name><surname>Kamali</surname><given-names>A.</given-names></name>; <name><surname>Kanitscheider</surname><given-names>I.</given-names></name>; <name><surname>Keskar</surname><given-names>N. S.</given-names></name>; <name><surname>Khan</surname><given-names>T.</given-names></name>; <name><surname>Kilpatrick</surname><given-names>L.</given-names></name>; <name><surname>Kim</surname><given-names>J. W.</given-names></name>; <name><surname>Kim</surname><given-names>C.</given-names></name>; <name><surname>Kim</surname><given-names>Y.</given-names></name>; <name><surname>Kirchner</surname><given-names>J. H.</given-names></name>; <name><surname>Kiros</surname><given-names>J.</given-names></name>; <name><surname>Knight</surname><given-names>M.</given-names></name>; <name><surname>Kokotajlo</surname><given-names>D.</given-names></name>; <name><surname>Kondraciuk</surname><given-names>&#x00141;.</given-names></name>; <name><surname>Kondrich</surname><given-names>A.</given-names></name>; <name><surname>Konstantinidis</surname><given-names>A.</given-names></name>; <name><surname>Kosic</surname><given-names>K.</given-names></name>; <name><surname>Krueger</surname><given-names>G.</given-names></name>; <name><surname>Kuo</surname><given-names>V.</given-names></name>; <name><surname>Lampe</surname><given-names>M.</given-names></name>; <name><surname>Lan</surname><given-names>I.</given-names></name>; <name><surname>Lee</surname><given-names>T.</given-names></name>; <name><surname>Leike</surname><given-names>J.</given-names></name>; <name><surname>Leung</surname><given-names>J.</given-names></name>; <name><surname>Levy</surname><given-names>D.</given-names></name>; <name><surname>Li</surname><given-names>C. M.</given-names></name>; <name><surname>Lim</surname><given-names>R.</given-names></name>; <name><surname>Lin</surname><given-names>M.</given-names></name>; <name><surname>Lin</surname><given-names>S.</given-names></name>; <name><surname>Litwin</surname><given-names>M.</given-names></name>; <name><surname>Lopez</surname><given-names>T.</given-names></name>; <name><surname>Lowe</surname><given-names>R.</given-names></name>; <name><surname>Lue</surname><given-names>P.</given-names></name>; <name><surname>Makanju</surname><given-names>A.</given-names></name>; <name><surname>Malfacini</surname><given-names>K.</given-names></name>; <name><surname>Manning</surname><given-names>S.</given-names></name>; <name><surname>Markov</surname><given-names>T.</given-names></name>; <name><surname>Markovski</surname><given-names>Y.</given-names></name>; <name><surname>Martin</surname><given-names>B.</given-names></name>; <name><surname>Mayer</surname><given-names>K.</given-names></name>; <name><surname>Mayne</surname><given-names>A.</given-names></name>; <name><surname>McGrew</surname><given-names>B.</given-names></name>; <name><surname>McKinney</surname><given-names>S. M.</given-names></name>; <name><surname>McLeavey</surname><given-names>C.</given-names></name>; <name><surname>McMillan</surname><given-names>P.</given-names></name>; <name><surname>McNeil</surname><given-names>J.</given-names></name>; <name><surname>Medina</surname><given-names>D.</given-names></name>; <name><surname>Mehta</surname><given-names>A.</given-names></name>; <name><surname>Menick</surname><given-names>J.</given-names></name>; <name><surname>Metz</surname><given-names>L.</given-names></name>; <name><surname>Mishchenko</surname><given-names>A.</given-names></name>; <name><surname>Mishkin</surname><given-names>P.</given-names></name>; <name><surname>Monaco</surname><given-names>V.</given-names></name>; <name><surname>Morikawa</surname><given-names>E.</given-names></name>; <name><surname>Mossing</surname><given-names>D.</given-names></name>; <name><surname>Mu</surname><given-names>T.</given-names></name>; <name><surname>Murati</surname><given-names>M.</given-names></name>; <name><surname>Murk</surname><given-names>O.</given-names></name>; <name><surname>M&#x000e9;ly</surname><given-names>D.</given-names></name>; <name><surname>Nair</surname><given-names>A.</given-names></name>; <name><surname>Nakano</surname><given-names>R.</given-names></name>; <name><surname>Nayak</surname><given-names>R.</given-names></name>; <name><surname>Neelakantan</surname><given-names>A.</given-names></name>; <name><surname>Ngo</surname><given-names>R.</given-names></name>; <name><surname>Noh</surname><given-names>H.</given-names></name>; <name><surname>Ouyang</surname><given-names>L.</given-names></name>; <name><surname>O&#x02019;Keefe</surname><given-names>C.</given-names></name>; <name><surname>Pachocki</surname><given-names>J.</given-names></name>; <name><surname>Paino</surname><given-names>A.</given-names></name>; <name><surname>Palermo</surname><given-names>J.</given-names></name>; <name><surname>Pantuliano</surname><given-names>A.</given-names></name>; <name><surname>Parascandolo</surname><given-names>G.</given-names></name>; <name><surname>Parish</surname><given-names>J.</given-names></name>; <name><surname>Parparita</surname><given-names>E.</given-names></name>; <name><surname>Passos</surname><given-names>A.</given-names></name>; <name><surname>Pavlov</surname><given-names>M.</given-names></name>; <name><surname>Peng</surname><given-names>A.</given-names></name>; <name><surname>Perelman</surname><given-names>A.</given-names></name>; <name><surname>de Avila Belbute Peres</surname><given-names>F.</given-names></name>; <name><surname>Petrov</surname><given-names>M.</given-names></name>; <name><surname>de Oliveira Pinto</surname><given-names>H. P.</given-names></name>; <name><surname>Michael</surname></name>; <name><surname>Pokorny</surname></name>; <name><surname>Pokrass</surname><given-names>M.</given-names></name>; <name><surname>Pong</surname><given-names>V. H.</given-names></name>; <name><surname>Powell</surname><given-names>T.</given-names></name>; <name><surname>Power</surname><given-names>A.</given-names></name>; <name><surname>Power</surname><given-names>B.</given-names></name>; <name><surname>Proehl</surname><given-names>E.</given-names></name>; <name><surname>Puri</surname><given-names>R.</given-names></name>; <name><surname>Radford</surname><given-names>A.</given-names></name>; <name><surname>Rae</surname><given-names>J.</given-names></name>; <name><surname>Ramesh</surname><given-names>A.</given-names></name>; <name><surname>Raymond</surname><given-names>C.</given-names></name>; <name><surname>Real</surname><given-names>F.</given-names></name>; <name><surname>Rimbach</surname><given-names>K.</given-names></name>; <name><surname>Ross</surname><given-names>C.</given-names></name>; <name><surname>Rotsted</surname><given-names>B.</given-names></name>; <name><surname>Roussez</surname><given-names>H.</given-names></name>; <name><surname>Ryder</surname><given-names>N.</given-names></name>; <name><surname>Saltarelli</surname><given-names>M.</given-names></name>; <name><surname>Sanders</surname><given-names>T.</given-names></name>; <name><surname>Santurkar</surname><given-names>S.</given-names></name>; <name><surname>Sastry</surname><given-names>G.</given-names></name>; <name><surname>Schmidt</surname><given-names>H.</given-names></name>; <name><surname>Schnurr</surname><given-names>D.</given-names></name>; <name><surname>Schulman</surname><given-names>J.</given-names></name>; <name><surname>Selsam</surname><given-names>D.</given-names></name>; <name><surname>Sheppard</surname><given-names>K.</given-names></name>; <name><surname>Sherbakov</surname><given-names>T.</given-names></name>; <name><surname>Shieh</surname><given-names>J.</given-names></name>; <name><surname>Shoker</surname><given-names>S.</given-names></name>; <name><surname>Shyam</surname><given-names>P.</given-names></name>; <name><surname>Sidor</surname><given-names>S.</given-names></name>; <name><surname>Sigler</surname><given-names>E.</given-names></name>; <name><surname>Simens</surname><given-names>M.</given-names></name>; <name><surname>Sitkin</surname><given-names>J.</given-names></name>; <name><surname>Slama</surname><given-names>K.</given-names></name>; <name><surname>Sohl</surname><given-names>I.</given-names></name>; <name><surname>Sokolowsky</surname><given-names>B.</given-names></name>; <name><surname>Song</surname><given-names>Y.</given-names></name>; <name><surname>Staudacher</surname><given-names>N.</given-names></name>; <name><surname>Such</surname><given-names>F. P.</given-names></name>; <name><surname>Summers</surname><given-names>N.</given-names></name>; <name><surname>Sutskever</surname><given-names>I.</given-names></name>; <name><surname>Tang</surname><given-names>J.</given-names></name>; <name><surname>Tezak</surname><given-names>N.</given-names></name>; <name><surname>Thompson</surname><given-names>M. B.</given-names></name>; <name><surname>Tillet</surname><given-names>P.</given-names></name>; <name><surname>Tootoonchian</surname><given-names>A.</given-names></name>; <name><surname>Tseng</surname><given-names>E.</given-names></name>; <name><surname>Tuggle</surname><given-names>P.</given-names></name>; <name><surname>Turley</surname><given-names>N.</given-names></name>; <name><surname>Tworek</surname><given-names>J.</given-names></name>; <name><surname>Uribe</surname><given-names>J.
F. C.</given-names></name>; <name><surname>Vallone</surname><given-names>A.</given-names></name>; <name><surname>Vijayvergiya</surname><given-names>A.</given-names></name>; <name><surname>Voss</surname><given-names>C.</given-names></name>; <name><surname>Wainwright</surname><given-names>C.</given-names></name>; <name><surname>Wang</surname><given-names>J. J.</given-names></name>; <name><surname>Wang</surname><given-names>A.</given-names></name>; <name><surname>Wang</surname><given-names>B.</given-names></name>; <name><surname>Ward</surname><given-names>J.</given-names></name>; <name><surname>Wei</surname><given-names>J.</given-names></name>; <name><surname>Weinmann</surname><given-names>C. J.</given-names></name>; <name><surname>Welihinda</surname><given-names>A.</given-names></name>; <name><surname>Welinder</surname><given-names>P.</given-names></name>; <name><surname>Weng</surname><given-names>J.</given-names></name>; <name><surname>Weng</surname><given-names>L.</given-names></name>; <name><surname>Wiethoff</surname><given-names>M.</given-names></name>; <name><surname>Willner</surname><given-names>D.</given-names></name>; <name><surname>Winter</surname><given-names>C.</given-names></name>; <name><surname>Wolrich</surname><given-names>S.</given-names></name>; <name><surname>Wong</surname><given-names>H.</given-names></name>; <name><surname>Workman</surname><given-names>L.</given-names></name>; <name><surname>Wu</surname><given-names>S.</given-names></name>; <name><surname>Wu</surname><given-names>J.</given-names></name>; <name><surname>Wu</surname><given-names>M.</given-names></name>; <name><surname>Xiao</surname><given-names>K.</given-names></name>; <name><surname>Xu</surname><given-names>T.</given-names></name>; <name><surname>Yoo</surname><given-names>S.</given-names></name>; <name><surname>Yu</surname><given-names>K.</given-names></name>; <name><surname>Yuan</surname><given-names>Q.</given-names></name>; <name><surname>Zaremba</surname><given-names>W.</given-names></name>; <name><surname>Zellers</surname><given-names>R.</given-names></name>; <name><surname>Zhang</surname><given-names>C.</given-names></name>; <name><surname>Zhang</surname><given-names>M.</given-names></name>; <name><surname>Zhao</surname><given-names>S.</given-names></name>; <name><surname>Zheng</surname><given-names>T.</given-names></name>; <name><surname>Zhuang</surname><given-names>J.</given-names></name>; <name><surname>Zhuk</surname><given-names>W.</given-names></name>; <name><surname>Zoph</surname><given-names>B.</given-names></name></person-group><article-title>GPT-4 Technical Report</article-title>. <source>arXiv [cs.CL]</source><year>2023</year>,<pub-id pub-id-type="doi">10.48550/arXiv.2303.08774</pub-id>.</mixed-citation></ref><ref id="ref283"><mixed-citation publication-type="journal" id="cit283"><person-group person-group-type="allauthors"><name><surname>Touvron</surname><given-names>H.</given-names></name>; <name><surname>Martin</surname><given-names>L.</given-names></name>; <name><surname>Stone</surname><given-names>K.</given-names></name>; <name><surname>Albert</surname><given-names>P.</given-names></name>; <name><surname>Almahairi</surname><given-names>A.</given-names></name>; <name><surname>Babaei</surname><given-names>Y.</given-names></name>; <name><surname>Bashlykov</surname><given-names>N.</given-names></name>; <name><surname>Batra</surname><given-names>S.</given-names></name>; <name><surname>Bhargava</surname><given-names>P.</given-names></name>; <name><surname>Bhosale</surname><given-names>S.</given-names></name>; <name><surname>Bikel</surname><given-names>D.</given-names></name>; <name><surname>Blecher</surname><given-names>L.</given-names></name>; <name><surname>Ferrer</surname><given-names>C. C.</given-names></name>; <name><surname>Chen</surname><given-names>M.</given-names></name>; <name><surname>Cucurull</surname><given-names>G.</given-names></name>; <name><surname>Esiobu</surname><given-names>D.</given-names></name>; <name><surname>Fernandes</surname><given-names>J.</given-names></name>; <name><surname>Fu</surname><given-names>J.</given-names></name>; <name><surname>Fu</surname><given-names>W.</given-names></name>; <name><surname>Fuller</surname><given-names>B.</given-names></name>; <name><surname>Gao</surname><given-names>C.</given-names></name>; <name><surname>Goswami</surname><given-names>V.</given-names></name>; <name><surname>Goyal</surname><given-names>N.</given-names></name>; <name><surname>Hartshorn</surname><given-names>A.</given-names></name>; <name><surname>Hosseini</surname><given-names>S.</given-names></name>; <name><surname>Hou</surname><given-names>R.</given-names></name>; <name><surname>Inan</surname><given-names>H.</given-names></name>; <name><surname>Kardas</surname><given-names>M.</given-names></name>; <name><surname>Kerkez</surname><given-names>V.</given-names></name>; <name><surname>Khabsa</surname><given-names>M.</given-names></name>; <name><surname>Kloumann</surname><given-names>I.</given-names></name>; <name><surname>Korenev</surname><given-names>A.</given-names></name>; <name><surname>Koura</surname><given-names>P. S.</given-names></name>; <name><surname>Lachaux</surname><given-names>M.-A.</given-names></name>; <name><surname>Lavril</surname><given-names>T.</given-names></name>; <name><surname>Lee</surname><given-names>J.</given-names></name>; <name><surname>Liskovich</surname><given-names>D.</given-names></name>; <name><surname>Lu</surname><given-names>Y.</given-names></name>; <name><surname>Mao</surname><given-names>Y.</given-names></name>; <name><surname>Martinet</surname><given-names>X.</given-names></name>; <name><surname>Mihaylov</surname><given-names>T.</given-names></name>; <name><surname>Mishra</surname><given-names>P.</given-names></name>; <name><surname>Molybog</surname><given-names>I.</given-names></name>; <name><surname>Nie</surname><given-names>Y.</given-names></name>; <name><surname>Poulton</surname><given-names>A.</given-names></name>; <name><surname>Reizenstein</surname><given-names>J.</given-names></name>; <name><surname>Rungta</surname><given-names>R.</given-names></name>; <name><surname>Saladi</surname><given-names>K.</given-names></name>; <name><surname>Schelten</surname><given-names>A.</given-names></name>; <name><surname>Silva</surname><given-names>R.</given-names></name>; <name><surname>Smith</surname><given-names>E. M.</given-names></name>; <name><surname>Subramanian</surname><given-names>R.</given-names></name>; <name><surname>Tan</surname><given-names>X. E.</given-names></name>; <name><surname>Tang</surname><given-names>B.</given-names></name>; <name><surname>Taylor</surname><given-names>R.</given-names></name>; <name><surname>Williams</surname><given-names>A.</given-names></name>; <name><surname>Kuan</surname><given-names>J. X.</given-names></name>; <name><surname>Xu</surname><given-names>P.</given-names></name>; <name><surname>Yan</surname><given-names>Z.</given-names></name>; <name><surname>Zarov</surname><given-names>I.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Fan</surname><given-names>A.</given-names></name>; <name><surname>Kambadur</surname><given-names>M.</given-names></name>; <name><surname>Narang</surname><given-names>S.</given-names></name>; <name><surname>Rodriguez</surname><given-names>A.</given-names></name>; <name><surname>Stojnic</surname><given-names>R.</given-names></name>; <name><surname>Edunov</surname><given-names>S.</given-names></name>; <name><surname>Scialom</surname><given-names>T.</given-names></name></person-group><article-title>Llama 2: Open
Foundation and Fine-Tuned Chat Models</article-title>. <source>arXiv
[cs.CL]</source><year>2023</year>,<pub-id pub-id-type="doi">10.48550/arXiv.2307.09288</pub-id>.</mixed-citation></ref><ref id="ref284"><mixed-citation publication-type="journal" id="cit284"><person-group person-group-type="allauthors"><name><surname>Ross</surname><given-names>J.</given-names></name>; <name><surname>Belgodere</surname><given-names>B.</given-names></name>; <name><surname>Chenthamarakshan</surname><given-names>V.</given-names></name>; <name><surname>Padhi</surname><given-names>I.</given-names></name>; <name><surname>Mroueh</surname><given-names>Y.</given-names></name>; <name><surname>Das</surname><given-names>P.</given-names></name></person-group><article-title>Large-Scale Chemical Language Representations
Capture Molecular Structure and Properties</article-title>. <source>arXiv [cs.LG]</source><year>2021</year>,<pub-id pub-id-type="doi">10.48550/arXiv.2106.09553</pub-id>.</mixed-citation></ref><ref id="ref285"><mixed-citation publication-type="journal" id="cit285"><name><surname>Loeffler</surname><given-names>H. H.</given-names></name>; <name><surname>He</surname><given-names>J.</given-names></name>; <name><surname>Tibo</surname><given-names>A.</given-names></name>; <name><surname>Janet</surname><given-names>J. P.</given-names></name>; <name><surname>Voronov</surname><given-names>A.</given-names></name>; <name><surname>Mervin</surname><given-names>L. H.</given-names></name>; <name><surname>Engkvist</surname><given-names>O.</given-names></name>
<article-title>Reinvent 4: Modern
AI-Driven Generative Molecule Design</article-title>. <source>J. Cheminform.</source>
<year>2024</year>, <volume>16</volume> (<issue>1</issue>), <fpage>20</fpage><pub-id pub-id-type="doi">10.1186/s13321-024-00812-5</pub-id>.<pub-id pub-id-type="pmid">38383444</pub-id>
</mixed-citation></ref><ref id="ref286"><mixed-citation publication-type="journal" id="cit286"><name><surname>Tetko</surname><given-names>I. V.</given-names></name>
<article-title>Associative Neural Network</article-title>. <source>Neural
Process. Lett.</source>
<year>2002</year>, <volume>16</volume> (<issue>2</issue>), <fpage>187</fpage>&#x02013;<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1023/A:1019903710291</pub-id>.</mixed-citation></ref><ref id="ref287"><mixed-citation publication-type="journal" id="cit287"><name><surname>Tetko</surname><given-names>I. V.</given-names></name>; <name><surname>Poda</surname><given-names>G. I.</given-names></name>
<article-title>Application of ALOGPS 2.1 to Predict
Log D Distribution Coefficient for Pfizer Proprietary Compounds</article-title>. <source>J. Med. Chem.</source>
<year>2004</year>, <volume>47</volume> (<issue>23</issue>), <fpage>5601</fpage>&#x02013;<lpage>5604</lpage>. <pub-id pub-id-type="doi">10.1021/jm049509l</pub-id>.<pub-id pub-id-type="pmid">15509156</pub-id>
</mixed-citation></ref><ref id="ref288"><mixed-citation publication-type="journal" id="cit288"><name><surname>Tetko</surname><given-names>I. V.</given-names></name>; <name><surname>Bruneau</surname><given-names>P.</given-names></name>
<article-title>Application of ALOGPS
to Predict
1-Octanol/water Distribution Coefficients, logP, and logD, of AstraZeneca
in-House Database</article-title>. <source>J. Pharm. Sci.</source>
<year>2004</year>, <volume>93</volume> (<issue>12</issue>), <fpage>3103</fpage>&#x02013;<lpage>3110</lpage>. <pub-id pub-id-type="doi">10.1002/jps.20217</pub-id>.<pub-id pub-id-type="pmid">15514985</pub-id>
</mixed-citation></ref><ref id="ref289"><mixed-citation publication-type="journal" id="cit289"><person-group person-group-type="allauthors"><name><surname>Vaswani</surname><given-names>A.</given-names></name>; <name><surname>Shazeer</surname><given-names>N.</given-names></name>; <name><surname>Parmar</surname><given-names>N.</given-names></name>; <name><surname>Uszkoreit</surname><given-names>J.</given-names></name>; <name><surname>Jones</surname><given-names>L.</given-names></name>; <name><surname>Gomez</surname><given-names>A. N.</given-names></name>; <name><surname>Kaiser</surname><given-names>L.</given-names></name>; <name><surname>Polosukhin</surname><given-names>I.</given-names></name></person-group><article-title>Attention Is All You Need</article-title>. <source>arXiv [cs.CL]</source><year>2017</year>,<pub-id pub-id-type="doi">10.48550/arXiv.1706.03762</pub-id>.</mixed-citation></ref><ref id="ref290"><mixed-citation publication-type="journal" id="cit290"><name><surname>He</surname><given-names>K.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Ren</surname><given-names>S.</given-names></name>; <name><surname>Sun</surname><given-names>J.</given-names></name>
<article-title>Deep Residual Learning
for Image Recognition</article-title>. <source>Proc. IEEE Comput. Soc.
Conf. Comput. Vis. Pattern Recognit.</source>
<year>2015</year>, <fpage>770</fpage>&#x02013;<lpage>778</lpage>. <pub-id pub-id-type="doi">10.1109/CVPR.2016.90</pub-id>.</mixed-citation></ref><ref id="ref291"><mixed-citation publication-type="journal" id="cit291"><person-group person-group-type="allauthors"><name><surname>Houlsby</surname><given-names>N.</given-names></name>; <name><surname>Giurgiu</surname><given-names>A.</given-names></name>; <name><surname>Jastrzebski</surname><given-names>S.</given-names></name>; <name><surname>Morrone</surname><given-names>B.</given-names></name>; <name><surname>de Laroussilhe</surname><given-names>Q.</given-names></name>; <name><surname>Gesmundo</surname><given-names>A.</given-names></name>; <name><surname>Attariyan</surname><given-names>M.</given-names></name>; <name><surname>Gelly</surname><given-names>S.</given-names></name></person-group><article-title>Parameter-Efficient Transfer
Learning for NLP</article-title>. <source>arXiv [cs.LG]</source>, <year>2019</year>,<pub-id pub-id-type="doi">10.48550/arXiv.1902.00751</pub-id>.</mixed-citation></ref><ref id="ref292"><mixed-citation publication-type="journal" id="cit292"><person-group person-group-type="allauthors"><name><surname>Hu</surname><given-names>E. J.</given-names></name>; <name><surname>Shen</surname><given-names>Y.</given-names></name>; <name><surname>Wallis</surname><given-names>P.</given-names></name>; <name><surname>Allen-Zhu</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Chen</surname><given-names>W.</given-names></name></person-group><article-title>LoRA: Low-Rank Adaptation of Large Language Models</article-title>. <source>arXiv [cs.CL]</source><year>2021</year>,<pub-id pub-id-type="doi">10.48550/arXiv.2106.09685</pub-id>.</mixed-citation></ref><ref id="ref293"><mixed-citation publication-type="journal" id="cit293"><name><surname>Thomas</surname><given-names>M.</given-names></name>; <name><surname>Ahmad</surname><given-names>M.</given-names></name>; <name><surname>Tresadern</surname><given-names>G.</given-names></name>; <name><surname>de Fabritiis</surname><given-names>G.</given-names></name>
<article-title>PromptSMILES: Prompting for Scaffold Decoration and
Fragment Linking in Chemical Language Models</article-title>. <source>J. Cheminform.</source>
<year>2024</year>, <volume>16</volume> (<issue>1</issue>), <fpage>77</fpage><pub-id pub-id-type="doi">10.1186/s13321-024-00866-5</pub-id>.<pub-id pub-id-type="pmid">38965600</pub-id>
</mixed-citation></ref><ref id="ref294"><mixed-citation publication-type="journal" id="cit294"><name><surname>Grygorenko</surname><given-names>O. O.</given-names></name>
<article-title>Enamine Ltd.: The Science and Business
of Organic Chemistry
and beyond</article-title>. <source>Eur. J. Org. Chem.</source>
<year>2021</year>, <volume>2021</volume> (<issue>47</issue>), <fpage>6474</fpage>&#x02013;<lpage>6477</lpage>. <pub-id pub-id-type="doi">10.1002/ejoc.202101210</pub-id>.</mixed-citation></ref><ref id="ref295"><mixed-citation publication-type="journal" id="cit295"><name><surname>Bran</surname><given-names>A. M.</given-names></name>; <name><surname>Cox</surname><given-names>S.</given-names></name>; <name><surname>Schilter</surname><given-names>O.</given-names></name>; <name><surname>Baldassari</surname><given-names>C.</given-names></name>; <name><surname>White</surname><given-names>A. D.</given-names></name>; <name><surname>Schwaller</surname><given-names>P.</given-names></name>
<article-title>Augmenting
Large Language Models
with Chemistry Tools</article-title>. <source>Nat. Mach Intell</source>
<year>2024</year>, <volume>6</volume> (<issue>5</issue>), <fpage>525</fpage>&#x02013;<lpage>535</lpage>. <pub-id pub-id-type="doi">10.1038/s42256-024-00832-8</pub-id>.<pub-id pub-id-type="pmid">38799228</pub-id>
</mixed-citation></ref><ref id="ref296"><mixed-citation publication-type="journal" id="cit296"><name><surname>White</surname><given-names>A. D.</given-names></name>; <name><surname>Hocky</surname><given-names>G. M.</given-names></name>; <name><surname>Gandhi</surname><given-names>H. A.</given-names></name>; <name><surname>Ansari</surname><given-names>M.</given-names></name>; <name><surname>Cox</surname><given-names>S.</given-names></name>; <name><surname>Wellawatte</surname><given-names>G. P.</given-names></name>; <name><surname>Sasmal</surname><given-names>S.</given-names></name>; <name><surname>Yang</surname><given-names>Z.</given-names></name>; <name><surname>Liu</surname><given-names>K.</given-names></name>; <name><surname>Singh</surname><given-names>Y.</given-names></name>; <name><surname>Pe&#x000f1;a Ccoa</surname><given-names>W. J.</given-names></name>
<article-title>Assessment of Chemistry Knowledge
in Large Language Models That Generate Code</article-title>. <source>Digit Discov</source>
<year>2023</year>, <volume>2</volume> (<issue>2</issue>), <fpage>368</fpage>&#x02013;<lpage>376</lpage>. <pub-id pub-id-type="doi">10.1039/D2DD00087C</pub-id>.<pub-id pub-id-type="pmid">37065678</pub-id>
</mixed-citation></ref><ref id="ref297"><mixed-citation publication-type="journal" id="cit297"><name><surname>Sadeghi</surname><given-names>S.</given-names></name>; <name><surname>Bui</surname><given-names>A.</given-names></name>; <name><surname>Forooghi</surname><given-names>A.</given-names></name>; <name><surname>Lu</surname><given-names>J.</given-names></name>; <name><surname>Ngom</surname><given-names>A.</given-names></name>
<article-title>Can Large Language
Models Understand Molecules?</article-title>. <source>BMC Bioinformatics</source>
<year>2024</year>, <volume>25</volume> (<issue>1</issue>), <fpage>225</fpage><pub-id pub-id-type="doi">10.1186/s12859-024-05847-x</pub-id>.<pub-id pub-id-type="pmid">38926641</pub-id>
</mixed-citation></ref><ref id="ref298"><mixed-citation publication-type="book" id="cit298"><person-group person-group-type="allauthors"><name><surname>Thomas</surname><given-names>M.</given-names></name>; <name><surname>Boardman</surname><given-names>A.</given-names></name>; <name><surname>Garcia-Ortegon</surname><given-names>M.</given-names></name>; <name><surname>Yang</surname><given-names>H.</given-names></name>; <name><surname>de
Graaf</surname><given-names>C.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name></person-group><article-title>Applications
of Artificial
Intelligence in Drug Design: Opportunities and Challenges</article-title>. In <source>Artificial Intelligence in Drug Design</source>; <person-group person-group-type="editor"><name><surname>Heifetz</surname><given-names>A.</given-names></name></person-group>, Ed.; <publisher-name>Springer
US</publisher-name>: <publisher-loc>New York, NY</publisher-loc>, <year>2022</year>; pp <fpage>1</fpage>&#x02013;<lpage>59</lpage>.</mixed-citation></ref><ref id="ref299"><mixed-citation publication-type="journal" id="cit299"><name><surname>Orsi</surname><given-names>M.</given-names></name>; <name><surname>Reymond</surname><given-names>J.-L.</given-names></name>
<article-title>Navigating a 1E+60 Chemical Space</article-title>. <source>ChemRxiv</source>
<year>2024</year>, <pub-id pub-id-type="doi">10.26434/chemrxiv-2024-bqd8c</pub-id>.</mixed-citation></ref><ref id="ref300"><mixed-citation publication-type="journal" id="cit300"><name><surname>Kearnes</surname><given-names>S.</given-names></name>
<article-title>Pursuing a
Prospective Perspective</article-title>. <source>Trends in Chemistry</source>
<year>2021</year>, <volume>3</volume>, <fpage>77</fpage><pub-id pub-id-type="doi">10.1016/j.trechm.2020.10.012</pub-id>.</mixed-citation></ref><ref id="ref301"><mixed-citation publication-type="journal" id="cit301"><name><surname>Hanser</surname><given-names>T.</given-names></name>; <name><surname>Barber</surname><given-names>C.</given-names></name>; <name><surname>Marchaland</surname><given-names>J. F.</given-names></name>; <name><surname>Werner</surname><given-names>S.</given-names></name>
<article-title>Applicability Domain: Towards a More Formal Definition</article-title>. <source>SAR QSAR Environ. Res.</source>
<year>2016</year>, <volume>27</volume> (<issue>11</issue>), <fpage>865</fpage>&#x02013;<lpage>881</lpage>. <pub-id pub-id-type="doi">10.1080/1062936X.2016.1250229</pub-id>.</mixed-citation></ref><ref id="ref302"><mixed-citation publication-type="journal" id="cit302"><name><surname>Arvidsson McShane</surname><given-names>S.</given-names></name>; <name><surname>Norinder</surname><given-names>U.</given-names></name>; <name><surname>Alvarsson</surname><given-names>J.</given-names></name>; <name><surname>Ahlberg</surname><given-names>E.</given-names></name>; <name><surname>Carlsson</surname><given-names>L.</given-names></name>; <name><surname>Spjuth</surname><given-names>O.</given-names></name>
<article-title>CPSign: Conformal Prediction
for Cheminformatics Modeling</article-title>. <source>J. Cheminform.</source>
<year>2024</year>, <volume>16</volume> (<issue>1</issue>), <fpage>75</fpage><pub-id pub-id-type="doi">10.1186/s13321-024-00870-9</pub-id>.<pub-id pub-id-type="pmid">38943219</pub-id>
</mixed-citation></ref><ref id="ref303"><mixed-citation publication-type="journal" id="cit303"><person-group person-group-type="allauthors"><name><surname>Lampa</surname><given-names>S.</given-names></name>; <name><surname>Alvarsson</surname><given-names>J.</given-names></name>; <name><surname>Arvidsson Mc Shane</surname><given-names>S.</given-names></name>; <name><surname>Berg</surname><given-names>A.</given-names></name>; <name><surname>Ahlberg</surname><given-names>E.</given-names></name>; <name><surname>Spjuth</surname><given-names>O.</given-names></name></person-group><article-title>Predicting Off-Target
Binding Profiles With Confidence Using Conformal Prediction</article-title>. <source>Front. Pharmacol.</source><year>2018</year>, <volume>9</volume>.<pub-id pub-id-type="doi">10.3389/fphar.2018.01256</pub-id>.</mixed-citation></ref><ref id="ref304"><mixed-citation publication-type="journal" id="cit304"><name><surname>McHugh</surname><given-names>M. L.</given-names></name>
<article-title>Interrater Reliability: The Kappa Statistic</article-title>. <source>Biochem. Med.</source>
<year>2012</year>, <volume>22</volume> (<issue>3</issue>), <fpage>276</fpage>&#x02013;<lpage>282</lpage>. <pub-id pub-id-type="doi">10.11613/BM.2012.031</pub-id>.</mixed-citation></ref><ref id="ref305"><mixed-citation publication-type="journal" id="cit305"><name><surname>Vincent</surname><given-names>F.</given-names></name>; <name><surname>Loria</surname><given-names>P. M.</given-names></name>; <name><surname>Weston</surname><given-names>A. D.</given-names></name>; <name><surname>Steppan</surname><given-names>C. M.</given-names></name>; <name><surname>Doyonnas</surname><given-names>R.</given-names></name>; <name><surname>Wang</surname><given-names>Y.-M.</given-names></name>; <name><surname>Rockwell</surname><given-names>K. L.</given-names></name>; <name><surname>Peakman</surname><given-names>M.-C.</given-names></name>
<article-title>Hit Triage
and Validation in Phenotypic Screening: Considerations and Strategies</article-title>. <source>Cell Chem. Biol.</source>
<year>2020</year>, <volume>27</volume> (<issue>11</issue>), <fpage>1332</fpage>&#x02013;<lpage>1346</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2020.08.009</pub-id>.<pub-id pub-id-type="pmid">32888500</pub-id>
</mixed-citation></ref><ref id="ref306"><mixed-citation publication-type="journal" id="cit306"><name><surname>Boldini</surname><given-names>D.</given-names></name>; <name><surname>Friedrich</surname><given-names>L.</given-names></name>; <name><surname>Kuhn</surname><given-names>D.</given-names></name>; <name><surname>Sieber</surname><given-names>S. A.</given-names></name>
<article-title>Machine
Learning Assisted Hit Prioritization for High Throughput Screening
in Drug Discovery</article-title>. <source>ACS Cent Sci.</source>
<year>2024</year>, <volume>10</volume> (<issue>4</issue>), <fpage>823</fpage>&#x02013;<lpage>832</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.3c01517</pub-id>.<pub-id pub-id-type="pmid">38680560</pub-id>
</mixed-citation></ref><ref id="ref307"><mixed-citation publication-type="journal" id="cit307"><name><surname>Truchon</surname><given-names>J.-F.</given-names></name>; <name><surname>Bayly</surname><given-names>C. I.</given-names></name>
<article-title>Evaluating Virtual
Screening Methods:
Good and Bad Metrics for the &#x0201c;Early Recognition&#x0201d; Problem</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2007</year>, <volume>47</volume> (<issue>2</issue>), <fpage>488</fpage>&#x02013;<lpage>508</lpage>. <pub-id pub-id-type="doi">10.1021/ci600426e</pub-id>.<pub-id pub-id-type="pmid">17288412</pub-id>
</mixed-citation></ref><ref id="ref308"><mixed-citation publication-type="journal" id="cit308"><name><surname>Wellnitz</surname><given-names>J.</given-names></name>; <name><surname>Jain</surname><given-names>S.</given-names></name>; <name><surname>Hochuli</surname><given-names>J.</given-names></name>; <name><surname>Maxfield</surname><given-names>T.</given-names></name>; <name><surname>Muratov</surname><given-names>E.</given-names></name>; <name><surname>Tropsha</surname><given-names>A.</given-names></name>; <name><surname>Zakharov</surname><given-names>A.</given-names></name>
<article-title>One Size Does
Not Fit
All: Revising Traditional Paradigms for QSAR-Based Virtual Screenings</article-title>. <source>J. Cheminform.</source>
<year>2025</year>, <volume>17</volume> (<issue>1</issue>), <fpage>7</fpage><pub-id pub-id-type="doi">10.1186/s13321-025-00948-y</pub-id>.<pub-id pub-id-type="pmid">39819357</pub-id>
</mixed-citation></ref><ref id="ref309"><mixed-citation publication-type="journal" id="cit309"><name><surname>Kir&#x000e1;ly</surname><given-names>P.</given-names></name>; <name><surname>Kiss</surname><given-names>R.</given-names></name>; <name><surname>Kov&#x000e1;cs</surname><given-names>D.</given-names></name>; <name><surname>Ballaj</surname><given-names>A.</given-names></name>; <name><surname>T&#x000f3;th</surname><given-names>G.</given-names></name>
<article-title>The Relevance of Goodness-of-Fit,
Robustness and Prediction Validation Categories of OECD-QSAR Principles
with Respect to Sample Size and Model Type</article-title>. <source>Mol. Inform.</source>
<year>2022</year>, <volume>41</volume> (<issue>11</issue>), <elocation-id>e2200072</elocation-id><pub-id pub-id-type="doi">10.1002/minf.202200072</pub-id>.<pub-id pub-id-type="pmid">35773201</pub-id>
</mixed-citation></ref><ref id="ref310"><mixed-citation publication-type="journal" id="cit310"><name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>Glen</surname><given-names>R. C.</given-names></name>
<article-title>A Discussion of Measures of Enrichment
in Virtual Screening: Comparing the Information Content of Descriptors
with Increasing Levels of Sophistication</article-title>. <source>J.
Chem. Inf. Model.</source>
<year>2005</year>, <volume>45</volume> (<issue>5</issue>), <fpage>1369</fpage>&#x02013;<lpage>1375</lpage>. <pub-id pub-id-type="doi">10.1021/ci0500177</pub-id>.<pub-id pub-id-type="pmid">16180913</pub-id>
</mixed-citation></ref><ref id="ref311"><mixed-citation publication-type="journal" id="cit311"><name><surname>Ben-David</surname><given-names>A.</given-names></name>
<article-title>About the Relationship between ROC
Curves and Cohen&#x02019;s
Kappa</article-title>. <source>Eng. Appl. Artif. Intell.</source>
<year>2008</year>, <volume>21</volume> (<issue>6</issue>), <fpage>874</fpage>&#x02013;<lpage>882</lpage>. <pub-id pub-id-type="doi">10.1016/j.engappai.2007.09.009</pub-id>.</mixed-citation></ref><ref id="ref312"><mixed-citation publication-type="journal" id="cit312"><name><surname>Esposito</surname><given-names>C.</given-names></name>; <name><surname>Landrum</surname><given-names>G. A.</given-names></name>; <name><surname>Schneider</surname><given-names>N.</given-names></name>; <name><surname>Stiefl</surname><given-names>N.</given-names></name>; <name><surname>Riniker</surname><given-names>S.</given-names></name>
<article-title>GHOST: Adjusting the Decision Threshold
to Handle Imbalanced Data in Machine Learning</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2021</year>, <volume>61</volume> (<issue>6</issue>), <fpage>2623</fpage>&#x02013;<lpage>2640</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.1c00160</pub-id>.<pub-id pub-id-type="pmid">34100609</pub-id>
</mixed-citation></ref><ref id="ref313"><mixed-citation publication-type="journal" id="cit313"><name><surname>Hunklinger</surname><given-names>A.</given-names></name>; <name><surname>Hartog</surname><given-names>P.</given-names></name>; <name><surname>&#x00160;&#x000ed;cho</surname><given-names>M.</given-names></name>; <name><surname>Godin</surname><given-names>G.</given-names></name>; <name><surname>Tetko</surname><given-names>I. V.</given-names></name>
<article-title>The openOCHEM Consensus Model Is
the Best-Performing Open-Source Predictive Model in the First EUOS/SLAS
Joint Compound Solubility Challenge</article-title>. <source>SLAS Discovery</source>
<year>2024</year>, <volume>29</volume> (<issue>2</issue>), <fpage>100144</fpage><pub-id pub-id-type="doi">10.1016/j.slasd.2024.01.005</pub-id>.<pub-id pub-id-type="pmid">38316342</pub-id>
</mixed-citation></ref><ref id="ref314"><mixed-citation publication-type="journal" id="cit314"><name><surname>Roy</surname><given-names>K.</given-names></name>; <name><surname>Chakraborty</surname><given-names>P.</given-names></name>; <name><surname>Mitra</surname><given-names>I.</given-names></name>; <name><surname>Ojha</surname><given-names>P. K.</given-names></name>; <name><surname>Kar</surname><given-names>S.</given-names></name>; <name><surname>Das</surname><given-names>R. N.</given-names></name>
<article-title>Some Case
Studies on Application of &#x0201c;r(m)2&#x0201d;
Metrics for Judging Quality of Quantitative Structure-Activity Relationship
Predictions: Emphasis on Scaling of Response Data</article-title>. <source>J. Comput. Chem.</source>
<year>2013</year>, <volume>34</volume> (<issue>12</issue>), <fpage>1071</fpage>&#x02013;<lpage>1082</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.23231</pub-id>.<pub-id pub-id-type="pmid">23299630</pub-id>
</mixed-citation></ref><ref id="ref315"><mixed-citation publication-type="journal" id="cit315"><name><surname>Shayanfar</surname><given-names>A.</given-names></name>; <name><surname>Shayanfar</surname><given-names>S.</given-names></name>
<article-title>Is Regression
through Origin Useful
in External Validation of QSAR Models?</article-title>. <source>Eur.
J. Pharm. Sci.</source>
<year>2014</year>, <volume>59</volume>, <fpage>31</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejps.2014.03.007</pub-id>.<pub-id pub-id-type="pmid">24721181</pub-id>
</mixed-citation></ref><ref id="ref316"><mixed-citation publication-type="journal" id="cit316"><name><surname>Alexander</surname><given-names>D. L. J.</given-names></name>; <name><surname>Tropsha</surname><given-names>A.</given-names></name>; <name><surname>Winkler</surname><given-names>D. A.</given-names></name>
<article-title>Beware
of R(2):
Simple, Unambiguous Assessment of the Prediction Accuracy of QSAR
and QSPR Models</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2015</year>, <volume>55</volume> (<issue>7</issue>), <fpage>1316</fpage>&#x02013;<lpage>1322</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.5b00206</pub-id>.<pub-id pub-id-type="pmid">26099013</pub-id>
</mixed-citation></ref><ref id="ref317"><mixed-citation publication-type="journal" id="cit317"><name><surname>Schwaighofer</surname><given-names>A.</given-names></name>; <name><surname>Schroeter</surname><given-names>T.</given-names></name>; <name><surname>Mika</surname><given-names>S.</given-names></name>; <name><surname>Hansen</surname><given-names>K.</given-names></name>; <name><surname>Ter Laak</surname><given-names>A.</given-names></name>; <name><surname>Lienau</surname><given-names>P.</given-names></name>; <name><surname>Reichel</surname><given-names>A.</given-names></name>; <name><surname>Heinrich</surname><given-names>N.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>K.-R.</given-names></name>
<article-title>A Probabilistic
Approach to Classifying Metabolic Stability</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2008</year>, <volume>48</volume> (<issue>4</issue>), <fpage>785</fpage>&#x02013;<lpage>796</lpage>. <pub-id pub-id-type="doi">10.1021/ci700142c</pub-id>.<pub-id pub-id-type="pmid">18327900</pub-id>
</mixed-citation></ref><ref id="ref318"><mixed-citation publication-type="journal" id="cit318"><name><surname>Abduljalil</surname><given-names>K.</given-names></name>; <name><surname>Cain</surname><given-names>T.</given-names></name>; <name><surname>Humphries</surname><given-names>H.</given-names></name>; <name><surname>Rostami-Hodjegan</surname><given-names>A.</given-names></name>
<article-title>Deciding on Success Criteria for Predictability of
Pharmacokinetic Parameters from in Vitro Studies: An Analysis Based
on in Vivo Observations</article-title>. <source>Drug Metab. Dispos.</source>
<year>2014</year>, <volume>42</volume> (<issue>9</issue>), <fpage>1478</fpage>&#x02013;<lpage>1484</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.114.058099</pub-id>.<pub-id pub-id-type="pmid">24989891</pub-id>
</mixed-citation></ref><ref id="ref319"><mixed-citation publication-type="journal" id="cit319"><name><surname>Turner</surname><given-names>R. M.</given-names></name>; <name><surname>Park</surname><given-names>B. K.</given-names></name>; <name><surname>Pirmohamed</surname><given-names>M.</given-names></name>
<article-title>Parsing Interindividual
Drug Variability: An Emerging Role for Systems Pharmacology</article-title>. <source>Wiley Interdiscip. Rev. Syst. Biol. Med.</source>
<year>2015</year>, <volume>7</volume> (<issue>4</issue>), <fpage>221</fpage>&#x02013;<lpage>241</lpage>. <pub-id pub-id-type="doi">10.1002/wsbm.1302</pub-id>.<pub-id pub-id-type="pmid">25950758</pub-id>
</mixed-citation></ref><ref id="ref320"><mixed-citation publication-type="journal" id="cit320"><name><surname>Thummel</surname><given-names>K. E.</given-names></name>; <name><surname>Lin</surname><given-names>Y. S.</given-names></name>
<article-title>Sources of Interindividual
Variability</article-title>. <source>Methods Mol. Biol.</source>
<year>2014</year>, <volume>1113</volume>, <fpage>363</fpage>&#x02013;<lpage>415</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-62703-758-7_17</pub-id>.<pub-id pub-id-type="pmid">24523121</pub-id>
</mixed-citation></ref><ref id="ref321"><mixed-citation publication-type="journal" id="cit321"><name><surname>Brown</surname><given-names>S. P.</given-names></name>; <name><surname>Muchmore</surname><given-names>S. W.</given-names></name>; <name><surname>Hajduk</surname><given-names>P. J.</given-names></name>
<article-title>Healthy
Skepticism:
Assessing Realistic Model Performance</article-title>. <source>Drug
Discovery Today</source>
<year>2009</year>, <volume>14</volume> (<issue>7&#x02013;8</issue>), <fpage>420</fpage>&#x02013;<lpage>427</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2009.01.012</pub-id>.<pub-id pub-id-type="pmid">19340931</pub-id>
</mixed-citation></ref><ref id="ref322"><mixed-citation publication-type="journal" id="cit322"><name><surname>Crusius</surname><given-names>D.</given-names></name>; <name><surname>Cipcigan</surname><given-names>F.</given-names></name>; <name><surname>Biggin</surname><given-names>P. C.</given-names></name>
<article-title>Are We
Fitting Data
or Noise? Analysing the Predictive Power of Commonly Used Datasets
in Drug-, Materials-, and Molecular-Discovery</article-title>. <source>Faraday Discuss.</source>
<year>2025</year>, <volume>256</volume>, <fpage>304</fpage><pub-id pub-id-type="doi">10.1039/D4FD00091A</pub-id>.<pub-id pub-id-type="pmid">39308206</pub-id>
</mixed-citation></ref><ref id="ref323"><mixed-citation publication-type="journal" id="cit323"><name><surname>Tetko</surname><given-names>I. V.</given-names></name>; <name><surname>van Deursen</surname><given-names>R.</given-names></name>; <name><surname>Godin</surname><given-names>G.</given-names></name>
<article-title>Be Aware of Overfitting
by Hyperparameter Optimization!</article-title>. <source>J. Cheminform.</source>
<year>2024</year>, <volume>16</volume> (<issue>1</issue>), <fpage>139</fpage><pub-id pub-id-type="doi">10.1186/s13321-024-00934-w</pub-id>.<pub-id pub-id-type="pmid">39654058</pub-id>
</mixed-citation></ref><ref id="ref324"><mixed-citation publication-type="journal" id="cit324"><name><surname>Varma</surname><given-names>S.</given-names></name>; <name><surname>Simon</surname><given-names>R.</given-names></name>
<article-title>Bias in Error Estimation
When Using
Cross-Validation for Model Selection</article-title>. <source>BMC Bioinformatics</source>
<year>2006</year>, <volume>7</volume> (<issue>1</issue>), <fpage>91</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-7-91</pub-id>.<pub-id pub-id-type="pmid">16504092</pub-id>
</mixed-citation></ref><ref id="ref325"><mixed-citation publication-type="weblink" id="cit325"><person-group person-group-type="allauthors"><name><surname>Walters</surname><given-names>P.</given-names></name></person-group><article-title>Some Thoughts
on Splitting Chemical Datasets</article-title>. <source>Practical
Cheminformatics</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://practicalcheminformatics.blogspot.com/2024/11/some-thoughts-on-splitting-chemical.html">https://practicalcheminformatics.blogspot.com/2024/11/some-thoughts-on-splitting-chemical.html</uri> (accessed 2025-03-23).</mixed-citation></ref><ref id="ref326"><mixed-citation publication-type="journal" id="cit326"><person-group person-group-type="allauthors"><name><surname>Guo</surname><given-names>Q.</given-names></name>; <name><surname>Hernandez-Hernandez</surname><given-names>S.</given-names></name>; <name><surname>Ballester</surname><given-names>P. J.</given-names></name></person-group><article-title>Scaffold Splits Overestimate Virtual Screening Performance</article-title>. <source>arXiv [q-bio.QM]</source><year>2024</year>,<pub-id pub-id-type="doi">10.48550/arXiv.2406.00873</pub-id>.</mixed-citation></ref><ref id="ref327"><mixed-citation publication-type="journal" id="cit327"><name><surname>Saha</surname><given-names>U. S.</given-names></name>; <name><surname>Vendruscolo</surname><given-names>M.</given-names></name>; <name><surname>Carpenter</surname><given-names>A. E.</given-names></name>; <name><surname>Singh</surname><given-names>S.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>Seal</surname><given-names>S.</given-names></name>
<article-title>Step Forward Cross
Validation for Bioactivity Prediction: Out of Distribution Validation
in Drug Discovery</article-title>. <source>bioRxiv</source>
<year>2024</year>, <pub-id pub-id-type="doi">10.1101/2024.07.02.601740</pub-id>.</mixed-citation></ref><ref id="ref328"><mixed-citation publication-type="journal" id="cit328"><name><surname>Landrum</surname><given-names>G. A.</given-names></name>; <name><surname>Beckers</surname><given-names>M.</given-names></name>; <name><surname>Lanini</surname><given-names>J.</given-names></name>; <name><surname>Schneider</surname><given-names>N.</given-names></name>; <name><surname>Stiefl</surname><given-names>N.</given-names></name>; <name><surname>Riniker</surname><given-names>S.</given-names></name>
<article-title>SIMPD: An Algorithm for Generating
Simulated Time Splits for Validating Machine Learning Approaches</article-title>. <source>J. Cheminform.</source>
<year>2023</year>, <volume>15</volume> (<issue>1</issue>), <fpage>119</fpage><pub-id pub-id-type="doi">10.1186/s13321-023-00787-9</pub-id>.<pub-id pub-id-type="pmid">38082357</pub-id>
</mixed-citation></ref><ref id="ref329"><mixed-citation publication-type="journal" id="cit329"><name><surname>Xiong</surname><given-names>Z.</given-names></name>; <name><surname>Cui</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>Z.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Hu</surname><given-names>M.</given-names></name>; <name><surname>Hu</surname><given-names>J.</given-names></name>
<article-title>Evaluating Explorative Prediction Power of Machine
Learning Algorithms for Materials Discovery Using K-Fold Forward Cross-Validation</article-title>. <source>Comput. Mater. Sci.</source>
<year>2020</year>, <volume>171</volume>, <fpage>109203</fpage><pub-id pub-id-type="doi">10.1016/j.commatsci.2019.109203</pub-id>.</mixed-citation></ref><ref id="ref330"><mixed-citation publication-type="journal" id="cit330"><name><surname>Kaneko</surname><given-names>H.</given-names></name>
<article-title>Evaluation
and Optimization Methods for Applicability
Domain Methods and Their Hyperparameters, Considering the Prediction
Performance of Machine Learning Models</article-title>. <source>ACS
Omega</source>
<year>2024</year>, <volume>9</volume> (<issue>10</issue>), <fpage>11453</fpage>&#x02013;<lpage>11458</lpage>. <pub-id pub-id-type="doi">10.1021/acsomega.3c08036</pub-id>.<pub-id pub-id-type="pmid">38496944</pub-id>
</mixed-citation></ref><ref id="ref331"><mixed-citation publication-type="journal" id="cit331"><name><surname>Fechner</surname><given-names>N.</given-names></name>; <name><surname>Jahn</surname><given-names>A.</given-names></name>; <name><surname>Hinselmann</surname><given-names>G.</given-names></name>; <name><surname>Zell</surname><given-names>A.</given-names></name>
<article-title>Estimation of the Applicability Domain of Kernel-Based Machine Learning
Models for Virtual Screening</article-title>. <source>J. Cheminform.</source>
<year>2010</year>, <volume>2</volume> (<issue>1</issue>), <fpage>2</fpage><pub-id pub-id-type="doi">10.1186/1758-2946-2-2</pub-id>.<pub-id pub-id-type="pmid">20222949</pub-id>
</mixed-citation></ref><ref id="ref332"><mixed-citation publication-type="book" id="cit332"><person-group person-group-type="allauthors"><name><surname>Preparata</surname><given-names>F. P.</given-names></name>; <name><surname>Shamos</surname><given-names>M. I.</given-names></name></person-group><source>Computational Geometry:
An Introduction</source>; <publisher-name>Springer Science &#x00026; Business
Media</publisher-name>, <year>2012</year>.</mixed-citation></ref><ref id="ref333"><mixed-citation publication-type="journal" id="cit333"><name><surname>Sushko</surname><given-names>I.</given-names></name>; <name><surname>Novotarskyi</surname><given-names>S.</given-names></name>; <name><surname>K&#x000f6;rner</surname><given-names>R.</given-names></name>; <name><surname>Pandey</surname><given-names>A. K.</given-names></name>; <name><surname>Cherkasov</surname><given-names>A.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Gramatica</surname><given-names>P.</given-names></name>; <name><surname>Hansen</surname><given-names>K.</given-names></name>; <name><surname>Schroeter</surname><given-names>T.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>K.-R.</given-names></name>; <name><surname>Xi</surname><given-names>L.</given-names></name>; <name><surname>Liu</surname><given-names>H.</given-names></name>; <name><surname>Yao</surname><given-names>X.</given-names></name>; <name><surname>&#x000d6;berg</surname><given-names>T.</given-names></name>; <name><surname>Hormozdiari</surname><given-names>F.</given-names></name>; <name><surname>Dao</surname><given-names>P.</given-names></name>; <name><surname>Sahinalp</surname><given-names>C.</given-names></name>; <name><surname>Todeschini</surname><given-names>R.</given-names></name>; <name><surname>Polishchuk</surname><given-names>P.</given-names></name>; <name><surname>Artemenko</surname><given-names>A.</given-names></name>; <name><surname>Kuz&#x02019;min</surname><given-names>V.</given-names></name>; <name><surname>Martin</surname><given-names>T. M.</given-names></name>; <name><surname>Young</surname><given-names>D. M.</given-names></name>; <name><surname>Fourches</surname><given-names>D.</given-names></name>; <name><surname>Muratov</surname><given-names>E.</given-names></name>; <name><surname>Tropsha</surname><given-names>A.</given-names></name>; <name><surname>Baskin</surname><given-names>I.</given-names></name>; <name><surname>Horvath</surname><given-names>D.</given-names></name>; <name><surname>Marcou</surname><given-names>G.</given-names></name>; <name><surname>Muller</surname><given-names>C.</given-names></name>; <name><surname>Varnek</surname><given-names>A.</given-names></name>; <name><surname>Prokopenko</surname><given-names>V. V.</given-names></name>; <name><surname>Tetko</surname><given-names>I. V.</given-names></name>
<article-title>Applicability Domains for Classification Problems:
Benchmarking of Distance to Models for Ames Mutagenicity Set</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2010</year>, <volume>50</volume> (<issue>12</issue>), <fpage>2094</fpage>&#x02013;<lpage>2111</lpage>. <pub-id pub-id-type="doi">10.1021/ci100253r</pub-id>.<pub-id pub-id-type="pmid">21033656</pub-id>
</mixed-citation></ref><ref id="ref334"><mixed-citation publication-type="journal" id="cit334"><name><surname>Baskin</surname><given-names>I. I.</given-names></name>; <name><surname>Kireeva</surname><given-names>N.</given-names></name>; <name><surname>Varnek</surname><given-names>A.</given-names></name>
<article-title>The One-Class
Classification
Approach to Data Description and to Models Applicability Domain</article-title>. <source>Mol. Inform.</source>
<year>2010</year>, <volume>29</volume> (<issue>8&#x02013;9</issue>), <fpage>581</fpage>&#x02013;<lpage>587</lpage>. <pub-id pub-id-type="doi">10.1002/minf.201000063</pub-id>.<pub-id pub-id-type="pmid">27463453</pub-id>
</mixed-citation></ref><ref id="ref335"><mixed-citation publication-type="journal" id="cit335"><name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Menke</surname><given-names>J.</given-names></name>; <name><surname>He</surname><given-names>J.</given-names></name>; <name><surname>Nittinger</surname><given-names>E.</given-names></name>; <name><surname>Tyrchan</surname><given-names>C.</given-names></name>; <name><surname>Koch</surname><given-names>O.</given-names></name>; <name><surname>Zhao</surname><given-names>H.</given-names></name>
<article-title>Similarity-Based
Pairing
Improves Efficiency of Siamese Neural Networks for Regression Tasks
and Uncertainty Quantification</article-title>. <source>J. Cheminform.</source>
<year>2023</year>, <volume>15</volume> (<issue>1</issue>), <fpage>75</fpage><pub-id pub-id-type="doi">10.1186/s13321-023-00744-6</pub-id>.<pub-id pub-id-type="pmid">37649050</pub-id>
</mixed-citation></ref><ref id="ref336"><mixed-citation publication-type="journal" id="cit336"><name><surname>Hirschfeld</surname><given-names>L.</given-names></name>; <name><surname>Swanson</surname><given-names>K.</given-names></name>; <name><surname>Yang</surname><given-names>K.</given-names></name>; <name><surname>Barzilay</surname><given-names>R.</given-names></name>; <name><surname>Coley</surname><given-names>C. W.</given-names></name>
<article-title>Uncertainty Quantification Using
Neural Networks for
Molecular Property Prediction</article-title>. <source>J. Chem. Inf.
Model.</source>
<year>2020</year>, <volume>60</volume> (<issue>8</issue>), <fpage>3770</fpage>&#x02013;<lpage>3780</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.0c00502</pub-id>.<pub-id pub-id-type="pmid">32702986</pub-id>
</mixed-citation></ref><ref id="ref337"><mixed-citation publication-type="journal" id="cit337"><name><surname>Aniceto</surname><given-names>N.</given-names></name>; <name><surname>Freitas</surname><given-names>A. A.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>Ghafourian</surname><given-names>T.</given-names></name>
<article-title>A Novel Applicability
Domain Technique for Mapping Predictive Reliability across the Chemical
Space of a QSAR: Reliability-Density Neighbourhood</article-title>. <source>J. Cheminform.</source>
<year>2016</year>, <volume>8</volume> (<issue>1</issue>), <fpage>1</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1186/s13321-016-0182-y</pub-id>.<pub-id pub-id-type="pmid">26807156</pub-id>
</mixed-citation></ref><ref id="ref338"><mixed-citation publication-type="journal" id="cit338"><person-group person-group-type="allauthors"><name><surname>D&#x02019;Amour</surname><given-names>A.</given-names></name>; <name><surname>Heller</surname><given-names>K.</given-names></name>; <name><surname>Moldovan</surname><given-names>D.</given-names></name>; <name><surname>Adlam</surname><given-names>B.</given-names></name>; <name><surname>Alipanahi</surname><given-names>B.</given-names></name>; <name><surname>Beutel</surname><given-names>A.</given-names></name>; <name><surname>Chen</surname><given-names>C.</given-names></name>; <name><surname>Deaton</surname><given-names>J.</given-names></name>; <name><surname>Eisenstein</surname><given-names>J.</given-names></name>; <name><surname>Hoffman</surname><given-names>M. D.</given-names></name>; <name><surname>Hormozdiari</surname><given-names>F.</given-names></name>; <name><surname>Houlsby</surname><given-names>N.</given-names></name>; <name><surname>Hou</surname><given-names>S.</given-names></name>; <name><surname>Jerfel</surname><given-names>G.</given-names></name>; <name><surname>Karthikesalingam</surname><given-names>A.</given-names></name>; <name><surname>Lucic</surname><given-names>M.</given-names></name>; <name><surname>Ma</surname><given-names>Y.</given-names></name>; <name><surname>McLean</surname><given-names>C.</given-names></name>; <name><surname>Mincu</surname><given-names>D.</given-names></name>; <name><surname>Mitani</surname><given-names>A.</given-names></name>; <name><surname>Montanari</surname><given-names>A.</given-names></name>; <name><surname>Nado</surname><given-names>Z.</given-names></name>; <name><surname>Natarajan</surname><given-names>V.</given-names></name>; <name><surname>Nielson</surname><given-names>C.</given-names></name>; <name><surname>Osborne</surname><given-names>T. F.</given-names></name>; <name><surname>Raman</surname><given-names>R.</given-names></name>; <name><surname>Ramasamy</surname><given-names>K.</given-names></name>; <name><surname>Sayres</surname><given-names>R.</given-names></name>; <name><surname>Schrouff</surname><given-names>J.</given-names></name>; <name><surname>Seneviratne</surname><given-names>M.</given-names></name>; <name><surname>Sequeira</surname><given-names>S.</given-names></name>; <name><surname>Suresh</surname><given-names>H.</given-names></name>; <name><surname>Veitch</surname><given-names>V.</given-names></name>; <name><surname>Vladymyrov</surname><given-names>M.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Webster</surname><given-names>K.</given-names></name>; <name><surname>Yadlowsky</surname><given-names>S.</given-names></name>; <name><surname>Yun</surname><given-names>T.</given-names></name>; <name><surname>Zhai</surname><given-names>X.</given-names></name>; <name><surname>Sculley</surname><given-names>D.</given-names></name></person-group><article-title>Underspecification Presents Challenges
for Credibility in Modern Machine Learning</article-title>. <source>arXiv [cs.LG]</source><year>2020</year>, <pub-id pub-id-type="doi">10.48550/arXiv.2011.03395</pub-id>.</mixed-citation></ref><ref id="ref339"><mixed-citation publication-type="journal" id="cit339"><name><surname>Rotundo</surname><given-names>L.</given-names></name>; <name><surname>Pyrsopoulos</surname><given-names>N.</given-names></name>
<article-title>Liver Injury Induced by Paracetamol
and Challenges Associated with Intentional and Unintentional Use</article-title>. <source>World J. Hepatol.</source>
<year>2020</year>, <volume>12</volume> (<issue>4</issue>), <fpage>125</fpage>&#x02013;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.4254/wjh.v12.i4.125</pub-id>.<pub-id pub-id-type="pmid">32685105</pub-id>
</mixed-citation></ref><ref id="ref340"><mixed-citation publication-type="journal" id="cit340"><name><surname>Muller</surname><given-names>P. Y.</given-names></name>; <name><surname>Milton</surname><given-names>M. N.</given-names></name>
<article-title>The Determination
and Interpretation
of the Therapeutic Index in Drug Development</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2012</year>, <volume>11</volume> (<issue>10</issue>), <fpage>751</fpage>&#x02013;<lpage>761</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3801</pub-id>.<pub-id pub-id-type="pmid">22935759</pub-id>
</mixed-citation></ref><ref id="ref341"><mixed-citation publication-type="journal" id="cit341"><name><surname>Schneider</surname><given-names>P.</given-names></name>; <name><surname>Walters</surname><given-names>W. P.</given-names></name>; <name><surname>Plowright</surname><given-names>A. T.</given-names></name>; <name><surname>Sieroka</surname><given-names>N.</given-names></name>; <name><surname>Listgarten</surname><given-names>J.</given-names></name>; <name><surname>Goodnow</surname><given-names>R. A.</given-names><suffix>Jr</suffix></name>; <name><surname>Fisher</surname><given-names>J.</given-names></name>; <name><surname>Jansen</surname><given-names>J. M.</given-names></name>; <name><surname>Duca</surname><given-names>J. S.</given-names></name>; <name><surname>Rush</surname><given-names>T. S.</given-names></name>; <name><surname>Zentgraf</surname><given-names>M.</given-names></name>; <name><surname>Hill</surname><given-names>J. E.</given-names></name>; <name><surname>Krutoholow</surname><given-names>E.</given-names></name>; <name><surname>Kohler</surname><given-names>M.</given-names></name>; <name><surname>Blaney</surname><given-names>J.</given-names></name>; <name><surname>Funatsu</surname><given-names>K.</given-names></name>; <name><surname>Luebkemann</surname><given-names>C.</given-names></name>; <name><surname>Schneider</surname><given-names>G.</given-names></name>
<article-title>Rethinking Drug Design in the Artificial Intelligence
Era</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2020</year>, <volume>19</volume> (<issue>5</issue>), <fpage>353</fpage>&#x02013;<lpage>364</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-019-0050-3</pub-id>.<pub-id pub-id-type="pmid">31801986</pub-id>
</mixed-citation></ref><ref id="ref342"><mixed-citation publication-type="journal" id="cit342"><name><surname>Horne</surname><given-names>R. I.</given-names></name>; <name><surname>Wilson-Godber</surname><given-names>J.</given-names></name>; <name><surname>D&#x000ed;az</surname><given-names>A. G.</given-names></name>; <name><surname>Brotzakis</surname><given-names>Z. F.</given-names></name>; <name><surname>Seal</surname><given-names>S.</given-names></name>; <name><surname>Gregory</surname><given-names>R. C.</given-names></name>; <name><surname>Possenti</surname><given-names>A.</given-names></name>; <name><surname>Chia</surname><given-names>S.</given-names></name>; <name><surname>Vendruscolo</surname><given-names>M.</given-names></name>
<article-title>Using Generative
Modeling to Endow
with Potency Initially Inert Compounds with Good Bioavailability and
Low Toxicity</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2023</year>, <volume>64</volume> (<issue>3</issue>), <fpage>590</fpage>&#x02013;<lpage>596</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.3c01777</pub-id>.</mixed-citation></ref><ref id="ref343"><mixed-citation publication-type="journal" id="cit343"><name><surname>Amberg</surname><given-names>A.</given-names></name>; <name><surname>Beilke</surname><given-names>L.</given-names></name>; <name><surname>Bercu</surname><given-names>J.</given-names></name>; <name><surname>Bower</surname><given-names>D.</given-names></name>; <name><surname>Brigo</surname><given-names>A.</given-names></name>; <name><surname>Cross</surname><given-names>K. P.</given-names></name>; <name><surname>Custer</surname><given-names>L.</given-names></name>; <name><surname>Dobo</surname><given-names>K.</given-names></name>; <name><surname>Dowdy</surname><given-names>E.</given-names></name>; <name><surname>Ford</surname><given-names>K. A.</given-names></name>; <name><surname>Glowienke</surname><given-names>S.</given-names></name>; <name><surname>Van Gompel</surname><given-names>J.</given-names></name>; <name><surname>Harvey</surname><given-names>J.</given-names></name>; <name><surname>Hasselgren</surname><given-names>C.</given-names></name>; <name><surname>Honma</surname><given-names>M.</given-names></name>; <name><surname>Jolly</surname><given-names>R.</given-names></name>; <name><surname>Kemper</surname><given-names>R.</given-names></name>; <name><surname>Kenyon</surname><given-names>M.</given-names></name>; <name><surname>Kruhlak</surname><given-names>N.</given-names></name>; <name><surname>Leavitt</surname><given-names>P.</given-names></name>; <name><surname>Miller</surname><given-names>S.</given-names></name>; <name><surname>Muster</surname><given-names>W.</given-names></name>; <name><surname>Nicolette</surname><given-names>J.</given-names></name>; <name><surname>Plaper</surname><given-names>A.</given-names></name>; <name><surname>Powley</surname><given-names>M.</given-names></name>; <name><surname>Quigley</surname><given-names>D. P.</given-names></name>; <name><surname>Reddy</surname><given-names>M. V.</given-names></name>; <name><surname>Spirkl</surname><given-names>H.-P.</given-names></name>; <name><surname>Stavitskaya</surname><given-names>L.</given-names></name>; <name><surname>Teasdale</surname><given-names>A.</given-names></name>; <name><surname>Weiner</surname><given-names>S.</given-names></name>; <name><surname>Welch</surname><given-names>D. S.</given-names></name>; <name><surname>White</surname><given-names>A.</given-names></name>; <name><surname>Wichard</surname><given-names>J.</given-names></name>; <name><surname>Myatt</surname><given-names>G. J.</given-names></name>
<article-title>Principles and Procedures for Implementation
of ICH M7 Recommended (Q)SAR Analyses</article-title>. <source>Regul.
Toxicol. Pharmacol.</source>
<year>2016</year>, <volume>77</volume>, <fpage>13</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.yrtph.2016.02.004</pub-id>.<pub-id pub-id-type="pmid">26877192</pub-id>
</mixed-citation></ref><ref id="ref344"><mixed-citation publication-type="journal" id="cit344"><name><surname>Bassan</surname><given-names>A.</given-names></name>; <name><surname>Alves</surname><given-names>V. M.</given-names></name>; <name><surname>Amberg</surname><given-names>A.</given-names></name>; <name><surname>Anger</surname><given-names>L. T.</given-names></name>; <name><surname>Auerbach</surname><given-names>S.</given-names></name>; <name><surname>Beilke</surname><given-names>L.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>Cronin</surname><given-names>M. T. D.</given-names></name>; <name><surname>Cross</surname><given-names>K. P.</given-names></name>; <name><surname>Hsieh</surname><given-names>J.-H.</given-names></name>; <name><surname>Greene</surname><given-names>N.</given-names></name>; <name><surname>Kemper</surname><given-names>R.</given-names></name>; <name><surname>Kim</surname><given-names>M. T.</given-names></name>; <name><surname>Mumtaz</surname><given-names>M.</given-names></name>; <name><surname>Noeske</surname><given-names>T.</given-names></name>; <name><surname>Pavan</surname><given-names>M.</given-names></name>; <name><surname>Pletz</surname><given-names>J.</given-names></name>; <name><surname>Russo</surname><given-names>D. P.</given-names></name>; <name><surname>Sabnis</surname><given-names>Y.</given-names></name>; <name><surname>Schaefer</surname><given-names>M.</given-names></name>; <name><surname>Szabo</surname><given-names>D. T.</given-names></name>; <name><surname>Valentin</surname><given-names>J.-P.</given-names></name>; <name><surname>Wichard</surname><given-names>J.</given-names></name>; <name><surname>Williams</surname><given-names>D.</given-names></name>; <name><surname>Woolley</surname><given-names>D.</given-names></name>; <name><surname>Zwickl</surname><given-names>C.</given-names></name>; <name><surname>Myatt</surname><given-names>G. J.</given-names></name>
<article-title>In Silico Approaches
in Organ Toxicity Hazard Assessment: Current Status and Future Needs
in Predicting Liver Toxicity</article-title>. <source>Comput. Toxicol</source>
<year>2021</year>, <volume>20</volume>, <fpage>100187</fpage><pub-id pub-id-type="doi">10.1016/j.comtox.2021.100187</pub-id>.<pub-id pub-id-type="pmid">35340402</pub-id>
</mixed-citation></ref><ref id="ref345"><mixed-citation publication-type="journal" id="cit345"><name><surname>Hornberg</surname><given-names>J. J.</given-names></name>; <name><surname>Laursen</surname><given-names>M.</given-names></name>; <name><surname>Brenden</surname><given-names>N.</given-names></name>; <name><surname>Persson</surname><given-names>M.</given-names></name>; <name><surname>Thougaard</surname><given-names>A. V.</given-names></name>; <name><surname>Toft</surname><given-names>D. B.</given-names></name>; <name><surname>Mow</surname><given-names>T.</given-names></name>
<article-title>Exploratory
Toxicology
as an Integrated Part of Drug Discovery. Part I: Why and How</article-title>. <source>Drug Discovery Today</source>
<year>2014</year>, <volume>19</volume> (<issue>8</issue>), <fpage>1131</fpage>&#x02013;<lpage>1136</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2013.12.008</pub-id>.<pub-id pub-id-type="pmid">24368175</pub-id>
</mixed-citation></ref><ref id="ref346"><mixed-citation publication-type="journal" id="cit346"><name><surname>Lumley</surname><given-names>J. A.</given-names></name>; <name><surname>Fallon</surname><given-names>D.</given-names></name>; <name><surname>Whatling</surname><given-names>R.</given-names></name>; <name><surname>Coupry</surname><given-names>D.</given-names></name>; <name><surname>Brown</surname><given-names>A.</given-names></name>
<article-title>vEXP: A Virtual Enhanced Cross Screen
Panel for off-Target Pharmacology
Alerts</article-title>. <source>Computational Toxicology</source>
<year>2024</year>, <volume>31</volume>, <fpage>100324</fpage><pub-id pub-id-type="doi">10.1016/j.comtox.2024.100324</pub-id>.</mixed-citation></ref><ref id="ref347"><mixed-citation publication-type="journal" id="cit347"><name><surname>Baltazar</surname><given-names>M. T.</given-names></name>; <name><surname>Cable</surname><given-names>S.</given-names></name>; <name><surname>Carmichael</surname><given-names>P. L.</given-names></name>; <name><surname>Cubberley</surname><given-names>R.</given-names></name>; <name><surname>Cull</surname><given-names>T.</given-names></name>; <name><surname>Delagrange</surname><given-names>M.</given-names></name>; <name><surname>Dent</surname><given-names>M. P.</given-names></name>; <name><surname>Hatherell</surname><given-names>S.</given-names></name>; <name><surname>Houghton</surname><given-names>J.</given-names></name>; <name><surname>Kukic</surname><given-names>P.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Lee</surname><given-names>M.-Y.</given-names></name>; <name><surname>Malcomber</surname><given-names>S.</given-names></name>; <name><surname>Middleton</surname><given-names>A. M.</given-names></name>; <name><surname>Moxon</surname><given-names>T. E.</given-names></name>; <name><surname>Nathanail</surname><given-names>A. V.</given-names></name>; <name><surname>Nicol</surname><given-names>B.</given-names></name>; <name><surname>Pendlington</surname><given-names>R.</given-names></name>; <name><surname>Reynolds</surname><given-names>G.</given-names></name>; <name><surname>Reynolds</surname><given-names>J.</given-names></name>; <name><surname>White</surname><given-names>A.</given-names></name>; <name><surname>Westmoreland</surname><given-names>C.</given-names></name>
<article-title>A next-Generation
Risk Assessment Case Study for Coumarin in Cosmetic Products</article-title>. <source>Toxicol. Sci.</source>
<year>2020</year>, <volume>176</volume> (<issue>1</issue>), <fpage>236</fpage>&#x02013;<lpage>252</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfaa048</pub-id>.<pub-id pub-id-type="pmid">32275751</pub-id>
</mixed-citation></ref><ref id="ref348"><mixed-citation publication-type="journal" id="cit348"><name><surname>Ouedraogo</surname><given-names>G.</given-names></name>; <name><surname>Alexander-White</surname><given-names>C.</given-names></name>; <name><surname>Bury</surname><given-names>D.</given-names></name>; <name><surname>Clewell</surname><given-names>H. J.</given-names><suffix>3rd</suffix></name>; <name><surname>Cronin</surname><given-names>M.</given-names></name>; <name><surname>Cull</surname><given-names>T.</given-names></name>; <name><surname>Dent</surname><given-names>M.</given-names></name>; <name><surname>Desprez</surname><given-names>B.</given-names></name>; <name><surname>Detroyer</surname><given-names>A.</given-names></name>; <name><surname>Ellison</surname><given-names>C.</given-names></name>; <name><surname>Giammanco</surname><given-names>S.</given-names></name>; <name><surname>Hack</surname><given-names>E.</given-names></name>; <name><surname>Hewitt</surname><given-names>N. J.</given-names></name>; <name><surname>Kenna</surname><given-names>G.</given-names></name>; <name><surname>Klaric</surname><given-names>M.</given-names></name>; <name><surname>Kreiling</surname><given-names>R.</given-names></name>; <name><surname>Lester</surname><given-names>C.</given-names></name>; <name><surname>Mahony</surname><given-names>C.</given-names></name>; <name><surname>Mombelli</surname><given-names>E.</given-names></name>; <name><surname>Naciff</surname><given-names>J.</given-names></name>; <name><surname>O&#x02019;Brien</surname><given-names>J.</given-names></name>; <name><surname>Schepky</surname><given-names>A.</given-names></name>; <name><surname>Tozer</surname><given-names>S.</given-names></name>; <name><surname>van der Burg</surname><given-names>B.</given-names></name>; <name><surname>van Vugt-Lussenburg</surname><given-names>B.</given-names></name>; <name><surname>Stuard</surname><given-names>S.</given-names></name>
<article-title>Cosmetics Europe. Read-across
and New Approach Methodologies Applied in a 10-Step Framework for
Cosmetics Safety Assessment - A Case Study with Parabens</article-title>. <source>Regul. Toxicol. Pharmacol.</source>
<year>2022</year>, <volume>132</volume>, <fpage>105161</fpage>.<pub-id pub-id-type="pmid">35508214</pub-id>
</mixed-citation></ref><ref id="ref349"><mixed-citation publication-type="journal" id="cit349"><name><surname>Mervin</surname><given-names>L.</given-names></name>; <name><surname>Voronov</surname><given-names>A.</given-names></name>; <name><surname>Kabeshov</surname><given-names>M.</given-names></name>; <name><surname>Engkvist</surname><given-names>O.</given-names></name>
<article-title>QSARtuna:
An Automated QSAR Modeling Platform for Molecular Property Prediction
in Drug Design</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2024</year>, <volume>64</volume>, <fpage>5365</fpage><pub-id pub-id-type="doi">10.1021/acs.jcim.4c00457</pub-id>.<pub-id pub-id-type="pmid">38950185</pub-id>
</mixed-citation></ref><ref id="ref350"><mixed-citation publication-type="journal" id="cit350"><name><surname>Fu</surname><given-names>L.</given-names></name>; <name><surname>Shi</surname><given-names>S.</given-names></name>; <name><surname>Yi</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>N.</given-names></name>; <name><surname>He</surname><given-names>Y.</given-names></name>; <name><surname>Wu</surname><given-names>Z.</given-names></name>; <name><surname>Peng</surname><given-names>J.</given-names></name>; <name><surname>Deng</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>W.</given-names></name>; <name><surname>Wu</surname><given-names>C.</given-names></name>; <name><surname>Lyu</surname><given-names>A.</given-names></name>; <name><surname>Zeng</surname><given-names>X.</given-names></name>; <name><surname>Zhao</surname><given-names>W.</given-names></name>; <name><surname>Hou</surname><given-names>T.</given-names></name>; <name><surname>Cao</surname><given-names>D.</given-names></name>
<article-title>ADMETlab 3.0:
An Updated Comprehensive Online ADMET Prediction Platform Enhanced
with Broader Coverage, Improved Performance, API Functionality and
Decision Support</article-title>. <source>Nucleic Acids Res.</source>
<year>2024</year>, <volume>52</volume> (<issue>W1</issue>), <fpage>W422</fpage>&#x02013;<lpage>W431</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkae236</pub-id>.<pub-id pub-id-type="pmid">38572755</pub-id>
</mixed-citation></ref><ref id="ref352"><mixed-citation publication-type="journal" id="cit352"><name><surname>Ruusmann</surname><given-names>V.</given-names></name>; <name><surname>Sild</surname><given-names>S.</given-names></name>; <name><surname>Maran</surname><given-names>U.</given-names></name>
<article-title>QSAR DataBank - an
Approach for the Digital Organization and Archiving of QSAR Model
Information</article-title>. <source>J. Cheminform.</source>
<year>2014</year>, <volume>6</volume> (<issue>1</issue>), <fpage>25</fpage><pub-id pub-id-type="doi">10.1186/1758-2946-6-25</pub-id>.<pub-id pub-id-type="pmid">24910716</pub-id>
</mixed-citation></ref><ref id="ref353"><mixed-citation publication-type="journal" id="cit353"><name><surname>Sushko</surname><given-names>I.</given-names></name>; <name><surname>Novotarskyi</surname><given-names>S.</given-names></name>; <name><surname>K&#x000f6;rner</surname><given-names>R.</given-names></name>; <name><surname>Pandey</surname><given-names>A. K.</given-names></name>; <name><surname>Rupp</surname><given-names>M.</given-names></name>; <name><surname>Teetz</surname><given-names>W.</given-names></name>; <name><surname>Brandmaier</surname><given-names>S.</given-names></name>; <name><surname>Abdelaziz</surname><given-names>A.</given-names></name>; <name><surname>Prokopenko</surname><given-names>V. V.</given-names></name>; <name><surname>Tanchuk</surname><given-names>V. Y.</given-names></name>; <name><surname>Todeschini</surname><given-names>R.</given-names></name>; <name><surname>Varnek</surname><given-names>A.</given-names></name>; <name><surname>Marcou</surname><given-names>G.</given-names></name>; <name><surname>Ertl</surname><given-names>P.</given-names></name>; <name><surname>Potemkin</surname><given-names>V.</given-names></name>; <name><surname>Grishina</surname><given-names>M.</given-names></name>; <name><surname>Gasteiger</surname><given-names>J.</given-names></name>; <name><surname>Schwab</surname><given-names>C.</given-names></name>; <name><surname>Baskin</surname><given-names>I. I.</given-names></name>; <name><surname>Palyulin</surname><given-names>V. A.</given-names></name>; <name><surname>Radchenko</surname><given-names>E. V.</given-names></name>; <name><surname>Welsh</surname><given-names>W. J.</given-names></name>; <name><surname>Kholodovych</surname><given-names>V.</given-names></name>; <name><surname>Chekmarev</surname><given-names>D.</given-names></name>; <name><surname>Cherkasov</surname><given-names>A.</given-names></name>; <name><surname>Aires-de-Sousa</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>Q.-Y.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>Nigsch</surname><given-names>F.</given-names></name>; <name><surname>Patiny</surname><given-names>L.</given-names></name>; <name><surname>Williams</surname><given-names>A.</given-names></name>; <name><surname>Tkachenko</surname><given-names>V.</given-names></name>; <name><surname>Tetko</surname><given-names>I. V.</given-names></name>
<article-title>Online Chemical
Modeling Environment (OCHEM): Web Platform for Data Storage, Model
Development and Publishing of Chemical Information</article-title>. <source>J. Comput. Aided Mol. Des.</source>
<year>2011</year>, <volume>25</volume> (<issue>6</issue>), <fpage>533</fpage>&#x02013;<lpage>554</lpage>. <pub-id pub-id-type="doi">10.1007/s10822-011-9440-2</pub-id>.<pub-id pub-id-type="pmid">21660515</pub-id>
</mixed-citation></ref><ref id="ref354"><mixed-citation publication-type="book" id="cit354"><person-group person-group-type="allauthors"><name><surname>Nikolov</surname><given-names>N. G.</given-names></name>; <name><surname>Wedebye</surname><given-names>E. B.</given-names></name></person-group><article-title>The Danish
(Q) SAR Database: Recent Updates</article-title>. In <source>SOT Annual
Meeting and ToxExpo 2022</source>; <publisher-name>Society of Toxicology</publisher-name>, <year>2022</year>; pp <fpage>437</fpage>&#x02013;<lpage>437</lpage>.</mixed-citation></ref><ref id="ref355"><mixed-citation publication-type="journal" id="cit355"><person-group person-group-type="allauthors"><name><surname>Seal</surname><given-names>S.</given-names></name>; <name><surname>Williams</surname><given-names>D. P.</given-names></name>; <name><surname>Hosseini-Gerami</surname><given-names>L.</given-names></name>; <name><surname>Spjuth</surname><given-names>O.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name></person-group><article-title>Improved
Early Detection of Drug-Induced Liver Injury by Integrating Predicted
in Vivo and in Vitro Data</article-title>. <source>bioArxiv</source><year>2024</year>,<pub-id pub-id-type="doi">10.1101/2024.01.10.575128</pub-id>.</mixed-citation></ref><ref id="ref356"><mixed-citation publication-type="journal" id="cit356"><name><surname>Card</surname><given-names>M. L.</given-names></name>; <name><surname>Gomez-Alvarez</surname><given-names>V.</given-names></name>; <name><surname>Lee</surname><given-names>W.-H.</given-names></name>; <name><surname>Lynch</surname><given-names>D. G.</given-names></name>; <name><surname>Orentas</surname><given-names>N. S.</given-names></name>; <name><surname>Lee</surname><given-names>M. T.</given-names></name>; <name><surname>Wong</surname><given-names>E. M.</given-names></name>; <name><surname>Boethling</surname><given-names>R. S.</given-names></name>
<article-title>History
of EPI Suite<sup>TM</sup> and Future Perspectives on Chemical Property
Estimation in US Toxic Substances Control Act New Chemical Risk Assessments</article-title>. <source>Environ. Sci. Process. Impacts</source>
<year>2017</year>, <volume>19</volume> (<issue>3</issue>), <fpage>203</fpage>&#x02013;<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1039/C7EM00064B</pub-id>.<pub-id pub-id-type="pmid">28275775</pub-id>
</mixed-citation></ref><ref id="ref357"><mixed-citation publication-type="journal" id="cit357"><name><surname>Ji</surname><given-names>C.</given-names></name>; <name><surname>Svensson</surname><given-names>F.</given-names></name>; <name><surname>Zoufir</surname><given-names>A.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>
<article-title>eMolTox: Prediction
of Molecular Toxicity with Confidence</article-title>. <source>Bioinformatics</source>
<year>2018</year>, <volume>34</volume> (<issue>14</issue>), <fpage>2508</fpage>&#x02013;<lpage>2509</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bty135</pub-id>.<pub-id pub-id-type="pmid">29522123</pub-id>
</mixed-citation></ref><ref id="ref358"><mixed-citation publication-type="journal" id="cit358"><name><surname>Schultz</surname><given-names>T. W.</given-names></name>; <name><surname>Diderich</surname><given-names>R.</given-names></name>; <name><surname>Kuseva</surname><given-names>C. D.</given-names></name>; <name><surname>Mekenyan</surname><given-names>O. G.</given-names></name>
<article-title>The OECD
QSAR Toolbox Starts Its Second Decade</article-title>. <source>Methods
Mol. Biol.</source>
<year>2018</year>, <volume>1800</volume>, <fpage>55</fpage>&#x02013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-7899-1_2</pub-id>.<pub-id pub-id-type="pmid">29934887</pub-id>
</mixed-citation></ref><ref id="ref359"><mixed-citation publication-type="journal" id="cit359"><name><surname>Pires</surname><given-names>D. E. V.</given-names></name>; <name><surname>Blundell</surname><given-names>T. L.</given-names></name>; <name><surname>Ascher</surname><given-names>D. B.</given-names></name>
<article-title>pkCSM: Predicting
Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based
Signatures</article-title>. <source>J. Med. Chem.</source>
<year>2015</year>, <volume>58</volume> (<issue>9</issue>), <fpage>4066</fpage>&#x02013;<lpage>4072</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00104</pub-id>.<pub-id pub-id-type="pmid">25860834</pub-id>
</mixed-citation></ref><ref id="ref360"><mixed-citation publication-type="journal" id="cit360"><name><surname>Banerjee</surname><given-names>P.</given-names></name>; <name><surname>Kemmler</surname><given-names>E.</given-names></name>; <name><surname>Dunkel</surname><given-names>M.</given-names></name>; <name><surname>Preissner</surname><given-names>R.</given-names></name>
<article-title>ProTox 3.0:
A Webserver for the Prediction of Toxicity of Chemicals</article-title>. <source>Nucleic Acids Res.</source>
<year>2024</year>, <volume>52</volume> (<issue>W1</issue>), <fpage>W513</fpage>&#x02013;<lpage>W520</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkae303</pub-id>.<pub-id pub-id-type="pmid">38647086</pub-id>
</mixed-citation></ref><ref id="ref361"><mixed-citation publication-type="journal" id="cit361"><name><surname>Daina</surname><given-names>A.</given-names></name>; <name><surname>Michielin</surname><given-names>O.</given-names></name>; <name><surname>Zoete</surname><given-names>V.</given-names></name>
<article-title>SwissADME: A Free Web
Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry
Friendliness of Small Molecules</article-title>. <source>Sci. Rep.</source>
<year>2017</year>, <volume>7</volume>, <fpage>42717</fpage><pub-id pub-id-type="doi">10.1038/srep42717</pub-id>.<pub-id pub-id-type="pmid">28256516</pub-id>
</mixed-citation></ref><ref id="ref362"><mixed-citation publication-type="journal" id="cit362"><name><surname>Patlewicz</surname><given-names>G.</given-names></name>; <name><surname>Jeliazkova</surname><given-names>N.</given-names></name>; <name><surname>Safford</surname><given-names>R. J.</given-names></name>; <name><surname>Worth</surname><given-names>A. P.</given-names></name>; <name><surname>Aleksiev</surname><given-names>B.</given-names></name>
<article-title>An Evaluation of the
Implementation of the Cramer Classification
Scheme in the Toxtree Software</article-title>. <source>SAR QSAR Environ.
Res.</source>
<year>2008</year>, <volume>19</volume> (<issue>5&#x02013;6</issue>), <fpage>495</fpage>&#x02013;<lpage>524</lpage>. <pub-id pub-id-type="doi">10.1080/10629360802083871</pub-id>.<pub-id pub-id-type="pmid">18853299</pub-id>
</mixed-citation></ref><ref id="ref363"><mixed-citation publication-type="weblink" id="cit363"><source>VEGA HUB - Virtual models for property Evaluation of chemicals
within
a Global Architecture</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.vegahub.eu/">https://www.vegahub.eu/</uri> (accessed 2024-07-12).</mixed-citation></ref><ref id="ref364"><mixed-citation publication-type="journal" id="cit364"><name><surname>Di Stefano</surname><given-names>M.</given-names></name>; <name><surname>Galati</surname><given-names>S.</given-names></name>; <name><surname>Piazza</surname><given-names>L.</given-names></name>; <name><surname>Granchi</surname><given-names>C.</given-names></name>; <name><surname>Mancini</surname><given-names>S.</given-names></name>; <name><surname>Fratini</surname><given-names>F.</given-names></name>; <name><surname>Macchia</surname><given-names>M.</given-names></name>; <name><surname>Poli</surname><given-names>G.</given-names></name>; <name><surname>Tuccinardi</surname><given-names>T.</given-names></name>
<article-title>VenomPred 2.0: A Novel In Silico Platform for an Extended
and Human Interpretable Toxicological Profiling of Small Molecules</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2024</year>, <volume>64</volume> (<issue>7</issue>), <fpage>2275</fpage>&#x02013;<lpage>2289</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.3c00692</pub-id>.<pub-id pub-id-type="pmid">37676238</pub-id>
</mixed-citation></ref><ref id="ref365"><mixed-citation publication-type="journal" id="cit365"><name><surname>Stankovic</surname><given-names>B.</given-names></name>; <name><surname>Marinkovic</surname><given-names>F.</given-names></name>
<article-title>A Novel Procedure
for Selection of
Molecular Descriptors: QSAR Model for Mutagenicity of Nitroaromatic
Compounds</article-title>. <source>Environ. Sci. Pollut. Res. Int.</source>
<year>2024</year>, <volume>31</volume>, <fpage>54603</fpage><pub-id pub-id-type="doi">10.1007/s11356-024-34800-x</pub-id>.<pub-id pub-id-type="pmid">39207617</pub-id>
</mixed-citation></ref><ref id="ref366"><mixed-citation publication-type="journal" id="cit366"><name><surname>Enoch</surname><given-names>S. J.</given-names></name>; <name><surname>Roberts</surname><given-names>D. W.</given-names></name>
<article-title>Predicting Skin
Sensitization Potency
for Michael Acceptors in the LLNA Using Quantum Mechanics Calculations</article-title>. <source>Chem. Res. Toxicol.</source>
<year>2013</year>, <volume>26</volume> (<issue>5</issue>), <fpage>767</fpage>&#x02013;<lpage>774</lpage>. <pub-id pub-id-type="doi">10.1021/tx4000655</pub-id>.<pub-id pub-id-type="pmid">23611145</pub-id>
</mixed-citation></ref><ref id="ref367"><mixed-citation publication-type="journal" id="cit367"><name><surname>Limban</surname><given-names>C.</given-names></name>; <name><surname>Nu&#x00163;&#x001ce;</surname><given-names>D.
C.</given-names></name>; <name><surname>Chiri&#x00163;&#x001ce;</surname><given-names>C.</given-names></name>; <name><surname>Negre&#x0015f;</surname><given-names>S.</given-names></name>; <name><surname>Arsene</surname><given-names>A. L.</given-names></name>; <name><surname>Goumenou</surname><given-names>M.</given-names></name>; <name><surname>Karakitsios</surname><given-names>S. P.</given-names></name>; <name><surname>Tsatsakis</surname><given-names>A. M.</given-names></name>; <name><surname>Sarigiannis</surname><given-names>D. A.</given-names></name>
<article-title>The Use of Structural Alerts to Avoid
the Toxicity of Pharmaceuticals</article-title>. <source>Toxicol Rep</source>
<year>2018</year>, <volume>5</volume>, <fpage>943</fpage>&#x02013;<lpage>953</lpage>. <pub-id pub-id-type="doi">10.1016/j.toxrep.2018.08.017</pub-id>.<pub-id pub-id-type="pmid">30258789</pub-id>
</mixed-citation></ref><ref id="ref368"><mixed-citation publication-type="journal" id="cit368"><name><surname>Rodgers</surname><given-names>S.</given-names></name>; <name><surname>Glen</surname><given-names>R. C.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>
<article-title>Characterizing
Bitterness:
Identification of Key Structural Features and Development of a Classification
Model</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2006</year>, <volume>46</volume> (<issue>2</issue>), <fpage>569</fpage>&#x02013;<lpage>576</lpage>. <pub-id pub-id-type="doi">10.1021/ci0504418</pub-id>.<pub-id pub-id-type="pmid">16562985</pub-id>
</mixed-citation></ref><ref id="ref369"><mixed-citation publication-type="journal" id="cit369"><name><surname>Zadeh</surname><given-names>L. A.</given-names></name>
<article-title>Fuzzy Logic&#x02014;a Personal Perspective</article-title>. <source>Fuzzy Sets and Systems</source>
<year>2015</year>, <volume>281</volume>, <fpage>4</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.fss.2015.05.009</pub-id>.</mixed-citation></ref><ref id="ref370"><mixed-citation publication-type="journal" id="cit370"><name><surname>Chen</surname><given-names>M.</given-names></name>; <name><surname>Borlak</surname><given-names>J.</given-names></name>; <name><surname>Tong</surname><given-names>W.</given-names></name>
<article-title>High Lipophilicity
and High Daily Dose of Oral Medications Are Associated with Significant
Risk for Drug-Induced Liver Injury</article-title>. <source>Hepatology</source>
<year>2013</year>, <volume>58</volume> (<issue>1</issue>), <fpage>388</fpage>&#x02013;<lpage>396</lpage>. <pub-id pub-id-type="doi">10.1002/hep.26208</pub-id>.<pub-id pub-id-type="pmid">23258593</pub-id>
</mixed-citation></ref><ref id="ref371"><mixed-citation publication-type="journal" id="cit371"><name><surname>Friederichs</surname><given-names>M.</given-names></name>; <name><surname>Fr&#x000e4;nzle</surname><given-names>O.</given-names></name>; <name><surname>Salski</surname><given-names>A.</given-names></name>
<article-title>Fuzzy Clustering of
Existing Chemicals according to Their Ecotoxicological Properties</article-title>. <source>Ecol. Modell.</source>
<year>1996</year>, <volume>85</volume> (<issue>1</issue>), <fpage>27</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/0304-3800(95)00009-7</pub-id>.</mixed-citation></ref><ref id="ref372"><mixed-citation publication-type="journal" id="cit372"><name><surname>Blomme</surname><given-names>E. A. G.</given-names></name>; <name><surname>Will</surname><given-names>Y.</given-names></name>
<article-title>Toxicology Strategies
for Drug Discovery:
Present and Future</article-title>. <source>Chem. Res. Toxicol.</source>
<year>2016</year>, <volume>29</volume> (<issue>4</issue>), <fpage>473</fpage>&#x02013;<lpage>504</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.5b00407</pub-id>.<pub-id pub-id-type="pmid">26588328</pub-id>
</mixed-citation></ref><ref id="ref373"><mixed-citation publication-type="journal" id="cit373"><name><surname>Stepan</surname><given-names>A. F.</given-names></name>; <name><surname>Walker</surname><given-names>D. P.</given-names></name>; <name><surname>Bauman</surname><given-names>J.</given-names></name>; <name><surname>Price</surname><given-names>D. A.</given-names></name>; <name><surname>Baillie</surname><given-names>T. A.</given-names></name>; <name><surname>Kalgutkar</surname><given-names>A. S.</given-names></name>; <name><surname>Aleo</surname><given-names>M. D.</given-names></name>
<article-title>Structural Alert/reactive
Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the
Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical
Examination of Trends in the Top 200 Drugs Marketed in the United
States</article-title>. <source>Chem. Res. Toxicol.</source>
<year>2011</year>, <volume>24</volume> (<issue>9</issue>), <fpage>1345</fpage>&#x02013;<lpage>1410</lpage>. <pub-id pub-id-type="doi">10.1021/tx200168d</pub-id>.<pub-id pub-id-type="pmid">21702456</pub-id>
</mixed-citation></ref><ref id="ref374"><mixed-citation publication-type="journal" id="cit374"><name><surname>Dambach</surname><given-names>D. M.</given-names></name>; <name><surname>Misner</surname><given-names>D.</given-names></name>; <name><surname>Brock</surname><given-names>M.</given-names></name>; <name><surname>Fullerton</surname><given-names>A.</given-names></name>; <name><surname>Proctor</surname><given-names>W.</given-names></name>; <name><surname>Maher</surname><given-names>J.</given-names></name>; <name><surname>Lee</surname><given-names>D.</given-names></name>; <name><surname>Ford</surname><given-names>K.</given-names></name>; <name><surname>Diaz</surname><given-names>D.</given-names></name>
<article-title>Safety Lead Optimization and Candidate
Identification: Integrating
New Technologies into Decision-Making</article-title>. <source>Chem.
Res. Toxicol.</source>
<year>2016</year>, <volume>29</volume> (<issue>4</issue>), <fpage>452</fpage>&#x02013;<lpage>472</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.5b00396</pub-id>.<pub-id pub-id-type="pmid">26625186</pub-id>
</mixed-citation></ref><ref id="ref375"><mixed-citation publication-type="journal" id="cit375"><name><surname>Altmann</surname><given-names>A.</given-names></name>; <name><surname>Tolo&#x0015f;i</surname><given-names>L.</given-names></name>; <name><surname>Sander</surname><given-names>O.</given-names></name>; <name><surname>Lengauer</surname><given-names>T.</given-names></name>
<article-title>Permutation
Importance: A Corrected Feature Importance Measure</article-title>. <source>Bioinformatics</source>
<year>2010</year>, <volume>26</volume> (<issue>10</issue>), <fpage>1340</fpage>&#x02013;<lpage>1347</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btq134</pub-id>.<pub-id pub-id-type="pmid">20385727</pub-id>
</mixed-citation></ref><ref id="ref376"><mixed-citation publication-type="journal" id="cit376"><person-group person-group-type="allauthors"><name><surname>Ribeiro</surname><given-names>M. T.</given-names></name>; <name><surname>Singh</surname><given-names>S.</given-names></name>; <name><surname>Guestrin</surname><given-names>C.</given-names></name></person-group><article-title>&#x0201c;Why
Should
I Trust You?&#x0201d;: Explaining the Predictions of Any Classifier</article-title>. <source>arXiv [cs.LG]</source>, <year>2016</year>.<pub-id pub-id-type="doi">10.48550/arXiv.1602.04938</pub-id>.</mixed-citation></ref><ref id="ref377"><mixed-citation publication-type="journal" id="cit377"><name><surname>Ponzoni</surname><given-names>I.</given-names></name>; <name><surname>Sebasti&#x000e1;n-P&#x000e9;rez</surname><given-names>V.</given-names></name>; <name><surname>Requena-Triguero</surname><given-names>C.</given-names></name>; <name><surname>Roca</surname><given-names>C.</given-names></name>; <name><surname>Mart&#x000ed;nez</surname><given-names>M. J.</given-names></name>; <name><surname>Cravero</surname><given-names>F.</given-names></name>; <name><surname>D&#x000ed;az</surname><given-names>M. F.</given-names></name>; <name><surname>P&#x000e1;ez</surname><given-names>J. A.</given-names></name>; <name><surname>Array&#x000e1;s</surname><given-names>R. G.</given-names></name>; <name><surname>Adrio</surname><given-names>J.</given-names></name>; <name><surname>Campillo</surname><given-names>N. E.</given-names></name>
<article-title>Hybridizing Feature
Selection and Feature Learning Approaches in QSAR Modeling for Drug
Discovery</article-title>. <source>Sci. Rep.</source>
<year>2017</year>, <volume>7</volume> (<issue>1</issue>), <fpage>2403</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-02114-3</pub-id>.<pub-id pub-id-type="pmid">28546583</pub-id>
</mixed-citation></ref><ref id="ref378"><mixed-citation publication-type="journal" id="cit378"><name><surname>Bolboaca</surname><given-names>S. D.</given-names></name>; <name><surname>J&#x000e4;ntschi</surname><given-names>L.</given-names></name>
<article-title>Quantitative
Structure-Activity Relationships:
Linear Regression Modelling and Validation Strategies by Example</article-title>. <source>BIOMATH</source>
<year>2013</year>, <volume>2</volume> (<issue>1</issue>), <fpage>1309089</fpage><pub-id pub-id-type="doi">10.11145/j.biomath.2013.09.089</pub-id>.</mixed-citation></ref><ref id="ref379"><mixed-citation publication-type="journal" id="cit379"><name><surname>Venkatraman</surname><given-names>V.</given-names></name>; <name><surname>Dalby</surname><given-names>A. R.</given-names></name>; <name><surname>Yang</surname><given-names>Z. R.</given-names></name>
<article-title>Evaluation
of Mutual
Information and Genetic Programming for Feature Selection in QSAR</article-title>. <source>J. Chem. Inf. Comput. Sci.</source>
<year>2004</year>, <volume>44</volume> (<issue>5</issue>), <fpage>1686</fpage>&#x02013;<lpage>1692</lpage>. <pub-id pub-id-type="doi">10.1021/ci049933v</pub-id>.<pub-id pub-id-type="pmid">15446827</pub-id>
</mixed-citation></ref><ref id="ref380"><mixed-citation publication-type="journal" id="cit380"><name><surname>Wellawatte</surname><given-names>G. P.</given-names></name>; <name><surname>Seshadri</surname><given-names>A.</given-names></name>; <name><surname>White</surname><given-names>A. D.</given-names></name>
<article-title>Model Agnostic
Generation
of Counterfactual Explanations for Molecules</article-title>. <source>Chem. Sci.</source>
<year>2022</year>, <volume>13</volume> (<issue>13</issue>), <fpage>3697</fpage>&#x02013;<lpage>3705</lpage>. <pub-id pub-id-type="doi">10.1039/D1SC05259D</pub-id>.<pub-id pub-id-type="pmid">35432902</pub-id>
</mixed-citation></ref><ref id="ref381"><mixed-citation publication-type="journal" id="cit381"><name><surname>Czub</surname><given-names>N.</given-names></name>; <name><surname>Pac&#x00142;awski</surname><given-names>A.</given-names></name>; <name><surname>Szl&#x00229;k</surname><given-names>J.</given-names></name>; <name><surname>Mendyk</surname><given-names>A.</given-names></name>
<article-title>Do AutoML-Based QSAR
Models Fulfill OECD Principles
for Regulatory Assessment? A 5-HT1A Receptor Case</article-title>. <source>Pharmaceutics</source>
<year>2022</year>, <volume>14</volume> (<issue>7</issue>), <fpage>1415</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics14071415</pub-id>.<pub-id pub-id-type="pmid">35890310</pub-id>
</mixed-citation></ref><ref id="ref382"><mixed-citation publication-type="journal" id="cit382"><name><surname>Sushko</surname><given-names>Y.</given-names></name>; <name><surname>Novotarskyi</surname><given-names>S.</given-names></name>; <name><surname>K&#x000f6;rner</surname><given-names>R.</given-names></name>; <name><surname>Vogt</surname><given-names>J.</given-names></name>; <name><surname>Abdelaziz</surname><given-names>A.</given-names></name>; <name><surname>Tetko</surname><given-names>I. V.</given-names></name>
<article-title>Prediction-Driven
Matched Molecular Pairs to Interpret QSARs and Aid the Molecular Optimization
Process</article-title>. <source>J. Cheminform.</source>
<year>2014</year>, <volume>6</volume> (<issue>1</issue>), <fpage>48</fpage><pub-id pub-id-type="doi">10.1186/s13321-014-0048-0</pub-id>.<pub-id pub-id-type="pmid">25544551</pub-id>
</mixed-citation></ref><ref id="ref383"><mixed-citation publication-type="journal" id="cit383"><name><surname>Antczak</surname><given-names>P.</given-names></name>; <name><surname>Ortega</surname><given-names>F.</given-names></name>; <name><surname>Chipman</surname><given-names>J. K.</given-names></name>; <name><surname>Falciani</surname><given-names>F.</given-names></name>
<article-title>Mapping Drug
Physico-Chemical Features to Pathway Activity Reveals Molecular Networks
Linked to Toxicity Outcome</article-title>. <source>PLoS One</source>
<year>2010</year>, <volume>5</volume> (<issue>8</issue>), <elocation-id>e12385</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0012385</pub-id>.<pub-id pub-id-type="pmid">20811577</pub-id>
</mixed-citation></ref><ref id="ref384"><mixed-citation publication-type="journal" id="cit384"><name><surname>Kr&#x000e4;mer</surname><given-names>A.</given-names></name>; <name><surname>Green</surname><given-names>J.</given-names></name>; <name><surname>Pollard</surname><given-names>J.</given-names><suffix>Jr</suffix></name>; <name><surname>Tugendreich</surname><given-names>S.</given-names></name>
<article-title>Causal Analysis Approaches in Ingenuity
Pathway Analysis</article-title>. <source>Bioinformatics</source>
<year>2014</year>, <volume>30</volume> (<issue>4</issue>), <fpage>523</fpage>&#x02013;<lpage>530</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btt703</pub-id>.<pub-id pub-id-type="pmid">24336805</pub-id>
</mixed-citation></ref><ref id="ref385"><mixed-citation publication-type="journal" id="cit385"><name><surname>Mayburd</surname><given-names>A. L.</given-names></name>; <name><surname>Martl&#x000ed;nez</surname><given-names>A.</given-names></name>; <name><surname>Sackett</surname><given-names>D.</given-names></name>; <name><surname>Liu</surname><given-names>H.</given-names></name>; <name><surname>Shih</surname><given-names>J.</given-names></name>; <name><surname>Tauler</surname><given-names>J.</given-names></name>; <name><surname>Avis</surname><given-names>I.</given-names></name>; <name><surname>Mulshine</surname><given-names>J. L.</given-names></name>
<article-title>Ingenuity
Network-Assisted Transcription Profiling: Identification of a New
Pharmacologic Mechanism for MK886</article-title>. <source>Clin. Cancer
Res.</source>
<year>2006</year>, <volume>12</volume> (<issue>6</issue>), <fpage>1820</fpage>&#x02013;<lpage>1827</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-2149</pub-id>.<pub-id pub-id-type="pmid">16551867</pub-id>
</mixed-citation></ref><ref id="ref386"><mixed-citation publication-type="journal" id="cit386"><name><surname>Huang</surname><given-names>L.-C.</given-names></name>; <name><surname>Wu</surname><given-names>X.</given-names></name>; <name><surname>Chen</surname><given-names>J. Y.</given-names></name>
<article-title>Predicting Adverse
Drug Reaction Profiles by Integrating Protein Interaction Networks
with Drug Structures</article-title>. <source>Proteomics</source>
<year>2013</year>, <volume>13</volume> (<issue>2</issue>), <fpage>313</fpage>&#x02013;<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1002/pmic.201200337</pub-id>.<pub-id pub-id-type="pmid">23184540</pub-id>
</mixed-citation></ref><ref id="ref387"><mixed-citation publication-type="journal" id="cit387"><name><surname>Feyen</surname><given-names>E.</given-names></name>; <name><surname>Cools</surname><given-names>J.</given-names></name>; <name><surname>Van Fraeyenhove</surname><given-names>J.</given-names></name>; <name><surname>Tubeeckx</surname><given-names>M.</given-names></name>; <name><surname>De Winter</surname><given-names>H.</given-names></name>; <name><surname>Audenaert</surname><given-names>D.</given-names></name>; <name><surname>De Keulenaer</surname><given-names>G. W.</given-names></name>; <name><surname>Segers</surname><given-names>V. F.</given-names></name>
<article-title>Identification of Small-Molecule
ERBB4 Agonists for the Treatment of Heart Failure</article-title>. <source>Cardiovasc. Res.</source>
<year>2022</year>, <volume>118</volume> (<issue>Supplement_1</issue>), <fpage>cvac066.098</fpage><pub-id pub-id-type="doi">10.1093/cvr/cvac066.098</pub-id>.</mixed-citation></ref><ref id="ref388"><mixed-citation publication-type="journal" id="cit388"><name><surname>Hosseini-Gerami</surname><given-names>L.</given-names></name>; <name><surname>Higgins</surname><given-names>I. A.</given-names></name>; <name><surname>Collier</surname><given-names>D. A.</given-names></name>; <name><surname>Laing</surname><given-names>E.</given-names></name>; <name><surname>Evans</surname><given-names>D.</given-names></name>; <name><surname>Broughton</surname><given-names>H.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>
<article-title>Benchmarking Causal
Reasoning Algorithms for Gene Expression-Based Compound Mechanism
of Action Analysis</article-title>. <source>BMC Bioinformatics</source>
<year>2023</year>, <volume>24</volume> (<issue>1</issue>), <fpage>154</fpage><pub-id pub-id-type="doi">10.1186/s12859-023-05277-1</pub-id>.<pub-id pub-id-type="pmid">37072707</pub-id>
</mixed-citation></ref><ref id="ref389"><mixed-citation publication-type="journal" id="cit389"><name><surname>Louw</surname><given-names>C.</given-names></name>; <name><surname>Truter</surname><given-names>N.</given-names></name>; <name><surname>Bergh</surname><given-names>W.</given-names></name>; <name><surname>van den
Heever</surname><given-names>M.</given-names></name>; <name><surname>Horn</surname><given-names>S.</given-names></name>; <name><surname>Oudrhiri</surname><given-names>R.</given-names></name>; <name><surname>van Niekerk</surname><given-names>D.</given-names></name>; <name><surname>Loos</surname><given-names>B.</given-names></name>; <name><surname>Singh</surname><given-names>R.</given-names></name>
<article-title>ALaSCA: A Novel in Silico Simulation
Platform to Untangle Biological Pathway Mechanisms, with a Case Study
in Type 1 Diabetes Progression</article-title>. <source>bioRxiv</source>
<year>2023</year>, <pub-id pub-id-type="doi">10.1101/2023.03.16.532913</pub-id>.</mixed-citation></ref><ref id="ref390"><mixed-citation publication-type="journal" id="cit390"><name><surname>Farrell</surname><given-names>D. J.</given-names></name>; <name><surname>Bower</surname><given-names>L.</given-names></name>
<article-title>Fatal Water Intoxication</article-title>. <source>J. Clin. Pathol.</source>
<year>2003</year>, <volume>56</volume> (<issue>10</issue>), <fpage>803</fpage>&#x02013;<lpage>804</lpage>. <pub-id pub-id-type="doi">10.1136/jcp.56.10.803-a</pub-id>.</mixed-citation></ref><ref id="ref391"><mixed-citation publication-type="journal" id="cit391"><name><surname>Walker</surname><given-names>D. K.</given-names></name>
<article-title>The Use of Pharmacokinetic and Pharmacodynamic
Data
in the Assessment of Drug Safety in Early Drug Development</article-title>. <source>Br. J. Clin. Pharmacol.</source>
<year>2004</year>, <volume>58</volume> (<issue>6</issue>), <fpage>601</fpage>&#x02013;<lpage>608</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2125.2004.02194.x</pub-id>.<pub-id pub-id-type="pmid">15563358</pub-id>
</mixed-citation></ref><ref id="ref392"><mixed-citation publication-type="journal" id="cit392"><name><surname>Bassani</surname><given-names>D.</given-names></name>; <name><surname>Parrott</surname><given-names>N. J.</given-names></name>; <name><surname>Manevski</surname><given-names>N.</given-names></name>; <name><surname>Zhang</surname><given-names>J. D.</given-names></name>
<article-title>Another
String to Your Bow: Machine Learning Prediction of the Pharmacokinetic
Properties of Small Molecules</article-title>. <source>Expert Opin.
Drug Discovery</source>
<year>2024</year>, <volume>19</volume> (<issue>6</issue>), <fpage>683</fpage>&#x02013;<lpage>698</lpage>. <pub-id pub-id-type="doi">10.1080/17460441.2024.2348157</pub-id>.</mixed-citation></ref><ref id="ref393"><mixed-citation publication-type="journal" id="cit393"><person-group person-group-type="allauthors"><name><surname>Mavroudis</surname><given-names>P. D.</given-names></name>; <name><surname>Teutonico</surname><given-names>D.</given-names></name>; <name><surname>Abos</surname><given-names>A.</given-names></name>; <name><surname>Pillai</surname><given-names>N.</given-names></name></person-group><article-title>Application of
Machine Learning
in Combination with Mechanistic Modeling to Predict Plasma Exposure
of Small Molecules</article-title>. <source>Front. Syst. Biol.</source><year>2023</year>, <volume>3</volume>.<pub-id pub-id-type="doi">10.3389/fsysb.2023.1180948</pub-id>.</mixed-citation></ref><ref id="ref394"><mixed-citation publication-type="journal" id="cit394"><name><surname>Schneckener</surname><given-names>S.</given-names></name>; <name><surname>Grimbs</surname><given-names>S.</given-names></name>; <name><surname>Hey</surname><given-names>J.</given-names></name>; <name><surname>Menz</surname><given-names>S.</given-names></name>; <name><surname>Osmers</surname><given-names>M.</given-names></name>; <name><surname>Schaper</surname><given-names>S.</given-names></name>; <name><surname>Hillisch</surname><given-names>A.</given-names></name>; <name><surname>G&#x000f6;ller</surname><given-names>A. H.</given-names></name>
<article-title>Prediction
of Oral Bioavailability in Rats: Transferring Insights from in Vitro
Correlations to (deep) Machine Learning Models Using in Silico Model
Outputs and Chemical Structure Parameters</article-title>. <source>J.
Chem. Inf. Model.</source>
<year>2019</year>, <volume>59</volume> (<issue>11</issue>), <fpage>4893</fpage>&#x02013;<lpage>4905</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.9b00460</pub-id>.<pub-id pub-id-type="pmid">31714067</pub-id>
</mixed-citation></ref><ref id="ref395"><mixed-citation publication-type="journal" id="cit395"><name><surname>Andrews-Morger</surname><given-names>A.</given-names></name>; <name><surname>Reutlinger</surname><given-names>M.</given-names></name>; <name><surname>Parrott</surname><given-names>N.</given-names></name>; <name><surname>Olivares-Morales</surname><given-names>A.</given-names></name>
<article-title>A Machine
Learning Framework to Improve Rat Clearance Predictions and Inform
Physiologically Based Pharmacokinetic Modeling</article-title>. <source>Mol. Pharmaceutics</source>
<year>2023</year>, <volume>20</volume> (<issue>10</issue>), <fpage>5052</fpage>&#x02013;<lpage>5065</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.3c00374</pub-id>.</mixed-citation></ref><ref id="ref396"><mixed-citation publication-type="journal" id="cit396"><name><surname>Handa</surname><given-names>K.</given-names></name>; <name><surname>Wright</surname><given-names>P.</given-names></name>; <name><surname>Yoshimura</surname><given-names>S.</given-names></name>; <name><surname>Kageyama</surname><given-names>M.</given-names></name>; <name><surname>Iijima</surname><given-names>T.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>
<article-title>Prediction of Compound
Plasma Concentration-Time Profiles in Mice Using Random Forest</article-title>. <source>Mol. Pharmaceutics</source>
<year>2023</year>, <volume>20</volume> (<issue>6</issue>), <fpage>3060</fpage>&#x02013;<lpage>3072</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.3c00071</pub-id>.</mixed-citation></ref><ref id="ref397"><mixed-citation publication-type="journal" id="cit397"><name><surname>Heyndrickx</surname><given-names>W.</given-names></name>; <name><surname>Mervin</surname><given-names>L.</given-names></name>; <name><surname>Morawietz</surname><given-names>T.</given-names></name>; <name><surname>Sturm</surname><given-names>N.</given-names></name>; <name><surname>Friedrich</surname><given-names>L.</given-names></name>; <name><surname>Zalewski</surname><given-names>A.</given-names></name>; <name><surname>Pentina</surname><given-names>A.</given-names></name>; <name><surname>Humbeck</surname><given-names>L.</given-names></name>; <name><surname>Oldenhof</surname><given-names>M.</given-names></name>; <name><surname>Niwayama</surname><given-names>R.</given-names></name>; <name><surname>Schmidtke</surname><given-names>P.</given-names></name>; <name><surname>Fechner</surname><given-names>N.</given-names></name>; <name><surname>Simm</surname><given-names>J.</given-names></name>; <name><surname>Arany</surname><given-names>A.</given-names></name>; <name><surname>Drizard</surname><given-names>N.</given-names></name>; <name><surname>Jabal</surname><given-names>R.</given-names></name>; <name><surname>Afanasyeva</surname><given-names>A.</given-names></name>; <name><surname>Loeb</surname><given-names>R.</given-names></name>; <name><surname>Verma</surname><given-names>S.</given-names></name>; <name><surname>Harnqvist</surname><given-names>S.</given-names></name>; <name><surname>Holmes</surname><given-names>M.</given-names></name>; <name><surname>Pejo</surname><given-names>B.</given-names></name>; <name><surname>Telenczuk</surname><given-names>M.</given-names></name>; <name><surname>Holway</surname><given-names>N.</given-names></name>; <name><surname>Dieckmann</surname><given-names>A.</given-names></name>; <name><surname>Rieke</surname><given-names>N.</given-names></name>; <name><surname>Zumsande</surname><given-names>F.</given-names></name>; <name><surname>Clevert</surname><given-names>D.-A.</given-names></name>; <name><surname>Krug</surname><given-names>M.</given-names></name>; <name><surname>Luscombe</surname><given-names>C.</given-names></name>; <name><surname>Green</surname><given-names>D.</given-names></name>; <name><surname>Ertl</surname><given-names>P.</given-names></name>; <name><surname>Antal</surname><given-names>P.</given-names></name>; <name><surname>Marcus</surname><given-names>D.</given-names></name>; <name><surname>Do Huu</surname><given-names>N.</given-names></name>; <name><surname>Fuji</surname><given-names>H.</given-names></name>; <name><surname>Pickett</surname><given-names>S.</given-names></name>; <name><surname>Acs</surname><given-names>G.</given-names></name>; <name><surname>Boniface</surname><given-names>E.</given-names></name>; <name><surname>Beck</surname><given-names>B.</given-names></name>; <name><surname>Sun</surname><given-names>Y.</given-names></name>; <name><surname>Gohier</surname><given-names>A.</given-names></name>; <name><surname>Rippmann</surname><given-names>F.</given-names></name>; <name><surname>Engkvist</surname><given-names>O.</given-names></name>; <name><surname>G&#x000f6;ller</surname><given-names>A. H.</given-names></name>; <name><surname>Moreau</surname><given-names>Y.</given-names></name>; <name><surname>Galtier</surname><given-names>M. N.</given-names></name>; <name><surname>Schuffenhauer</surname><given-names>A.</given-names></name>; <name><surname>Ceulemans</surname><given-names>H.</given-names></name>
<article-title>MELLODDY: Cross-Pharma Federated
Learning at Unprecedented Scale Unlocks Benefits in QSAR without Compromising
Proprietary Information</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2024</year>, <volume>64</volume> (<issue>7</issue>), <fpage>2331</fpage>&#x02013;<lpage>2344</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.3c00799</pub-id>.<pub-id pub-id-type="pmid">37642660</pub-id>
</mixed-citation></ref><ref id="ref398"><mixed-citation publication-type="journal" id="cit398"><name><surname>Peteani</surname><given-names>G.</given-names></name>; <name><surname>Huynh</surname><given-names>M. T. D.</given-names></name>; <name><surname>Gerebtzoff</surname><given-names>G.</given-names></name>; <name><surname>Rodr&#x000ed;guez-P&#x000e9;rez</surname><given-names>R.</given-names></name>
<article-title>Application
of Machine Learning Models
for Property Prediction to Targeted Protein Degraders</article-title>. <source>Nat. Commun.</source>
<year>2024</year>, <volume>15</volume> (<issue>1</issue>), <fpage>5764</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-49979-3</pub-id>.<pub-id pub-id-type="pmid">38982061</pub-id>
</mixed-citation></ref><ref id="ref399"><mixed-citation publication-type="journal" id="cit399"><name><surname>Paul</surname><given-names>S. M.</given-names></name>; <name><surname>Mytelka</surname><given-names>D. S.</given-names></name>; <name><surname>Dunwiddie</surname><given-names>C. T.</given-names></name>; <name><surname>Persinger</surname><given-names>C. C.</given-names></name>; <name><surname>Munos</surname><given-names>B. H.</given-names></name>; <name><surname>Lindborg</surname><given-names>S. R.</given-names></name>; <name><surname>Schacht</surname><given-names>A. L.</given-names></name>
<article-title>How to
Improve R&#x00026;D Productivity: The Pharmaceutical Industry&#x02019;s
Grand Challenge</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2010</year>, <volume>9</volume> (<issue>3</issue>), <fpage>203</fpage>&#x02013;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3078</pub-id>.<pub-id pub-id-type="pmid">20168317</pub-id>
</mixed-citation></ref><ref id="ref400"><mixed-citation publication-type="book" id="cit400"><person-group person-group-type="allauthors"><name><surname>Strovel</surname><given-names>J.</given-names></name>; <name><surname>Sittampalam</surname><given-names>S.</given-names></name>; <name><surname>Coussens</surname><given-names>N. P.</given-names></name>; <name><surname>Hughes</surname><given-names>M.</given-names></name>; <name><surname>Inglese</surname><given-names>J.</given-names></name>; <name><surname>Kurtz</surname><given-names>A.</given-names></name>; <name><surname>Andalibi</surname><given-names>A.</given-names></name>; <name><surname>Patton</surname><given-names>L.</given-names></name>; <name><surname>Austin</surname><given-names>C.</given-names></name>; <name><surname>Baltezor</surname><given-names>M.</given-names></name>; <name><surname>Beckloff</surname><given-names>M.</given-names></name>; <name><surname>Weingarten</surname><given-names>M.</given-names></name>; <name><surname>Weir</surname><given-names>S.</given-names></name></person-group><source>Early Drug Discovery and Development Guidelines:
For Academic Researchers, Collaborators, and Start-up Companies</source>; <publisher-name>Eli Lilly &#x00026; Company and the National Center
for Advancing Translational Sciences</publisher-name>, <year>2016</year>.</mixed-citation></ref><ref id="ref401"><mixed-citation publication-type="journal" id="cit401"><name><surname>Aronson</surname><given-names>J. K.</given-names></name>; <name><surname>Green</surname><given-names>A. R.</given-names></name>
<article-title>Me-Too Pharmaceutical
Products: History,
Definitions, Examples, and Relevance to Drug Shortages and Essential
Medicines Lists</article-title>. <source>Br. J. Clin. Pharmacol.</source>
<year>2020</year>, <volume>86</volume> (<issue>11</issue>), <fpage>2114</fpage>&#x02013;<lpage>2122</lpage>. <pub-id pub-id-type="doi">10.1111/bcp.14327</pub-id>.<pub-id pub-id-type="pmid">32358800</pub-id>
</mixed-citation></ref><ref id="ref402"><mixed-citation publication-type="journal" id="cit402"><name><surname>Krieger</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>D.</given-names></name>; <name><surname>Papanikolaou</surname><given-names>D.</given-names></name>
<article-title>Missing Novelty
in Drug Development*</article-title>. <source>Rev. Financ. Stud.</source>
<year>2022</year>, <volume>35</volume> (<issue>2</issue>), <fpage>636</fpage>&#x02013;<lpage>679</lpage>. <pub-id pub-id-type="doi">10.1093/rfs/hhab024</pub-id>.</mixed-citation></ref><ref id="ref403"><mixed-citation publication-type="journal" id="cit403"><name><surname>Adeshina</surname><given-names>Y. O.</given-names></name>; <name><surname>Deeds</surname><given-names>E. J.</given-names></name>; <name><surname>Karanicolas</surname><given-names>J.</given-names></name>
<article-title>Machine Learning
Classification Can Reduce False Positives in Structure-Based Virtual
Screening</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2020</year>, <volume>117</volume> (<issue>31</issue>), <fpage>18477</fpage>&#x02013;<lpage>18488</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2000585117</pub-id>.<pub-id pub-id-type="pmid">32669436</pub-id>
</mixed-citation></ref><ref id="ref404"><mixed-citation publication-type="journal" id="cit404"><name><surname>Provins</surname><given-names>L.</given-names></name>; <name><surname>Jnoff</surname><given-names>E.</given-names></name>; <name><surname>Genicot</surname><given-names>C.</given-names></name>
<article-title>Back-up Strategies
in Drug Discovery: What, How and When?</article-title>. <source>Drug
Discovery Today</source>
<year>2014</year>, <volume>19</volume> (<issue>11</issue>), <fpage>1808</fpage>&#x02013;<lpage>1811</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2014.07.001</pub-id>.<pub-id pub-id-type="pmid">25017046</pub-id>
</mixed-citation></ref><ref id="ref405"><mixed-citation publication-type="journal" id="cit405"><name><surname>Segall</surname><given-names>M. D.</given-names></name>; <name><surname>Barber</surname><given-names>C.</given-names></name>
<article-title>Addressing Toxicity
Risk When Designing
and Selecting Compounds in Early Drug Discovery</article-title>. <source>Drug Discovery Today</source>
<year>2014</year>, <volume>19</volume> (<issue>5</issue>), <fpage>688</fpage>&#x02013;<lpage>693</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2014.01.006</pub-id>.<pub-id pub-id-type="pmid">24451294</pub-id>
</mixed-citation></ref><ref id="ref406"><mixed-citation publication-type="journal" id="cit406"><name><surname>Lexchin</surname><given-names>J.</given-names></name>
<article-title>How Safe and Innovative Are First-in-Class
Drugs Approved
by Health Canada: A Cohort Study</article-title>. <source>Healthc. Policy</source>
<year>2016</year>, <volume>12</volume> (<issue>2</issue>), <fpage>65</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.12927/hcpol.2016.24851</pub-id>.<pub-id pub-id-type="pmid">28032825</pub-id>
</mixed-citation></ref></ref-list></back></article>